

67th ASH Annual Meeting and Exposition

DECEMBER 6-9, 2025 | ORLANDO, FLORIDA

PROGRAM-AT-A-GLANCE







Land on the latest data with DARZALEX® and DARZALEX FASPRO®

See current data in the treatment space at the 2025 ASH® Annual Meeting

December 6-9 · Visit Booth #1315







Scan the QR code* to visit DARZALEXHCP.com

© Johnson & Johnson and its affiliates 2025 10/25 cp-546182v1

PROGRAM OF THE 67TH ANNUAL MEETING OF

AMERICAN SOCIETY OF HEMATOLOGY



December 6 - 9, 2025



Greetings from the President

On behalf of the American Society of Hematology, it is my privilege and pleasure to welcome you to the 67th ASH Annual Meeting and Exposition. Whether you are attending the meeting in person or virtually, I am confident you're going to enjoy stimulating presentations, discussions, and workshops that will inspire all of us in our quest to conquer blood diseases.

I've been attending the ASH annual meeting since 1985, and this gathering seems especially meaningful. Coming at the end of a year that has been incredibly challenging for anyone who cares about scientific research and medical care, the ASH annual meeting is both a balm and a timely affirmation of all that we are doing as scientists and clinicians.

We are here because we know that sound science matters, that research saves lives, and that global collaboration enriches us — all of which leads to better patient care. After a year of hearing and reading about U.S. federal cuts and policy changes that seem to question the very value of our work, here at ASH 2025 we are among peers who recognize the transformative power of science and the societal benefits of investing in robust research. We are here because we believe hematology is worth fighting for today, tomorrow — and well into the future. The record number of abstract submissions received this year speaks to our sustained interest in learning together and advancing our field.

On the pages of this program book, you will find details about many events that will engage your mind and move your spirit, including the ASH Studio, which will feature "Treating Fairly" presentations on health disparities and socially responsible medicine. ASH stands firm in its commitment to support hematologists in ways that reflect and serve the world that we live in.

Independent of the formal program, I'd like to highlight two items worthy of mention.

- First, I am proud to share that ASH stepped up this year to commit a record amount -- more than \$20 million -- to its awards and mentorship programs to help protect hematology research, fuel innovation, and strengthen hematology careers at every stage.
- Second, we need your support, so that we can continue to grow the careers of hematologists. Please visit the **Fight4Hematology Action Hub** to learn how you can help, including donating to the **ASH Foundation.**

Thank you for attending the ASH annual meeting. Its success has long had its roots in those who participate. Your continued commitment to hematology will help to ensure that the future of our field remains as exciting and impactful as ever!

Belinda R. Avalos, MD

President



Fight4Hematology
Action Hub



ASH Foundation

2 Letter from President

Table of Contents

OCIETY OF LIFT OCIO	About ASH	
	ASH Executive and Program Committees	5
	Reviewers of Abstracts and Hematology 2025	8
	Corporate Acknowledgements	11
	Recipients of Awards	14
	Guide to Navigating the Meeting	
	General Information	25

Meeting Schedule	
Schedule-At-A-Glance	43

Non-CME Sessions

Advancing Excellence and Addressing Health Disparities at ASH®

Browse by Session Type	
Marquee Sessions	65
Scientific Sessions	67
Education Sessions	79
Special Interest Sessions and Studios	91
Trainee Activities	103
Scientific Categories	109
Oral and Poster Abstract Sessions	111

continued on next page

37

41

Table of Contents 3

Table of Contents

Interact with Industry	
Satellite Symposia	125
Product Theaters	137
Industry Theaters	141
Industry Forums	142
Company Showcases	143
Clinical Trials Showcase	144
Exhibitor Directory	145
Browse by Disease	
Browse By Disease Introduction	153
Bleeding and Clotting	155
Bone Marrow Failure Syndrome	159
Genetic Disorders	161
Hemoglobinopathies	163
Immune Disorders	165
Lymphoid Malignancies	167
Metabolic Disorders	175
Myeloid Malignancies	177

Table of Contents

AMERICAN SOCIETY OF HEMATOLOGY EXECUTIVE COMMITTEE

STAFF LIAISONS:

Martha Liggett, Esq., mliggett@hematology.org
Matthew Gertzog, MBA, CAE, mgertzog@hematology.org
LaFaundra Neville Ingram, CAP, Ineville@hematology.org

OFFICERS:

President: Belinda Avalos, MD
President-Elect: Robert Negrin, MD
Vice President: Cynthia E. Dunbar, MD
Secretary: Jennifer R. Brown, MD, PhD
Treasurer: Joseph R. Mikhael, MD

COUNCILLORS:

Chancellor E. Donald, MD ('28)
Christopher R. Flowers, MD, MSc ('26)
H. Leighton Grimes, PhD ('27)
Jennifer Holter-Chakrabarty, MD ('28)
Mary M. Horowitz, MD ('27)
Charlotte Marie Niemeyer, MD ('26)
Sarah H. O'Brien, MD ('25)
Wendy Stock, MD ('25)

Leaders 5

PROGRAM COMMITTEE

STAFF LIAISON:

Ana Velarde E-mail: avelarde@hematology.org

Belinda Avalos, MD ('25) - Chairperson, President

Robert Negrin, MD ('25) - Ex-Officio: President-Elect Joseph R. Mikhael, MD ('26) - Ex-Officio: Treasurer Jennifer R. Brown, MD, PhD ('28) - Ex-Officio: Secretary Cynthia E. Dunbar, MD ('26) - Ex-Officio: Vice President

Catherine M. Bollard, MD ('29) - Liaison, Editor-in-Chief, *Blood Advances*Hetty Eileen Carraway, MD, MBA ('26) - Liaison, Chair, Committee on Training
Jorge Cortes, MD ('29) - Liaison, Editor Designee, *Blood Global Hematology*Adam Cuker, MD ('25) - Liaison, Chair, Committee on Quality

Amy E. DeZern, MD ('26) - Liaison, Chair, Committee on Educational Affairs

Willem E. Fibbe, MD ('29) - Liaison, Editor Designee, Blood Immunology & Cellular Therapy

Patrick G. Gallagher, MD ('29) - Liaison, Editor Designee, $Blood\ Red\ Cells\ \&\ Iron$

Aaron T. Gerds, MD, MS ('25) - Liaison, Editor-in-Chief, ASH Clinical News

Phoebe Joy Ho, MBBS ('25) - Liaison, Chair, International Members Committee

Judith Kleinerman, MD ('25) - Liaison, Chair, CME Accreditation Committee Jonathan D. Licht, MD ('28) - Liaison, Editor-in-Chief, *Blood Neoplasia*

Keith R. McCrae, MD ('28) - Liaison, Editor-in-Chief, Blood Vessels, Thrombosis & Hemostasis

Mary-Elizabeth M. Percival, MD ('25) - Liaison, Chair, Committee on Practice Andrew W. Roberts, MBBS, PhD ('29) - Liaison, Editor-in-Chief, *Blood*

Surbhi Sidana, MD ('26) - Liaison, Chair, Committee on Communications

Alison R. Walker, MD, MBA, MPH ('26) - Liaison, Chair, Committee on Advancing Excellence and Population Health Andrew S. Weyrich, PhD ('26) - Liaison, Deputy Editor, *Blood Advances* Alisa S. Wolberg, PhD ('26) - Liaison, Chair, Committee on Scientific Affairs

6 Leaders

ANNUAL MEETING ACCREDITED EDUCATION COMMITTEE

STAFF LIAISON:

Ana Velarde
E-mail: avelarde@hematology.org

Payal C. Desai, MD ('25) - Co-Chairperson, 2025 Education Program Co-Chair Rayne H. Rouce, MD ('25) - Co-Chairperson, 2025 Education Program Co-Chair Esther A. Obeng, MD, PhD ('25) - 2025 Scientific Program Co-Chair Betty Pace, MD ('25) - 2025 Scientific Program Co-Chair

Maureen Okam Achebe, MD, MPH ('26) - 2026 Education Program Co-Chair Robert Zeiser, MD ('26) - 2026 Scientific Program Co-Chair Ami S. Bhatt, MD ('26) - 2026 Scientific Program Co-Chair Saar Gill, MD, PhD ('26) - 2026 Education Program Co-Chair Lori S. Muffly, MD ('25) - Executive Editor, Hematology Bhavana Bhatnagar, DO ('25) - Appointed Member Hetty Eileen Carraway, MD, MBA ('25) - Appointed Member Thomas D. Coates, MD ('25) - Appointed Member Anna Dabrowska-Iwanicka, MD, PhD ('25) - Appointed Member Courtney D. DiNardo, MD, MSc ('25) - Appointed Member Torsten Haferlach, MD, PhD ('25) - Appointed Member Michael V. Jaglal, MD ('25) - Appointed Member Judith Kleinerman, MD - Appointed Member, Chair, CME Accreditation Committee Mary Ann Knovich, MD ('25) - Appointed Member Alice D. Ma, MD ('25) - Appointed Member Deepa Manwani, MD ('25) - Appointed Member Marshall A. Mazepa, MD ('25) - Appointed Member Rachel E. Rau, MD ('25) - Appointed Member Vijay G. Sankaran, MD, PhD ('25) - Appointed Member Tulika Seth, MD, MBBS ('25) - Appointed Member Jay Spiegel, MD, FRCPC ('25) - Appointed Member Sumithira Vasu, MD, MBBS ('25) - Appointed Member Rahma Warsame, MD ('25) - Appointed Member

Leaders 7

2025 REVIEWERS

The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of *Hematology* 2025, the ASH Education Program.

ASH ABSTRACTS COORDINATING REVIEWERS

Maya Abdallah Hisham Abdel Suchitra Acharya Inhye Ahn Imo Akpan Andrew Artz Yesim Aydinok Benjamin Barwick Rafet Basar Lisa Baumann Silvia Bea Lina Benajiba Rusha Bhandari Shruti Bhatt Piers Blombery Danielle Brander Susan Branford Naresh Bumma Andres Chang Dai Chihara Hannah Choe Satheesh Chonat Elise Chong Stephen Chung

Sabino Ciavarella

Nathan Connell

Catherine Coombs Francis Coyne Nicholas Cross Jennifer Davila Akiva Diamond Carlo Dufour Alejandro Ferrer Aaron Gerds George Goshua Michael Green Natalie Grover Elisa Hacken Claudia Haferlach Konstantine Halkidis Mehdi Hamadani Eliza Hawkes Gregor Hoermann Seethal Jacob Radoslaw Kaczmarek Marina Konopleva Madhavi Lakkaraja Jeffrey Lebensburger

Madhavi Lakkaraja Jeffrey Lebensburg Holly Lee Suzanne Lentzsch Alexander Lesokhin Jane Little Hongtao Liu Daniel Lucas-Alcaraz Marlise Luskin Johnny Mahlangu Ajay Major Camila Masias Christine McMahon Christopher Melani Francois Mercier Linde Miles Alice Mims

Guillermo Montalban-Bravo Lee Mozessohn Rupa Narayan Samuel Ng Elizabeth O'Donnell Folashade Otegbeye Giovanni Palladini Christopher Park Oren Pasvolsky Bhavisha Patel Alexander Perl

Mortimer Poncz Jacqueline Poston Vinod Pullarkat John Quigley

Aleksander Chojecki

Lisa Chu

Sandeep Raj

Guillaume Richard-Carpentier David Russler-Germain R. Leo Sakemura Sol Schulman Akshay Sharma Warren Shlomchik Nicholas Short Tanaya Shree Surbhi Sidana

Andrew Srisuwananukorn Michele Stanchina Deborah Stephens Christopher Su Guru Subramanian Sarah Tasian Gita Thanarajasingam Judith Trotman Bert Van der Reijden Abi Vijenthira Eunice Wang

ASH ABSTRACTS REVIEWERS

Nadine Abdallah Aby Abraham Elisabetta Abruzzese Lionel Ades Sonia Aguila Martinez Othman Akhtar Juan Alderuccio Mattia Algeri Maha Al-Ghafry Naveed Ali Taha Al-Juhaishi Aseel Alsougi Emmanuela Ambrose Jennifer Amengual Lauren Amos Mathew Angelos Tomohiro Aoki Jacob Appelbaum Connie Arthur Joseph Aslan Ehab Atallah Shebli Atrash Mohammad Azam Pavan Bachireddy Emmanuel Bachy Steven Bair John Baird Brianna Bakow Susan Bal

Brian Ball

Ramesh Balusu

Rahul Banerjee

Monica Balzarotti

Stefan Barta Ana Basquiera Pamela Becker M. Bender Callie Berkowitz Alison Bertuch Jan Philipp Bewersdorf Evandro Bezerra Seema Bhat Manisha Bhutani Giulia Biancon Lawrence Boise Niccolo Bolli Claire Booth Francesc Bosch Albareda Joshua Brandstadter Elizabeth Brem James Bussel Veronika Buxhofer-Ausch Cecelia Calhoun Elias Campo Vincent Camus Jose Cancelas Spero Cataland Rohini Chakravarthy Ayushi Chauhan Yi-Bin Chen Marta Chesi Carol Yuk-Man Cheung

Vasant Chinnabhandar

Meera Chitlur

Michael Choi

Timothy Chlon

Michael Roost Clausen Julia Coleman Alexander Coltoff **Todd Cooper** Paul Coppo Fernando Costa Caitlin Costello Marta Crespo Lori Crosby Lea Cunningham Emily Curran Kate Cwynarski Maria da Silva Mattia D'Agostino May Daher, MD Aleksandra Dain Sandeep Dave Blachy Davila Saldana Silvia Deaglio Ozgen Deniz Marta Derecka Amrita Desai Niray Dhanesha Maria Diez-Campelo Danai Dima Martin Dreyling Bruno Duarte Christen Ebens Jan-Niklas Eckardt Cornelia Eckert Michael Eckrich

Eduardo Edelman Saul Dimitar Efremov Najla El Jurdi Ola Elgamal Hany Elmariah Thomas Ernst Andrew Evens Xing Fan John Fargo Francesca Ferraro **Brent Ferrell** Kleber Fertrin **Tobias Feuchtinger** Warren Fingrut Mark Fleming Gian Luca Forni Yolanda Fortenberry Charles Foucar Ellen Fraint Matthew Frank Matthew Frigault Zachary Frosch Jing Fu Hideaki Fujiwara Fateeha Furgan Nico Gagelmann Patrick Gallagher Maciej Garbowski Kate Gardner Charles Gaulin Bernhard Gentner Alina Gerrie Gabriel Ghiaur

8 Reviewers

2025 REVIEWERS

Armin Ghobadi Taumoha Ghosh Ingrid Glimelius Kelly Godby Richard Godby Jahnavi Gollamudi Mahasweta Gooptu Steven Goossens Jason Gotlib Katharina S. Götze Zachary Graff Timothy Graubert Hildegard Greinix Tim Grob Tanja Gruber Stephanie Guarino Terri Guinipero Li Guo Kalpna Gupta Jonathan Gutman Cynthia Hahn Xu Han Hyojeong Han Shivani Handa Patrick Hayden Julie Haydu

Florian Heidel Merja Heinäniemi Johannes Hellmuth Mallorie Heneghan Cedric Hermans

Jose Angel Hernandez Rivas

Erin Hertlein LaQuisa Hill Elizabeth Hill Kirsty Hillier Phoebe Joy Ho Eldad Hod Daniel Hodson

Jennifer Holter-Chakrabarty Junshik Hong Hitomi Hosoya Christopher Hourigan Chi-Joan How Boyu Hu Sandra Huber Monica Hulbert Scott Huntington Eric Huselton Stephan Hutter Gloria lacoboni Ibrahim Idris Anton Ilich Alessandro Isidori Raphael Itzykson Franco Izzo Ryan Jacobs

Amanda Jacobson-Kelly

Salvia Jain Jayanshu Jain Nitin Jain

Sri Lakshmi Jamalapur Scott James Murali Janakiram Sakshi Jasra Anuja Java Christopher Jensen Chetan Jeurkar

Sizun Jiang Victor Jimenez-Zepeda

Charles Jonassaint Laure Joseph Martin Kaiser Theodosia Kalfa

Elizabeth Kang Yogendra Kanthi Sargam Kapoor Yasmin Karimi Kristine Karkoska Jonathan Kaufman Supreet Kaur Gurbakhash Kaur Vanessa Kennedy Marie José Kersten Amany Keruakous Arushi Khurana Paul Kim

Thomas Knight Manpreet Kochhar Jean Koff Valery Kogler Mika Kontro Neha Korde Laura Korin Anu Korula Elizabeth Krakow Michael Kramer

Jakub Krejcik

Giedre Krenciute Robert Kridel Matthew Ku Florian Kuchenbauer Matthew Kudek Eitan Kugler Michael Kühn Anupama Kumar

Curtis Lachowiez Rahul Lakhotia Kentson Lam Nicole Lamanna Jatinder Lamba Daniel Landsburg Hugo Lara-Martinez Thomas Larsen Michelle Lavin Avi Leader Michelle Lee Michelle Lee Hans Lee Kelvin Lee Stephanie Lee

Andri Leo Lemarquis Steven Lentz Hojun Li Loretta Li Raphael Lizcano Camille Lobry Sanam Loghavi Kah Poh (Melissa) Loh

Frank Leebeek

Sun Loo Alice Ma Nicoletta Machin Kellie Machlus Nicola Maciocia Anjlee Mahajan Sham Mailankody Abhishek Maiti Florent Malard Punam Malik Gabriel Mannis Els Mansell Anna Marneth

Olufunke Martin Alejandro Martin Garcia-Sancho

Jennifer Marvin-Peek Riccardo Masetti Vikram Mathews

Francesco Maura Luca Maurillo Jori May

Meghann McManus

Ari Melnick

Johanna Melo-Cardenas Megan Melody Thomas Mercher Michele Merli Lauren Merz Ruben Mesa Marcus Messmer Ara Metjian Klaus Metzeler Hira Mian Peter Miller Alain Mina Roberto Mina Coraline Mlynarczyk Scott Moerdler Razan Mohty

Riccardo Moia Peter Mollee Patrizia Mondello Ryan Morin James Morrissey Pedro Moura Tamara Moyo Ann Mullally Erin Mulvey Pashna Munshi

Moaath Mustafa Ali Nicola Mutch June Myklebust Kalyan Nadiminti Antonella Nai Ranjit Nair Lalitha Nayak Aziz Nazha Elizabeta Nemeth

Martin Neumann Michelle Ng Ashley Ng Jessica Nordlund Igor Novitzky-Basso

Ariela Noy

Panagiotis Ntziachristos Mofiyinfoluwa Obadina

Sarah O'Brien Kristen O'Dwyer Vivian Oehler Ugochi Ogu

Oluwaseun 'kemi Olaiya

Rebecca Olin Adam Olszewski Carolyn Owen Margareth Ozelo Eric Padron Simona Pagliuca Orrin Pail Raffaele Palmieri Sandhya Panch Manu Pandev Jens Panse Helen Papadaki Terri Parker Sant-Rayn Pasricha

Rushad Patell Mrinal Patnaik Naveen Pemmaraju Mary-Elizabeth Percival

Cheryl Peretz Karlo Perica Scott Peslak

Andrew Picca Joseph Pidala Martina Pigazzi Yana Pikman **Thomas Pincez** Sandra Pinho Allyson Pishko Gizelle Popradi Nicola Potter Olga Pozdnyakova Pedro Prata Keith Pratz Jaime Preussler Susan Prockop Alexandre Puissant Ya-Wei Qiang David Qualls Marc Raaijmakers Sabarinath Radhakrishnan

James Phelan

Jerald Radich Alex Radzisheuskaya

Sarwish Rafig

Prashant Raghavendran Archana Ramgopal Chittalsinh Raulji John Reagan David Rees Erin Reid Damien Reynaud

Daniel Richardson Ingo Ringshausen Lorenzo Rizzo Kerry Rogers Gregory Roloff Rizwan Romee Mark Roschewski Melissa Rose Richard Rosenquist Sandrine Roulland Leo Ruhnke Jenny Ruiz Christine Ryan Teresa Sadras Kathleen Sakamoto

Nathan Salomonis Deepa Sampath Jose Sandoval-Sus Amanda Sankar Jean-Emmanuel Sarry

Bipin Savani Caner Saygin David Scadden

Andromachi Scaradavou

Jordan Schaefer Eric Schafer Phillip Scheinberg Florian Scherer Johannes Schetelig Fredrik Schjesvold Kelly Schoenbeck Michelle Schoettler Liora Schultz Marc Schwartz **Bart Scott** Valentina Serafin Mazvar Shadman

Naranie Shanmuganathan

Bo Shen Patricia Shi Deborah Siegal Rebecca Silbermann Shireen Sirhan

Neil Shah

Reviewers

2025 REVIEWERS

Sigrid Skånland Sarah Skuli Chi Wai Eric So Katja Sockel Iberia Sosa Meera Sridharan Meera Srikanthan Richard Stone Robert Stuver Senthil Sukumar Clare Sun Pamela Sung Mahesh Swaminathan David Swoboda

Jeff Szer Koichi Takahashi

Kaoru Takasaki

Hannah Tamary

Cristina Tognon
Marialejandra Torres Viera
Fabiola Traina
Douglas Tremblay
Roochi Trikha
Eirini Trompouki
David Valcarcel
Mounica Vallurupalli
Niels W.C.J. van de Donk
Antiopi Varelias
Cindy Varga
Anant Vatsayan
Rahul Vedula
Sangeetha Venugopal
Eric Vick

Francesco Paolo Tambaro

Sigrun Thorsteinsdóttir

Madhav Vissa Evangelia Vlachodimitropoulou Giacomo Volpe Timothy Voorhees Ajay Vora Sebastian Vosberg Elvin Wagenblast Anem Waheed David Wald Shannon Walker Sarah Wall Lili Wang Jiasheng Wang Julia Warren Jonathan Webster Niels Weinhold Jonathan Weiss

Andrea Visentin

Megan Weivoda Angela Weyand Matthew Wieduwilt Tanya Wildes Jennifer Wilkes Hope Wilson Allison Winter Amanda Winters Marcin Wlodarski Manja Wobus Nicole Wong Doo Nicola Wright Kitsada Wudhikarn

ASH ABSTRACTS TRAINEE REVIEWERS

ZZachary M. Avigan Hong de Sa Ryan Mack Megan Metzger Nicole L. Michmerhuizen Andres Noyola-Perez Zulfa Omer Laura Samples

Carlo Visco

Andrew Song Yun Kyoung Claire Tiger Seda S. Tolu Bryan Valcarcel

Yannis K. Valtis Cristoph Weigel

HEMATOLOGY 2025 REVIEWERS

Jithma P. Abevkoon Mouhamed Yazan Abou-Ismail Hanny Al-Samkari Ibrahim Aldoss Jessie L Alexander Jessica K. Altman Joseph H. Antin Ana G. Antun Cihan Ay Ross lan Baker Tiziano Barbui Stefan K. Barta Nancy L. Bartlett Callie Berkowitz Marisol Betensky Alexander Boucher Catherine Broome James B. Bussel Marc Carrier Giovanni Cazzaniga Shruti Chaturvedi Yi-Bin Chen Thomas D. Coates Raffaella Colombatti Raffaella Colombatti Nathan T Connell Luciano J. Costa Caitlin L. Costello Susan E Creary Adam Cuker Anita D'Souza Matthew S. Davids

Kara L. Davis

Daphne de Jong Michael J R Desborough

Michael Dickinson

Adam S DuVall Hany Elmariah Rawan G. Faramand Amir T. Fathi Veronica H Flood Patrick G. Gallagher Radhika Gangaraju David A Garcia Norbert Gattermann Gauray Goval Morag Griffin Elizabeth A. Griffiths Sumit Gupta Betty K. Hamilton Adrienne Marie Hammill Alessandro Isidori Zalaya K Ivy Paula D. James Murali Janakiram Anuia Java Michael Raymond Jeng Theodosia A. Kalfa Manali Kamdar Reem Karmali Seth E. Karol Margaret Kasner Efstathios Kastritis Vanessa E Kennedy Marie José Kersten Barbara A Konkle Shaji K Kumar Curtis A. Lachowiez Catherine Lai Michele P Lambert Saskia M.C. Langemeijer Sarah Larson

Jessica T. Leonard Nelson Leung Mark J. Levis Emily C. Liang Mina Y Lim Tasha L Lin Aaron C Logan Hannah Lust Alice Ma Gabriel N. Mannis Karlyn Martin Shannon L. Maude Jori Ellen May Kenneth L McClain Patrick T. McGann Lauren E Merz Joseph R. Mikhael Narla Mohandas Philippe Moreau Johann Morelle Khaled M. Musallam Igor Novitzky-Basso David O'Connor Caspian Oliai Sandhva Ramanathan Panch Sameer A Parikh Anand A Patel Christopher J Patriquin Christopher Jordan Patriquin Giulia Petrone Antonio Pierini Rob Pieters

Patrick M. Reagan Michael Recht Josep-Maria Ribera Annalisa Ruggeri Sarah C. Rutherford Jesús F. San-Miguel Kristen Sanfilippo Yazeed Sawalha Natalia Scaramellini Marie Scully Tulika Seth Mazyar Shadman Kenneth H Shain Amy D. Shapiro Akshay Sharma Aditi Shastri Suiit Sheth Andrew Shih Kristin A Shimano Nicholas J. Short Sonali M. Smith Senthil R Sukumar Julie-An M. Talano **David Trent Teachey** William Temple Will Thomas Tzu-Fei Wang Jonathan Allen Webster Ted Wun Patricia Young

10 Reviewers

Steven W. Pipe

Noopur S. Raje

Raiiv K Pruthi

Parul Rai

CORPORATE ACKNOWLEDGMENTS

2025 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 21, 2025.

2025 ASH Annual Meeting Foundation Run/Walk Supporters

PREMIER

Acrotech Biopharma
AstraZeneca
Gilead and Kite Oncology
GSK
Johnson & Johnson

LEAD

AbbVie

2025 ASH Annual Meeting Education Supporters

ASH would like to acknowledge the following companies for the educational grants provided in support of the 2025 ASH Annual Meeting:

General Education Grant

AstraZeneca
GlaxoSmithKline
Lilly USA, LLC
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Hematology 2025: The Education Program

AbbVie
AstraZeneca
GlaxoSmithKline
Merck Sharp & Dohme Corp
Novartis Pharmaceuticals Corporation

2025 ASH Independent Medical Education Supporters

ASH would like to acknowledge the following companies for their support:

Agios Pharmaceuticals Inc.

bluebird bio, Inc.

Janssen Scientific Affairs, LLC

Novartis Pharmaceuticals Corporation

Novo Nordisk

Pfizer Inc.

Vertex Pharmaceuticals Incorporated

Corporate Acknowledgments 11

2025 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 21, 2025.

2025 ASH Award Supporters

ASH would like to acknowledge and thank the following companies for supporting the ASH Bridge Grant, Hematology Inclusion Pathway and Scholar Award programs:

AstraZeneca

2025 Annual Meeting Corporate Supporters

ASH would like to acknowledge the following companies for their support of the 2025 ASH Annual Meeting:

AstraZeneca

Exhibit Hall Aisle Signs

Eli Lilly and Company

Photo Zone Social Media Wall

GSK

ASH Hotel Door Drop Bag Mobile Device Charging Stations

Johnson & Johnson

Headshot Alley Mobile Device Charging Stations

Merck

ASH Park @ the Plaza - Table Clings

NMDP

ASH-a-Palooza – Platinum Level Supporter

PharmaEssentia

Mobile Device Charging Stations

Syndax

Mobile App

2025 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 21, 2025.

2025 ASH Corporate Friends

ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy throughout the year is sincerely appreciated.

ASH is grateful for the generous support of the following companies:

Premier Circle	Partner Circle	Advocate Circle	Insider Circle	Signature Circle
GSK	AstraZeneca	AbbVie	Autolus	Nurix
Johnson & Johnson	Bristol Myers Squibb	Agios	Genetix	
Novartis	Daiichi-Sankyo	Amgen	Geron	
Pfizer	Fulcrum Therapeutics	Astellas	Kura Oncology	
Regeneron	Kite	BeOne	Orca Bio	
	Lilly	Genentech	Secura Bio	
	Vertex	Genmab		
		Merck		
		Sanofi		
		Syndax		
		Takeda		

2025 Health Impact Collective

The Health Impact Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH's work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the members for their laudable work:

Genentech	Kite
GSK	Merck
Johnson & Johnson	

CORPORATE ACKNOWLEDGMENTS

RECIPIENTS OF AWARDS

WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

2025	Rainer Storb	2018	Victor Hoffbrand	2011	David G. Nathan
2024	Éliane Gluckman	2017	Marshall A. Lichtman	2010	Volker Diehl
2023	Blanche P. Alter	2016	Thalia Papayannopoulou	2009	H. Franklin Bunn
2022	Irving Weissman	2015	Aaron Marcus	2008	Robert Kyle
2021	Harvey Lodish	2014	Kanti Rai	2007	Ernest Beutler
2020	Mohandas Narla	2013	Sir David John Weatherall		

2012 James George

2019 Richard H. Aster

2014 Tomas Ganz

ERNEST BEUTLER LECTURE AND PRIZE

2025 2024		2019	Sriram Krishnaswamy and Jeffrey I. Weitz	2013	Kenneth Kaushansky and David J. Kuter
2023	Takehisa Kitazawa and	2018	Alan D'Andrea and Neal Young	2012	Bruce R. Blazar and Carl H. June
	Johnny Mahlangu	2017	Luigi Naldini and Marina Cavazzana	2011	Janet D. Rowley and Brian J. Druker
2022	John Atkinson and Peter Hillmen	2016	Hugues de Thé and Zhu Chen	2010	Barry S. Coller and Joel S. Bennett
2021	Margaret Shipp and Stephen Ansell	2015	Alfred Goldberg and Paul Richardson	2009	Yuet Wai Kan and Thomas Maniatis
2020	Courtney DiNardo and Ari Melnick	2014	Michael R. DeBaun and Robert P. Hebbel		

E. DONNALL THOMAS LECTURE AND PRIZE

2025	Nancy Speck	2013	Katherine A. High	2001	Samuel E. Lux, IV
2024	Sean J. Morrison	2012	Timothy J. Ley	2000	David Ginsburg
2023	Katy Rezvani	2011	George Q. Daley	1999	Irving Weissman
2022	Bruce Blazar	2010	Leonard I. Zon	1998	Stuart H. Orkin
2021	Connie Westhoff	2009	John E. Dick	1997	Robert Rosenberg
2020	Toshio Suda	2008	Neal S. Young	1996	Stanley Korsmeyer
2019	Philip D. Greenberg	2007	Hal Broxmeyer	1995	Charles Esmon
2018	Connie J. Eaves	2006	E. Richard Stanley	1994	Thomas P. Maniatis
2017	James R. Downing	2005	Rainer Storb	1993	Thomas P. Stossel
2016	David Scadden	2004	Donald Metcalf	1992	Stuart Kornfeld
2015	Barbara C. Furie and Bruce Furie	2003	Ernest Beutler		

2002 Kenneth Mann

WILLIAM DAMESHEK PRIZE

2025	Mark Dawson	2007	William Vainchenker	1990	Thalia Papayannopoulou and George
2024	Ami Bhatt	2006	Riccardo Dalla-Favera		Stamatoyannopoulos
2023	Omar Abdel-Wahab	2005	John Dick	1989	Samuel E. Lux IV
2022	Irene Ghobrial	2004	Ronald Levy	1988	Theodore S. Zimmerman
2021	Elizabeta Nemeth	2003	Gary Gilliland	1987	Charles Sherr
2020	Adolfo Ferrando	2002	Catherine Verfaillie	1986	Stuart Orkin
2019	Emmanuelle Passegué	2001	Brian Druker	1985	Thomas F. Deuel
2018	Ross L. Levine	2000	David A. Williams	1984	Barbara C. and Bruce Furie
2017	Benjamin L. Ebert	1999	Salvador Moncada	1983	Thomas P. Stossel
2016	Charles Mullighan	1998	J. Evan Sadler	1982	Janet D. Rowley
2015	John Byrd	1997	Björn Dahlbäck	1981	Philip W. Majerus
2014	Scott Armstrong	1996	Kenneth Kaushansky	1979	Yuet Wai Kan
2013	Andrew Weyrich	1995	James Ihle	1978	Robert D. Rosenberg
2012	Margaret A. Goodell	1994	George J. Broze, Jr.	1977	Yale Nemerson
2011	Christoph Klein	1993	Owen Witte	1976	Robert I. Weed
2010	David T. Scadden	1992	Richard D. Klausner	1975	Charlotte Friend
2009	Louis M. Staudt	1991	Makio Ogawa	1974	Robert C. Gallo
2008	Kenneth Anderson				

ASH ADVANCING INCLUSIVE EXCELLENCE AWARD

2025	Diane Krause	2021	Deepika Darbari	2018	Cage S. Johnson and José A. López
2024	James George	2020	Edward J. Benz Jr.	2017	Betty Pace
2023	Alexis A. Thompson	2019	Griffin P. Rodgers		
2022	James Gavin and David Wilkes				

HENRY M. STRATTON MEDAL

HENRY M. STRATTON LECTURE (1970-1991)

1991	Ralph L. Nachman	1983	Eugene P. Cronkite	1975	E. Donnall Thomas
1990	Malcolm Moore	1982	Ernest A. McCulloch	1974	Ernest Beutler
1989	Aaron J. Marcus	1981	Clement A. Finch	1973	Albert S. Gordon
1988	Robert S. Schwartz	1980	Yuet Wai Kan	1972	Oscar D. Ratnoff
1987	Robert C. Gallo	1979	Henry S. Kaplan	1971	H.G. Kunkel
1986	Bernard Babior	1978	William N. Valentine	1970	W.R. Bruce
1985	Vincent DeVita	1977	Thomas A. Waldmann		
1984	Samuel Rapaport	1976	Wendell F. Rosse		

Brenner

ASH MENTOR AWARD

2025	Jorge Di Paola and Sophie Lanzkron	2018	John E. Dick and Reed E. Drews	2010	Mary M. Horowitz and Harvey F. Lodish
2024	Stephen D. Nimer and Charles A.	2017	Ronald Hoffman and Oliver W. Press	2009	Arthur Nienhuis and Stuart H. Orkin
	Schiffer	2016	Laurence Boxer and Ralph L. Nachman	2008	George R. Buchanan and Timothy J.
2023	Stephen Sallan and Helen Heslop	2015	Curt Civin and Craig Kitchens		Ley
2022	Michael Caligiuri and Christopher	2014	Grover C. Bagby Jr. and John F.	2007	Edward J. Benz Jr and Harold R.
	Flowers		DiPersio		Roberts
2021	Anthony Goldstone and Jonathan Licht	2013	John Adamson and Stanley Schrier	2006	Samuel E. Lux and Deane F. Mosher
2020	Judith Gasson and Wendy Stock	2012	Beverly S. Mitchell and Rainer F. Storb		
2019	Michael R. DeBaun and Leonard I. Zon	2011	Nancy C. Andrews and Malcolm K.		

ASH OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

2025 AWARDEE

Bharath Dileep Kumar

National Heart, Lung, and Blood Institute, National Institutes of Health

MEDICAL STUDENT

Anna Clara Bader

Dana-Farber Cancer Institute

GRADUATE STUDENT

Pengcheng Zhang

The University of Alabama at Birmingham Heersink School of Medicine

RESIDENT PHYSICIAN

Niklas Kehl

Heidelberg Institute for Stem Cell Technology and Experimental Medicine

POST-DOCTORAL FELLOW

Wenhui Li

Harvard University Brigham and Women's Hospital

ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the British Society of Hematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first-or-senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

Giuli Simini

Cancer Institute - University College London

Aditya Tedjaseputra

King's College London

Phuong To

Queen Mary University of London, Barts Cancer Institute

ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

Michael Ashby

Australian Centre for Blood Diseases, Monash University

ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan

Haryoon Kim

National Cancer Center Research Institute

Jiyuan Liao

The Institute of Medical Science, The University of Tokyo

Wataru Saika

The University of Osaka

ASH-SOCIETY ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted up to two Italian trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of SIE and reside in Italy.

Simona Maria Di Modica

Marcello Turi

IRCCS San Raffaele Scientific Institute

Candiolo Cancer Institute - Fondazione del Piemonte per L'Oncologia - IRCCS

ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure.

Matthew Holt

Caitlin Roger

University of Leeds St. James University Hospital

JOANNE LEVY, MD. MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

Juan Barajas

St. Jude Children's Hospital

MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand's disease.

Nardeen Ayad

Washington University in St. Louis

ASH DAVID M. GOLDENBERG CLINICAL RESEARCH TRAINING INSTITUTE AWARD

This annual award, made possible by the Goldenberg Family Foundation, is granted to four trainees from the CRTI cohort (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract.

Access Representation and Population Health Lauren Merz University of Michigan

Classical Luke Smart University of Cincinnati College of Medicine

International Nicholas Chornenki University of Toronto: Institute of Health Policy, Management, and **Evaluation**

Malignant Alfred Chung University of California San Francisco

ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or postdoctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

Luca Lanino

Yale University

ASH-LATIN AMERICA ABSTRACT ACHIEVEMENT AWARD

This annual award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of the most meritorious abstract submitted for the HIP Graduate Student Abstract Achievement Award.

Andres Novola-Perez

Universidad Autonoma de Nuevo Leon

ASH-BERTHA BOURONCLE. MD HIP GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

This annual award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of the most meritorious abstract submitted for the HIP Graduate Student Abstract Achievement Award

Jennifer Feigin

Mayo Clinic

ASH-SHIU Y. KWOK, MD, PHD FAMILY DISTINGUISHED ABSTRACT ACHIEVEMENT AWARD

This annual award is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or postdoctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious abstracts in the area of Hemophagocytic Lymphohistiocytosis and Cytokine Storm.

Gopal Sinhal

Xi Yang

Amrita Institute of Medical

University of Michigan

Science

ASH-RICHARD T. SILVER, MD ABSTRACT ACHIEVEMENT AWARD FOR MYELOPROLIFERATIVE NEOPLASMS

This annual award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of the most meritorious abstract in the area of Myeloproliferative Neoplasms (MPNs).

Aleksei Martianov

University of North Carolina at Chapel Hill

HEMATOLOGY INCLUSION PATHWAY (HIP) GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology, offers merit-based HIP Graduate Student Abstract Achievement Awards to select graduate students to acknowledge their accomplishments in the field of hematology.

Nicole Arellano The University of Utah

Corbin Azucenas University of Cincinnati

Michaela BhoorasinghJohns Hopkins University

Dejah Blake Emory University

Jessica Diarra Stanford University School of

Medicine

Kiana Guillermo University of California, Irvine

David Jung University of Calgary

Alejandra Lorenzen The University of Texas Health Science Center at San Antonio Syed Mahamad McMaster University

Judith Sokei

Washington University in St. Louis

ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology, offers merit-based Abstract Achievement Awards (formerly Travel Awards) to select individuals to acknowledge the accomplishments of hematologists-in-training. This year's Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Solomon Abate Mina Abdelmalek Dor Abelman Anuja Abhyankar Muhammad Bilal Abid Arooj Abidi Nada Aboelella Yomna Abu-Farsakh Abdulaziz Abu-Haimed Tristan Achterberg James Ackley Rachael Adams Sadiksha Adhikari Nazia Afrin Althea Agdamag Jeff Justin Aguilar Syed Ahmad

Hazim Ababneh

Gaddiel Ahmed-Robles
Jaehyun Ahn
Rafi Aibani
Marisa Aitken
Rachael Ajiboye
Yu Akahoshi
Anna Akaogi
Abdul Rahman Al Armarshi

Abdul Rahman Al Arma Farah Al Haj Adekunle Alagbe Francesca Albano Moath Albliwi Gabriel Aleixo Zahra AlHaj Issa Hanan Alharthy Abdullah Alhumaid Hossam M. Ali Sana Ali Fatemeh Alikarami
Laila Alkhouli
Shree Allada
Sabine Allam
Cecily Allen
Jowan Al-Nusair
Ruth Alonso Alonso
Naifah Alshameri
Camila Amado Rottier
Justice Ameyi
Ava Amidei
Fnu Amisha
Fnu Amritpal Singh
Zhuo-Yu An

Annabelle Anandappa

Anil Ananthaneni Kwan-Keat Ang Kseniya Anishchenko Tharani Anpalagan Karen Arane Gabriel Araujo Luca Arcuri **Christopher Arends** Amy Argabright Donovan Argueta Benat Ariceta Akshaya Arjunan Ria Arora Kirti Arora Sankalp Arora Arun Arunachalam Yaiur Arva Shuhei Asada Omer Ashruf Amirsaman Ashtari

Frida Bugge Askeland

Victoria Assmann Eleftheria Atalla Abraham Attah Narsis Attar Alicia Au Inci Aydemir Persis Ayeh Selin Aytac Eyupoglu Corbin Azucenas Oluwaseun Babatunde Kavva Babu Kalaivani Babu Francesco Baccelli Cameron Bader Songa Bae Abhirup Bagchi Wanyu Bai Jie Bai

Hannah R Bailey
Anna Baj
Nora Balas
Shiva Balasubramanian
Mario Ballerini
Kavya Balusu
Gbolahan Bamgbose
Giuliano Banco
Thilinie Bandara
Saumya Bansal
Abhilash Barpanda
Wysterlanyo Kayo Barros
Elan Baskir
Bianca Bean

Francisco Beas

Nathan Becker

Sufyan Baig

Aymen Baig

Anne-Marie Becking Konan Beke Hayden Bell Santiago Beltran Medha Belwadi

Nana Adjoa Ben-Crentsil
Maddalena Benetton
Laura Bennett
Molly Benson
Michael Bern
Philipp Berning
Philipp Berning
Abigale Berry
Anna Besschetnova
Rahul Bhansali
Vanthana Bharathi
Prateek Bhardwaj
Mira Bhatia
Karanpreet Bhatia
Dipabarna Bhattacharya
Michaela Bhoorasingh

Michaela Bhoorasingh Fnu Bhuvan Honghao Bi Aram Bidikian Daniel Rilek Stephen Blackmore Cole Blanford Viktoria Blumenberg Audrey Bochi-Layec Julie Boiko Abiola Bolarinwa Valentina Boldrini James Boncan Adriana Bornacelly Carla Isabel Borre Mitchell Boshkos

Kruti Bosmia Yiiin Chen Weihao Chen Ikram Bouquern Alexis Boulter Chia-Jo Chen Leora Boussi Yu-Xiu Chen Sara Bowman Matthew Cheng Sriveda Boyalakuntla Zhanrui Cheng John Brabson Aaron Cheng Zachary Brady Qiao Cheng Eugene Brailovski **Zhangliang Cheng** Julie Braish Shuyuan Cheng Jiali Cheng Molly Brakhane Zachary Braunstein Mengna Chi Carlos Bravo-Perez Amon Chirwa **Bailey Brooks** Guranda Chitadze Tyler Bruno Felix Chiu Heiko Bruns Hae Lin Cho Camille Brzechffa Kibaek Choe Sikander Chohan Andrew Bueno Karan Chohan Melinda Burgess Eleonora Calabretta Fliana Choi

Virginia Camacho Daniel Sungchul Choi Sergi Camarillas Rozalyn Chok Leticia Campoverde George Cholack Mutian Cao Stephen Chong Fabliha Chowdhury Wenjing Cao Y. Emily Chu Maria Capilla-Guerra Abigail Chutnik Carly Carbery Valentina Cardenas Castro Bryan Ciccarelli Kader Cicek

Martina Cardillo Janick Caron-L'Ecuver Nicoletta Cieri Matthew Carter William Ciurylo Alberto Carturan Ivan Civettini Catelyn Cashion Megan Civitello Henry Castellani John Claiborne Brenda Castillo Anyka Clouden-James Melanie Castro Mollo **Hunter Cochran** Nina Castrogiovanni Ivan Cohen Luiz Catto Jessica Cohen Max Cohen Samanta Catueno Maryn Cavalier **Amy Cooper**

Luis Antonio Corchete Sanchez Sabina Cenciarelli **Newton Centuriao** David Cordas Dos Santos

Kadriye Nehir Cosgun

Kira Cozzolino

Carolyne Croizier

Katia Crisler

Beatriz Coutinho De Oliveira

Valeria Ceolin Emma Cordover Ela Cerovska Francesco Corrado Lyam Carlo Chacon Rangel Elysa Cortez

Zhirong Chai

Priyasmita Chakrabarti

Meghna Chakraborty Jenny Chan Irenaeus Chan

Antonia Chan Manuel Aleiandro Cruz Martinez

Li Yuan Chan Clifford Csizmar

Melinda Chance Alvaro Cuesta-Dominguez

Thea Chandler Anna Cvrtak **Howard Chang** Gal Dadi Tien-Ching Chang Weigian Dai Guanghui Chang Prisla Dalton Mathilde Chanut Katelyn Daniels Sangya Chatterjee Christina Darwish Jahnavi Chaudhari Nikita Dave Robert Chavez Jonathan Day

Felipe de Almeida Sartori Mahija Cheekati Asfand Yar Cheema Eduardo de Camargo Magalhaes

Yu-Hsiang Chen Anna de Daniel Aili Chen Jonathan de Wilde Maria Debernardi Mark deBettencourt Pierre-Edouard Debureaux Grace DeFranco Maria Victoria del Rosal Kady Dennis Nidhi Desai Krishna Desai Vismay Deshani Mattia Dessena Logan Deyo Vikramjit Dhillon

Sandhya Dhiman Lohitha Dhulipalla Rim Diab Bharath Dileep Kumar Deepika Dilip

Abbigail Di-Nardo Fan Ding Yiyang Ding Canan Dirican Wimeth Dissanayake

Christen Dillard

Brian Do

Venkatasai Rahul Dogiparthi Roman Doll Roberta Dollinger **Huang Dong**

Marina Dorigatti Borges

Van Anh Do-Thi Nicoy Downie

Tim Dreier Abigail Dropik Criselle Dsouza Ting Du Chenxiao Du Hanzhi Du, MD

Brian Dulmovits Wangqing Dun Ashley Dunton Amanda Duplan Michael Durante Arda Durmaz

Rudra Prasad Dutta Kayla Dyson Saumya Easaw Timothy Ebsworth

Eduardo Edelman Saul Orly Efros Michael Egan Yomna Eissa

Selma EL Jabbouri Jessica El-Asmar Yasmin Elgammal Omar Elghawy Salem Elias Habib El-Khoury Ramy Elsaid

Daniel Enriquez-Vera Julius Enssle Silvia Escribano Serrat Ali Eshaghpour

Flliot Fton Chiara Evans

Najmeh Eskandari

Edward Evans Mostafa Evsha Jean-Eudes Fahrner

Ayo Falade Priyansh Faldu **Cuiging Fan** Zhong Fan David Fandrei Teng Fang Fei Fang Pedrom Farid Safana Farooq Saubia Fathima Gianmarco Favrin Enrica Federti Frin Feliciano

> Yang Feng Shi Feng Yupiao Feng xiaomeng feng Justin Ferdinandus Andrew Ferrar

Rafaella Ferreira De Araujo Litvin

Grace Ferri Viktor Fetsch Caroline Fileni Nicole Fincato Giuseppe Fiorica Julianna Fisher

Thomas Carroll Fisher-Heath

Kwame Forbes Magdalene Ford Mark Forsberg Sofia Forsten Jodi Forward Kane Foster Valentina Fragliasso Alana Franceski Edgardo Franco Madeline Franke Marisa Frausto

Tyler Freeland Stephanie Frenz-Wiessner

Mirco Friedrich Benjamin Frost Ya-Yuan Fu Denggang Fu Yu-Hsuan Fu Takeshi Fuiino Thomas Fusillo Lilla Gaal

Maria Gabarros-Subira Nico Gagelmann Abbas Gain Nikolai Gajic Alexandra Galls Sara Gama

Dona Hasini Vathsalya Gammune

Helen Gandler Xiang Gao Shijinqiu Gao Xiaoyue Gao Fei Gao Camila Garcia

Joaquin Garcia-Solorio

Mikaela Garza Macy Gatti Vaishali Gautam Estefania Gauto Mariotti

Jana Gawron Shuaishuai Ge Thomas George Kriti Gera

Ted Getz **Brandon Gheller** Jason Gilbert Mia Giles Victoria Gill Michelle Gillespie Aaron Gillmor Lewis Go Yugal Goel Paran Goel

Utkarsh Goel Aaron Goff Nathaniel Goldfarb Kennedy Goldsborough Carmen Gonzalez Alexia E. Gonzalez-Lozano

Britten Gordon Anton Gorodov Vishaka Gorur Alexander Gorzewski Sascha Gottert

Narendra Varma Gottumukkala

Hannah Goulart Anmol Goyal Emma Gray Nora Grieb Luca Guarnera Veronica Guerra Nehemias Guevara Alberto Guijosa Kiana Guillermo

Allana Guimaraes de Carvalho

Esra Gulderen

Samhitha Gundakaram

Qiuyu Guo Qianqian Guo Linda Guo

Saurabh Kumar Gupta Siddharth Gupta Anna Gurevich Shapiro Johan Gustafsson Joshua Gustine Sarah Gutch Marc Gutierrez Jeremy Haaf

Katharina Habenicht

Aino Hakkinen Trent Hall Muataz Ali Hamad Kory Hamane Lubna Hamdan Laith Hamed M Bakri Hammami Estelle Hamon Jing-Li Han Xu Han

Yiwen Han

Xinli Han Seungbin Han Shrevas Hanmantgad

John Hanna Kaito Harada Kristen Harkins Alessandra Hartke Husham Hashim Taha Hassan Dunia Hatabah Catherine Hawley Zachary Hawula Taha Bartu Hayal Naoki Hayase Xu-Dong He Xin He Sean Healton

Tamer Hellou Mayra Henry Shelley Herbrich Marina Herrero Lopez Elizabeth Herrity Oscar Hinojosa Shigeki Hirabayashi Tatsuro Hirao **Amjad Hmaid Bridget Hoag** Yuki Hodo Fieke Hoff Elisa Hofmeister Troy Holden Midori Hosoda

Jenyvette Hsia

Mengmeng Huang

Virginia Hsiao

Lauren Heine

Xin Huang Jingtao Huang Tina Huang **Amy Huang** Qiu-Sha Huang Jennifer Huang Shamshul Huda Bethan Hudson-Lund Abigail Huetteman Putzer Hung Cameron Hunter Zachary Hunzeker

Yingying Huo Henri C. Hupe Syed Hussain **Zachary Hutchins** Katie Huynh

Genevieve Huynh-Trudeau

Omar Ibrahim Onaiite Ifie Jana Ihlow Junji Ikeda Jack Illingworth Gabriele Inchingolo Ami Inokuchi Dr Zafar Iqbal Umar Iqbal Eric Irons

Jonathan Isenberg

Kai Ishimaru Varun lyengar Poornima Iver Yazan Jabban Ariana Jacobs Othmane Jadi

Gaspard Jadot

Manu Jamwal

Guneet Janda Johann-Christoph Jann Alyssa Jarabek

Saad Javaid Nathalie Javidi-Sharifi

Lisa Jeffers Hanzala Jehangir Rui Ji

Baosen Jia Xin Jiang Zhenzhen Jiang Binggian Jiang Yuanyuan Jin Mingyu Jin Jia xiang Jin Mara John Michael Jones Cailin Jordan

Subhashini Joshi Bhagwati Joshi Silvia Juarez Rojas David Jung Ronit Juthani Matthew Kaczynski Sofie-Katrin Kadel Allison Kagerer Satoshi Kaito Amra Kajdic

Kerttu Kalander Brandon Kale Guneet Kaleka Kazuharu Kamachi Ruhi Kanwar

Nilesh Kapoor Negin Karisani Sadik Karma Saumya Karne Erin Kaser

Khanmi Kasomva

Alyssa Kassouf Christina Kaszuba Abhishek Kataria Shota Kato Deeksha Katoch Leon D. Kaulen Sarah Kayser Marvam Kazerani Sarada Ketharnathan Roman Khadka Candrika Khairani Niranjan Khaire Noor Khalid Mohamed Khalil

Muhammad Ali Khan

Ayaz Khan Reham Khedr

Phimpraphan Khumngeon

Quynh Long Khuong

Junichiro Kida Adam Kidwell Won Sung Kim Lana Kim Hve Na Kim Sungjae Kim Kyung Lock Kim Yi June Kim Won Jun Kim Dong Hyun Kim James Kim

Nelly Kiriza Kawita Kitichotkul Ahmad Kiwan Anezka Klubalova Tanja Knopp Amica Ko Eun Ko Sun-Hye Ko Miku Kobayashi Asami Kodera Ryo Koizumi Kairi Kojo Vladimir Kolyadko

Zena Komrokji Kaori Kondo Isabella Kong Tiago Koppe Max Koppel Rawan Korman Katharina Korn Elena Kostenko Manasa Kotamraju Lili Kotmayer **Dimitrios Kotsos** Khouloud Kouidri Ira Kraft

Nathan Krah Anne Marijn Kramer Lea Kramer

Aishwarya Krishnan Josefine Kruger Alexander Krule Tomoyo Kubo Thomas Kuczmarski

Julia Kuehn Paresh Kulkarni Narender Kumar Rathan Kumar Kohei Kume Mariia Kumskova Rupayan Kundu Po-Lun Kung Kara Kushwaha Jeong-Eun Kwak Kunye Kwak Alex Kwan Husayn Ladha Danyal Ladha Kartik Lakhotiya

Vi Lam Stephen Sze Yuen Lam

Erica Lamkin Gianfranco Lapietra

Audrey Lasry Amanda Lussier Heidi Latiolais Anna Lux Madeline Lauener Peter Lvon Henrik Marius Laukli Xiao Lyu Anouchka Laurent Tianfang Ma Tessa Lavorgna Haotian Ma Cuona Le Sirui Ma Cristiano Machado De Freitas Catherine Le

Noemie Leblay Ryan Mack Stella LeChasseur Himil Mahadevia Stella Lee Syed Mahamad Nawar Maher Hannah Mahjoub

James Lee Holly Lee Dasom (Caroline) Lee Hanheng Mai Yuan Yee Lee Alisa Maier In Kyu Lee Sarah Makhani Panagiotis Malandrakis TAEK GYU LEE

Jimmy Lee Camille Malbrun Seung-Hwan Lee Ehsan Malek Seonghan Lee Vasu Malhotra Woo Joo Lee Selene Mallia Jinho Lee Michael Malloy Jamila Mammadova Nicholas Lee Kara Lehner Manuela Mancini Jean Lemoine Aashray Mandala Joan Mane Pujol llia Leontari Etienne Leveille Qiangian Mao Sebastian Leyes Porello Xinjian Mao Ariel Leyte-Vidal Leticia Marani

Anlun Li Elena Maroto Martin Haikuo Li Amira Marouf Yun Li Manuel Maroun Paola Marra Mengjie Li William D. Marrero Qun Li Alexander Li Irune Marti Larrucea **Emily Liang** Anna Martin Carrizosa Ruigi Liao Stephen Martindale Keli Lima Leandro Martinez

Francisco Marchi

Xijuan Lin Esperanza Martin-Sanchez Gefei Lin Atsushi Marumo Jennifer Marvin-Peek Katherine Lind

Frederico Lisboa Nogueira Bibi Maryam

Zhixue Li

Shirley Liu Jose Miguel Mateos Perez Yunqing Liu Christina Mayerhofer Meng Liu Ross McCauley Shan Liu Benjamin McCormick Fuguo Liu Andrew McIntyre Jianlin Liu Maggie McNeill Yuntong Liu Giovanni Medico Lianxuan Liu Elena Medina Lisa Liu Ansh Mehta Alice Lo Romy Meier Arielle Locke Ana Mellado Jason Lofters Victor Mendiola (Justin) Ching Ting Loke Ana Mendoza Martinez Giorgia Longo Eva Daniela Mendoza Ortiz Paolo Lopedote Svatava Merkle Jessica Lopez Espinosa Rachel Mersfelder

Alejandra Lorenzen David E Mery Haiyang LU Luana Messa Michel Lu Syed Mian Alexandra Lubin Agrima Mian Qingyu Luo Julius Michel Ya Luo Katarina Micin Kevin Miller Toru Miyajima Kyle Miyazaki Shirley Mo Dimpy Modi Sara Mohamed Alfonso Molina Sally Momoh Paritosh Mondal Rachelle Monteau

Anamaria Morales-Alvarez

Analy Mora Josquin Moraly Michelle Morcos Yael Morgenstern Alexa Moschella **Dominique Mosley** Masanori Motomura Tarek Mouhieddine Perrine Moyer Ditipriya Mukherjee Christopher Mullen Ryanne Mulligan Carea Mullin **Umair Munawar** Malak Munir Joshua Muniz Tinatin Muradashvili Aarya Murali Josiah Murray Ali Mushtag Rohini Muthukumar Jurik Mutter Mitin Nachu Keiki Nagaharu

Rifat Najnin Ritsuko Nakai Akihiro Nakaiima Takahisa Nakamura Keiichi Nakata Riya Nandi

Sushmitha Nanja Reddy Ottavio Napolitano Kristina Nasr Nour Nassour Aneesha Nath Ivan Negara Ricky Nelles Teigen Nelson Melissa F. Neumann Karun Neupane Lay She Ng Anh Ngo

Annie Hoai Nguyen Matthew Nauven Maria Alexandra Nica Melissa Nicholas Fanhao Nie

Jannaldo Nieves-Salva Mira Nigudkar Jessica Nino De Rivera Noriko Nishimura Cara Noel Sara Nofal Julia Han Noll

Isla Nosratzadeh Hinako Notoh Sandra Novoa Jauregui Ioannis Ntanasis-Stathopoulos Athina Ntoumaziou Michelle Nwachukwu Kimberly O'Brien Mario Ochoa Rodriguez

Troy Noordenbos

Olisaemeka Ogbue Timothy Oh Yuki Okamura Koji Okazaki Izel Okcu Olayinka Okeleji Blessing I. Okoye Temiloluwa Okusolubo Aina Oliver-Caldes Daniel Olivieri T. Anders Olsen

Artem Oganesyan

Chinonso Onuoha Ysaith Orellana Ascencio Mark Orland

Noa Omer Vilk

Giorgio Orofino Daniela Ortiz Chavez Weronika Ortmann Shinichiro Oshima Aleksandra Oszer Edward Owusu Kwarteng

Oladayo Oyebanji Oluwafemifola Oyedeji Camila Pabon **Daniel Packard** Julia Paczkowska

Thalia Padilla Kelley Minwoo Pak Andrew Palmer Yi Pan

Lili Pan Victoria Panagiota Sipra Panda Garima Pandey Suravi Pandey Arjun Pandey Rajat Pant Emma Pappano

Phani Krishna Parcha Makayla Pardo Jenny Paredes Deevyashali Parekh Ekaterina Parfenova Kyung won Park Inae Park Hvun Park Nicolas Parnell Tyler Parsons Luca Paruzzo Verena Passerini Abhinav Pasupuleti Chandni Patel

Khushbu Patel

Mayank Patel

Heta Patel

Ronak Patel
Jeet Patel
Harshank Patel
Kishan Patel
Gokul Patil
Manuel Patino
Carlos Patino
Ana Patino

Bonell Patino-Escobar Shaun Patterson Lincy Paul Allan Pavy

Alian Pavy
Andree-Anne Pelland
Claudia Pellin Jou
Benedikt Pelzer
Yebo Peng
Juan Peng
Livius Penter
Pedro Perez

Pedro Perez
Ana Perez Gonzalez
Mark Perfetto
Luiza Perruso
Alicia Perzolli
Sarah Peterson
Chana Peysin
Kirsten Pfeffer
Jeremiah Pfitzer

Tuan Phan Witsanu Phetsai Benjamin Philipson Simone Piane Sara Piccinelli Martin Pietzsch Kelly Pimenta

Alfredo Pinedo Rodriguez

Lucio Pinheiro
Elisha Pinker
Ted Piorczynski
Benjamin Podvin
Mia Poleksic
Elizabeth Pollard
Petri Polonen
Lauren Pomerantz
Mansour Poorebrahim
Patrizia Porazzi

Antonio Porlan

Olivier Pouliot

Irina Portier

Aishwarya Pradeep Debolina Pramanik Parash Prasad Preeti Preeti Abena Prempeh Raja Prince-Eladnani Shuangshuang Pu Nicholas Pua Noemi Puccio Manas Pustake

Mark Pusung

Zhu Qianzhe

Zhuang Qilin

Jiaqian Qi

Hu Qian

Rong Qiu Sofia Isabel Quezada Ramirez Marco Gabriele Raddi Simone Ragaini

Vasantharaja Raguraman Nabil Rahman

Sudhanshi Raina Reeja Raj

Vinothkumar Rajan Srinishant Rajarajan Anisha Rajavel

Akhil Rajendra Nirupama Ramadas Izola Ramalho Hari Raman Masooma Rana Shivani Ranga Nikhil Ranjan Giulia Rappa

Georgios Rassidakis Johanna Rausch Om Raval Aditya Ravindra Arindam Ray Upasana Ray Suravi Raychaudhuri Farnaz Razmkhah

Christian Reardon-Lochbaum

Mallikarjun Reddy Daniel Reef Mouna Reghis Julia Grace Reinke

Julia Grace Reinke Kehan Ren Lili Ren Simon Renders Rachel Renji Paloma Resende Valentina Restrepo Kevin Reyes

Laura Reyes-Uribe

Paula Ribeiro
Fausto Rios-Olais
Carola Riva
Joshua Rivenbark
Logan Rivera
Andrea Rivero
Samantha Rizzo
Macarena Roa
Kameron Rodrigues
Martin Rodriguez

Frida Rodriguez Contreras Alfonso Rodriguez Espada Alba Rodriguez-Meira Sergio Rodriguez-Rodriguez Juan Jose Rodriguez-Sevilla

Benjamin Rolles
Zhan Rong
Lukas Ronner
Sebastiano Rontauroli
Daniel Rosas
Matthew Ross
Yuhua Ru
Marta Rubin
Saskia Rudat
Leo Ruhnke
Jorge Ruiz Lopez

Bradley Rutherford

Anna Sabouret Yoni Sacknovitz Yasutaka Sadaga Rafeh Safdar Manpreet Saini Kenki Saito Kazuki Sakurai McKailey Salard Suruchi Salgar

Maria Luiza Salustiano-Bandeira Jose Manuel Sanchez Albarran Maria Sanchez-Tabernero Isabel Sandner

Nurefsan Sariipek
Shreyashree Sarkar
Caitlin Sarubbi
Archana Sasi
Hatice Satilmis
Lukas Scheller
Walker Schmidt
Martin Schonlein
Christopher Schorr
Jan Christian Schroeder
Alexandra Schurer
Anna Schwartz
Alix Schwarz

Alexander Sanjurjo

Abdulsabur Sanni

Nora Rebecca Schwingen Karnsasin Seanoon Tara Sebastian Stephanie Sendker Marion Serra Marina Serra Carrera Sarah Sertich

Sarah Sertich Renata Sesti-Costa Tahereh Setayesh Jansi Sethuraj Kimberly Seymour Nirvana Shaaban Sanjana Shah Darshi Shah Divyash Shah Sanket Shah

Sanket Shah Aashka Shah Dhyani Shah Anand Shah Nirja Shah Vishrut Shah Rahul Shah Orthi Shahzad Mehak Shaikh Hila Shaim

Orthi Shahzad
Mehak Shaikh
Hila Shaim
Mohamed Sharaf
Preeti Sharma
Shivangi Sharma
Devyani Sharma
Toral Shastri
Catherine Sheehy
lianghua shen
Kexin Shen
Zhilling Shi
Junming Shi
Shuyu Shi
Ce Shi

Henyun Shi
Li-Yang Shiau
Sho Shibata
Aya Shibuya
Sahana Shiggaon
Young Jun Shim
Kevin Shim
Yuki Shimizu
Koki Shimizu
Ruka Shimura
Kamma Shiraishi
Abdalla Shoaib
Rajib Shome
Asmita Shukla

Quinlan Sievers
Thomas Silfverberg
Martha Sim
Miranda Siminski
Elisa Simoncini
Aabhran Singh
Varsha Singh
Diljot Singh
Gunin Singhal
Sachi Singhal
Adit Singhal
Maria Sirenko
Olivia Sirpilla

Evgenii Shumilov

Ronald Siebenaler

Ayyanar Sivanantham
Barath Sivasubramanian
Sladjana Slavkovic
Gordon Smilnak
Jackson Smith
Natalie Smith
Arianna Smith
Sofia Smith
Cameron Smith
Abigail Sneider
Marisa Sobczak
Haris Sohail
Judith Sokei

Zureyat Sola-Odeseye

Marissa Solow Juanjuan Song Yuanbin Song Yang Song Junzhe Song Selma Sorri Felipe Soto Manraj Sra

Manraj Sra
Prakhyath Srikaram
Hrishikesh Srinagesh
Shreya Srivastava
Emma St. Martin
Gaby Stegemann
Laurenz Steiner
Max Steinhardt
Sophie Steinhauser
Federico Stella
Patrick Stelmach
Victoria Stepanyants
Carli Stewart
Colin Stewart
Jonathan St-Onge

Charlotte Story Fatima Tuz Zahra Alexander Streuer Eno-obong Udoh Shengqin Su Paulo Ugarte-Pelaez Varun Sudunagunta Chidiebube Ugwu Takeshi Sugio Fabian Ullrich **ERSAN UNLU** Jaehvun Suh Charles Sukin Serhan Unlu Michael Sullivan Angimar Uriepero Ryan Sun Estibaliz Urizar Compains Bin Sun Salman Sadullah Usmani Minghao Sun Vivian Uzoechi Xiyue Sun Bryan Valcarcel **Arvind Suresh** Rafael Valdez Tabea Sutter Hilde Van Der Galien Rudra Narayan Swain Merel van der Meulen Arshi Syal Alanna Van Huizen

Rikako Tabata Nikita Vantsev Hector Alejandro Vaquera Alfaro Cristian Taborda Shodai Takahashi Akhil Deepak Vatvani Zahrah Talawala Vanessa Velazquez Maria Velegraki Annalisa Tameni Carolina Velez-Mejia Jordan Yong Ming Tan Mathilde Veneziano Broccia Melody Tan Jia Yi Tan Ondrej Venglar **Ankit Tanwar** Rathnam Venkat

Stefan Tarnawsky Ajit Venkatakrishnan Yusuke Tashiro Rasika Venkataraman Jason Taslim Priyanka Venkatesh Michael Tassia Christina Verbruggen Allison O. Taylor Nikki Verma Daniel Teitelbaum Francesco Versino Guangshuai Teng Xavier Vesco Sabrina Testa Carmen Vicente Jesse Tettero Junia Vieira Mohamad Ali Tfaily Ilaria Vigliotta Rahul Thakur

Jaya Lakshmi Thangaraj Matthew Villaume
Anusha Thangaraja Madhav Vissa
Serena Tharakan Simon Voelkl
Hishan Tharmaseelan Nikhil Vojjala
Apoorva Thatavarty Dhvani Vora
Foteini Theodorakakou Jan Vorwerk
Elana Thieme Nikolina Vrdoljak
Asha Thomas Laura Walsh
Ronay Thomas

Asha Thomas Laura Walsh Ronay Thomas Bo Wan Zanshe Thompson Xueer Wang Danielle Thor **Daniel Wang** Natalia Tijaro Ovalle Julia Wang Remi Tilmont Pan Wang Dongyao Wang Sun Ting Joyce Tiong Shijing Wang Rosa Toenges Kaili Wang Masanori Toho Yu-Hung Wang LU WANG Jaromir Tomasik Oliver Tomkins Yutong Wang Esteban Toro Velez Mena Wana Astrid Hundeboell Torpe Helen Wang **Leonel Torres** Alice Wang

Leonel Torres Alice Wang
Sara Torres-Esquius Cong Wang
Georgios Tousinas Kexin Wang
Nicolas Trad Xingchen Wang
Valerie Tran Shuyang Wang
Sydney Treichel Qi Wang
Mariantonietta Tripodo Shuwen Wang
Steven Tur Ting Wang

Zahra Junyu Wang
g Udoh Chenyun Wang
rte-Pelaez Guo-Ling Wang
e Ugwu Rui Wang
ich Yannan Wang
ILU Chalothorn Wannaphut
lu Grace Ward

aliz Urizar Compains John Weber
an Sadullah Usmani Samuel Weeks
n Uzoechi Graham Wehmeyer
n Valcarcel Wen Wei
el Valdez Jia Wei
Van Der Galien Ruowen Wei

Van Der Galien Ruowen Wei
I van der Meulen Julia Weingart
Alisha Weiss-Haug
Vantsev Rui Wen
Or Alejandro Vaquera Alfaro Qing Wen

Deepak Vatvani
sa Velazquez
Velegraki
na Velez-Mejia
de Veneziano Broccia
rj Venglar
am Venkat
renkatakrishnan
a Venkataraman
ka Venkatesh
ina Verbruggen
Verma
Daniela Wenge
Bailey West
Lara Wiechers
Patrick Willard
Hannah Willis
Lindsay Wilson
David Wilson
Hannah Lea Wirth
Joshua Wischmeyer
Evelyn Wooley
Jacob Wright

Francesco Versino Corbin Wright
Xavier Vesco Jieya Wu
Carmen Vicente Lixin Wu
Junia Vieira Xia Wu
Ilaria Vigliotta Xiancheng Wu
Alejandro Villar-Prados Rebecca Wurm

Rebecca Wurm-Kuczera Chiara Wychera

Maxima Warmuzova

loanna Xagoraris
Zhizhou Xia
Bingtao Xiang
Meng-Yu Xiao
Wei Xiao
Annie Xiao
Alexander Xiao
Jiajun Xie
Xiaodong Xie
Jia Qi Xiong
Vasiliki Xirou
Chengyang Xu
Jason Xu
Jane J Xu
Ran Xu

Ran Xu
Xiyue Xu
Jian Xu
Yaqun Xu
Zixuan Xu
Jingyu Xu
Yuan Xu
Chang Xu
Miao Xu
Saveg Yadav
Saurabh Yadav
Jotaro Yamamoto
Murat Yaman
Yusuke Yamashita

Eliezer Yampel Wengiang Yan Can Yang Meng Yang Zhe Yang Hee Doo Yang Ling Yang Xingcheng Yang Zhuming Yang Yi-Han Yang Guancui Yang **Tingting Yang** Li-Ping Yang Yuan Yao Samuel Yates Jinhui Ye Veronica Yeung Zhenyi Yi

Tiankai Yin
Taishi Yonezawa
Jihye Yoon
Satoshi Yoshimura
Hongying You
Madeline Young
Shunjie Yu
Heye Yu
Dandan Yu
Yi Yu
Weiping Yuan
Qingchen Yuan
Ridzky Yuda
Lu Yue

Saeed ZakaKhosravi Ghassan Zammar Matteo Zampini

Almudena Zaratiegui Vergara

Maiah Zarrabi Agisilaos Zerdelis Linquan Zhan Lindsey Zhang Liqian Zhang Jiaxin Zhang Qian Zhang Honghai Zhang Yan Zhang Vida Zhang Jingliao Zhang Renxia Zhang Yanan Zhang Xuan Zhang Wanying Zhang Raymond Zhang Yiheng Zhang Yirong Zhang Qiqi Zhanq Xiaoshuai Zhana Runging Zhang Xuan Zhang Ruoxuan Zhang Xiaoyi Zhang Ao-Ran Zhang Miaoyan Zhang Xiaohui Zhang

Ellen Zhang

Yongping Zhang

Chen Zhang
Zhifan Zhao
Yajing Zhao
Zhizhuang Zhao
Xuefei Zhao
Tianming Zhao
Peng Zhao
Lin-Pierre Zhao
Yijing Zhao
Eric J. Zhao

Simon Zhen Leon Zheng Haiqiong Zheng Guangcai Zhong Jian-Ying Zhou Zhipeng Zhou Li Zhou Anqi Zhou Fuling Zhou Linghui Zhou Qianqian Zhou Xiang Zhou Xiao Zhou Kevin Zhu Panpan Zhu Tony Zhuang Nanfang Zhuo Veronika Zimolova Rachelle Zipper Eli Zolotov Ken Zou Hadil Zureigat

AMERICAN SOCIETY OF HEMATOLOGY 67TH ASH® ANNUAL MEETING AND EXPOSITION

MEETING DATES: DECEMBER 6-9, 2025 GENERAL INFORMATION

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

PURPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to foster high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the Society's annual meeting, is to facilitate the global exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing

and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

At this year's annual meeting, ASH will continue to offer an inclusive environment for all participants, including a focus on making the in-person meeting in Orlando and the virtual platform as accessible as possible for attendees with disabilities. ASH will offer mobility, vision, hearing, and other resources as needed. For more information or for questions regarding these services, please contact accessibility@hematology.org.

TWO WAYS TO ATTEND THE 67TH ASH ANNUAL MEETING

ASH is pleased to continue to offer the 67th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in Orlando or participate using ASH's virtual platform. All participants, regardless of location, will have access to the virtual platform built for learning, collaboration,

and networking. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions and participate in real time.

REGISTRATION

ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual platform through January 1, 2026.

Registration is available now at hematology.org/meetings/annual-meeting/registration-information. Those who have previously registered may upgrade their subscription to extend their access to the meeting's virtual platform at any time by contacting the Registration Center.

IN-PERSON MEETING

When you register for the in-person meeting, you will receive complimentary access to the virtual platform through January 1, 2026. In-person registrants have the option to extend their access to the virtual platform for an additional fee.

VIRTUAL ACCESS REGISTRATION PACKAGE OPTIONS

The virtual meeting packages were designed to give attendees maximum flexibility. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions

and participate in real time. The platform will also include ondemand recordings of all sessions (unless otherwise noted), as well as access to networking opportunities, exhibits, and more.

• Real-Time Experience: Access through January 1, 2026

Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC credits can be claimed through April 10, 2026 by viewing the qualifying sessions on the virtual platform.

• Extended Flexibility: Access through February 1, 2026

Provides ongoing access to continue watching on-demand sessions after the meeting ends. CME/MOC credits can be claimed through April 10, 2026 by viewing qualifying sessions on the virtual platform.

• Best Value: Access through March 1, 2026

Provides maximum flexibility to continue accessing ondemand sessions at the best price per day of access. CME/ MOC credits can be claimed through April 10, 2026 by viewing qualifying sessions on the virtual platform.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 23)

Registration Category	In-Person or Real-Time Experience (Virtual access through January 1, 2026)	In-Person or Virtual Extended Flexibility: (Virtual access through February 1, 2026)	In-Person or Virtual Best Value: (Virtual access through March 1, 2026)
Member (Active and International)	\$950	\$1,050	\$1,150
Non-Member	\$1,700	\$1,800	\$1,900
Associate or International Member	\$175	\$200	\$225
Medical Student, Graduate Student, or Resident Member	\$175	\$200	\$225
Non-Member in Training*	\$275	\$300	\$325
Allied Health Professional	\$850	\$950	\$1,050
Spouse/Guest (in person only)	\$175	NA	NA
Honorary/Emeritus (before 1/1/15)	\$0	\$50	\$100
Honorary/Emeritus (after 1/1/15)	\$175	\$200	\$225
Non-Profit Patient Advocacy Organization Representative (Application for approval is required in advance)	\$0	\$0	\$0

^{*} Advance registration rates for Non-Members in Training are available through December 1, 2025.

BADGE COLORS

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

Member
Non-Member
Associate MemberBlue
International Associate MemberBlue
Non-Member in TrainingBlue
Graduate/Medical Student Member Blue
Resident MemberBlue
Honorary/Emeritus MemberWhite
Allied Health Professional Purple
Exhibitor Booth PersonnelBlack
Spouses/GuestYellow
MediaOrange

BADGES

Badges will be mailed in advance of the meeting to North American attendees who have registered by October 22. International attendees may pick up their badge at one of several registration locations in Orlando, including at the Orlando International Airport. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

OVERVIEW OF THE MEETING SCHEDULE PREVIEW DAYS: DECEMBER 3-4, 2025

Beginning December 3, 2025, the ASH annual meeting virtual platform will be available to all registered participants at annualmeeting.hematology.org.

All registered attendees are encouraged to log in early to get acquainted with the site's navigation. To log into the platform, you will need your ASH username and password used to register for the meeting.

WHO TO CONTACT

If you are having difficulty accessing the meeting's virtual platform, please contact the ASH Customer Service department by emailing customerservice@hematology.org or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for International callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Fastern time.

Over the dates of the meeting, extended customer service hours will be offered; please visit www.hematology.org/contact-us for specific hours.

If you have successfully accessed the meeting's virtual platform but are having difficulty with one of its features, please use the online support form feature within the platform for technical assistance.

FRIDAY-ONLY PROGRAMMING: December 5, 2025

There are pre-meeting activities scheduled on Friday, December 5, 2025.

• Friday Satellite Symposia

• ASH-a-Palooza

Scientific Workshops

Refer to schedule at-a-glance or the mobile app for specific session times.

OFFICIAL MEETING DAYS: December 6-9, 2025

The 67th ASH Annual Meeting and Exposition will take place December 6–9, 2025 in Orlando, Florida, and on the meeting's virtual platform. All times listed reflect the Eastern time zone.

Saturday, December 6Refer to schedule-at-a-glance or the mobile app for specific session times.Sunday, December 7Refer to schedule-at-a-glance or the mobile app for specific session times.Monday, December 8Refer to schedule-at-a-glance or the mobile app for specific session times.

Tuesday, December 9 All sessions will occur in the Marquee Session Room beginning at 7:30 a.m. The meeting

concludes at 1:00 p.m.

All sessions will be presented at the in-person meeting in Orlando and, unless otherwise noted, all events will stream simultaneously on the virtual platform. Session recordings will be available on demand on the virtual platform for the duration of your registration package. Scientific Workshops will be available until January 1, 2026.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

CATCH UP DAYS: December 10-12, 2025

After the official dates of the annual meeting, ASH Poster Walks will be held on Wednesday, December 10, on the meeting's virtual platform.

BINGE WATCHING—CATCH UP ON CONTENT

Participants will also be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting through the end of their virtual meeting registration package.

NETWORKING

ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. In Orlando, small gathering and seating areas will be available indoors and outdoors to informally meet with colleagues.

ASH's virtual platform makes connecting with colleagues in Orlando and all around the world easy. On the meeting's virtual platform click on Networking to connect with your peers.

ASH SOCIAL MEDIA WALLS

Take a break from the science and visit the ASH Social Media Walls located on the meeting's virtual platform and throughout the convention center to view and contribute to a real-time scientific conversation and engage with colleagues on a variety of topics.

This year, the Walls will feature a dedicated #Fight4Hematology feed to highlight posts related to ASH's Fight4Hematology campaign.

SPEAKER INFORMATION

SPEAKER READY ROOM

The Speaker Ready Room will be located in ASH Central in West Hall C at the Orange County Convention Center. All times are in Fastern time.

Speaker Ready Room Hours

Thursday, December 4 3:00 p.m. – 6:00 p.m.
Friday, December 5 7:00 a.m. – 6:00 p.m.
Saturday, December 6 7:00 a.m. – 6:00 p.m.
Sunday, December 7 7:00 a.m. – 6:00 p.m.
Monday, December 8 7:00 a.m. – 6:00 p.m.
Tuesday, December 9 7:00 a.m. – 11:00 a.m.

All speakers should bring a copy of their presentation to the Speaker Ready Room on a CD-R, DVD-R, or USB flash drive (memory stick, jump drive, etc.). A professional audio-visual (AV) technician will be available to consult with you on any of the guidelines and to make certain your slides are properly identified

for your specific session. Please turn in your presentation to the Speaker Ready Room according to the following guidelines:

24 hours before your presentation if you would like the AV technician to assist you in formatting your presentation to ensure clear and readable images.

24 hours before your presentation, if your PowerPoint presentation was prepared on an Apple computer.

At least 6 hours before your presentation if your presentation contains movies or other videos.

At least 4 hours before your presentation if your presentation is final and requires no modifications.

CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), all meeting session chairs, speakers, and moderators are required to disclose in writing any financial relationships they may have prior to the meeting. All poster presenters are required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. If bias, actual or perceived, occurs during the presentations,

session attendees are encouraged to address such bias during the question-and-answer periods following the presentations.

All ASH annual meeting presenters (including chairs, speakers, and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity's Board of Directors or advisory committee, and any other financial relationship.

Any questions about this policy or concerns regarding disclosures should be directed to CME@hematology.org.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

CONTINUING MEDICAL EDUCATION INFORMATION

EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be able to:

- Employ the knowledge gained regarding the diagnosis and treatment of classical and malignant hematologic disorders to improve patient care;
- Discuss state-of-the-art research in hematology; and
- Analyze the potential contribution of novel, not-yetapproved modalities of therapy to current evidence-based management of hematologic disorders.

ACCREDITATION

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of **90** *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with their participation in the live activity.

CME CERTIFICATE ELIGIBILITY

ASH is accredited to provide **AMA PRA Category 1 Credits™** to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for *AMA PRA Category 1 Credits*™.

HOW TO OBTAIN A CME CERTIFICATE

A processing fee of \$50 will be charged for CME certificates. Attendees must complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website (www.hematology.org) by clicking the CME link on the homepage. The online process for claiming CME credits and printing a CME certificate for the 67th ASH Annual Meeting must be completed no later than April 10, 2026.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 90 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. In addition to completing the evaluation survey, attendees must submit a reflective statement on how they intend to change their practice based on the knowledge gained from participation in the meeting. Attendees must also provide their ABIM number and date of birth. Upon review and approval of the reflective statement, points will be submitted to the ACCME by ASH and will appear in the ABIM Physician Portal within 48 hours. Points will only be submitted if all the steps are completed. To receive ABIM MOC points for the 67th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 10, 2026. By requesting MOC points through ASH's CME Portal, learners agree to allow ASH to share completion/participation information with ABIM via ACCME's program and reporting system.

CERTIFICATE OF PARTICIPATION

Non-physicians and other health-care professionals attending the meeting may print a Certificate of Participation **after** completing the Annual Meeting Evaluation Surveys through the ASH website (www.hematology.org) beginning Saturday, December 6, 2025. The online process of **filling out the annual meeting survey and printing the certificate must be completed no later than April 10, 2026. There is no charge to meeting registrants for this service.**

EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT

ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website (http://ebah.org). For information about claiming EBAH CME for the 67th ASH Annual Meeting email cme@hematology.org.

QUALIFYING ACCREDITED SESSIONS

Attendees can claim CME for viewing qualifying sessions as they are broadcast in-person and on the virtual platform. Credit can also be claimed for viewing qualifying sessions on the platform after they have concluded.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

ATTENDEE SERVICES

ASH CENTRAL

ASH Central, a place where hematologists can gather to collaborate, is located in West Hall C at the Orange County Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or donate to the ASH Foundation. The following resources are also offered at ASH Central: the ASH Studio, fASHion boutique for the hematologist with style, smASH Pickleball, ASH Store, Collaboration Rooms, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio. Additional seating and charging areas are also offered in ASH Central.

ASH Studio

The ASH Studio hosts brief, targeted talks that focus on removing barriers to high-quality care, principles of medical education, and cutting-edge teaching techniques. These sessions will include short presentations by an in-person speaker followed by an interactive discussion. These microsessions will also be available on the virtual platform.

ASH Store

ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at (www.hematology.org/Store).

ASH Wellness Studio

In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy work life balance through wellness.

Collaboration Rooms

Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to reserve for up to 45 minutes. Each reservation starts at the top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple back-to-back reservations cannot be accommodated. Outside food and beverage and/ or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website (www.hematology. org) via the mobile application or the Collaboration Room Help Desk in Hall C to reserve a Collaboration Room.

Collaboration Room Hours

Friday, December 5 7:00 a.m. – 5:45 p.m. Saturday, December 6 . . . 7:00 a.m. - 5:45 p.m. Sunday, December 7.....7:00 a.m. - 5:45 p.m. Monday, December 8 7:00 a.m. – 5:45 p.m. Tuesday, December 9....7:00 a.m. – 12:45 p.m.

fASHion

For the hematologist with style! Visit the fASHion boutique for ASH-branded apparel, ranging from outerwear, athletic

wear, golf polos, hematology specialty socks, bow ties, neck ties, scarves, and kids' apparel, too. Items will be available for purchase in an array of sizes while supplies last.

Headshot Alley

Need a new professional headshot? Get one for free at Headshot Alley in ASH Central. Your headshot will be sent to you via email for immediate downloading.

Photo Zone

Capture the excitement of the annual meeting with your friends and colleagues by taking a photo in the ASH photo zone, located in ASH Central. Various props and backdrops will be available and will change daily.

Trainee Lounge

Attendees with a blue badge are invited to visit the Trainee Lounge in ASH Central, a relaxing place for trainees to meet with colleagues and recharge with complimentary refreshments.

ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

Meeting wi-fi



To increase the protection and security of wi-fi for users, ASH will require users to enter a password to gain access to the exclusive wi-fi network.

The wi-fi network name (SSID) is ASHMEETING and the password is hematology. The password is all lower-case letters. After entering this password once, the wi-fi network should recognize your device without having to enter the password again—however, if you switch devices, you will need to enter the password again.

Mobile App

ASH's mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2025 annual meeting. The application includes the full text of the abstracts and the articles available in Hematology 2025 (the ASH Education Program). The application will allow users to add a session to their device's calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

ASH FOUNDATION DONOR LOUNGE

Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of \$250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit the ASH Foundation page for more information. The Donor Lounge will be located in the Gary Sain Cafe on Level 3 of the Orange County Convention Center. The Gary Sain Cafe is located above the West Hall C lobby.

ASH MANAGEMENT OFFICE

The ASH Staff Office is located in Room W205AB on the second level of the Orange County Convention Center.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

ASH PARK @ THE PLAZA

ASH Park @ the Plaza will be located on the grassy knoll outside of the Orange County Convention Center West Hall C lobby. This area will feature early morning yoga, life-sized games, and lounge furniture. There will also be ample seating and tables outdoors for those who wish to take a break and enjoy the Orlando sunshine.

BUSINESS CENTER

The Orange County Convention Center has a FedEx Office that provides full-service business needs for your convenience located in the West Hall C lobby of the convention center. FedEx Office provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

CHILD CARE ROOM

ASH has once again made arrangements with KiddieCorp to provide child-care services for children ranging in age from 6 months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for over 25 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenir arts and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and trained childcare specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for nursing mothers to store milk after using the lactation room. The deadline for reserving space for your child is November 14.

The cost for child-care service is completely free and is subsidized by ASH, however a cancellation penalty will be assessed if you cancel after the November 14 preregistration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Friday, December 5, through Tuesday, December 9.

The child-care room is located in room W110 on Level 1 of the Orange County Convention Center.

Child Care Room Hours

Friday, December 5 6:30 a.m. – 7:30 p.m. Saturday, December 6 . . . 6:30 a.m. – 7:30 p.m. Sunday, December 7 6:30 a.m. – 8:00 p.m. Monday, December 8 6:30 a.m. – 8:00 p.m. Tuesday, December 9 7:30 a.m. – 1:30 p.m.

COAT/BAG CHECK

Complimentary coat and bag check is available in the Level 1 concourse and West Hall E/F Lobby (Registration Office 17) of the Orange County Convention Center as well as on the Convention Level of the Hyatt Regency Orlando, across from the Information Desk. Electronic items will not be accepted.

Coat/Bag Check Hours

Friday, December 5 7:00 a.m. – 8:30 p.m.

Saturday, December 6 . . . 7:00 a.m. – 8:00 p.m.

Sunday, December 7 7:00 a.m. – 8:30 p.m.

Monday, December 8 7:00 a.m. – 8:30 p.m.

Tuesday, December 9* . . . 7:00 a.m. – 2:00 p.m.

*(Convention Center Locations Only)

FRIENDS OF BILL W.

A meeting room for the Friends of Bill W. is located in room W107 at the Orange County Convention Center.

HEMATOLOGY MEETUPS

To encourage interaction among attendees, Hematology MeetUp areas consisting of public meeting spaces with chairs and tables will be placed throughout the convention center. Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that attendees can coordinate meeting up with each other at a specific location.

INTERNET STATIONS

Internet Stations are placed throughout the Orange County Convention Center and Hyatt Regency Orlando. Attendees can utilize the Internet and do any of the following at all Internet Stations:

- Check email
- Print a boarding pass
- Print a registration receipt
- Access ASH Job Center
- View the Annual Meeting Program online
- Complete the Meeting Evaluation
- Obtain a Certificate of Attendance
- Register for the ASH Foundation Run/Walk (up to 6:00 p.m. on Saturday night)

LOST AND FOUND

Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room W102 on Level 1 of the Orange County Convention Center.

NURSING MOTHERS' LOUNGES

Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the Orange County Convention Center and Hyatt Regency Orlando. Each nursing mothers' lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is also a complimentary refrigerator located in the Child Care Room, Room W110 at the Orange County Convention Center.

Nursing Mothers' Lounges Locations

Orange County Convention Center:

- Level 1 Concourse Wellness Room
- Hall C Lobby Wellness Room
- Hall E/F Lobby Wellness Room
- Gary Sain Foyer Wellness Room
- Valencia Ballroom Lobby Wellness Room

Hyatt Regency Orlando

• Rock Spring II

QUIET ROOMS

Two quiet rooms are located in Orange County Convention Center. Room W108A is designated as the Female Quiet Room and room W108B is designated as the Male Quiet Room.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

PRESS COMPLEX

The Press Complex, open to registered members of the media, is located on in room W221 at the Orange County Convention Center.

Press Room Hours

Friday, December 5 9:00 a.m. – 5:00 p.m.

Saturday, December 6 7:00 a.m. – 6:00 p.m.

Sunday, December 7 7:00 a.m. – 6:00 p.m.

Monday, December 8 7:00 a.m. – 6:00 p.m.

Tuesday, December 9 7:00 a.m. – 1:00 p.m.

RESTAURANTS/CONCESSIONS

Consult the ASH Campus Map and ASH Food Guide for detailed information regarding concessions and dining options throughout the Orange County Convention Center and Hyatt Regency Orlando. The map will provide information on what type of food is available where so that you can easily find meals and snacks throughout the ASH campus.

TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

VISITOR SAFETY

To stay safe during your visit to Orlando, please follow the tips provided below:

Never hand your phone to someone else (i.e. handing to an Uber or Taxi driver to show them directions or asking a stranger to take your photo).

Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.

Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.

Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.

When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.

When driving, keep all car doors locked.

SHUTTLE SERVICE

ASH will provide complimentary shuttle service between most hotels in the ASH housing block and the Orange County Convention Center; additionally, 4 hotels are within walking distance of the Orange County Convention Center.

Shuttle Boarding Locations

• Routes 1-6	OCCC West Concourse bus lane in front of
	lobbies A-B

- Routes 7–10 OCCC West Concourse bus lane in front of lobbies D-E
- Routes 11–14 OCCC West Concourse bus lane in front of lobbies E-F
- Routes 15–19 OCCC West Concourse Westwood Lobby entrance
- Route 20 OCCC West Lot (W1)

Shuttle Hours

Thursday, December 4 No shuttle service
Friday, December 5 6:30 a.m. – 10:30 p.m.
Saturday, December 6 6:30 a.m. – 9:30 p.m.
Sunday, December 7 6:30 a.m. – 9:30 p.m.
Monday, December 8 6:30 a.m. – 9:30 p.m.
Tuesday, December 9 6:30 a.m. – 2:00 p.m.
Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

Service will not be provided for the following hotels, located within walking distance of the Orange County Convention Center:

- · Hyatt Regency Orlando
- Rosen Centre
- · Rosen Plaza
- Tru by Hilton Orlando Convention Center

AIRPORT SHUTTLE INFORMATION

The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes from the Orange County Convention Center to the Orlando International Airport during the days and times indicated below.

Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall C Lobby, Level 2 of the Orange County Convention Center. Tickets cost \$20 (credit card only)

Tickets Sales Hours

Monday, December 89:00 a.m. - 7:00 p.m. Tuesday, December 97:00 a.m. - 1:45 p.m.

Shuttle Hours

Monday, December 812:00 noon - 6:00 p.m. Tuesday, December 99:00 a.m. - 2:00 p.m.

Departure Location: Orange County Convention Center, Buses load outside curbside in front of Hall C Lobby.

PARKING

On-site private vehicle parking is available at the Orange County Convention Center as well as nearby parking options that serve the Downtown Orlando area. For detailed parking information, visit https://www.occc.net/attendee-parking.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

GETTING AROUND

The area's public transportation system, LYNX Bus Service, has routes servicing the Orlando Convention Center with connections to the Orlando International Airport and downtown Orlando. To

plan your journey and obtain the latest fares, visit https://www.golynx.com.

Taxis in Orlando are billed using a base fare between \$2.40 and \$2.90, with a per mile charge between \$2.50 and \$3.06.

EXPOSITION

Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 67th ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls A3-B2 in the Orange County Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, **no one** under the age of 18 will be permitted within the exhibit areas.

Exhibit Hours

Saturday, December 6...... 11:00 a.m. – 5:00 p.m. Sunday, December 7....... 10:00 a.m. – 5:00 p.m. Monday, December 8...... 10:00 a.m. – 2:00 p.m.

LUNCH AVAILABLE SUNDAY AND MONDAY

Your "ticket" for lunch is encoded in your badge, which will be scanned for entry into the "ticketed" event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Exhibit Hall. Lunch will be served from the ASH Café areas located in the back of the Exhibit Hall.

Lunch Hours

ASH BOOTH (#1101) – YOUR GATEWAY TO ALL ASH HAS TO OFFER

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1101). Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of *Blood*, see what materials are available to hematologists

around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.

CORPORATE PRESENTATIONS

Corporate Presentations include Product Theaters, Industry Theaters, Industry Forums, Clinical Trial Showcases, and Company Showcases, which feature new research findings, company overviews, and products presented to small groups of annual meeting attendees (no more than 150). All corporate presentations will take place on Level 2 of the Orange County Convention Center (Rooms W203AB, W204BC, W206A, W207BC, W208AB, W209AB, and W209C). Check the mobile app for the specific room number of the presentation you wish to attend. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

Corporate Presentation Theater Hours

Saturday, December 6 8:00 a.m. – 9:00 a.m.
11:30 a.m. – 12:30 p.m.
1:30 p.m. – 1:45 p.m.
3:30 p.m. – 3:45 p.m.
8:00 a.m. – 9:00 a.m.,
11:30 a.m. – 12:30 p.m.
4:00 p.m. – 4:30 p.m.
Monday, December 8 8:00 a.m. – 9:00 a.m.
10:00 a.m. – 10:15 a.m.
12:15 p.m. – 1:15 p.m.

Please see pages 137-14 for detailed Corporate Presentation program information.

POSTER SESSIONS

Poster sessions are held in West Halls B3-B4 of the Orange County Convention Center. Receptions are scheduled for Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

Saturday, December 6

8:00 a.m. – 7:30 p.m. Poster Session I – Viewing 5:30 p.m. – 7:30 p.m. Poster Session I – Presentations

Sunday, December 7

8:00 a.m. – 8:00 p.m. Poster Session II – Viewing 6:00 p.m. – 8:00 p.m. Poster Session II – Presentations

Monday, December 8

8:00 a.m. – 8:00 p.m. Poster Session III – Viewing 6:00 p.m. – 8:00 p.m. Poster Session III – Presentations

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SOCIAL EVENTS

POSTER HALL RECEPTIONS

Saturday, December 6 5:30 p.m. – 7:30 p.m. Sunday, December 7 6:00 p.m. – 8:00 p.m. Monday, December 8 6:00 p.m. – 8:00 p.m.

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2025 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.

ASH FOUNDATION RUN/WALK Sunday, December 7, 2025, 7:00 a.m. – 9:00 a.m.

Outside of the South Concourse of the Orange County Convention Center

Begin your day in a fun, healthy, and philanthropic way by participating in the 12th annual ASH Foundation Run/Walk before attending the sessions on Sunday, December 7. Participants may run or walk through the designated event course, choosing either a 3K or 5K route. Not attending in person this year? Don't worry! You can still support the Foundation by choosing your own virtual 3K or 5K route.

Proceeds from all individual and group registration fees as well as additional individual donations will benefit the ASH Minority Recruitment Initiative Fund. ASH and the ASH Foundation may opt to designate a portion of, or all corporate sponsorship revenues associated with the run/walk to help support the cost of administering the event. Learn more and register at https://www.hematology.org/foundation/run-walk

MEETING RULES AND REGULATIONS

CODE OF CONDUCT

ASH is committed to providing a welcoming meeting environment for all attendees. This Code of Conduct applies to all in-person and virtual participants, including members, volunteers, guests, exhibitors, vendors, staff, and any other attendee.

All attendees will conduct themselves in a collegial and respectful manner, free from any form of discrimination, harassment, or retaliation. Attendees will commit to creating a safe, inclusive, and professional atmosphere. Inappropriate conduct, including but not limited to harassment; threatening physical or verbal actions; or disorderly or disruptive conduct, will not be tolerated.

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact *customerservice@hematology.org* as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

MEETING AND SESSION PARTICIPATION

Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct, including but not limited to harassment, threatening physical or verbal actions, or disorderly or disruptive conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual platform. As a result, ASH reserves the right to expel all parties involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the Orange County Convention Center:

1. I AM AN ADULT OVER THE AGE OF 18, AND I KNOWINGLY AND VOLUNTARILY ASSUME ANY

AND ALL RISKS AND DANGERS THAT MAY OCCUR PURSUANT TO MY ATTENDANCE AND PARTICIPATION IN THE ASH ANNUAL MEETING, INCLUDING THE RISK OF ILLNESS, INJURY, DEATH, OR PROPERTY DAMAGE AND I RELEASE ASH AND THE ORANGE COUNTY CONVENTION CENTER FROM ANY AND ALL SUCH LIABILITY. I agree, for myself and any heirs, not to sue ASH or the Orange County Convention Center or otherwise assert any claim for damages arising out of any illness (including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.

 I agree that I will not pass my registration badge to another individual or otherwise allow anyone else to use my badge. I understand that violating this requirement will result in immediate revocation of my access to the meeting, and possibly future meetings.

FINANCIAL PROFESSIONALS

Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priorities. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries.

PROHIBITED BEHAVIOR

In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshal.

GENERAL INFORMATION

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

CHILDREN

For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted the exhibit hall or poster sessions.

Additionally, ASH prohibits all children and infants from the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

TECHNOLOGY

RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE

As part of ASH's ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. No identifying personal information will be stored in the RFID badge, only an ID number. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

VIRTUAL PLATFORM DATA COLLECTION

As a participant of the meeting, you have read and agreed to ASH's Privacy Policy and ASH's Terms of Service that are available on the ASH website. Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

A. General

Materials presented at the American Society of Hematology ("ASH") annual meeting, including all slides, written and oral presentations, posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the "Meeting Materials"), are protected by copyright and may not be publicly displayed or republished (including social media) without the express written consent of the copyright owner, ASH, or (in the case of the slides and posters) the presenter or author except as expressly provided in this Policy.

B. Photographs and Audio Recording

- 1. Limited Right to Share: Except as provided in Sections A and B.2 of this Policy, attendees of the ASH meeting may take photographs and make audio recordings (but no video recordings) of meeting materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the meeting materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:
- a. Attribution: an attendee must give appropriate credit to the original author, and may not in any way suggest that the original author endorses the attendee or his or her use;
- Non-Commercial: an attendee may not use the meeting materials for commercial purposes; and
- c. No Derivatives: if an attendee remixes, transforms, or builds upon the meeting material, he or she may not distribute or publish the modified material.

2. Poster and Exhibit Hall Presentations: Attendees of the ASH meeting may take photographs and make recordings of meeting materials associated with Poster and Exhibit Hall presentations and displays for personal, non-commercial, use only. Attendees are strictly prohibited from sharing meeting materials associated with poster presentations or exhibit hall displays without the express consent of the presenter or exhibitor, respectively, and the copyright owner of such meeting materials.

C. No Disruptive Recordings or Photos

Attendees taking photos or audio recording of meeting materials must do so in a non-disruptive manner so as not to disturb the presenter and other attendees. Flash photography is strictly prohibited.

D. No Video Recording, Live Audio, or Video Streaming

Sharing any recordings of meeting materials, including live streaming audio or video recordings, is strictly prohibited.

E. Violators

Violators of this Policy may be asked to leave the room or session and may be escorted and barred from the ASH meeting. Repeat violators may have their ASH meeting badges and/or virtual meeting access revoked and not be allowed to return to attend the remainder of the ASH meeting.

F. Disclaimer

ASH will have professional photographers present at the meeting, and portions of the meeting will be recorded. Any photographs or recordings taken during the meeting may be used in future ASH publications, online, or in other ASH materials. Attendance or participation in the meeting constitutes an agreement with ASH by the registrant for the Society to digitally store, use, and distribute the registrant's image or voice in photographs, audiotapes, or other electronic media pertaining to the ASH meeting events and activities, or other work of the Society.

Credentialed media/press will also attend the meeting and have permission to capture photos, video, and audio in public areas of the convention center. Registered media attendees are required to always display their press badge and camera tags while on site at the meeting.

PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

The ASH Annual Meeting Copyright and Reuse Policy for Abstracts, Presentations, and Presentation Materials can be found at hematology.org/meetings/annual-meeting/abstracts/copyright-and-reuse-policy.

General Information 35



Progress in **Hematology**Powered by **Philanthropy**

ASH Foundation
Moving Hematology Forward

The ASH Foundation fuels the future of hematology through your generous contributions.

Every dollar you donate directly supports the groundbreaking programs and initiatives led by the American Society of Hematology.

Your donation helps to advance progress in hematology and patient care worldwide.

With 100% of your donation going to critical programs, you're helping shape a brighter future for patients and professionals.

Donate now.



A gift to the ASH Foundation is an investment in the continued growth of every facet of hematology, especially in translating advances to patients with blood disorders worldwide.



James LaBelle, MD, PhD, Chair, ASH Foundation Committee, 2024–2025



Visit **hematology.org/foundation** to learn more and contribute today.

Moving hematology forward

ADVANCING EXCELLENCE AND ADDRESSING **HEALTH DISPARITIES AT ASH**

As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care

communities. ASH's efforts to foster excellence and improve health outcomes for all apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes. Join us for the following events at the 67th ASH Annual Meeting to help advance the highest quality outcomes across all segments of the population through advancing medical research on hematologic diseases and disorders and in the practice of hematology.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

THE ASH STUDIO (non-CME)

Saturday, Sunday, Monday

West Hall C

As part of our commitment the American Society of Hematology (ASH) is offering innovative content at the ASH Studio, located in ASH Central. This brave space is designed to provide sessions focused on expanding our understanding of the drivers that lead to differing outcomes in distinct communities. ASH has long recognized the importance of addressing these disparities and remains committed to advancing equitable and fair outcomes for all patients. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve outcomes for all patients in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution.

ANNUAL MEETING SESSIONS THAT HIGHLIGHT ACCESS. REPRESENTATION, AND POPULATION

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data	Satellite Symposia	W224CDGH	
Friday	3:00-6:00 p.m.	Bringing Emerging Treatments to All Patients: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices	Satellite Symposia	Valencia Room W415BC	
Saturday	9:00–9:30 a.m.	Promoting Language Equity in Care and Research	Treating Fairly Talks	West Hall C (ASH Studio)	
Saturday	9:30–10:45 a.m.	Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine	Special-Interest Sessions	W314	CME
Saturday	9:30–11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Biological and Clinical Nuances in Patient Outcomes	Oral Abstract Session	Valencia Room W415BC	
Saturday	9:30–11:00 a.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: Transforming Care Delivery and the Patient Experience	Oral Abstract Session	W311EFGH	
Saturday	9:30–11:00 a.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Clinical decision making and supportive care	Oral Abstract Session	W230	
Saturday	11:00–11:30 a.m.	Impact of Geography on Care	Treating Fairly Talks	West Hall C (ASH Studio)	
Saturday	11:15 a.m.–12:15 p.m.	Career Development Lunch	Trainee Activities	Hyatt - Windemere Ballroom	
Saturday	1:30-2:00 p.m.	From Precision Medicine to Personalized Care: Meeting Patients Where They Are	Treating Fairly Talks	West Hall C (ASH Studio)	

ADVANCING EXCELLENCE AND ADDRESSING HEALTH DISPARITIES AT ASH

Day	Time	Session Title	Program	Location	CME
Saturday	2:00–3:15 p.m.	CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias	Scientific Program	Tangerine Ballroom F3-4	CME
Saturday	2:00–3:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Barriers and bridges: Improving access to hematologic cancer care across diverse populations	Oral Abstract Session	W224ABEF	
Saturday	2:00-3:30 p.m.	908. Outcomes Research: Myeloid Malignancies: Real-World Outcomes in AML	Oral Abstract Session	Valencia Room W415A	
Saturday	3:30-4:00 p.m.	Breaking Financial Barriers to Care Through Affordable Innovation	Treating Fairly Talks	West Hall C (ASH Studio)	
Saturday	4:00–5:30 p.m.	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Insights into Diagnostics and Therapeutics of Bleeding in Inherited, Acquired Coagulopathies and BDUC	Oral Abstract Session	W304EFGH	
Saturday	4:00-5:30 p.m.	ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia	Special-Interest Sessions	Hyatt - Regency Ballroom OPQ	CME
Sunday	7:00–9:00 a.m.	Medical Educators' Symposium	Special-Interest Sessions	Hyatt - Plaza Int'l DEFG	CME
Sunday	9:00–9:30 a.m.	From Precision Medicine to Personalized Care: Meeting Patients Where They Are	Treating Fairly Talks	West Hall C (ASH Studio)	
Sunday	9:30–10:45 a.m.	Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery	Education Program	Hyatt - Regency Ballroom S	CME
Sunday	9:30-11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Lessons from across the age spectrum	Oral Abstract Session	Valencia Room W415BC	
Sunday	9:30–11:00 a.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: AML Biomarkers in Action: Prognosis, Risk, and Real-World Insights	Oral Abstract Session	Valencia Room W415A	
Sunday	9:30–11:00 a.m.	653. Multiple Myeloma: Clinical and Epidemiological: From Biomarkers to Biology: Evolving Risk Stratification and Disease Modeling in Multiple Myeloma	Oral Abstract Session	West Hall D1	
Sunday	9:30–11:00 a.m.	How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?	Special- Interest Sessions	Hyatt - Plaza Int'l HIJK	CME
Sunday	9:30–11:00 a.m.	Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults	Special- Interest Sessions	W414CD	CME
Sunday	11:00–11:30 a.m.	Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations	Treating Fairly Talks	West Hall C (ASH Studio)	
Sunday	11:00 a.m.–12:30 p.m.	LGBTQIA+ Community Networking Brunch	Special- Interest Sessions	Hyatt - Plaza Int'l DEFG	
Sunday	11:15 a.m.–12:30 p.m.	ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns	Special- Interest Sessions	Hyatt - Florida Ballroom	CME
Sunday	11:30 a.m.–12:30 p.m.	Treating Fairly Rounds Lunch	Special- Interest Sessions	Hyatt - Manatee Spring	CME

ADVANCING EXCELLENCE AND ADDRESSING HEALTH DISPARITIES AT ASH

Day	Time	Session Title	Program	Location	СМЕ
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non- Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing	Oral Abstract Session	W304ABCD	
Sunday	1:30–2:00 p.m.	A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary	Treating Fairly Talks	West Hall C (ASH Studio)	
Sunday	2:00-4:00 p.m.	Plenary Scientific Session	Oral Abstract Session	West Hall D2	
Sunday	4:00-4:30 p.m.	Promoting Language Equity in Care and Research	Treating Fairly Talks	West Hall C (ASH Studio)	
Sunday	4:30-6:00 p.m.	905. Outcomes Research: Non- Malignant Conditions Excluding Hemoglobinopathies: Cancer, Clots and Coagulation	Oral Abstract Session	W308	
Monday	8:30–9:00 a.m.	A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary	Treating Fairly Talks	West Hall C (ASH Studio)	
Monday	10:00–10:30 a.m.	Impact of Geography on Care	Treating Fairly Talks	West Hall C (ASH Studio)	
Monday	10:30–11:45 a.m.	Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally	Scientific Program	Tangerine Ballroom F2	CME
Monday	10:30–11:45 a.m.	Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients	Education Program	W307	CME
Monday	10:30 a.m.–12:00 p.m.	909. Education, Communication, and Workforce: Innovating to Bridge Gaps and Improve Access: Education, Communication, and Workforce in Hematology	Oral Abstract Session	Hyatt - Regency Ballroom OPQ	
Monday	12:00–12:30 p.m.	Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations	Treating Fairly Talks	West Hall C (ASH Studio)	
Monday	12:00–1:30 p.m.	Celebrating Diverse Voices: Enriching Hematology Lunch	Special- Interest Sessions	Hyatt - Florida Ballroom A	
Monday	12:15–1:15 p.m.	Trainee Didactic Session: Outcomes Research in Hematology	Trainee Activities	W308	
Monday	12:30–1:30 p.m.	Leukemia in Latin America: Bridging Gaps in Genetics, Access, and Innovation	Scientific Program	West Halls B3-B4	
Monday	1:00–1:30 p.m.	Breaking Financial Barriers to Care Through Affordable Innovation	Treating Fairly Talks	West Hall C (ASH Studio)	
Monday	2:45–4:15 p.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-World data on clinical predictors of outcome	Oral Abstract Session	Tangerine Ballroom F3-4	
Monday	2:45-4:15 p.m.	632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Therapeutic agents to enhance patient outcomes	Oral Abstract Session	Chapin Theater (W320)	

ADVANCING EXCELLENCE AND ADDRESSING HEALTH DISPARITIES AT ASH

Day	Time	Session Title	Program	Location	CME
Monday	2:45–4:15 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond	Oral Abstract Session	W331	
Monday	2:45–4:15 p.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: From Screening to Access: Pathways to Improving Care	Oral Abstract Session	W311ABCD	
Monday	2:45–4:15 p.m.	905. Outcomes Research: Non- Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care	Oral Abstract Session	W304ABCD	
Monday	2:45-4:15 p.m.	908. Outcomes Research: Myeloid Malignancies: Health Disparities and Patient-Centred Care	Oral Abstract Session	W414CD	
Monday	4:30-6:00 p.m.	901. Health Services and Quality Improvement: Non- Malignant Conditions Excluding Hemoglobinopathies: Risk Assessment, and Care Optimization, and Al, Oh my! The Spectrum of Quality in Classical Hematology	Oral Abstract Session	W308	
Monday	4:30-6:00 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Innovations to address real-world barriers and optimize delivery of CAR-T and bispecific antibody therapies	Oral Abstract Session	W224ABEF	
Monday	4:30-6:00 p.m.	903. Health Services and Quality Improvement: Myeloid Malignancies: Where smarter care begins: technological innovations and quality improvement in myeloid malignancies	Oral Abstract Session	W314	
Monday	4:30-6:00 p.m.	904. Outcomes Research: Hemoglobinopathies: Global burden of Hemoglobinopathies: From Crisis to Care	Oral Abstract Session	W311ABCD	
Monday	4:30-6:00 p.m.	905. Outcomes Research: Non- Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps	Oral Abstract Session	W307	
Wednesday	10:00–11:00 a.m.	ASH Poster Walk on Population Health and Access to Care	Scientific Program	Virtual Program	

NON-CME SESSIONS

ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education's (ACCME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any

presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of Non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform, and an up-to-date list of sessions will also be available.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

Due to stricter ACCME guidelines regarding who may be allowed to control/present accredited content, the following sessions will not be certified for CME credit.

Marquee Sessions

Best of ASH Late-Breaking Abstracts Session Plenary Scientific Session

Special-Interest Sessions

ASH Foundation Run/Walk

ASH Hemostasis and Thrombosis Community Networking Reception

Back to Business Breakfast

Blood Presents: How to Get Published in a Peer Review Journal

Blood Advances Presents: How to Peer Review a Scientific Paper

Celebrating Diverse Voices: Enriching Hematology Lunch

Center for Sickle Cell Disease Initiatives Reception

Distinguished Abstract Achievement Award Ceremony

Hematology Inclusion Pathway: Presentations and Reception

Leveraging Real-World Data in Multiple Myeloma for Regulatory Purposes

Leveraging Real-World Data in Sickle Cell Disease to Identify and Study Specific Cohorts of Interest

LGBTQIA+ Community Networking Brunch Women in Hematology Networking Event

Non-CME Programs

All sessions in the following programs are not accredited for CME credit:

ASH Poster Walks
ASH Studio
ASH Wellness Studio
ASH-a-Palooza Events
Blood Journals Studio
Clinical Trial Showcases
Company Showcases
Industry Forums
Industry Theaters
Oral and Poster Abstracts
Product Theaters
Scientific Workshops

Trainee Activities and Services













Pursuing cancer cures at the speed of life.

City of Hope is redefining blood cancer care with over 20,000 bone marrow transplants, 2,000+ patients treated with CAR T cell therapies and 80+ clinical trials, advancing next-generation treatments and expanding access through locations in Southern California, Phoenix, Atlanta, and Chicago.





SCHEDULE-AT-A-GLANCE

AMERICAN SOCIETY OF HEMATOLOGY 67TH ASH® ANNUAL MEETING AND EXPOSITION

SCHEDULE-AT-A-GLANCE

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

WEDNESDAY, DECEMBER 3, 2025

9:00 a.m. - 11:59 p.m.

Preview Day on the Virtual Platform

Virtual Platform

THURSDAY, DECEMBER 4, 2025

12:00 a.m. - 11:59 p.m. Preview Day on the Virtual Platform

Virtual Platform

Registration and Materials Pick-Up at the

Airport (for in-person participants)

Orlando International Airport

8:00 a.m. - 9:00 p.m.

3:00 p.m. – 7:00 p.m. Registration and Materials Pick-Up (for in-person participants)

West Building Level 1

FRIDAY, DECEMBER 5, 2025

7:00 a.m. – 6:00 p.m. Registration and Materials Pick-Up (for in-person participants)

Westwood Lobby
West Building Level 1

Hyatt Regency Orlando, Regency Tower Lobby

8:00 a.m. – 9:00 p.m. Registration and Materials Pick-Up at the Airport (for in-person participants)

Orlando International Airport

7:00 a.m. – 6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)

West Hall C

7:00 a.m. – 10:00 a.m. Satellite Symposia

Advances in Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders: Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond

W224ABEF

Aligning Discovery with Clinical Practice: Applying Expert Consensus Guidelines to Improve Patient Outcomes in CLL/SLL

Virtual Symposium Only

Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma

Hyatt Regency Orlando, Regency Ballroom R

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Acute Myeloid Leukemia **Hyatt Regency Orlando, Regency TUV**

Many Roads to Myeloma Remission: Making Sequential Choices with BCMA and non-BCMA Immunotherapies

Hyatt Regency Orlando, Plaza Int'l HIJK

MASTER MDS for Enhanced Patient Care: <u>M</u>odern <u>A</u>dvances with <u>ST</u>andard and <u>Emerging</u>, <u>R</u>isk-adapted Treatment

Hyatt Regency Orlando, Plaza Int'l DEFG

Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes

Valencia Room W415D

Momentum in MDS: Making Progress and Shaping a Better Future Tangerine Ballroom F2

Moving Forward in B-ALL: Insights on Modern and Emerging Standards with Off-the-Shelf Bispecific Antibodies

Valencia Room W415BC

Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond

Valencia Room W415A

Paroxysmal Nocturnal Hemoglobinuria: What we have learned from the introduction of new therapies

Tangerine Ballroom F1

Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care

Hyatt Regency Orlando, Orlando Ballroom

Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data

W224CDGH

Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options & Modern Clinical Decision-making in Newly Diagnosed Disease

Hyatt Regency Orlando, Regency Ballroom S

Rising to the Graft-vs-Host Disease Challenge: Progress in Treatment and Post-HCT Outcomes Across Hematologic Cancers

W331

Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment

Hyatt Regency Orlando, Regency Ballroom OPQ

9:00 a.m. – 12:00 p.m. Training Program Directors Workshop

Sea World Orlando - Ports of Call 1

11:00 a.m. – 2:00 p.m. Satellite Symposia

A Master Class in CP-CML: New Agents, Treatment Goals, and Clinical Challenges

Hyatt Regency Orlando, Regency Ballroom R

Accelerating Evidence Into Practice: Leveraging QI-Driven Insights and Practical Tools to Integrate Bispecific Antibodies Into Care for Patients With R/R DLBCL and FL

W331

Advancing Hemophilia Care—Uniting Expert Insights and Community Voices to Shape the Future of Non-Factor Replacement Therapy

Hyatt Regency Orlando, Orlando Ballroom

Advancing Outcomes in Lymphoma Care: A Master Class on Integrating the CAR T-Cell Therapies into Clinical Practice

Hyatt Regency Orlando, Regency Ballroom OPQ

Cases & Conversations™: Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

W224ABEF

Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia **Hyatt Regency Orlando, Regency TUV**

From Indolent to Aggressive: Case-Based Strategies Across the Spectrum of Systemic Mastocytosis

W224CDGH

Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Tangerine Ballroom F1

Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

Tangerine Ballroom F2

Rare Clinical Spotlight: Exploring Castleman Disease, Cold Agglutinin Disease, and Acute Intermittent Porphyria

Hyatt Regency Orlando, Plaza Int'l HIJK

Tailoring Bispecific Antibodies to Individualize R/R Follicular Lymphoma Care: A Case-Based Discussion

W311EFGH

Targeted Therapies in R/R PCNSL: New Frontiers in Treatment and Management

Hyatt Regency Orlando, Plaza Int'l DEFG

The Growing Role of CAR T-Cell Therapy in Multiple Myeloma: New Data on Earlier Lines of Therapy, Expanding Access to Treatment

W230

'Four' Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care with Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapies

Valencia Room W415D

12:00 p.m. – 5:00 p.m. ASH-a-Palooza (Open to Trainees Only)

SeaWorld Orlando, Sea Harbor Pavilions

3:00 p.m. - 6:00 p.m. Satellite Symposia

Achieving Comprehensive Care for Chronic Immune Thrombocytopenia: Exploring Emerging Therapies to Address Patient-centric Hematological and Non-Hematological Outcomes

Hyatt Regency Orlando, Regency Ballroom R

Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management

Hyatt Regency Orlando, Plaza Int'l HIJK

Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access W230

Bringing Emerging Treatments to All Patients: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices

Valencia Room W415BC

Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations

Tangerine Ballroom F1

Cracking the Code: Menin Inhibitors and the Next Frontier in AML Treatment W331

Expert Second Opinion: Investigators Discuss the Optimal Management of Patients with Myelofibrosis and Systemic Mastocytosis

Hyatt Regency Orlando, Regency TUV

Filling in the Gaps in Hemophilia Guideline Recommendations: Evidence-Based Strategies to Optimize Patient-Relevant Outcomes Valencia Room W415A

Medical Crossfire®: Navigating GVHD Prophylaxis, Acute and Chronic Care -Targeted Strategies to Elevate Patient Outcomes

Tangerine Ballroom F2

Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs

Hyatt Regency Orlando, Regency Ballroom OPQ

Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy: A Case-Based Discussion

W311EFGH

PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma

Tangerine Ballroom F3-4

Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management —A CME COMPETE™: SCD Edition

W224CDGH

Visualizing Novel Pathways to Optimizing Care for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

W224ABEF

3:00 p.m. - 6:00 p.m. Scientific Workshops

Scientific Workshop on Aging and Hematology W312

Scientific Workshop on Disease Severity Scoring and Clinical Trial Endpoints
Beyond Vaso-occlusive Pain in Sickle Cell Disease
W315

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

W307

Scientific Workshop on Host Factors in Cell and Gene Therapy: Impact on Efficacy and Toxicity

W304ABCD

Scientific Workshop on Interplay between Coagulation and Malignancy W304EFGH

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer and Normal Hematopoiesis- From Discovery to Patients

W414AB

Scientific Workshop on State of the Art: Integrating Functional and Genomic Precision Medicine for Hematologic Malignancies

W30

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

W414CD

Scientific Workshop on Translational diagnostics in MRD – NGS, ctDNA and beyond

W311ABCD

5:00 p.m. – 7:00 p.m. Trainee Welcome Reception (Open to Trainees Only)

SeaWorld Orlando, Sea Harbor Pavilions

7:00 p.m. - 10:00 p.m. Satellite Symposia

EXPERT SECOND OPINION: Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Hyatt Regency Orlando, Regency TUV

Hot Topics in Myelofibrosis Management: Navigating the Latest Therapeutic Advances in Clinical Practice

W331

SATURDAY, DECEMBER 6, 2025

7:00 a.m 6:00 p.m.	Registration and Materials Pick-Up (for
	in-person participants)

Westwood Lobby

West Building Level 1

Hyatt Regency Orlando, Regency Tower Lobby

7:00 a.m. – 6:00 p.m.	Learn, Engage, and Relax in ASH Central
	(for in-person participants)

West Hall C

7:00 a.m. – 7:45 a.m.	ASH Yoga (for in-person participants)

ASH Park @ The Plaza

West Hall C

8:00 a.m. – 7:30 p.m.	Poster Session I - Viewing

West Halls B3-B4

8:00 a.m. – 9:00 a.m.	How I Treat (Ticketed Session)

How I Treat: How I Navigate Arterial Thrombosis: A Hematologist's Perspective

Hyatt Regency Orlando, Bayhill 23

How I Treat: How I Use NGS in the Pre and Post-HSCT and Cell Therapy Setting

Hyatt Regency Orlando, Bayhill 29

How I Treat: Isolated CNS Relapse of B-ALL in the Era of Immunotherapy Hyatt Regency Orlando, Bayhill 27,

How I Treat: Multiple Myeloma Progression after Upfront Quadruplet Therapy

Hyatt Regency Orlando, Bayhill 31

How I Treat: The Balancing Act of Anticoagulant Management in Hemoglobinopathies

Hyatt Regency Orlando, Bayhill 25

Clinical Management and Unmet Needs in Immune Thrombocytopenia (ITP) **W209AB**

Enhancing Sickle Cell Disease Care Through Patient Partnership W207BC

Evolving Patient Support Programs: Access, Education and Affordability in Oncology Care

W203AB

Rethinking Control in Polycythemia Vera - Uncovering the Clinical Unmet Needs and Potential to Address Them with Emerging Therapies

8:00 a.m. - 9:00 a.m. Meet the Scientist (Ticketed Session)

Meet The Scientist: Genomics and Targeted Therapy in Pediatric Acute Leu-

Hvatt Regency Orlando, Bayhill 19

Meet The Scientist: Myeloma Biology and Therapy

Hyatt Regency Orlando, Bayhill 20

Meet The Scientist: Never Go Into Transplant Waters Alone **Hyatt Regency Orlando, Bayill 22**

Meet The Scientist: Somatic Genetic Rescue in Bone Marrow Failure Syndromes - Friend or Foe?

Hyatt Regency Orlando, Bayhill 17

8:30 a.m. - 8:55 a.m. **Blood Journals Studio**

Meet the Journal Editors: Blood Immunology & Cellular Therapy West Halls B3-B4

9:00 a.m. - 9:30 a.m. **Blood Journals Studio**

Meet the Journal Editors: Blood Vessels, Thrombosis & Hemostasis West Halls B3-B4

9:00 a.m. - 9:30 a.m. Coffee Break in the Poster Hall (for inperson participants)

West Halls B3-B4

9:00 a.m. - 9:30 a.m. **ASH Studio (Treating Fairly Talks)**

Promoting Language Equity in Care and Research West Hall C

ASH Wellness Studio 9:05 a.m. - 9:15 a.m.

The Chair Check West Hall C

9:15 a.m. - 9:25 a.m. **ASH Wellness Studio**

Reset Your Posture

West Hall C

9:30 a.m. - 10:45 a.m. **Education Program**

Bleeding Disorder of Unknown Cause—What Do We Know? W307

Immune Cytopenias: Addressing Challenges and Advancing Treatments **Hyatt Regency Orlando, Regency Ballroom S**

9:30 a.m. - 10:45 a.m. Scientific Program

Scientific Committee on Epigenetics and Genomics: Dissecting Enhancer Function in Hematopoietic Development and Disease W312

Scientific Committee on Iron and Heme: Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy Hyatt Regency Orlando, Regency Ballroom OPQ

Scientific Committee on Plasma Cell Neoplasia: Exploring the Origins of Multiple Myeloma: Germline Predisposition and Early Deregulations West Hall D1

Scientific Committee on Transplant Biology and Cellular Therapies: Strategies to Improve Outcomes After Hematopoietic Cell Transplantation and Adoptive Cell Therapy

W331

9:30 a.m. - 10:45 a.m. **Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine**

W314

9:30 a.m. - 11:00 a.m. **Oral Abstract Sessions**

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Mechanistic Insights into Sickle Cell Pathobiology and Disease Progression

W311ABCD

321. Coagulation and Fibrinolysis: Basic and Translational: Deciphering new and old conundrums of coagulation

W304EFGH

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Risk Assessment and Management of Thromboembolism in Cancer: Genomics, Biomarkers, and Real-World Evidence

W304ABCD

508. Bone Marrow Failure Acquired: Immune dysregulation and molecular insights

Hyatt Regency Orlando, Plaza Int'l HIJK

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Prognostic Genetic and Therapeutic Response Factors in Adult and Pediatric B-ALL W224CDGH

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Biological and Clinical Nuances in Patient Outcomes

Valencia Room W415BC

617. Acute Myeloid Leukemias: Commercially Available Therapies: Frontline treatment with intensive or lower-intensity regimens

Valencia Room W415A

621. Lymphomas: Translational – Molecular and Genetic - Subtyping strategies to unlock new therapeutic vulnerabilities

Tangerine Ballroom F1

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Frontline BTKi-based Combination Therapy in DLBCL and PCNSL

Tangerine Ballroom F3

629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Overcoming Barriers in Frontline Therapy: Bispecific Antibodies for Older Adults with DLBCL

Tangerine Ballroom F2

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN

W414AB

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Decoding the Molecular Drivers of response and resistance

Valencia Room W415D

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome

W414CD

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation

W224ARFF

653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Immune-Based Therapies in Myeloma: From T-Cell Fitness to Clinical Outcomes West Hall D2

654. Multiple Myeloma: Pharmacologic Therapies: Advancing the Standard: Improving Myeloma Treatment through Diagnosis, Maintenance and Relapse West Hall E1

702. CAR-T Cell Therapies: Basic and Translational: In vivo CAR-T cell platforms and resistance mechanisms

Sunburst Room (W340)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications

Chapin Theater (W320)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Transformative AI and Omics Approaches in Hematologic Malignancies **Hyatt Regency Orlando, Regency Ballroom R**

900. Health Services and Quality Improvement: Hemoglobinopathies: Transforming Care Delivery and the Patient Experience
W311EFGH

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Clinical decision making and supportive care **W230**

907. Outcomes Research: Plasma Cell Disorders: Real-world Outcomes of Targeted Immunotherapies in Patients with Multiple Myeloma
West Hall E2

9:30 a.m. – 11:00 a.m.	Leveraging Real-World Data in Sickle Cell
	Disease to Identify and Study Specific
	Cohorts of Interest

W308

11:00 a.m. – 11:30 a.m. ASH Studio (Treating Fairly Talks)

Impact of Geography on Care **West Hall C**

11:00 a.m. – 12:30 p.m.	Live Music and Outdoor Lunch Seating (for
	in-person participants)

ASH Park @ The Plaza

|--|

11:00 a.m. – 5:00 p.m.	Exhibits Open

West Halls A3-B2

11:05 a.m. – 11:15 a.m. ASH Wellness Studio

The Typing Timeout
West Hall C

11:15 a.m. - 12:15 p.m. ASH Poster Walks

Inherited Bleeding Disorders Poster Walk Hosted by **Blood Vessels, Thrombosis & Hemostasis West Halls B3-B4**

11:15 a.m. – 12:15 p.m.	Blood Presents: How to Get Published in a
	Peer Review Journal

W314

11:15 a.m. – 12:15 p.m. Career Development Lunch (Open to Trainees Only)

Hyatt Regency Orlando, Windemere Ballroom

11:15 a.m. - 12:15 p.m. Grassroots Network Lunch

Hyatt Regency Orlando, Florida Ballroom

11:20 a.m. - 11:30 a.m. ASH Wellness Studio

Emotional Freedom Technique West Hall C

11:30 a.m. - 12:30 p.m. Product Theaters

A Treatment Option for Adults with Certain R/R DLBCL After ≥2 Prior Lines of Systemic Therapy

W209AB

Frontline Therapy in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

W203AB

Hear Jen's Journey, Then Explore the Data

W204BC

Rapid NGS: Transforming Molecular Profiling of Myeloid and Lymphoid Malignancies

W209C

Shifting Currents in Hemophilia Care: Exploring the Impact of Antithrombin Lowering

W206A

Unlocking the Benefits of Time-Off Treatment with a BCL-2 Inhibitor as the Proven Backbone of Targeted, Fixed-Duration Therapy in CLL W208AB

Unlocking the Potential of CAR T: When and Why it Matters W207BC

11:35 a.m. - 11:45 a.m. ASH Wellness Studio

Brain-Boosting Break **West Hall C**

12:00 p.m. - 1:30 p.m. Oral Abstract Sessions

603. Lymphoid Oncogenesis: Basic - Mechanistic studies of lymphoid leukemias and lymphomas

W224ABEF

622. Lymphomas: Translational - Non-Genetic: Insights into immune niches of CNS and Hodgkin Lymphoma via multi-omic and spatial profiling Tangerine Ballroom F1

624. Hodgkin Lymphomas: Clinical and Epidemiological: Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling, and Predictive Tools

Tangerine Ballroom F2

701. Experimental Transplantation: Basic and Translational: GVHD, thymopoiesis and the host regenerative response

Chapin Theater (W320)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients

W331

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Donor selection and maintenance strategies

Sunburst Room (W340)

904. Outcomes Research: Hemoglobinopathies: Clinical Phenotypes and Outcomes in Hemoglobinopathies

W308

12:30 p.m. - 1:30 p.m. Ham-Wasserman Lecture

West Hall D2

1:30 p.m. - 1:45 p.m. Clinical Trial Showcases

Evaluating Osivelotor in Sickle Cell Disease: Pivotal Trial Updates

W209AB

1:30 p.m. - 1:45 p.m. Company Showcases

Fast, Fresh, Fit: Unlocking the Potential of Cell Therapy through a Transformative, Scalable, and Accessible Approach to Impact More Patients Globally W208AB

1:30 p.m. - 1:55 p.m. Blood Journals Studio

Meet the Journal Editors: Blood Advances

West Halls B3-B4

1:30 p.m. – 2:00 p.m. Coffee Break in the Exhibit Hall (for inperson participants)

West Halls A3-B2

1:30 p.m. – 2:00 p.m. ASH Studio (Treating Fairly Talks)

From Precision Medicine to Personalized Care: Meeting Patients Where They

West Hall C

1:35 p.m. – 1:45 p.m. ASH Wellness Studio

Snacks For Better Fuel

West Hall C

1:45 p.m. – 1:55 p.m. ASH Wellness Studio

Center Yourself

West Hall C

2:00 p.m. – 2:45 p.m. Blood Journals Studio

Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work

West Halls B3-B4

2:00 p.m. – 3:00 p.m. Distinguished Abstract Achievement Award Ceremony

W300

2:00 p.m. - 3:15 p.m. Education Program

Complementopathies: Modern Diagnosis and Management

Hyatt Regency Orlando, Regency Ballroom S

Down the Rabbit Hole: An Update on Histiocytic Disorders Hyatt Regency Orlando, Regency Ballroom OPQ

riyatt Regency Orlando, Regency Banroom Or Q

Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges

W230

Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma Tangerine Ballroom F1

The Changing Landscape of the Care of Patients with Immune-Mediated and Congenital TTP

W304EFGH

2:00 p.m. – 3:15 p.m. Scientific Program

Scientific Committee on Blood Disorders in Childhood: CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias

Tangerine Ballroom F3

Scientific Committee on Lymphoid Neoplasia: Innovative Models of Lymphoma

West Hall E2

Scientific Committee on Red Cell Biology: Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy

Sunburst Room (W340)

2:00 p.m. – 3:15 p.m. Scientific Symposia

Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes

Hyatt Regency Orlando, Plaza Int'l HIJK

Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease

W308

2:00 p.m. - 3:30 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Nursing erythropoiesis in sickness and in health

W314

201. Granulocytes, Monocytes, and Macrophages: Histiocytic and granulocytic Disorders

W312

301. Platelets and Megakaryocytes: Basic and Translational: Novel mechanisms of platelet signaling

W304ABCD

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Thrombosis and thrombotic microangiopathy: New mechanisms and new therapies

W307

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Chromatin and transcriptional regulation in hematopoietic lineage commitment

W311EFGH

602. Myeloid Oncogenesis: Basic: Identification of new vulnerabilities in therapy-resistant AML

W414CD

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Redefining AML: Genetic, Phenotypic and Response-Based Insights

W414AB

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: FL and WM

Tangerine Ballroom F2

636. Myelodysplastic Syndromes: Basic and Translational: Innovative Approaches to Target Novel Vulnerabilities in MDS Pathobiology Valencia Room W415D

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes

Valencia Room W415BC

641. Chronic Lymphocytic Leukemia: Basic and Translational: Clonal evolution, tumor microenvironment and immunotherapy

W224CDGH

654. Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma

West Hall D'

655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma

West Hall E1

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and Strategies

Chapin Theater (W320)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next Generation CAR-T Clinical Trials in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Multiple Myeloma

West Hall D2

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Acute and Chronic GVHD and Immune Reconstitution W331

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: MRD Assays and Novel Drug Discovery Pipelines

Hyatt Regency Orlando Regency Ballroom R

902. Health Services and Quality Improvement: Lymphoid Malignancies: Barriers and bridges: Improving access to hematologic cancer care across diverse populations

W224ABEF

908. Outcomes Research: Myeloid Malignancies: Real-World Outcomes in AML

Valencia Room W415A

2:00 p.m 3:30 p.m.	ASH Clinical Practice Guidelines on	
	Hydroxyurea for Sickle Cell Disease	

W311ABCD

How to Create a Strong Visual Abstract

West Halls B3-B4

3:30 p.m. – 3:45 p.m.	Clinical Trial Showcases

The ALPHA3 Trial: Improving Outcomes Through the Combination of Nextgen CAR T and Advanced MRD Testing in LBCL **W209C**

3:30 p.m. - 3:45 p.m. Company Showcases

Charting Proteomic Landscapes of Relapse and Resistance in Hematological Malignancies

W208AB

3:30 p.m. – 4:00 p.m.	Coffee Break in the Exhibit Hall (for in-
	person participants)

West Halls A3-B2

3:30 p.m. – 4:00 p.m. ASH Studio (Treating Fairly Talks)	
--	--

Breaking Financial Barriers to Care Through Affordable Innovation West Hall C

3:35 p.m. – 3:45 p.m.	ASH Wellness Studio	

Plug Into Nature
West Hall C

3:45 p.m. – 3:55 p.m.	ASH Wellness Studio	
-----------------------	---------------------	--

Movement Bites
West Hall C

4:00 p.m. - 5:15 p.m.

Between Clots and Complications: A New Era of Anticoagulation in Cance	er

Education Program

West Hall D2

Hemoglobinopathies and Increased Risk of Venous Thromboembolism **W308**

Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why? Tangerine Ballroom F3

Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician

Tangerine Ballroom F2

4:00 p.m. - 5:15 p.m. Scientific Program

Scientific Committee on Immunology and Host Defense: New Frontiers in Neutrophil Biology

W311EFGH

Scientific Committee on Stem Cells and Regenerative Medicine: Tracing Bloodlines: Decoding Embryonic Waves of Blood Cell Production and Their Contribution to Disease

W312

Scientific Committee on Thrombosis and Vascular Biology: Thromboinflammation

W314

4:00 p.m. - 5:30 p.m. Oral Abstract Sessions

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Prognosis, the heart, and the kidney in SCD

W311ABCD

322. Hemophilia A and B: Clinical and Epidemiological: Prophylaxis Across the Age Spectrum

W304ABCD

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Insights into Diagnostics and Therapeutics of Bleeding in Inherited, Acquired Coagulopathies and BDUC

W304EFGH

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Bleeding: Real-World Insights Across Diverse Patient Populations W307

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel strategies to overcome therapy resistance in AML

Valencia Room W415D

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms:
Beyond Genomic Resistance: epigenetics, metabolism and more

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Critical biomarkers and classifiers in B-ALL and T-ALL ontogeny and outcomes

W224CDGH

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel AML Biomarkers: Mechanisms, Mutations, and Targets

Valencia Room W415BC

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: From Detection to Decision: MRD as the Compass in AML

Valencia Room W415A

621. Lymphomas: Translational – Molecular and Genetic: Towards Precision Medicine in Lymphoma: Multi-Omics Discovery of Prognostic and Predictive Riomarkers

Tangerine Ballroom F1

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Drivers, vulnerabilities and resistance in CML and MPN W414AB

653. Multiple Myeloma: Clinical and Epidemiological: Genomic and Cytogenetic Drivers of Prognosis in Multiple Myeloma

West Hall D1

654. Multiple Myeloma: Pharmacologic Therapies: Are we achieving cures for multiple myeloma patients using early intervention strategies?

West Hall E1

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients Sunburst Room (W340)

801. Gene Therapies: Advances in Gene Therapy for Blood Disorders Chapin Theater (W320)

802. Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies?

W331

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Prediction Models and Novel Molecular Markers

Hyatt Regency Orlando, Regency Ballroom R

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T and Bispecifics in Lymphoma - Real World Outcomes and Endpoints

W224ABEF

907. Outcomes Research: Plasma Cell Disorders: Innovations in Myeloma: Therapy, Prevention & Patient-Centered Care West Hall F2

4:00 p.m. – 5:30 p.m.	ASH Clinical Practice Guidelines on
	Diagnosis of Iron Deficiency with and
	without Anemia

Hyatt Regency Orlando, Regency Ballroom OPQ

4:00 p.m. – 5:30 p.m.	ASH Clinical Practice Guidelines on
	Myelofibrosis

W414CD

4:00 p.m. – 5:30 p.m.	Joint Session: Advancing Hematology
	Through Artificial Intelligence

Hyatt Regency Orlando, Regency Ballroom S,

4:00 p.m. – 5:35 p.m.	Scientific Program	

Scientific Committee on Bone Marrow Failure and Scientific Committee on Myeloid Neoplasia: JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia

Hyatt Regency Orlando, Plaza Int'l HIJK

5:30 p.m. – 7:30 p.m.	Welcome Reception in the Poster Hall (for
	in-person participants)

West Halls B3-B4

5:30 p.m. – 7:30 p.m.	Poster Session I – Presentations (for in-
	person participants)

West Halls B3-B4

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1099–1123)

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster I (1124–1134)

112. Thalassemia and Globin Gene Regulation: Poster I (1135–1145)

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1146–1160)

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1161–1199)

201. Granulocytes, Monocytes, and Macrophages: Poster I (1200–1223)

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1224–1236)

301. Platelets and Megakaryocytes: Basic and Translational: Poster I (1237–1250)

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1251–1274)

321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1275–1284)

322. Hemophilia A and B: Clinical and Epidemiological: Poster I (1285–1299)

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I (1300–1315)

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I (1316–1324)

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I (1325–1339)

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1340–1363)

401. Blood Transfusion: Poster I (1364–1371)

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1372–1384)

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I (1385–1401)

- 506. Bone Marrow Microenvironment: Poster I (1402–1412)
- 508. Bone Marrow Failure: Acquired: Poster I (1413–1434)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1435–1445)
- 602. Myeloid Oncogenesis: Basic: Poster I (1446–1473)
- 603. Lymphoid Oncogenesis: Basic: Poster I (1474–1486)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1487–1518)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1519–1539)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1540–1560)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I (1561–1582)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I (1583–1598)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1599–1638)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I (1639–1657)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I (1658–1690)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I (1691–1736)
- 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster I (1737–1744)
- 621. Lymphomas: Translational Molecular and Genetic: Poster I (1745–1772)
- 622. Lymphomas: Translational Non-Genetic: Poster I (1773–1793)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1794–1840)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I (1841–1855)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I (1856–1881)
- 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster I (1882–1903)
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster 1(1904–1927)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster I (1928-1954)
- 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster I (1955–1972)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1973–1991)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1992–2012)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (2013–2053)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster I (2054–2066)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I (2067–2097)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I (2098–2106)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (2107–2137)

- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (2138–2180)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (2181–2197)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster I (2198–2252)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster I (2253-2289)
- 655. Multiple Myeloma: Cellular Therapies: Poster I (2290–2302)
- 701. Experimental Transplantation: Basic and Translational: Poster I (2303–2318)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster I (2319–2351)
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I (2352–2363)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I (2364–2400)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I (2401–2411)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I (2412–2445)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I (2446–2479)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I (2480–2510)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2511–2530)
- 801. Gene Therapies: Poster I (2531-2544)
- 802. Chemical Biology and Experimental Therapeutics: Poster I (2545–2554)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I (2555–2587)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I (2588–2603)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2604–2621)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I (2622–2647)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster 1 (2648–2660)
- 904. Outcomes Research: Hemoglobinopathies: Poster I (2661–2676)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2677–2703)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I (2704–2783)
- 907. Outcomes Research: Plasma Cell Disorders: Poster I (2784–2823)
- 908. Outcomes Research: Myeloid Malignancies: Poster I (2824–2860)
- 909. Education, Communication, and Workforce: Poster I (2861-2875)

6:30 p.m. – 8:00 p.m.	Hematology Inclusion Pathway (HIP) Oral
	Presentations - Classical Hematology

Hyatt Regency Orlando, Florida Ballroom C

6:30 p.m. – 8:00 p.m.	Hematology Inclusion Pathway (HIP) Oral
	Presentations – Health Services Outcomes

Hyatt Regency Orlando Plaza Int'l F

6:30 p.m 8:00 p.m.	Hematology Inclusion Pathway (HIP) Oral
	Presentations - Malignant Hematology I

Hyatt Regency Orlando Florida Ballroom A

6:30 p.m. – 8:00 p.m. Hematology Inclusion Pathway (HIP) Oral Presentations – Malignant Hematology II

Hyatt Regency Orlando, Florida Ballroom B

8:00 p.m. – 9:00 p.m. Hematology Inclusion Pathway Reception

Hyatt Regency Orlando, Plaza Int'l DE,

SUNDAY, DECEMBER 7, 2025

7:00 a.m. – 5:00 p.m.	Registration and Materials Pick-Up (for
	in-person participants)

West Building Level 1
Westwood Lobby

7:00 a.m. – 6:00 p.m.	Learn, Engage, and Relax in ASH Central
	(for in-person participants)

West Hall C

7:00 a.m. – 9:00 a.m.	ASH Foundation Run/Walk

South Building Driveway

7:00 a.m. – 9:00 a.m.	Medical Educators' Symposium

Hyatt Regency Orlando, Plaza Int'l DEFG,

8:00 a.m 9:00 a.m.	Coffee and Collaboration in ASH Central
	(for in-person participants)

West Hall C

8:00 a.m. – 8:00 p.m.	Poster Session II - Viewing

West Halls B3-B4

Chemotherapy-Free Treatments for Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma Hosted by Blood Neoplasia

West Halls B3-B4

8:00 a.m. – 9:00 a.m.	How I Treat (Ticketed Session)

How I Treat: Baby on Board: Managing the Hematological Pregnant Patient Hyatt Regency Orlando, Bayhill 23

How I Treat: Clinical Management of Refractory ITP

Hyatt Regency Orlando, Bayhill 27

How I Treat: How I Incorporate Mutational Profiling into Treatment of AML: Considerations Based on Age, Complex Cytogenetics, and Other Clinical Factors

Hyatt Regency Orlando, Bayhill 31

How I Treat: How I Incorporate Novel Therapies into Hodgkin Lymphoma Treatment: Frontline vs. Relapse

Hyatt Regency Orlando, Bayhill 29

How I Treat: How I Optimize Hemophilia Management: The Role of Novel Treatments

Hyatt Regency Orlando, Bayhill 25

8:00 a.m. - 9:00 a.m. Industry Theaters

Studying Measurable Residual Disease by Phenotype and Genotype Using Flow Cytometry

W209C

8:00 a.m. – 9:00 a.m. Meet the Scientist (Ticketed Session)

Meet The Scientist: Clonal Evolution in Acute Myeloid Leukemia **Hyatt Regency Orlando, Bayhill 19**

Meet The Scientist: Hematopoietic Clones - To Be or Not To Be **Hyatt Regency Orlando, Bayhill 22**

Meet the Scientist: Molecularly Targeted Therapies in Lymphoma Hyatt Regency Orlando, Bayhill 17

Meet The Scientist: Novel Genetic Markers in Blood Transfusion for Improved Matching

Hyatt Regency Orlando, Bayhill 20

8:00 a.m. - 9:00 a.m. Product Theaters

A Consideration for Patients with Relapsed or Refractory Multiple Myeloma W2084R

A New BsAb Treatment for R/R Multiple Myeloma After 4 Prior Lines
W204BC

Advancing Care in RRMM: Clinical Evidence for a BCMA-Directed Bispecific Antibody Treatment Option (Program will begin with a patient's own story)
W209AB

Cablivi (caplacizumab-yhdp) Real-World Evidence in 1,000+ Patients: Early Initiation Matters

W207BC

Transforming Thalassemia Care: Introducing a New Treatment Option from Agios Pharmaceuticals

W206A

8:30 a.m. – 9:00 a.m. ASH Studio (MedEd Talks)

Classical Hematology Advancement Mentorship Program (CHAMP) West Hall C

9:00 a.m. – 9:30 a.m. Coffee Break in the Poster Hall (for inperson participants)

West Halls B3-B4

9:00 a.m. – 9:30 a.m. ASH Studio (Treating Fairly Talks)

From Precision Medicine to Personalized Care: Meeting Patients Where They Are

West Hall C

9:05 a.m. - 9:15 a.m. ASH Wellness Studio

Sneaky Ways to Move More West Hall C

9:15 a.m. - 9:25 a.m.

ASH Wellness Studio

The Chair Check
West Hall C

9:15 a.m. - 9:45 a.m.

Blood Journals Studio

Meet the Journal Editors: Blood Neoplasia

West Halls B3-B4

9:30 a.m. - 10:45 a.m. Education Program

Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders W304ABCD

Our Patient Is Pregnant: Comanaging Obstetric Patients with Complex Hematologic Issues During Their Pregnancy and Delivery

Hyatt Regency Orlando, Regency Ballroom S

Treatment Refinement in Multiple Myeloma West Hall E2

What's New and Current in the World of Bone Marrow Failure
Hyatt Regency Orlando, Regency Ballroom OPQ

9:30 a.m. - 10:45 a.m. Scientific Program

Scientific Committee on Hemostasis: Harnessing the Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins
W311EFGH

......

9:30 a.m. - 11:00 a.m. Oral Abstract Sessions

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Orphans of an orphan disease: HbSC and HbSBeta+ sickle cell Disease

W308

301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders

W304EFGH

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets, leukocytes, and endothelium in thrombotic and vascular disease

W307

506. Bone Marrow Microenvironment: The microenvironment in homeostasis and aging

Hyatt Regency Orlando, Regency Ballroom R

602. Myeloid Oncogenesis: Basic: Targeting the NPM1/KMT2A/Menin axis **W314**

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Therapy resistance across B-cell maturation - from B-ALL to myeloma **W224CDGH**

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Emerging Treatment Paradigms in ALL

W224ABEF

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Lessons from across the age spectrum

Valencia Room W415BC

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: AML Biomarkers in Action: Prognosis, Risk, and Real-World Insights

Valencia Room W415A

621. Lymphomas: Translational – Molecular and Genetic - Decoding Lymphomagenesis through Multiomics

Tangerine Ballroom F1

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Immunotherapies for Follicular Lymphoma

West Hall D2

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Clinical and Biological Predictors of Outcome

Tangerine Ballroom F2

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Targeted Agents and Chemotherapy Intensification in Aggressive B-cell Lymphomas Tangerine Ballroom F3

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Between a Rock and a Ropeg - Innovative Therapies for MPNs **W414AB**

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML

Valencia Room W415D

653. Multiple Myeloma: Clinical and Epidemiological: From Biomarkers to Biology: Evolving Risk Stratification and Disease Modeling in Multiple Myeloma West Hall D1

702. CAR-T Cell Therapies: Basic and Translational: Product biology and single-cell states shaping CAR-T cell outcomes
Sunburst Room (W340)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Factors Influencing Transplant Outcomes

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Biologic Predictors and Novel Platforms Integrating CAR T with Transplant

Chapin Theater (W320)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Redefining supportive care: Development of novel safety, patient engagement, and delivery models in hematologic oncology **W230**

9:30 a.m. – 11:00 a.m.	How Can Community-Based and Academic
	Hematologists Foster Clinical Trial
	Participation as Part of Patient Care?

Hyatt Regency Orlando Plaza Int'l HIJK

9:30 a.m. – 11:00 a.m.	Leveraging Real-World Data in Multiple Myeloma for Regulatory Purposes
West Hall E1	
9:30 a.m. – 11:00 a.m.	To, Through and Thereafter: Guiding Sickle
	Cell Disease Patients Considering Gene
	Therapy

W311ABCD

9:30 a.m. – 11:00 a.m. Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults

W414CD

9:30 a.m. - 11:05 a.m. Scientific Program

Scientific Committee on Hematopathology and Clinical Laboratory Hematology and Scientific Committee on Hematopoiesis: JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging W312

10:00 a.m. - 5:00 p.m. Exhibits Open

West Halls A3-B2

11:00 a.m. - 11:30 a.m. ASH Studio (Treating Fairly Talks)

Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations

West Hall C

11:00 a.m. – 12:30 p.m. Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

West Halls A3-B2

11:00 a.m. – 12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ The Plaza

11:00 a.m. - 12:30 p.m. LGBTQIA+ Community Networking Brunch

Hyatt Regency Orlando, Plaza Int'l DEFG

11:05 a.m. - 11:15 a.m. ASH Wellness Studio

Reignite Your Resilience

West Hall C

11:15 a.m. - 12:15 p.m. ASH Poster Walks

Exploring and Targeting Emerging Mechanisms of Disease to Advance Human Health Hosted by Blood Red Cells and Iron

West Halls B3-B4

11:15 a.m. – 12:15 p.m. Blood Advances Presents: How to Peer Review a Scientific Paper

W314

11:15 a.m. – 12:15 p.m. Trainee Didactic Sessions (Open to Trainees Only)

Basic Statistics for Hematologists **W308**

Drug Development **W307**

11:15 a.m. – 12:30 p.m. ASH Clin

ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns

Hyatt Regency Orlando, Florida Ballroom

11:20 a.m. - 11:30 a.m. ASH Wellness Studio

Brain-Boosting Break

West Hall C

11:30 a.m. - 12:00 p.m. ASH Studio (MedEd Talks)

Online Hematology Curriculum/Podcast

West Hall C

11:30 a.m. - 12:30 p.m. Product Theaters

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

W207BC

A New Treatment Option in Multiple Myeloma

***ZOOA

Discover a New Way Forward with WAYRILZ

W209C

Exploring a Subcutaneous Treatment Option in Hemophilia Care with HYMPAVZI (marstacimab-hncq)

W206A

First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma

W203AB

Latest POLARIX Primary and 5-Year Outcomes Data

W209AB

Reignite the Spark: Clinical Conversations about Jaypirca (pirtobrutinib)

W204BC

11:30 a.m. - 12:30 p.m. Treating Fairly Rounds Lunch

Hyatt Regency Orlando, Manatee Spring

11:35 a.m. - 11:45 a.m. ASH Wellness Studio

Emotional Freedom Technique

West Hall C

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Erythropoiesis, Inflammation and Hematologic Recovery: The Iron and Heme Drama Unfolds

W311EFGH

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: On the Horizon: Biomarkers Guiding Outcomes in Hemoglobinopathies

W311ABCD

322. Hemophilia A and B: Clinical and Epidemiological: Innovations Shaping the Future of Hemophilia Care

W304EFGH

401. Blood Transfusion: Transfusion Frontlines: Research Driving Safer, Smarter Care

Sunburst Room (W340)

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Optimizing risk stratification, treatment, and diagnostics of ALL in the immunotherapy era

W224ABEF

622. Lymphomas: Translational - Non-Genetic: T cell interactions in the lymphoma microenvironment - the good and the bad

Tangerine Ballroom F1

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Fresh insight for Cutaneous and Virus-associated TCLs

Tangerine Ballroom F2

628. Aggressive Lymphomas: Cellular Therapies: Clinical Insights and Determinants of Resistance to Cellular Therapies in Aggressive Lymphomas

Tangerine Ballroom F3

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Emerging Myeloma Disease Mechanisms and Therapeutic Strategies **West Hall E1**

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Redefining diagnosis, monitoring and treatment approaches

West Hall E2

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Biomarkers and Targets

Chapin Theater (W320)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and elucidating relapse

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing

W304ABCD

908. Outcomes Research: Myeloid Malignancies: Treatment and Outcomes in the Real-World

W414CD

12:30 p.m. – 1:30 p.m.	ASH-EHA Joint Symposium
West Hall D2	
1:30 p.m. – 2:00 p.m.	Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Advancing Inclusive Excellence Award, and the Outstanding Service Award
West Hall D2	

1:30 p.m. – 2:00 p.m. ASH Studio (Treating Fairly Talks)

A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary

West Hall C

2:00 p.m. – 4:00 p.m.	Plenary Scientific Session
West Hall D2	

4:00 n m = 4:15 n m	Clinical Trial Showcases
4:00 p.m. – 4:15 p.m.	Cillical Irial Showcases

LIBRA – SCD: A Group Sequential Phase 2/3 Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD) W208AB

4:00 p.m. – 4:30 p.m. Blood Journals Studio

Meet the Journal Editors: Blood

West Halls B3-B4

4:00 p.m. – 4:30 p.m. Coffee Break in the Exhibit Hall (for inperson participants)

West Halls A3-B2

4:00 p.m. – 4:30 p.m. ASH Studio (Treating Fairly Talks)

Promoting Language Equity in Care and Research
West Hall C

4:05 p.m. – 4:15 p.m. ASH Wellness Studio

Snacks For Better Fuel

West Hall C

4:15 p.m. – 4:25 p.m. ASH Wellness Studio

Center Yourself West Hall C

4:15 p.m. - 4:30 p.m. Clinical Trial Showcases

LUMINA 3 – wAIHA: A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)

W208AB

4:30 p.m. – 5:45 p.m. Education Program

Arterial Disease and the Hematologist **W307**

Decoding the Enigma: Challenges in Classical Hematology Consultations W304ABCD

Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?

Hyatt Regency Orlando, Regency Ballroom R

New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives) **W331**

Sickle Cell Therapies: The Who, What, When, and Where West Hall D2

4:30 p.m. - 5:45 p.m. Education Spotlight Sessions

The Changing Face of Chronic Myelogenous Leukemia **W414AB**

4:30 p.m. – 5:45 p.m. Scientific Spotlight Sessions

The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It

Sunburst Room (W340)

4:30 p.m. - 6:00 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis: clinical relevance

W311EFGH

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Therapies in Sickle Cell Disease: Finding Progress in Existing Drugs
W311ABCD

201. Granulocytes, Monocytes, and Macrophages: New findings in neutropenia and myelopoiesis

W314

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: The immune system's first move: early lymphocyte development to disease states

Hyatt Regency Orlando, Regency Ballroom OPQ

503. Clonal Hematopoiesis, Aging, and Inflammation: Novel approaches in suppressing clonal hematopoiesis

W312

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance mechanisms and targeting approaches

Valencia Room W415D

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Adapted Treatment and Immune Targeting for Frontline and Relapsed ALL in Pediatric and Adults

W224CDGH

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and chemotherapy combinations in AML

Chapin Theater (W320)

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis

Valencia Room W415BC

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Novel Treatments for and Insights into Mantle Cell Lymphoma

Tangerine Ballroom F2

628. Aggressive Lymphomas: Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas

Tangerine Ballroom F3

636. Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression

Valencia Room W415A

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL

W224ABEF

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic, Gene Regulatory, Immune Evolution in MM

West Hall E2

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: New therapies and treatment goals for AL amyloidosis

Tangerine Ballroom F1

654. Multiple Myeloma: Pharmacologic Therapies: Bi, Tri and Beyond: Innovations in Bispecific and Trispecific Antibodies for Multiple Myeloma
West Hall E1

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Cancer, Clots and Coagulation **W308** 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Quality of Life and Supportive Care in Lymphoid Malignancies **W230**

907. Outcomes Research: Plasma Cell Disorders: Therapeutic Toxicity in Multiple Myeloma: Real-World Evidence and Clinical Approaches **West Hall D1**

908. Outcomes Research: Myeloid Malignancies: Real-World Experiences **W414CD**

4:30 p.m 6:00 p.m.	ASH Clinical Practice Guidelines on
	Aplastic Anemia

Hyatt Regency Orlando, Plaza Int'l HIJK

4:30 p.m. – 6:00 p.m.	Early Faculty Career Development Session	
Hyatt Regency Orlando, Regency Ballroom S		
4:30 p.m. – 6:00 p.m.	Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults	
W304EFGH		
6:00 p.m. – 8:00 p.m.	Poster Hall Reception (for in-person participants)	

West Halls B3-B4

6:00 p.m. – 8:00 p.m.	Poster Session II - Presentations (for in-
	person participants)

West Halls B3-B4

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2876–2900)
- 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II (2901–2911)
- 112. Thalassemia and Globin Gene Regulation: Poster II (2912–2921)
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II (2922–2937)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II (2938–2976)
- 201. Granulocytes, Monocytes, and Macrophages: Poster II (2977–2999)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (3000–3011)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster II (3012–3026)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (3027–3049)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (3050–3060)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster II (3061–3076)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II (3077–3092)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II (3093–3101)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II (3102–3116)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (3117–3140)
- 401. Blood Transfusion: Poster II (3141-3147)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (3148–3159)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II (3160–3177)

- 506. Bone Marrow Microenvironment: Poster II (3178–3187)
- 508. Bone Marrow Failure: Acquired: Poster II (3188–3210)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (3211–3222)
- 602. Myeloid Oncogenesis: Basic: Poster II (3223-3250)
- 603. Lymphoid Oncogenesis: Basic: Poster II (3251-3263)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (3264–3295)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (3296–3316)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (3317–3336)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II (3337–3359)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II (3360–3374)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (3375–3414)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II (3415–3433)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II (3434–3466)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II (3467–3511)
- 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster II (3512–3519)
- 621. Lymphomas: Translational Molecular and Genetic: Poster II (3520–3548)
- 622. Lymphomas: Translational Non-Genetic: Poster II (3549-3568)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3569–3616)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II (3617–3630)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II (3631–3657)
- 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster II (3658–3680)
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II (3681–3704)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster II (3705–3731)
- 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II (3732–3748)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3749–3768)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3769–3789)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3790–3829)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster II (3830–3841)

- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II (3842–3874)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II (3875–3882)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3883–3913)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3914–3957)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3958–3974)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster II (3975–4028)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster II (4029–4065)
- 655. Multiple Myeloma: Cellular Therapies: Poster II (4066-4079)
- 701. Experimental Transplantation: Basic and Translational: Poster II (4080–4095)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster II (4096–4128)
- 703. Cellular Immunotherapies other than CAR-T Cells: Poster II (4129–4140)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II (4141–4177)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II (4178–4188)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II (4189–4221)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II (4222–4256)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II (4257–4287)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (4288–4307)
- 801. Gene Therapies: Poster II (4308-4321)
- 802. Chemical Biology and Experimental Therapeutics: Poster II (4322–4330)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II (4331–4363)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II (4364–4379)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4380–4397)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II (4398–4424)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II (4425–4436)
- 904. Outcomes Research: Hemoglobinopathies: Poster II (4437–4453)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4454–4479)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II (4480–4561)
- 907. Outcomes Research: Plasma Cell Disorders: Poster II (4562–4601)
- 908. Outcomes Research: Myeloid Malignancies: Poster II (4602–4638)
- 909. Education, Communication, and Workforce: Poster II (4639–4653)

MONDAY, DECEMBER 8, 2025

7:00 a.m. – 5:00 p.m. Registration and Materials Pick-Up (for in-person participants)

7:00 a.m. – 6:00 p.m.

Learn, Engage, and Relax in ASH Central (for in-person participants)

West Hall C

West Building Level 1

57

7:00 a.m. – 7:45 a.m.	ASH Yoga (for in-person participants)
ASH Park @ The Plaza	
8:00 a.m. – 9:00 a.m.	Coffee and Collaboration in ASH Central (for in-person participants)
West Hall C	

8:00 a.m. - 8:00 p.m. Poster Session III - Viewing

West Halls B3-B4

8:00 a.m. - 9:00 a.m. **ASH Poster Walks**

Rewiring T Cells: Emerging Strategies to Boost Cancer Immunotherapy Hosted by Blood Immunology & Cellular Therapy

West Halls B3-B4

8:00 a.m. - 9:00 a.m. **Product Theaters**

Introducing a Therapeutic Option in Relapsed/Refractory Acute Leukemia W208AB

Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL W209C

8:00 a.m. - 9:00 a.m. **Back to Business Breakfast**

Hyatt Regency Orlando, Florida Ballroom A

8:30 a.m. - 9:00 a.m. **ASH Studio (Treating Fairly Talks)**

A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary

West Hall C

9:00 a.m. - 10:00 a.m. E. Donnall Thomas Lecture and Prize

West Hall D2

10:00 a.m. – 10:15 a.m. Company Showcases

Innovative Transplant Strategies: Omidubicel Interim Phase II Results in Severe Aplastic Anemia W209C

10:00 a.m. - 10:30 a.m. **Blood Journals Studio**

Meet the Journal Editors: Blood Red Cells & Iron

West Halls B3-B4

10:00 a.m. - 10:30 a.m. ASH Studio (Treating Fairly Talks)

Impact of Geography on Care

West Hall C

10:00 a.m. - 2:00 p.m. **Exhibits Open**

West Halls A3-B2

10:00 a.m. - 10:30 a.m. Coffee Break in the Exhibit Hall (for inperson participants)

West Halls A3-B2

ASH Wellness Studio 10:05 a.m. – 10:15 a.m.

Reset Your Posture

West Hall C

ASH Wellness Studio 10:15 a.m. - 10:25 a.m.

Happy Hands and Wrists

West Hall C

10:30 a.m. - 11:45 a.m. Education Program

Invasion of the Immunotherapies: Where We Are and Where We Are Going in Leukemia, Lymphoma, and Myeloma

West Hall D2

Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit

West Hall D1

Targeted Therapy for AML (Triplets and More)

W414CD

Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/ Issues in Older Patients

W307

10:30 a.m. - 11:45 a.m. **Scientific Program**

Scientific Committee on Transfusion Medicine: TRIMming the Immune Response: Cutting-Edge Insights into Transfusion-Related Immunomodulation

10:30 a.m. - 11:45 a.m. Scientific Symposia

Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny

W312

10:30 a.m. - 11:45 a.m. Education Spotlight Sessions

Asparaginase in ALL/LBL: Balancing the Risk/Benefit of New Efficacious **Preparations**

W230

Transfusion Medicine for Practicing Hematologists: How to Prevent and Treat Potentially Fatal Reactions in Sickle Cell Disease

10:30 a.m. - 11:45 a.m. Scientific Spotlight Sessions

Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally

Tangerine Ballroom F2

Creative and Novel Statistical Techniques to Design and Analyze Data for Trials Focused on Rare Hematologic Diseases

Hyatt Regency Orlando, Regency Ballroom R

10:30 a.m. - 12:00 p.m. ASH-FDA Joint Symposium on Newly Approved Therapies I

Hyatt Regency Orlando, Regency Ballroom S

10:30 a.m. – 12:00 p.m. Oral Abstract Sessions

112. Thalassemia and Globin Gene Regulation: Murine models and a clinical approach to reduce toxicity, modulate hemoglobin F and improve outcomes in thalassemia

W311ABCD

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: The Evolving ITP Toolkit: Maximizing Efficacy, Minimizing Side Effects W304EFGH

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Innovations in Thrombosis and Bleeding: Diagnostics, Therapeutics, and Predictive Modeling

W304ABCD

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Inheritance to Innovation

Hyatt Regency Orlando, Plaza Int'l HIJK

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel targets and drugs

Valencia Room W415BC

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Predicting and improving outcomes in common and rare subgroups of pediatric ALL W224CDGH

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin inhibitors and FLT3 inhibitors in AML

Chapin Theater (W320)

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Decoding the Immunopathobiology of Acute Myeloid Leukemia

W414AB

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell Lymphoma

Tangerine Ballroom F1

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-world data to assess CAR outcomes and frailty

Tangerine Ballroom F3

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Lower risk Myelodysplastic Syndromes and Myelodysplastic/ Myeloproliferative Neoplasms

Valencia Room W415A

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: MRD Guided Therapy and Emergence of Resistance

W224ABEF

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: T Cell-Redirecting Therapies in Myeloma: Novel therapeutic strategies and biology

West Hall E1

702. CAR-T Cell Therapies: Basic and Translational: Mechanisms of CAR-T cell toxicity and persistence

W331

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging CAR-T Cell Therapies for Acute Leukemias and Autoimmune Diseases

Valencia Room W415D

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Clinical and Translational Insights

Sunburst Room (W340)

907. Outcomes Research: Plasma Cell Disorders: Special Populations in Plasma Cell Disorders: Efficacy and Safety of Therapies in Real-World Settings West Hall E2

909. Education, Communication, and Workforce: Innovating to Bridge Gaps and Improve Access: Education, Communication, and Workforce in Hema-

Hyatt Regency Orlando, Regency Ballroom OPQ

12:00 p.m. - 12:20 p.m. Blood Journals Studio

Meet the Journal Editors: Blood Global Hematology West Halls B3-B4

12:00 p.m. - 12:30 p.m. **ASH Studio (Treating Fairly Talks)**

Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations

West Hall C

12:00 p.m. – 1:30 p.m.	Complimentary Light Lunch in the Exhibit
	Hall (for in-person participants)

West Halls A3-B2

12:00 p.m. – 1:30 p.m.	Live Music and Outdoor Lunch Seating (f	
	in-person participants)	

ASH Park @ The Plaza

12:00 p.m. – 1:30 p.m.	Celebrating Diverse Voices: Enriching
	Hematology Lunch

Hyatt Regency Orlando, Florida Ballroom A

12:05 p.m. - 12:15 p.m. **ASH Wellness Studio**

Emotional Freedom Technique West Hall C

12:15 p.m. - 1:15 p.m. Trainee Didactic Sessions (Open to Trainees Only)

Application of Microarray and Bioinformatics in Hematology

Outcomes Research in Hematology W308

12:15 p.m. - 1:15 p.m. **Industry Theaters**

Pyruvate Kinase Activation in Hemolytic Anemias and Insights into its Mechanism

W206A

12:15 p.m. - 1:15 p.m. **Product Theaters**

First-Line Treatment Option for Anemia in Lower-Risk MDS COMMANDS Trial Overview

W209C

From Innovation to Impact: Real Stories of Transformation in PNH Management

W207BC

Making the Case for Early Use of CAR-T Therapy in Multiple Myeloma

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

W208AB

12:20 p.m. - 12:30 p.m. ASH Wellness Studio

Reignite Your Resilience

West Hall C

12:30 p.m. – 1:00 p.m. ASH Studio (MedEd Talks)

Innovative Teaching Approaches for Adult Learning West Hall C

12:30 p.m. – 1:30 p.m. ASH Poster Walks

Leukemia in Latin America: Bridging Gaps in Genetics, Access, and Innovation Hosted by Blood Global Hematology

West Halls B3-B4

12:35 p.m. - 12:45 p.m. ASH Wellness Studio

Shake It Off West Hall C

1:00 p.m. – 1:30 p.m. ASH Studio (Treating Fairly Talks)

Breaking Financial Barriers to Care Through Affordable Innovation
West Hall C

1:30 p.m. – 2:30 p.m. Ernest Beutler Lecture and Prize

West Hall D2

2:30 p.m. – 2:45 p.m. Coffee Break in the Poster Hall (for inperson participants)

West Halls B3-B4

2:35 p.m. - 2:45 p.m. ASH Wellness Studio

Plug Into Nature

West Hall C

2:45 p.m. – 4:00 p.m. Education Program

B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders?

West Hall D2

Biology-Based Management of Iron Toxicity and Overload in Hematology

Hyatt Regency Orlando, Regency Ballroom OPQ

Genomics in Pediatric Acute Leukemia Risk Stratification

W224CDGH

Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR-Ts, allo-HSCT - How, When, and Why?

West Hall E2

2:45 p.m. - 4:00 p.m. Scientific Program

Scientific Committee on Megakaryocytes and Platelets: The Critical Role of Metabolism in Megakaryocyte and Platelet Biology

W314

Scientific Committee on Myeloid Biology: Mechanisms that Direct and Derail Lineage-Specific Gene Expression Programs in Myelopoiesis

Valencia Room W415D

2:45 p.m. - 4:00 p.m. Scientific Symposia

Targeting Cancer Metabolism – Innovative Methods to Translation W312

2:45 p.m. – 4:00 p.m. Education Spotlight Sessions

Joint Session with ASPHO: Transition to Adult Care in Malignant and Classical Hematology

Hyatt Regency Orlando, Regency Ballroom S

2:45 p.m. – 4:00 p.m. Scientific Spotlight Sessions

Epigenomic Frontiers in the Diagnosis of Hematological Malignancies **W230**

2:45 p.m. – 4:15 p.m. Oral Abstract Sessions

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Translational Therapeutics - Emerging Targets in Sickle Cell Disease

W308

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Game Changers in Platelet disorders: A Look at Novel Therapies

W304EFGH

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Old Dogs, New Tricks; Advances in Thrombotic Microangiopathy Diagnosis and Treatment

W307

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism and signaling in hematopoietic stem cell fate W311EFGH

506. Bone Marrow Microenvironment: The microenvironment in regenerative and pre/malignant hematopoiesis

Hyatt Regency Orlando, Plaza Int'l HIJK

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Optimizing Standards of Care

Valencia Room W415A

617. Acute Myeloid Leukemias: Commercially Available Therapies: Pediatric, adolescent and young adult AML

Valencia Room W415BC

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL

Tangerine Ballroom F1

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: From bench to bedside and retrospective studies to inform treatment consideration in TCL

Tangerine Ballroom F2

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-World data on clinical predictors of outcome

Tangerine Ballroom F3

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Therapeutic agents to enhance patient outcomes

Chapin Theater (W320)

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Beyond JAK Inhibition - Therapeutic Innovation and Transplant Strategies in Myelofibrosis

W414AB

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Enhancing Immune Therapy in MM

West Hall D1

653. Multiple Myeloma: Clinical and Epidemiological: Novel Baseline and Dynamic Risk Factors in Multiple Myeloma

West Hall E1

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Optimizing CAR T-Cell Therapy: Focus on Adjuvant Strategies and Toxicity Sunburst Room (W340)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond

W331

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Enhancing Clinical Decision-Making with Next-Generation Molecular and Cellular Technologies

Hyatt Regency Orlando, Regency Ballroom R

900. Health Services and Quality Improvement: Hemoglobinopathies: From Screening to Access: Pathways to Improving Care

W311ABCD

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care W304ABCD

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Novel topics in CAR-T and T-cell engager therapies

W224ABFF

908. Outcomes Research: Myeloid Malignancies: Health Disparities and Patient-Centered Care

W414CD

4:30 p.m. – 5:45 p.m. Education Program

Monoclonal Gammopathies of Clinical Significance
West Hall E2

4:30 p.m. - 5:45 p.m. Education Spotlight Sessions

How to Prevent and Manage Infections in Immunocompromised Patients in the Era of Immunotherapy and Growing Antibiotic Resistance **Hyatt Regency Orlando, Regency Ballroom OPQ**

4:30 p.m. – 5:45 p.m. Scientific Spotlight Sessions

Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias

W224CDGH

4:30 p.m. – 6:00 p.m. Scientific Symposia

Special Symposium on the Basic Science in Hemostasis and Thrombosis
Valencia Room W415D

4:30 p.m. – 6:00 p.m. ASH-FDA Joint Symposium on Newly Approved Therapies II

Hyatt Regency Orlando, Regency Ballroom S

4:30 p.m. – 6:00 p.m. ASH's SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care

W230

4:30 p.m. - 6:00 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Erythroid differentiation W311EFGH

503. Clonal Hematopoiesis, Aging, and Inflammation: New insights into inflammatory drivers of normal and clonal hematopoiesis W312

508. Bone Marrow Failure Acquired: Therapeutic advancements in AA, PNH, and VEXAS

Hyatt Regency Orlando, Plaza Int'l HIJK

602. Myeloid Oncogenesis: Basic: New insights in clonal evolution and models of disease **W414CD**

615. Acute Myeloid Leukemias: Clinical and Epidemiological: AML Medley: Mutations, complications, classifications

W414AB

617. Acute Myeloid Leukemias: Commercially Available Therapies: Combination regimens and targeted therapies

Chapin Theater (W320)

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Follicular Lymphoma

Tangerine Ballroom F2

628. Aggressive Lymphomas: Cellular Therapies: Emerging Approaches to Enhance Cellular Therapies and Real World Outcomes in Aggressive Lymphomas

Tangerine Ballroom F3

629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Improving Outcomes in Rare Large Cell Lymphomas

Tangerine Ballroom F1

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Drivers and Mast Cells and Blasts, Oh My! - Insights and Treatments for MPNs and Mastocytosis.

West Hall D2

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Determinants of Immunotherapy Response in Multiple Myeloma

West Hall E1

653. Multiple Myeloma: Clinical and Epidemiological: Direct from podium to clinic

West Hall D1

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Advancing Cell Therapies in T Cell Malignancies and AML

Valencia Room W415BC

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization

Hyatt Regency Orlando, Regency Ballroom R

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Precision AML Care; Reducing Relapse and Enhancing Survival Valencia Room W415A

801. Gene Therapies: Technological Developments in Gene Therapy Sunburst Room (W340)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Risk Assessment, and Care Optimization, and AI, Oh my! The Spectrum of Quality in Classical Hematology W308

902. Health Services and Quality Improvement: Lymphoid Malignancies: Innovations to address real-world barriers and optimize delivery of CAR-T and bispecific antibody therapies

W224ABEF

903. Health Services and Quality Improvement: Myeloid Malignancies: Where smarter care begins: technological innovations and quality improvement in myeloid malignancies

W314

904. Outcomes Research: Hemoglobinopathies: Global burden of Hemoglobinopathies: From Crisis to Care

W311ABCD

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps **W307**

6:00 p.m. – 7:30 p.m.	ASH Hemostasis and Thrombosis Community Networking Reception
Valencia Foyer	
6:00 p.m. – 8:00 p.m.	Center for Sickle Cell Disease Initiatives Reception
W240	
6:00 p.m. – 8:00 p.m.	Poster Hall Reception (for in-person participants)

West Halls B3-B4

6:00 p.m. – 8:00 p.m.	Poster Session III - Presentations (for in-
	person participants)

West Halls B3-B4

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (4654–4677)
- 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster III (4678–4688)
- 112. Thalassemia and Globin Gene Regulation: Poster III (4689–4699)
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (4700–4715)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (4716–4754)
- 201. Granulocytes, Monocytes, and Macrophages: Poster III (4755–4776)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (4777–4789)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster III (4790–4803)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (4804–4827)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (4828–4837)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster III (4838–4853)

- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III (4854–4868)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III (4869–4877)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III (4878–4893)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4894–4918)
- 401. Blood Transfusion: Poster III (4919-4925)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4926–4937)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III (4938–4955)
- 506. Bone Marrow Microenvironment: Poster III (4956–4966)
- 508. Bone Marrow Failure: Acquired: Poster III (4967-4988)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4989–4999)
- 602. Myeloid Oncogenesis: Basic: Poster III (5000-5029)
- 603. Lymphoid Oncogenesis: Basic: Poster III (5030-5042)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (5043–5072)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (5073–5094)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (5095–5114)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III (5115–5136)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III (5137–5151)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (5152–5192)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III (5193–5211)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III (5212–5244)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III (5245–5290)
- 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster III (5291–5298)
- 621. Lymphomas: Translational Molecular and Genetic: Poster III (5299–5326)
- 622. Lymphomas: Translational Non-Genetic: Poster III (5327–5347)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (5348–5394)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III (5395–5408)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III (5409–5434)
- 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster III (5435–5457)
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III (5458–5481)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster III (5482–5507)
- 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III (5508–5525)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (5526–5544)

- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (5545–5567)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (5568–5608)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster III (5609–5620)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III (5621–5652)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III (5653–5661)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (5662–5692)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (5693–5735)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (5736–5751)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster III (5752–5807)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster III (5808-5845)
- 655. Multiple Myeloma: Cellular Therapies: Poster III (5846-5857)
- 701. Experimental Transplantation: Basic and Translational: Poster III (5858–5873)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster III (5874–5906)
- 703. Cellular Immunotherapies other than CAR-T Cells: Poster III (5907–5918)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III (5919–5955)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III (5956–5967)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III (5968–6001)

- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III (6002–6035)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III (6036–6064)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (6065–6086)
- 801. Gene Therapies: Poster III (6087-6099)
- 802. Chemical Biology and Experimental Therapeutics: Poster III (6100-6109)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III (6110–6143)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III (6144–6159)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6160–6176)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III (6177–6203)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III (6204–6215)
- 904. Outcomes Research: Hemoglobinopathies: Poster III (6216-6231)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6232–6258)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III (6259–6340)
- 907. Outcomes Research: Plasma Cell Disorders: Poster III (6341–6379)
- 908. Outcomes Research: Myeloid Malignancies: Poster III (6380–6416)
- 909. Education, Communication, and Workforce: Poster III (6417–6430)

7:30 p.m. – 9:30 p.m. Women in Hematology Networking Event

Hyatt Regency Orlando, Plaza International Ballroom D-G

TUESDAY, DECEMBER 9, 2025

7:00 a.m. – 1:30 p.m.	Registration and Materials Pick-Up (for in-person participants)	9:30 a.m. – 9:45 a.m.	Announcement of Awards: William Dameshek Prize and Henry M. Stratton
West Building Level 1			Medals
		West Hall D2	
7:00 a.m. – 1:30 p.m.	Learn, Engage, and Relax in ASH Central		
·	(for in-person participants)	9:45 a.m. – 11:15 a.m.	Presidential Symposium
West Hall C		West Hall D2	
7:00 a.m. – 9:30 a.m.	Morning Coffee (for in-person participants)	11:15 a.m. – 11:30 a.m.	Business Meeting and Ceremonial Passing of the ASH President's Gavel
West Hall D2		West Hall D2	
7:30 a.m. – 9:00 a.m.	Late-Breaking Abstracts Session	11:30 a.m. – 1:00 p.m.	Best of ASH

West Hall D2

West Hall D2

WEDNESDAY, DECEMBER 10, 2025

12:00 a.m. – 11:59 p.m. Binge-Watch Content on the Virtual Platform

Virtual Platform

10:00 a.m. - 11:00 a.m. ASH Poster Walks

ASH Poster Walk on Population Health and Access to Care Virtual Platform

ASH Poster Walk on State of the Art Artificial Intelligence in Hematology Virtual Platform

THURSDAY, DECEMBER 11, 2025

12:00 a.m. – 11:59 p.m. Binge-Watch Content on the Virtual Platform

Virtual Platform

FRIDAY, DECEMBER 12, 2025

12:00 a.m. – 11:59 p.m. Binge-Watch Content on the Virtual

Platform

Virtual Platform

MARQUEE SESSIONS

These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential

Symposium. Many of the Marquee Sessions also honor distinguished leaders in the field through awards and special lectures.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY

Ham-Wasserman Lecture

Saturday 12:30 p.m. – 1:30 p.m. West Hall D2

Chair:

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

Speaker:

Chiara Bonini, MD, Vita-Salute San Raffaele University, Milan, Italy

Gene Transfer and Genome Editing of T Cells for Cancer Immunotherapy

SUNDAY

ASH-EHA Joint Symposium

Sunday 12:30 p.m. – 1:30 p.m. West Hall D2

Menin Inhibitors: Novel Targeted Agents for Treatment of Acute Myeloid Leukemia

Co-Chairs:

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

Konstanze Döhner, MD, President, European Hematology Association, University Hospital of Ulm, Ulm, Germany

Speakers:

Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Design and Development of Menin Inhibitors, Mechanisms of Action, Clinical Trial Results, and Safety

Marc Raaijmakers, MD, Erasmus Medical Center, Rotterdam, Netherlands

Review of Menin Inhibitors; Translational Aspects and Clinical Trials Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Advancing Inclusive Excellence Award, and the Outstanding Service Award

Sunday 1:30 p.m. – 2:00 p.m. West Hall D2

Chair:

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

Plenary Scientific Session

Sunday 2:00 p.m. – 4:00 p.m. West Hall D2

Chair:

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

MONDAY

E. Donnall Thomas Lecture and Prize

9:00 a.m. - 10:00 a.m. Monday West Hall D2

Chair:

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

Speaker:

Nancy Speck, PhD, University of Pennsylvania, Philadelphia, PA

Core Binding Factor in Blood Cell Formation and Leukemia

Ernest Beutler Lecture and Prize

Monday 1:30 p.m. - 2:30 p.m. West Hall D2

Myeloproliferative Neoplasms: How JAK2 Became Key to Better Diagnosis, Prognosis, and Targeted Therapy

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

Speakers:

Radek Skoda, MD, Baylor College of Medicine, Houston, TX Basic Science

Ruben A. Mesa, MD, Atrium Health Wake Forest, Winston-Salem, NC

Clinical/Translational Science

TUESDAY

Late-Breaking Abstracts Session

7:30 a.m. - 9:00 a.m. **Tuesday**

West Hall D2

Co-Chairs:

Payal Desai, MD, Levine Cancer Institute, Advocate Health, Wake Forest School of Medicine Charlotte, Charlotte, NC

Rayne Rouce, MD, Texas Children's Hospital, Houston, TX

Speakers:

Jane Churpek, MD, MS, University of Wisconsin-Madison, Madison, WI

Germline Predisposition for Myeloid Neoplasms

Eric Pietras, PhD, University of Colorado, Aurora, CO Role of the Microenvironment in Leukemogenesis

John DiPersio, MD, Washington University School of Medicine, Saint Louis, MO

Business Meeting and Ceremonial Passing of

11:15 a.m. – 11:30 a.m.

Novel Therapeutic Approaches

the ASH President's Gavel

Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals

Tuesday 9:30 a.m. - 9:45 a.m. West Hall D2

Chair:

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

Best of ASH

Tuesday

Tuesday 11:30 a.m. - 1:00 p.m. West Hall D2

West Hall D2

Co-Chairs:

Esther Obeng, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Betty Pace, MD, Augusta University, Augusta, GA

Presidential Symposium

Tuesday 9:45 a.m. - 11:15 a.m. West Hall D2

Clonal Hematopoiesis and the Path to Myeloid Malignancy

Chair:

Belinda Avalos, MD, President, American Society of Hematology, Advocate Health, Atrium Health Levine Cancer, Charlotte, NC

Scientific Program Co-Chairs: Esther Obeng, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Betty Pace, MD, Augusta University, Augusta, GA

Scientific Program

Scientific Program Sessions were developed by the Society's 18 Scientific Committees. They highlight emerging areas of science in the field of hematology and address topics referenced in ASH's Agenda for Hematology Research. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained.

Scientific Symposia

Scientific Symposia are crowd-sourced from the hematology community and feature transformative basic, translational, and clinical research poised to advance the field. There will be a panel discussion at the end of each session, during which questions from the audience will be entertained.

Scientific Spotlight Sessions

Scientific Spotlight Sessions are crowd-sourced from the hematology community and cover niche topic areas that are of interest to specific communities. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained.

Scientific Workshops

The Scientific Workshops are interactive discussions of the latest science developments in a particular field of hematology. All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

ASH Poster Walks

ASH Poster Walks highlight posters selected for the Annual Meeting that showcase emerging science in hematology. Five poster walks will take place as in-person sessions in the Blood Journals Studio during the Annual Meeting, and two will take place virtually following the Annual Meeting.

ASH Poster Walks are not offered for CME credit.

Meet the Scientist (Ticketed)

Meet the Scientist sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed breakfast will be provided.

Tickets are restricted to research and medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 5, at the Ticketed Sessions Counter in the Orange County Convention Center, Level 1 Concourse.

Ticket Prices (per session)

Active or International Members and Non-Members

Associate, International Associate, Resident, Graduate/Medical Student, Non-Member in Training, Allied Health Professional, or Honorary /Emeritus Members

\$50

\$90

Marrow Failure (non-CME)

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

FRIDAY

Scientific Workshop on Aging and Hematology (non-CME)

Friday 3:00 p.m. - 6:00 p.m. **W312BC**

Co-Chairs:

Richard Lin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Megan Weivoda, PhD, Mayo Clinic, Rochester, MN

3:00 p.m. - 3:03 p.m. **Opening Remarks**

3:03 p.m. - 3:44 p.m. The Natural Intervention: Diet

and Exercise-Based Strategies for Reversing Hematologic

Aging

Engineering the Immune 3:44 p.m. - 4:25 p.m.

System to Reverse Hematologic

4:35 p.m. - 5:16 p.m. Small Molecules, Big Impact:

Reversing Hematologic Aging by Targeting Senescence and

Inflammaging

A New Horizon in Hematology: 5:16 p.m. – 5:57 p.m.

Novel Strategies for Reversing

Aging

5:57 p.m. - 6:00 p.m. Closing Remarks

Friday 3:00 p.m. – 6:00 p.m. W307ABCD Co-Chairs: Lucy Godley, MD, PhD, Northwestern University, Chicago, ΙL Marcin Wlodarski, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN 3:00 p.m. - 3:05 p.m. **Opening Remarks** 3:06 p.m. - 3:48 p.m. Disease Models and Mechanisms: Bridging the Gap

Scientific Workshop on Germline Predisposition

to Hematopoietic Malignancies and Bone

Ribosomopathies: From 3:49 p.m. – 4:31 p.m. Diamond-Blackfan Anemia to Shwachman-Diamond Syndrome and Beyond

4:31 p.m. - 4:36 p.m.

4:36 p.m. - 5:12 p.m. DNA Repair Defects and

Germline Predisposition

5:12 p.m. – 5:55 p.m. Emerging Discoveries in Germline Predisposition

5:56 p.m. - 6:00 p.m. Closing Remarks

Scientific Workshop on Disease Severity Scoring and Clinical Trial Endpoints Beyond Vaso-occlusive Pain in Sickle Cell Disease

(non-CME)

Friday 3:00 p.m. - 6:00 p.m. **W315AB**

Co-Chairs:

Jane Hankins, MD, MS, St. Jude Children's Research Hospital, Memphis, TN

Dunia Hatabah, MD, Emory University, Atlanta, GA

Caterina Minniti, MD, Einstein College of Medicine, Chevy Chase, MD

Claudia Morris, MD, Emory University School of Medicine, Atlanta, GA

3:00 p.m. - 3:05 p.m. Opening Remarks

3:05 p.m. - 3:45 p.m. Disease Severity Scoring in Sickle Cell Disease

Endpoints and Surrogate 3:45 p.m. - 4:35 p.m.

Biomarkers

Acute Vaso-occlusive Pain 4:35 p.m. – 5:15 p.m. Clinical Trial Endpoints Beyond

Time-to-Crisis-Resolution in Sickle Cell Disease (SCD)

Where Do We Go from Here: 5:15 p.m. - 6:00 p.m. Stakeholder Discussion

6:00 p.m. - 6:00 p.m. Closing Remarks

Scientific Workshop on Host Factors in Cell and **Gene Therapy: Impact on Efficacy and Toxicity**

(non-CME)

Friday 3:00 p.m. - 6:00 p.m. W304ABCD

Co-Chairs:

Marina Cavazzana, MD, PhD, Necker Hospital, Paris, France

Daniel Powell, PhD, University of Pennsylvania, Philadelphia, PA

Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA

3:00 p.m. - 3:05 p.m. **Opening Remarks**

3:05 p.m. - 4:35 p.m. The Evolving Role of Exercise,

Obesity, Microbiome, and Diet in Cancer Immunotherapy

The Evolving Role of Sex, 4:31 p.m. – 5:57 p.m.

Inflammation and Aging in Cancer

Immunotherapy

5:57 p.m. - 6:00 p.m. Closing Remarks

Scientific Workshop on Interplay between Coagulation and Malignancy COO-CME

Friday 3:00 p.m. - 6:00 p.m.

W304GH

Co-Chairs:

Lisa Baumann Kreuziger, MD, MS, Versiti Blood Research Institute, Milwaukee, WI

Jeffrey Zwicker, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

3:00 p.m. - 3:04 p.m. Opening Remarks

3:04 p.m. - 4:04 p.m. Role of Coagulation in Cancer

Progression

4:04 p.m. – 5:45 p.m. Pathophysiology and Prediction

of Thrombosis in Patients with

Cancer

Closing Remarks 5:45 p.m. – 5:50 p.m.

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer and Normal **Hematopoiesis- From Discovery to Patients**

(non-CME)

Friday 3:00 p.m. - 6:00 p.m. **W414AB**

Co-Chairs:

Aaron Schimmer, MD, PhD, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Sarah Skuli, MD, PhD, University of Pennsylvania, Philadelphia, PA

3:00 p.m. - 3:05 p.m. **Opening Remarks**

Mitochondria and Metabolism -3:05 p.m. -3:55 p.m. Fundamental Discovery

3:55 p.m. -4:05 p.m. Break

4:05 p.m. - 4:55 p.m. Translational Research -

Targeting Mitochondria and Metabolism in Cancery4

4:55 p.m. -5:05 p.m.

Mitochondria and Metabolism -5:05 p.m. - 5:55 p.m.

Clinical Trials

5:55 p.m. - 6:00 p.m. Closing Remarks

Scientific Workshop on State of the Art: **Integrating Functional and Genomic Precision** Medicine for Hematologic Malignancies CON-CME

Friday 3:00 p.m. - 6:00 p.m. W308CD

Co-Chairs:

Pamela Becker, MD, PhD, City of Hope, Duarte, CA

Jun Yang, PhD, St. Jude Children's Research Hospital, Memphis, TN

3:00 p.m. - 3:05 p.m. **Opening Remarks**

3:05 p.m. - 4:40 p.m. Current Methodology for

Functional Drug Screening

4:40 p.m. - 4:50 p.m.

4:50 p.m. - 5:55 p.m. Response Prediction and Clonal

Evolution

Closing Remarks 5:55 p.m. - 6:00 p.m.

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies (non-CME)

Friday 3:00 p.m. - 6:00 p.m. W414CD

Co-Chairs:

Christina Glytsou, PhD, Rutgers, The State University of New Jersey, Piscataway, NJ

Panagiotis Ntziachristos, PhD, Ghent University, Ghent, Belgium

Daniel Starczynowski, PhD, Cincinnati Children's Hospital, Cincinnati, OH

3:00 p.m. - 3:01 p.m. **Opening Remarks**

Epigenetic And Chromatin 3:01 p.m. - 3:42 p.m.

Mechanisms

3:43 p.m. - 4:24 p.m. Post-Transcriptional

Mechanisms

4:24 p.m. - 4:32 p.m. Break

4:32 p.m. - 5:13 p.m. Translational and Post-

Translational Mechanisms

5:13 p.m. - 5:53 p.m. Metabolic Mechanisms and

Mitochondria Biology

5:54 p.m. - 6:00 p.m. Closing Remarks

69

Scientific Workshop on Translational Diagnostics in MRD - NGS, ctDNA and Beyond

(non-CME)

Friday 3:00 p.m. - 6:00 p.m.

W311ABCD

Co-Chairs:

Piers Blombery, MBBS, Peter MacCallum Cancer Centre,

Melbourne, Victoria, Australia

Torsten Haferlach, MD, PhD, Munich Leukemia

Laboratory, Munich, Germany

Ella Thompson, PhD, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Wencke Walter, MD, PhD. Munich Leukemia Laboratory, Munich, Germany

3:00 p.m. – 3:04 p.m. **Opening Remarks**

3:04 p.m. – 4:23 p.m. Translating ctDNA MRD for

patients with B-cell lymphoma

4:23 p.m. - 4:38 p.m. BREAK

4:38 p.m. - 5:57 p.m. New Developments in

> Measurable Residual Disease for Patients with Acute Myeloid

Leukemia

5:57 p.m. - 6:00 p.m. Closing Remarks

SATURDAY

Meet The Scientist: Genomics and Targeted Therapy in Pediatric Acute Leukemia (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m. **Hyatt - Bayhill 19**

Speaker: Yana Pikman, MD, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA

Meet The Scientist: Myeloma Biology and Therapy (ticketed session for in-person participants)

8:00 a.m. - 9:00 a.m. Saturday

Hyatt - Bayhill 20

Speaker:

Lawrence Boise, PhD, Emory University, Atlanta, GA

Meet The Scientist: Never Go Into Transplant Waters Alone (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m. **Hyatt - Bayhill 22**

Speaker:

Sonata Jodele, MD, Cincinnati Children's, Cincinnati, OH

Meet The Scientist: Somatic Genetic Rescue in Bone Marrow Failure Syndromes – Friend or Foe? (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m. Hyatt - Bayhill 17-18

Speaker:

Marcin Wlodarski, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Somatic Genetic Rescue in Bone Marrow Failure Syndromes -Friend or Foe?

Scientific Program: Dissecting Enhancer **Function in Hematopoietic Development and Disease**

Saturday 9:30 a.m. - 10:45 a.m. W312

Scientific Committee on Epigenetics and Genomics

Megan McNerney, MD, PhD, The University of Chicago, Chicago, IL

Speakers:

Anders Hansen, PhD, MIT Biological Engineering, Cambridge, MA

Imaging and Systems Biology Approaches For Studying **Enhancer Activity**

Martin Rivas, PhD, MS, University of Miami, Miami, FL

Enhancer Function in Lymphoid Development and Lymphoma

Mira Kassouf, DPhil, Oxford University, Oxford, United Kingdom

Multi-partite Enhancer Assembly and Chromatin Architecture

Scientific Program: Exploring the Origins of Multiple Myeloma: Germline Predisposition and **Early Deregulations**

Saturday 9:30 a.m. - 10:45 a.m. West Hall D1

Scientific Committee on Plasma Cell Neoplasia

Salomon Manier, MD, PhD, Lille University Hospital, Lille, France

Speakers:

Celine Vachon, PhD, Mayo Clinic, Rochester, MN Germline Genetic Variants and Predisposition to Multiple Myeloma

Rodger Tiedemann, MD, PhD, University of Aukland, Auckland, New Zealand

Identifying and Characterizing the Cells of Origin in Multiple Myeloma

Romanos Sklavenitis-Pistofidis, MD, Dana-Farber Cancer Institute, Boston, MA

Early Molecular and Immune Deregulations in Premalignant Conditions

Scientific Program: Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy

Saturday 9:30 a.m. – 10:45 a.m. **Hyatt - Regency Ballroom OPQ**

Scientific Committee on Iron and Heme

Yvette Yien, PhD, University of Pittsburgh, Pittsburgh, PA

Speakers:

Samit Ghosh, PhD, Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA

Heme Trafficking and Its Role in Modifying Physiology and Hematopoietic Diseases

Michelle Sholzberg, MD, University of Toronto, Toronto, Ontario, Canada

Iron Deficiency/Overload and Its Considerations In Design of Therapeutic Strategies

Stefano Rivella, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

Targeting Iron Deficiency/Overload as a Therapeutic Strategy in Treating Hematologic Disease

Scientific Program: Strategies To Improve **Outcomes After Hematopoietic Cell** Transplantation and Adoptive Cell Therapy

Saturday 9:30 a.m. - 10:45 a.m. W331

Scientific Committee on Transplant Biology and Cellular Thera-

Chair:

Craig Byersdorfer, MD, PhD, University of Minnesota, Minneapolis, MN

Speakers:

Marie Bleakley, PhD, MBBS, MMSc, Fred Hutchinson Cancer Research Center, Seattle, WA

Novel Graft Manipulation Strategies - From Bench to Bedside

Leslie Kean, MD, PhD, Boston Children's Hospital, Boston, MA

New Preclinical and Translational Approaches to Prevent

Kai Rejeski, MD, LMU University Hospital, Munich, Germany

Ways to Predict and/or Minimize Hematotoxicity, Infections and Non-Relapse Mortality After Immunotherapy

ASH Poster Walks: Inherited Bleeding Disorders Poster Walk Hosted by Blood Vessels. Thrombosis & Hemostasis

Saturday 11:15 a.m. – 12:15 p.m. West Halls B3-B4

Chair:

Nathan Connell, MD, MPH, Brigham and Women's Hospital, Boston, MA

Scientific Program: CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias

Saturday 2:00 p.m. – 3:15 p.m. Tangerine Ballroom F3-4

Scientific Committee on Blood Disorders in Childhood

Chair:

Julie Jaffray, MD, Rady Children's Hospital, University of California—San Diego, San Diego, CA

Speakers:

Sara Ghorashian, FRCPath, PhD, Great Ormond Street Institute of Child Health, London, United Kingdom

CAR T-Cell Breakthroughs: Shaping the Future of B-Cell ALL Treatment

Maksim Mamonkin, **PhD**, Baylor College of Medicine, Houston, TX

T-Cell ALL Meets CAR-T: Advancements and Breakthroughs

Paulina Velasquez, MD, St. Jude Children's Hospital, Memphis, TN

Harnessing CAR-T: A New Era in AML Treatment

Scientific Program: Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy

Saturday 2:00 p.m. – 3:15 p.m. Sunburst Room (W340)

Scientific Committee on Red Cell Biology

Chair:

Jian Xu, PhD, St. Jude Children's Research Hospital, Memphis, TN

Speakers:

Merlin Crossley, PhD, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia

Identifying and Targeting New Regulators of Hemoglobin Switching

Daniel Bauer, MD, PhD, Harvard Medical School, Boston, MA

Preclinical Development of Gene Editing Approaches for Hemoglobin Disorders

Giuliana Ferrari, **PhD**, Istituto Scientifico H. San Raffaele, Milan, Italy

Developing Gene Therapy Approaches for Treating Hemoglobin Disorders

Scientific Program: Innovative Models of Lymphoma

Saturday 2:00 p.m. – 3:15 p.m. West Hall E2

Scientific Committee on Lymphoid Neoplasia

Chair

Oliver Weigert, **MD**, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany

Speakers:

Ankur Singh, PhD, Georgia Institute of Technology, Atlanta, GA

Bioengineering Synthetic Lymphoma Models: Advancements in Ex Vivo Systems

Michael R. Green, **PhD**, MD Anderson Medical Center, Houston, TX

Utilizing Refined Lymphoma Models for Treatment Studies: Innovations in Syngeneic Transplants, Patient-Derived Xenografts, and Humanized Mouse Model

Wendy Béguelin, PhD, Weill Cornell Medical College, New York, NY

Genetically Engineered Mouse Models (GEMMs): Dissecting Subtype Specific Biologies

Scientific Symposia: Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes

Saturday 2:00 p.m. – 3:15 p.m. Hyatt - Plaza Int'l HIJK

Chair:

Austin Kulasekararaj, MD, MBBS, FRCPath, MRCP, King's College Hospital, London, United Kingdom

Speakers:

Deena Iskander, MD, PhD, FRCPath, St. Mary's Hospital & Imperial College London, London, United Kingdom

The Role of Ribosome Dysregulation in Erythropoiesis

Luis Batista, **PhD**, Washington University in St. Louis, St. Louis. MO

The Connections Between Telomere Biology and Hematopoiesis

Meng Wang, MD, PhD, Cornell University, Ithaca, NY

Genotoxic Aldehydes, DNA Repair, and Premature Aging in Fanconi Anemia

Scientific Symposia: Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease

Saturday 2:00 p.m. - 3:15 p.m. W308

Chair:

Hyacinth Hyacinth, MD, PhD, MPH, University of Cincinnati College of Medicine, Cincinnati, OH

Speakers:

Kalpna Gupta, PhD, University of California, Irvine, CA

Two Sides of the Same Coin: Sickle Cell Pathobiology and Neural Mechanisms that Evoke, Maintain and Perceive Pain

Bin He, PhD, Carnegie Mellon University, Pittsburgh, PA

Treat the Pain in My Brain: Understanding Neuromodulation and Technology Enhanced Interventions for Sickle Cell Disease Pain

Jahnavi Gollamudi, MD, University of Cincinnati, Cincinnati, OH

It Refuses to Leave: The Challenging Bone Pain in Sickle Cell Disease

Scientific Program: JOINT SESSION: The **Emerging Landscape of Germline Predisposition** to Bone Marrow Failure and Leukemia

Saturday 4:00 p.m. - 5:35 p.m. **Hyatt - Plaza Int'l HIJK**

Scientific Committee on Bone Marrow Failure and Scientific Committee on Myeloid Neoplasia

Co-Chairs:

Giuseppe Saglio, MD, University of Turin, Turin, Italy Sharon Savage, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD

Speakers:

Lisa McReynolds, MD, PhD, National Cancer Institute, National Institutes of Health, Bethesda, MD

Inherited Susceptibility to Bone Marrow Failure and Leukemia is More Common Than you Think

R. Coleman Lindsley, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Beyond Malignancy: How Insights from IBMFS Inform Clonal Hematopoiesis Malignancy Risk More Broadly

Timothy Chlon, PhD, Cincinnati Children's Hospital, Cincinnati, OH

Defining the Biology of DDX41

Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York, NY

Somatic Mutations may Precede Acute Myeloid Leukemia Even Years Before Diagnosis

Scientific Program: New Frontiers in Neutrophil Biology

Saturday 4:00 p.m. - 5:15p.m. W311EFGH

Scientific Committee on Immunology and Host Defense

Chair:

Katherine King, MD, PhD, Baylor College of Medicine, Houston, TX

Speakers:

Renato Ostuni, PhD, San Raffaele Scientific Institute, Milan, Italy

Single Cell Insights Into Neutrophil Ontogeny

Dominique Bonnet, PhD, The Francis Crick Institute, London, United Kingdom

Effect on Clonal Hematopoiesis Associated Mutations on Neutrophil Function

Emily Gwyer Findlay, PhD, University of Edinburgh, Edinburgh, United Kingdom

Neutrophils in Tumor Immunity

Scientific Program: Thromboinflammation

Saturday 4:00 p.m. - 5:30 p.m. W314

Scientific Committee on Thrombosis and Vascular Biology

Chair:

Peter Gross, MD, University Health Network and Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada

Speakers:

Sonata Jodele, MD, Cincinnati Children's, Cincinnati, OH Complement On Fire

Markus Sperandio, MD, Ludwig-Maximilians-University, Planegg-Martinsried, Germany

The Inflammasone: E-selection-Driven Activation

Luisa Iruela-Arispe, PhD, Northwestern Feinberg School of Medicine, Chicago, IL

Endothelial Chemo-Mechanical Signaling in Response to Shear Stress

Scientific Program: Tracing Bloodlines: Decoding Embryonic Waves of Blood Cell Production and Their Contribution to Disease

Saturday 4:00 p.m. – 5:15 p.m. W312

Scientific Committee on Stem Cells and Regenerative Medicine

Chair:

Shannon McKinney-Freeman, PhD, St. Jude Children's Research Hospital, Memphis, TN

Speakers:

Momoko Yoshimoto, MD, PhD, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI

New Insights Into the Dynamics and Heterogeneity of Waves of Blood Production During Development

Claudia Waskow, PhD, Leibniz Institute on Aging, Germany, Jena, Germany

Highlighting the Role of Fetal Blood Cells In Shaping the Life-Long Blood System

Elvin Wagenblast, PhD, Icahn School of Medicine/Mount Sinai, New York, NY

Recent Insights Into the Pathophysiology of Hematologic Disease With Fetal Origins

SUNDAY

ASH Poster Walks: Chemotherapy-Free Treatments for Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma Hosted by *Blood Neoplasia*

Sunday 8:00 a.m. – 9:00 a.m. West Halls B3-B4

Chair:

Paolo Strati, MD, MD Anderson Cancer Center, Houston,

Meet The Scientist: Clonal Evolution in Acute Myeloid Leukemia (ticketed session for inperson participants)

Sunday 8:00 a.m. – 9:00 a.m. Hyatt - Bayhill 19

Speaker:

Ulrich Steidl, **PhD**, **MD**, Albert Einstein College of Medicine - Montefiore Einstein, Bronx, NY

Meet The Scientist: Hematopoietic Clones - To Be or Not To Be (ticketed session for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m. Hyatt - Bayhill 22

Speaker:

Benjamin Ebert, MD, PhD. Dana-Farber Cancer Institute, Boston, MA

Meet the Scientist: Molecularly Targeted Therapies in Lymphoma (ticketed session for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m. Hyatt - Bayhill 17-18

Speakers:

Oliver Weigert, **MD**, Ludwig-Maximilians-Universität München, Munich, Germany

Molecularly Targeted Therapies in Lymphoma

Meet The Scientist: Novel Genetic Markers in Blood Transfusion for Improved Matching (ticketed session for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m. Hyatt - Bayhill 20

Speakers:

Stella Chou, MD, University of Pennsylvania School of Medicine, Philadelphia, PA

Scientific Program: Harnessing The Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins

Sunday 9:30 a.m. - 10:45 a.m. W311EFGH

Scientific Committee on Hemostasis

Rinku Majumder, PhD, LSU Health Science Center, New Orleans, LA

Speakers:

Enrico Di Cera, MD, Saint Louis University School of Medicine, St. Louis, MO

Unveiling the Hemostasis Interactome: A Structure-Guided Discovery of Blood's Hidden Secrets

Rodney Camire, PhD, University of Pennsylvania, Philadelphia, PA

Unlocking the Hemostasis Interactome: Activity-Guided Discovery of Blood's Key Connections

Raja Prince-Eladnani, PhD, Bern University Hospital, Inselspital, Bern, Switzerland

Decoding the Hemostasis Interactome: A Genetics-Guided Exploration of Blood's Blueprint

Scientific Program: JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging

9:30 a.m. - 11:05 a.m. Sunday W312

Scientific Committee on Hematopathology and Clinical Laboratory Hematology and Scientific Committee on Hematopoiesis

Chair:

Ingo Ringshausen, MD, University College London, London, United Kingdom

Peter van Galen, PhD, Brigham and Women's Hospital, Boston, MA

Speakers:

Adam Mead, MBBChir, University of Oxford, Oxford, United Kingdom

Embryogenesis and Early Mutations in Hematopoietic Stem

Grant Challen, PhD, Washington University, St. Louis, MO

Genetic-Epigenetic Regulators Providing a Competitive Advantage to HSCs

Michael Milsom, PhD, DKFZ, Heidelberg, Germany Inflammation and Expansion of Dysregulated Stem Cells Nancy Gillis, PharmD, PhD, Moffitt Cancer Center, Tampa, FL

Clonal Hematopoiesis: The Good, the Bad, and the Unknown

ASH Poster Walks: Exploring and Targeting Emerging Mechanisms of Disease to Advance Human Health Hosted by Blood Red Cells and Iron

Sunday 11:15 a.m. – 12:15 p.m. West Halls B3-B4

Chair:

Laura Silvestri, PhD, San Raffaele Scientific Institute, Milan, Italy

Patrick Gallagher, MD, Yale University, Columbus, OH

Scientific Spotlight Sessions: The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It

Sunday 4:30 p.m. – 5:45 p.m. Sunburst Room (W340)

Speakers:

Marco Ruella, MD, Abramson Cancer Center & University of Pennsylvania, Philadelphia, PA

Current Clinical Evidence of Allogeneic Cellular Products Failure and Mechanisms

May Daher, MD, MD Anderson Cancer Center, Houston,

Strategies to Reduce Immune Rejection of Off-the-Shelf Cell Therapies

MONDAY

ASH Poster Walks: Rewiring T Cells: Emerging Strategies to Boost Cancer Immunotherapy Hosted by *Blood Immunology & Cellular Therapy*

Monday 8:00 a.m. – 9:00 a.m. West Halls B3-B4

Chair:

Anamaria Morales-Alvarez, PhD, University of Central Florida, Orlando, FL

Scientific Program: TRIMming the Immune Response: Cutting-Edge Insights into Transfusion-Related Immunomodulation

Monday 10:30 a.m. – 11:45 a.m. W314

Scientific Committee on Transfusion Medicine

Chair

France Pirenne, MD, PhD, University Paris-Est Créteil, Creteil, France

Speakers:

Benoit Vingert, PhD, INSERM U955, Creteil, France

Little Secrets: Microparticles in Blood Products as Immune Modulators

Nilam Mangalmurti, MD, Perelman School of Medicine, Philadelphia, PA

Donor Alert: Immunomodulatory Roles of Red Blood Cells

Karina Yazdanbakhsh, PhD, New York Blood Center, New York, NY

Special Effects: Recipient Innate Immunity and Transfusion Immunomodulation

Scientific Spotlight Sessions: Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally

Monday 10:30 a.m. – 11:45 a.m. Tangerine Ballroom F2

Speakers:

Mark Roschewski, MD, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Translating Knowledge about Burkitt Lymphoma Genomics and Microenvironment into Novel Clinical Trials

Clara Chamba, MD, PhD, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania

Burkitt Lymphoma Research in Africa: Overcoming Challenges and Unlocking Translational Potential

Scientific Spotlight Sessions: Creative and Novel Statistical Techniques to Design and Analyze Data for Trials Focused on Rare Hematologic Diseases

Monday 10:30 a.m. – 11:45 a.m. Hyatt - Regency Ballroom R

Chair:

Fangxin Hong, PharmD, Pfizer Inc., Cambridge, MA

Speakers:

Arzu Onar-Thomas, **PhD**, St. Jude's Children Hospital, Memphis, TN

Rational Compromises in Trial Design for Rare Diseases -Lessons from Pediatric Cancer

Ernest Amankwah, PhD, Johns Hopkins All Children's Hospital, St. Petersburg, FL & Johns Hopkins University School of Medicine. Baltimore. MD

Design and Application of RCT for Rare/Low-Frequency Diseases: From Traditional Parallel-Cohort to Novel Contemporaneous Control Recapture

Scientific Symposia: Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny

Monday 10:30 a.m. – 11:45 a.m. W312

Chair:

Stephanie Halene, **MD**, Yale University School of Medicine, New Haven, CT

Speakers:

Marta Derecka, **PhD**, St. Jude Children's Research Hospital, Memphis, TN

Context Matters: HSC Regeneration in the Cellular Niche

Leif Ludwig, **MD**, Berlin Institute for Medical Systems Biology (Max Delbrück Center) & Berlin Institute of Health at Charité Universitätsmedizin Berlin, Berlin, Germany

Mitochondrial DNA Mosaicism and Clonality in Human Hematopoiesis

Eirini Trompouki, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR7284, INSERM U1081, Université Cote d'Azur, Nice, France

Preventing Fires: Targeting Strategies to Mitigate Clonal Evolution

ASH Poster Walks: Leukemia in Latin America: Bridging Gaps in Genetics, Access, and Innovation Hosted by *Blood Global Hematology*

Monday 12:30 p.m. – 1:30 p.m. West Halls B3-B4

Chair:

Melanie Castro Mollo, MD, Dana Farber Cancer Institute, Boston, MA

Scientific Program: Mechanisms that Direct and Derail Lineage-Specific Transcription Factor Complexes

Monday 2:45 p.m. – 4:00 p.m. Valencia Room W415D

Scientific Committee on Myeloid Biology

Chair:

Olga A. Guryanova, MD, PhD, University of Florida, Gainesville, FL

Speakers:

Bruno Di Stefano, PhD, BSc, MSc, Baylor College of Medicine, Houston, TX

RNA Condensates in Leukemia and Hematopoietic Stress

Ulrich Steidl, PhD, MD, Albert Einstein College of Medicine - Montefiore Einstein, Bronx, NY

Understanding and Targeting Transcriptional Noise in Normal and Malignant Hematopoiesis

Julie Lessard, **PhD**, Institute for Research in Immunology and Cancer, Montreal, Quebec, Canada

Chromatin Remodeling in Normal and Malignant Myelopoiesis

Scientific Program: The Critical Role of Metabolism in Megakaryocyte and Platelet Biology

Monday 2:45 p.m. – 4:00 p.m. W314

Scientific Committee on Megakaryocytes and Platelets

Chair:

Alessandra Balduini, MD, Tufts University, Medford, MA

Speakers:

Jesse Rowley, **PhD**, University of Utah Health, Salt Lake City, UT

Mitochondria Morphology, Function and Platelet Activation Responses

Koji Eto, MD, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan

Lipid Metabolism, Megakaryocyte Function and Platelet Production

Kathleen Freson, PhD, Katholieke Universiteit Leuven, Leuven, Belgium

Altered Metabolisms and Platelet Disorders

Scientific Spotlight Sessions: Epigenomic Frontiers in the Diagnosis of Hematological Malignancies

Monday 2:45 p.m. – 4:00 p.m. W230

Chair:

Bert Van der Reijden, PhD, Radboudumc, Nijmegen, Netherlands

Speakers:

Volker Hovestadt, PhD, Dana-Farber Cancer Institute, Boston, MA

Long-Read Epigenomic Classification of Acute Leukemia

Florence Nguyen-Khac, MD, PhD, Centre de recherche des Cordeliers/INSERM1138 & Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France

Chromatin-Based Diagnosis in Lymphocytic Leukemia

Scientific Symposia: Targeting Cancer Metabolism – Innovative Methods to Translation

Monday 2:45 p.m. – 4:00 p.m. W312

Chair:

Mala Shanmugam, PhD, Winship Cancer Institute, Emory University, Atlanta, Georgia

Speakers:

Matthew Vander Heiden, MD, PhD, Massachusetts Institute of Technology, Cambridge, MA

Nutrient Environment Considerations for Understanding Leukemia Therapy

Jeffrey Rathmell, PhD, University of Chicago, Chicago, IL *Metabolic Sources of Immune Cell Dysfunction*

Andrew Intlekofer, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Enzyme Hyperactivation to Target Oncometabolism

Scientific Spotlight Sessions: Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias

Monday 4:30 p.m. – 5:45 p.m. W224CDGH

Speakers:

Catherine Smith, MD, University of California, San Francisco, San Francisco, CA

Multi-omic Analysis Reveals the Heterogeneity and Stem Cell Origin of Acute Leukemia of Ambiguous Lineage/Mixed Phenotype Acute Leukemia

Ruud Delwel, PhD, Erasmus MC Cancer Institute and Oncode Institute, Rotterdam, Netherlands

Epigenetic Dysregulation Drives Mixed Phenotype Acute Leukemia

Scientific Symposia: Special Symposium on the Basic Science in Hemostasis and Thrombosis

Monday 4:30 p.m. – 6:00 p.m. Valencia Room W415D

Co-Chairs:

Alessandra Balduini, MD, Tufts University, Medford, MA

Peter Gross, MD, University Health Network and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

Rinku Majumder, PhD, Louisiana State University Health Sciences Center, New Orleans, LA

Speakers:

Ashley Brown, North Carolina State University & UNC Chapel Hill, Raleigh, NC

Clots, Cuts, and Healing: The Dynamic trio of Coagulation, Platelets, and Fibrinolysis

Tirthadipa Pradhan-Sundd, PhD, Versiti Blood Research Institute, Milwaukee, WI

Blood, Clots, and Scars: Unraveling the Hidden Links Between Coagulation and Liver Cirrhosis

Marlys Koschinsky, PhD, Robarts Research Institute London, Ontario, Canada

Lipoprotein(a) and Venous Thromboembolism: A Silent Culprit or Innocent Bystander?

WEDNESDAY

ASH Poster Walks: Population Health and Access to Care

Wednesday 10:00 a.m. – 11:00 a.m. Virtual Program

Chair:

Warren Fingrut, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX

ASH Poster Walks: State of the Art Artificial Intelligence in Hematology

Wednesday 5:00 p.m. – 6:00 p.m. Virtual Program

Chair:

Andrew Srisuwananukorn, MD, The Ohio State University, Columbus, OH

EDUCATION SESSIONS

Education Program Co-Chairs:

Payal Desai, MD, Levine Cancer Institute, Advocate Health, Wake Forest School of Medicine Charlotte, Charlotte, NC

Rayne Rouce, MD, Texas Children's Hospital, Houston, TX

Education Program Sessions

Education Program Sessions will be held from Saturday, December 6, through Monday, December 8. A question-and-answer period will occur at the end of the final presentation. Chapters based on these sessions will be published in Hematology 2025, the ASH Education Program.

Education Spotlight Sessions

Education Spotlight Sessions are intended to provide an in-depth review on specific clinical topics. Speakers will discuss current challenges and controversies in exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions.

Each 90-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

How I Treat Sessions (Ticketed)

How I Treat Sessions will provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives on specific disease topics. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, firstserved basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may bé purchased on site during registration hours beginning Thursday, December 5, at the Ticketed Sessions Counter in the Orange County Convention Center, Level 1 Concourse.

How I Treat Ticket Prices (per session)

Active or International Members and Non-Members \$90

Associate, International Associate, Resident, Graduate/Medical Student, Non-Member in Training, Allied Health Professional, or Honorary/Emeritus Members \$50

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY

How I Treat: How I Navigate Arterial Thrombosis: A Hematologist's Perspective (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 p.m. **Hyatt - Bayhill 23**

Speaker:

Jori May, MD, University of Alabama at Birmingham, Birmingham, AL

How I Navigate Arterial Thrombosis: A Hematologist's Perspective

How I Treat: How I Treat Isolated CNS Relapse of B-ALL in the Era of Immunotherapy (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m. **Hyatt - Bayhill 27**

Speaker:

Colleen Annesley, MD, University of Washington, Seattle,

How I Treat Isolated CNS Relapse of B-ALL in the Era of *Immunotherapy*

How I Treat: How I Treat Multiple Myeloma Progression After Upfront Quadruplet Therapy (ticketed session for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m. Hyatt - Bayhill 31-32

Speaker:

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL

How I Treat Multiple Myeloma Progression after Upfront Quadruplet Therapy

How I Treat: How I Treat the Balancing Act of Anticoagulant Management in Hemoglobinopathies (ticketed session for inperson participants)

Saturday 8:00 a.m. – 9:00 a.m. Hyatt - Bayhill 25-26

Speaker:

Ted Wun, MD, University of California, Davis, Sacramento, CA

How I Treat the Balancing Act of Anticoagulant Management in Hemoglobinopathies

How I Treat: How I Use NGS in the Pre- and Post-HSCT and Cell Therapy Setting (ticketed session for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m. Hyatt - Bayhill 29-30

Speaker:

Michael Pulsipher, MD, University of Utah Health, Salt Lake City, UT

How I Use NGS in the Pre and Post-HSCT and Cell Therapy Setting

Education Program: Bleeding Disorder of Unknown Cause—What Do We Know?

Saturday 9:30 a.m. – 11:00 a.m. W307

Chair:

Paula James, MD, Queen's University, Kingston, Ontario, Canada

Speakers:

Callie Berkowitz, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

Buckle Up! Managing Surgery in Patients with Bleeding Disorder of Unknown Cause (BDUC)

Paula James, MD, FRCPC, Queen's University, Kingston, Ontario, Canada

Diagnosis of Bleeding Disorder of Unknown Cause: How Many Tests is Enough to Diagnose BDUC?

Ingrid Pabinger, MD, Vienna, Austria

Predictors for Future Bleeding in Bleeding Disorder of Unknown Cause

Education Program: Immune Cytopenias: Addressing Challenges and Advancing Treatments

Saturday 9:30 a.m. – 11:00 a.m. Hyatt - Regency Ballroom S

Chair:

Sandhya Panch, MD, Fred Hutch Cancer Center & University of Washington, Seattle, WA

Speakers:

Sigbjorn Berentsen, **MD**, Haugesund Hospital, Haugesund, Norway

Diagnosis and Management of Cold Agglutinin Disease

Wilma Barcellini, MD, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy

Management of Autoimmune Hemolytic Anemia

Sandhya Panch, MD, Fred Hutch Cancer Center & University of Washington, Seattle, WA

Refractory ITP: Revisiting Definitions, Diagnostics and Management Paradigms

Education Program: Complementopathies: Modern Diagnosis and Management

Saturday 2:00 p.m. – 3:30 p.m. Hyatt - Regency Ballroom S

Chair:

Christopher Patriquin, MD, MSc, University Health Network, Toronto, Ontario, Canada

Speakers:

Vahid Afshar-Kharghan, MD, MD Anderson Cancer Center, Houston, TX

Long-term Outcome and Management of Complement-Mediated Thrombotic Microangiopathy/aHUS

Christopher Patriquin, MD, MSc, University Health Network, Toronto, Ontario, Canada

The Varieties of Therapeutic Experience: Navigating Treatment Options for Patients with PNH

Michael Cole, MD, DPhil, Johns Hopkins University, Baltimore, MD

Update in the Diagnosis of Complement-Mediated Thrombotic Microangiopathy/Atypical Hemolytic Uremic *Syndrome*

Education Program: Down the Rabbit Hole: An Update on Histiocytic Disorders

Saturday 2:00 p.m. - 3:30 p.m.

Hyatt - Regency Ballroom OPQ

Chair:

Gaurav Goyal, MD, University of Alabama at Birmingham, Birmingham, AL

Speakers:

Olive Eckstein, MD, Texas Children's Hospital, Houston,

Langerhans Cell Histiocytic and Rosai-Dorfman: Combination Therapies, Response Criteria and Biomarkers

Gaurav Goyal, MD, University of Alabama at Birmingham, Birmingham, AL

The Xanthogranuloma Family of Histiocytic Neoplasms in the Molecular Era: Erdheim-Chester Disease and Beyond

Paul La Rosée, MD, University of Freiburg, Villingen-Schwenningen, Germany

Hemophagocytic Lymphohistiocytosis: Do We Have a Solution for TMI (Too much Inflammation)?

Education Program: Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges

Saturday 2:00 p.m. - 3:30 p.m. W230

Chair:

Sumit Gupta, MD, PhD, Hospital for Sick Children, Toronto, Ontario, Canada

Speakers:

Kristen O'Dwyer, MD, University of Rochester Medical Center, Rochester, NY

Immune Targeting in Ph Negative and Ph Positive B-ALL: Improving Outcomes and Minimizing Chemotherapy in Adult B-ALL

Sumit Gupta, MD, PhD, Hospital for Sick Children, Toronto, Ontario, Canada

The Challenge of De-Intensifying Chemotherapy for Children and Adolescents With B-ALL in The Immunotherapy Era

Ryan Cassaday, MD, Fred Hutchinson Cancer Center & University of Washington, Seattle, WA

Sanctuary Sites and Extramedullary Relapses in the Chemofree World: Insights from Immunotherapies in B-ALL

Education Program: Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma

Saturday 2:00 p.m. - 3:30 p.m. **Tangerine Ballroom F1**

Chair:

Sarah Rutherford, MD, Weill Cornell Medicine, New York,

Speakers:

Jennifer Crombie, MD, Dana Farber Cancer Institute, Boston, MA

Could Treatment Modification Based on Early Response Assessment Improve Results in DLBCL?

Franck Morschhauser, PhD, Centre Hospitalier Régional Universitaire De Lille, Nord, France

Selecting the Best Treatment Approach and Optimizing Sequencing Strategies in Large B-cell Lymphoma

Sarah Rutherford, MD, Weill Cornell Medicine, New York,

Molecular Subtypes of DLBCL- Are We Ready to Translate Our Knowledge Into the Change of Treatment Paradigms?

Education Program: The Changing Landscape of the Care of Patients With Immune-Mediated and **Congenital TTP**

Saturday 2:00 p.m. - 3:30 p.m. W304EFGH

Chair:

Senthil Sukumar, MD, MSc, Baylor College of Medicine, Houston, TX

Speakers:

Linus Voelker, MD, University of Cologne, Germany

Tailored Treatment of Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura

Senthil Sukumar, MD, MSc, Baylor College of Medicine, Houston, TX

Challenges and Opportunities in the Long-Term Management of Immune-Mediated TTP

Alice Taylor, MBBS, MD, Great Ormond Street Hospital, London, United Kingdom

Modern Management of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Education Program: Between Clots and Complications: A New Era of Anticoagulation in Cancer

Saturday 4:00 p.m. – 5:30 p.m. West Hall D2

Chair:

Marc Carrier, MD, The Ottawa Hospital, Ottawa, Ontario, Canada

Speakers:

Damon Houghton, MD, MS, Mayo Clinic, Rochester, MN *Anticoagulants in Hematologic Malignancies: What is the Data?*

Marc Carrier, MD, The Ottawa Hospital, Ottawa, Ontario, Canada

Implementation Failure: Thromboprophylaxis in Ambulatory Patient with Cancer

Michael Jaglal, MD, Moffitt Cancer Center, Tampa, FL Direct Oral Anticoagulants in Cancer Associated Thrombosis: 10 Year Follow Up

Education Program: Hemoglobinopathies and Increased Risk of Venous Thromboembolism

Saturday 4:00 p.m. – 5:30 p.m. W308

Chair:

Ted Wun, MD, University of California, Davis, Sacramento,

Speakers:

Ted Wun, MD, University of California, Davis, Sacramento, CA

Sickle Cell Disease: Managing Thromboembolism

Maria Domenica Cappellini, MD, Foundation IRCCS Ca' Granda Policlinico Milano - University of Milan, Milano, Italy

Thalassemia and Hypercoagulability

Rakhi Naik, MD, MHS, Johns Hopkins University School of Medicine & Johns Hopkins University, Baltimore, MD When Sickle Trait Is Not Just Trait: Risk of VTE

Education Program: Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why?

Saturday 4:00 p.m. – 5:30 p.m. Tangerine Ballroom F3-4

Chair:

Mark Levis, MD, PhD, Johns Hopkins University, Baltimore, MD

Speakers:

Mary-Elizabeth Percival, MD, Fred Hutchinson, Seattle, WA

Peri-transplant Conundrums: Optimizing Maintenance Therapy Using MRD-Directed Approaches

Mark Levis, MD, PhD, Johns Hopkins University, Baltimore, MD

Post-HCT Maintenance Therapy for AML: Who, When, Why, How Long?

Jurgen Kuball, MD, University Medical Center Utrecht, Utrecht, Netherlands

Post-Transplant Cells for the Win? DLI and Adoptive Cell Therapy to Eradicate MRD

Education Program: Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician

Saturday 4:00 p.m. – 5:30 p.m. Tangerine Ballroom F2

Chair:

Marie José Kersten, MD, Academic Medical Center, Amsterdam, Netherlands

Speakers:

Clementine Sarkozy, MD, PhD, Institut Curie, Saint Cloud, France

How to Diagnose and Treat Mediastinal Gray Zone Lymphoma in the Era of Targeted Agents?

Andrew Davies, PhD, University of Southampton, Southampton, United Kingdom

High-grade B-Cell Lymphomas: High Difficulties to Diagnose and Treat?

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston,

When Immature Plasma Cells Form Lymphoma: How to Improve on Diagnostics and Treatment of Plasmablastic Lymphoma?

SUNDAY

How I Treat: How I Incorporate Mutational **Profiling into Treatment of AML: Considerations** Based on Age, Complex Cytogenetics, and Other Clinical Factors (ticketed session for inperson participants)

Sunday 8:00 a.m. - 9:00 a.m. Hyatt - Bayhill 31-32

Speaker:

Jessica Altman, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

How I Incorporate Mutational Profiling into Treatment of AML: Considerations Based on Age, Complex Cytogenetics, and Other Clinical Factors

How I Treat: How I Incorporate Novel Therapies into Hodgkin Lymphoma Treatment: Frontline vs. Relapse (ticketed session for in-person participants)

Sunday 8:00 a.m. - 9:00 a.m. Hyatt - Bayhill 29-30

Speaker:

Alex Herrera, MD, City of Hope, Duarte, CA

How I Incorporate Novel Therapies into Hodgkin Lymphoma Treatment: Frontline vs. Relapse

How I Treat: How I Optimize Hemophilia Management: The Role of Novel Treatments (ticketed session for in-person participants)

8:00 a.m. - 9:00 a.m. Sunday Hyatt - Bayhill 25-26

Speaker:

Mark Reding, MD, University of Minnesota, Minneapolis,

How I Optimize Hemophilia Management: The Role of Novel **Treatments**

How I Treat: How I Treat Baby on Board: Managing the Hematological Pregnant Patient (ticketed session for in-person participants)

8:00 a.m. - 9:00 a.m. Sunday Hyatt - Bayhill 23-24

Speaker:

Sarah O'Brien, Nationwide Children's Hospital, Columbus,

How I Treat Baby on Board: Managing the Hematological Pregnant Patient

How I Treat: How I Treat Clinical Management of Refractory ITP (ticketed session for in-person participants)

Sunday 8:00 a.m. - 9:00 a.m. **Hyatt - Bayhill 27**

Speaker:

Sandhya Panch, MD, University of Washington, Seattle,

How I Treat Clinical Management of Refractory ITP

Education Program: Challenges in Diagnosing and Managing Mucocutaneous Bleeding **Disorders**

Sunday 9:30 a.m. - 11:00 a.m. W304ABCD

Chair:

Veronica Flood, MD, Medical College of Wisconsin, Milwaukee, WI

Speakers:

Veronica Flood, MD, Medical College of Wisconsin, Milwaukee, WI

(Un) Diagnosing von Willebrand Disease

Catherine Hayward, MD, McMaster University & Hamilton Health Sciences, Hamilton, Ontario, Canada

When It's Not Glanzmann Thrombasthenia or Bernard Soulier Syndrome: Diagnosing Other Qualitative Platelet Disorders

Raj Kasthuri, MBBS, University of North Carolina at Chapel Hill, Chapel Hill, NC

What's New in Hereditary Hemorrhagic Telangiectasia?

Education Program: Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery

Sunday 9:30 a.m. – 11:00 a.m.

Hyatt - Regency Ballroom S

Chair:

Alice Ma, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

Speakers:

Bethany Samuelson Bannow, MD, PhD, Oregon Health & Science University, Portland, OR

Pregnancy Management for Patients with Bleeding Disorders

Donald Arnold, MD, McMaster University, Hamilton, Ontario, Canada

A Practical Approach to Immune Thrombocytopenia in Pregnancy

Lydia Pecker, MD, Johns Hopkins University, Baltimore, MD

Proactive Management to Improve Outcomes in High-Risk Sickle Cell Disease Pregnancy

Education Program: Treatment Refinement in Multiple Myeloma

Sunday 9:30 a.m. – 11:00 a.m. West Hall E2

Chair:

Jesus San-Miguel, MD, PhD, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain

Speakers:

Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY

"Endless" Possibilities and How to Exploit Them? What Is the Optimal Treatment Sequence?

Benjamin Derman, MD, University of Chicago, Chicago, IL

Can I Stop My Treatment, Doctor? Is MRD-Guided Therapy Ready for Prime Time?

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

How to Approach the High-Risk Myeloma from Induction through Relapse?

Education Program: What's New and Current in the World of Bone Marrow Failure

Sunday 9:30 a.m. – 11:00 a.m.

Hyatt - Regency Ballroom OPQ

Chair:

Akshay Sharma, MBBS, St. Jude Children's Research Hospital, Memphis, TN

Speakers:

Zhuoer Xie, MD, MS, Moffitt Cancer Center, Tampa, FL *Demystifying the Diagnosis and Management of ICUS, CHIP, and CCUS*

Akshay Sharma, MBBS, St. Jude Children's Research Hospital, Memphis, TN

The Latest on Aplastic Anemia Management

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

Updates on Low/Intermediate-Risk MDS

Education Program: Arterial Disease and the Hematologist

Sunday 4:30 p.m. – 6:00 p.m.

W307

Chair

Jori May, MD, University of Alabama at Birmingham, Birmingham, AL

Speakers:

William Powers, Duke University, Durham, NC *Cryptogenic Stroke: Definitions and Management*

Freda Passam, MD, PhD, University of Sydney, Sydney, New South Wales, Australia

Managing Patients with a History of Arterial Disease and New Venous Thromboembolism

Amy Pollak, MD, Mayo Clinic, Jacksonville, FL

Updates in Antithrombotic Therapy in Coronary and Peripheral Artery Disease

Education Program: Decoding the Enigma: Challenges in Classical Hematology Consultations

Sunday 4:30 p.m. - 6:00 p.m. W304ABCD

Chair:

Tulika Seth. MD. MBBS. All India Institute of Medical Sciences (AIIMS), New Delhi, India

Speakers:

Thomas Ortel, MD, PhD, Duke University Medical Center, Durham, NC

Anticoagulation in Malignancy - The Patient Who Bleeds and Clots Simultaneously

Naseema Gangat, MBBS, Mayo Clinic, Rochester, MN

JAK2 Wild-Type Erythrocytosis: Concept, Differential Diagnosis, Diagnostic Steps and Treatment Approaches

Kathryn Webert, MD, MSc, Canadian Blood Services, Ancaster, Ontario, Canada

The Untransfusable Patient

Education Program: Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?

Sunday 4:30 p.m. - 6:00 p.m.

Hyatt - Regency Ballroom R

Chair:

Theodosia Kalfa, MD, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Speakers:

Uma Borate, MD, MSc, The Ohio State University, Columbus, OH

Molecular Approach to Cytopenia and Bone Marrow Failure

Xiao Peng, MD, PhD, The Children's Hospital at Montefiore, Bronx, NY

Molecular Diagnostics 101: How to Use Genetic Tests in Classical Hematology

Theodosia Kalfa, MD, PhD, Cincinnati Children's Hospital Medical Center & University of Cincinnati Medical School, Cincinnati, OH

Molecular Surprises in Evaluations of Red Cell Disorders

Education Program: New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and **Pediatric Perspectives)**

4:30 p.m. - 6:00 p.m. Sunday W331

Chair:

Julie-An Talano, MD, Medical College of Wisconsin, Milwaukee, WI

Speakers:

Julie-An Talano, MD, Medical College of Wisconsin, Milwaukee, WI

Donor Selection, Graft Engineering and Dosing Oh My!

John Koreth, MD, MBBS, PhD, DPhil, Dana-Faber Cancer Institute & Harvard Medical School, Boston, MA

New Age GVHD Prophy Regimens: What Works for What Donor and Why

Brenda Sandmaier, MD, University of Washington School of Medicine & Fred Hutchinson Cancer Center, Seattle, WA

New Age HCT Conditioning Regimens: What Works and Why?

Education Program: Sickle Cell Therapies: The Who, What, When, and Where

Sunday 4:30 p.m. - 6:00 p.m. West Hall D2

Chair:

Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy

Speakers:

Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy

Optimizing the "Right" Patient Selection for Treatment for Sickle Cell Disease

Seethal Jacob, MD, MS, Indiana University School of Medicine, Indianapolis, IN

Optimizing the Right Time to Start Sickle Cell Therapies

Sheinei Alan, MD, PhD, Inova Medical Center, Fairfax, VA

The Right Patient, the Right Treatment: Tailoring Sickle Cell Disease Care

Education Spotlight Sessions: The Changing Face of Chronic Myelogenous Leukemia

Sunday 4:30 p.m. – 6:00 p.m. W414AB

Chair:

Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA

Speakers:

Jorge Cortes, MD, Georgia Cancer Center at Augusta University, Augusta, GA

Frontline Treatment Selection for CML in 2025

Francois-Xavier Mahon, MD, PhD, Institut Bergonié and Bordeaux University, Bordeaux, France

Can I Stop Taking My TKI Yet?

MONDAY

Education Program: Invasion of the Immunotherapies: Where We Are and Where We Are Going in Leukemia, Lymphoma, and Myeloma

Monday 10:30 a.m. – 12:00 p.m. West Hall D2

Chair:

Sonali Smith, MD, University of Chicago, Chicago, IL

Speakers:

Doris Hansen, MD, Moffitt Cancer Center & Research Institute, Tampa, FL

CAR T-cell and Bispecific Antibodies in the Management of Multiple Myeloma

Sonali Smith, MD, University of Chicago, Chicago, IL *Emerging Immunotherapy Advances for Non-Hodgkin Lymphomas: Engaging T cells in the Fight*

Nicolas Boissel, MD, PhD, Hôpital Saint-Louis, Paris, France

Where Do Immunotherapies Stand in Management of Acute Leukemia in Adults?

Education Program: Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit

Monday 10:30 a.m. – 12:00 p.m. West Hall D1

Chair:

Noopur Raje, MD, Mass General Hospital Cancer Center, Boston, MA

Speakers:

Cesar Rodriguez Valdes, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Transplant in Myeloma: What is its Role?

Jonathan Kaufman, MD, Emory Winship, Atlanta, GA *What is the Best Induction for Myeloma for the FIT patient?*

Noopur Raje, MD, Mass General Hospital Cancer Center, Boston, MA

Choosing the Optimal Maintenance Strategy in Multiple Myeloma

Education Program: Targeted Therapy for AML (Triplets and More)

Monday 10:30 a.m. – 12:00 p.m. W414CD

Chair:

Jessica Altman, MD, Northwestern University, Chicago, IL

Speakers:

Jessica Altman, MD, Northwestern University, Chicago, IL Targeted Triplet Therapies incorporating FLT3 or IDH Inhibitors: Ready for Prime Time?

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

The Promise of Menin Inhibitors: From Approval to Triplet Regimens

Andrew Wei, MBBS, PhD, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

Triplet Regimens for All: Genomically Agnostic Approaches to Improve on HMA + VEN in AML?

Education Program: Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients

Monday 10:30 a.m. – 12:00 p.m. W307

Chair

Amy Shapiro, MD, Indiana Hemophilia & Thrombosis Center, Indianapolis, IN

Speakers:

Mark Reding, MD, University of Minnesota Medical School, Minneapolis, MN

New Therapies in Hemophilia: Extend the Half-Life, Bypass, or Rebalance?

Guy Young, MD, Children's Hospital Los Angeles, Los Angeles, CA

Deconstructing Gene Therapy in Hemophilia for the Clinician

Ming Lim, MBBCh, University of Utah, Salt Lake City, UT The Ageing Hemophilia Patient

Education Spotlight Sessions: Asparaginase in ALL/LBL: Balancing the Risk/Benefit of New **Efficacious Preparations**

Monday 10:30 a.m. - 12:00 p.m. W230

Chair:

Rachel Rau, MD, Seattle Children's Hospital, Seattle, WA

Speakers:

Birgitte Albertsen, MD, PhD, Aarhus University Hospital and Aarhus University, Aarhus, Denmark

Asparaginase Hypersensitivity Incidence, Manifestations, and Management

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA

Beyond Hypersensitivity: The Gamut of Other Asparaginase Associated Toxicities

Education Spotlight Sessions: Transfusion Medicine for Practicing Hematologists: How to **Prevent and Treat Potentially Fatal Reactions in** Sickle Cell Disease

Monday 10:30 a.m. - 12:00 p.m. W308

Chair:

Ravindra Sarode, MD, University of Texas Southwestern Medical Center, Dallas, TX

Stella Chou, MD, University of Pennsylvania School of Medicine, Philadelphia, PA; Children's Hospital of Philadelphia, Philadelphia, PA

Incorporation of Genetics into Transfusion Medicine Therapy

Susan Weiss, MD, Carolinas Pathology Group & Atrium Health, Charlotte, North Carolina

Hyperhemolysis Syndrome: A Frequently Overlooked Yet Deadly Transfusion Complication

Education Program: B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell **Disorders?**

Monday 2:45 p.m. - 4:15 p.m. West Hall D2

Chair:

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Center, Seattle, WA

Speakers:

Tanya Siddiqi, MD, City of Hope, Irvine, CA

The Role of MRD Monitoring and Options for CLL Management in Relapsed/Refractory Disease

Andrea Sitlinger, MD, Duke University, Durham, NC

Updates in the Management of Newly Diagnosed Chronic Lymphocytic Leukemia

Salman Fazal, MD, Allegheny Health Network Cancer Institute, Pittsburgh, PA

What to Know About Rare B-Cell Malignancies in 2025

Education Program: Biology-Based Management of Iron Toxicity and Overload in Hematology **Practice**

Monday 2:45 p.m. - 4:15 p.m. **Hyatt - Regency Ballroom OPQ**

Chair:

Thomas Coates, MD, Children's Hospital of LA, Los Angeles, CA

Speakers:

Heather Leitch, MD, St. Paul's Hospital University of British Columbia, Vancouver, British Colombia, Canada

Management of Iron Overload in Adult Myelodysplastic *Syndrome*

Emanuele Angelucci, MD, Armando Bisinco Oncology Hospital, Cagliari, Sardegna, Italy

Iron Toxicity and Hemopoietic Cell Transplantation: Do We Understand Why Iron Affects Transplant Outcome?

Thomas Coates, MD, Children's Hospital of Los Angeles, Los Angeles, CA

From Treatment to Biology and Back: Managing Iron Overload in Transfused Hemoglobinopathies

Education Program: Genomics in Pediatric Acute Leukemia Risk Stratification

Monday 2:45 p.m. – 4:15 p.m. W224CDGH

Chair:

David Teachey, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Speakers:

Mignon Loh, MD, Seattle Children's Hospital, Seattle, WA

Revisiting Novel Genomic Classifiers in the Era of Immunotherapy for Pediatric B-ALL

David Teachey, MD, Children's Hospital of Philadelphia, Philadelphia, PA

The Genomics of Pediatric T-ALL

Martina Pigazzi, MMSc, PhD, University of Padova, Padova, Italy

Using Genomics to Refine Pediatric AML Risk Stratification

Education Program: Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR-Ts, allo-HSCT - How, When, and Why?

Monday 2:45 p.m. – 4:15 p.m. West Hall E2

Chair:

Shannon Maude, MD, The Children's Hospital of Philadelphia, Philadelphia, PA

Speakers:

Adam Lamble, MD, Seattle Children's Hospital, Seattle, WA

Have CARs Stalled for Non-B Cell Malignancies? Where Are We, and Where Are We Going?

Maria Gabelli, MD, PhD, University Hospital of Padova, Padova, Italy

Maintenance after CAR-T? Are We There Yet? Reducing the risk of relapse after loss of anti-CD19 CAR T-cell persistence in ALL

Shannon Maude, MD, The Children's Hospital of Philadelphia, Philadelphia, PA

With BiTEs at the Kiddie Table, Where do CARs Come in for Pediatric B-ALL?

Education Spotlight Sessions: Joint Session with ASPHO: Transition to Adult Care in Malignant and Classical Hematology

Monday 2:45 p.m. – 4:15 p.m. Hyatt - Regency Ballroom S

Chair:

Deepa Manwani, MD, St. Jude Children's Research Hospital, Memphis, TN

Speakers:

Jerlym Porter, PhD, MPH, St. Jude Children's Research Hospital, Memphis, TN

Quality after Quality Improvement Projects for Improved Transition: Lessons Learned in Sustainability and Predictors of Success

David Robert Freyer, DO, USC Norris Comprehensive Cancer Center & Children's Hospital Los Angeles, Los Angeles, California

Models and Importance of Successful Transition in Leukemia/ Lymphoma Survivors

Education Program: Monoclonal Gammopathies of Clinical Significance

Monday 4:30 p.m. – 6:00 p.m. West Hall E2

Chair:

Joseph Mikhael, MD, Translational Genomics Research Institute, Phoenix, AZ

Speakers:

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN *POEMS: Syndrome Diagnosis, Treatments, and Outcomes*

Heather Landau, MD, Weill Cornell Medical Center & Memorial Sloan-Kettering Cancer Center, New York, NY

Monoclonal Gammopathy of Renal Significance from a Hematologic Perspective

Arnaud Jaccard, MD, PhD, University Hospital, Limoges, France

Monoclonal Related Neuropathies: Diagnosis, Prognosis, and Outcomes

Education Spotlight Sessions: How to Prevent and Manage Infections in Immunocompromised Patients in the Era of Immunotherapy and **Growing Antibiotic Resistance**

Monday 4:30 p.m. - 6:00 p.m.

Hyatt - Regency Ballroom OPQ

Chair:

Lidia Gil, MD, University of Medical Sciences, Poznan, Poland

Speakers:

Randy Taplitz, MD, City of Hope National Medical Center, Duarte, CA

Measures to Minimize Infection Risk in Immunocompromised Patients after Cellular Therapies - How, for Whom, for How Long?

Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Protection Without Complete Disruption (of the microbiome): Management of Febrile Neutropenia in Immunocompromised Patients in 2025





In the face of executive orders and other federal actions, ASH is fighting for hematology.

Join the **#Fight4Hematology** campaign with a donation to the ASH Greatest Needs Fund, supporting ASH awards to ensure hematologists can continue their vital research.

HELPING HEMATOLOGISTS CONQUER BLOOD DISEASES WORLDWIDE

Moving hematology forward through charitable support for:

- Hematology Research
- Sickle Cell Disease Initiatives
- Career Development Programs
- Quality Care and Education
- Global Programs

\$6.5M+
raised for ASH
initiatives

100+ ASH awards supported **35+**ASH programs supported

WAYS TO GIVE



Donate Online hematology.org/Donate



Mail a Donation P.O. Box 37577 Baltimore, MD 21297



Taxwise Giving
Donor Advised Funds or Gifts from
Your IRA Appreciated Stock

Donate to Support Hematology Research Funding: hematology.org/Donate #Fight4Hematology



SPECIAL INTEREST SESSIONS

These smaller sessions provide the opportunity for ASH's various communities to focus on specific topics of interest, ranging from coping with physician stress and burnout, to counseling fellows on careers in hematology, to the impact of ASH's international outreach programs.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

FRIDAY

Training Program Directors Workshop

9:00 a.m. - 12:00 p.m. **Friday** SeaWorld - Ports of Call 1

Chair:

Robert Stern, MD, Dana-Farber Cancer Institute, Boston, MA

Speakers:

Rakhi Naik, MD, MHS, Johns Hopkins University, Baltimore, MD; Johns Hopkins University School of Medicine, Baltimore, MD

Lisa Chu, MD, University of Colorado Anschutz Medical Center, Aurora, CO

Jennifer Yui, MD, MSc, Johns Hopkins University School of Medicine, Baltimore, MD Innovations Large and Small in Hematology/Oncology Fellowship Training

Yannis Valtis, MD, Memorial Sloan Kettering Cancer Center, New York, NY

John Molina, MD, MEd, Cleveland Clinic, Cleveland, OH

Med Peds Path to Heme/Onc Training

Jennifer Kesselheim, MD, MEd, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston,

Jennifer Cooperrider, MD, University of Chicago, Chicago, IL

Professionalism

SATURDAY STUDIOS

ASH Studio, West Hall C (non-CME)

1:30 p.m. – 2:00 p.m.	Treating Fairly Talks: From Precision Medicine to Personalized Care: Meeting Patients Where They Are		
3:30 p.m. – 4:00 p.m.	Treating Fairly Talks: Breaking Financial Barriers to Care Through Affordable Innovation		
ASH Wellness Studio, West Hall C (non-CME)			

0.00 a.m. 0.10 a.m.	THE OHAII OHOOK
9:15 a.m. – 9:25 a.m.	Reset Your Posture
11:05 a.m. – 11:15 a.m.	The Typing Timeout
11:20 a.m. – 11:30 a.m.	Emotional Freedom Technique
11:35 a.m. – 11:45 a.m.	Brain-Boosting Break
1:35 p.m. – 1:45 p.m.	Snacks for Better Fuel
1:45 p.m. – 1:55 p.m.	Center Yourself
3:35 p.m. – 3:45 p.m.	Plug Into Nature
3:45 p.m. – 3:55 p.m.	Movement Bites

The Chair Check

Blood Journals Studio, West Halls B3-B4 (non-CME)

8:30 a.m. – 8:55 a.m.	Meet the Journal Editors: Blood Immunology & Cellular Therapy
9:00 a.m. – 9:30 a.m.	Meet the Journal Editors: Blood Vessels, Thrombosis & Hemostasis

Poster Walk: Inherited Bleeding Disorders Poster Walk Hosted by Blood Vessels, 11:15 a.m. - 12:15 p.m.

Thrombosis & Hemostasis

Meet the Journal Editors: Blood Advances 1:30 p.m. – 1:55 p.m.

2:00 p.m. - 2:45 p.m. Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work

3:00 p.m. - 4:00 p.m. How to Create a Strong Visual Abstract

9:05 a.m. - 9:15 a.m.

SATURDAY

Meet the Journal Editors: *Blood Immunology & Cellular Therapy*

Saturday 8:30 a.m. - 8:55 a.m.

West Halls B3-B4 (Blood Journals

Studio)

Speakers:

Willem Fibbe, MD, PhD, Leiden University Medical Center, Leiden, Netherlands

Caron Jacobson, MD, MMSc, Dana Farber Cancer Institute, Boston, MA

Meet the Journal Editors: *Blood Vessels, Thrombosis & Hemostasis*

Saturday 9:00 a.m. - 9:30 a.m.

West Halls B3-B4 (Blood Journals

Studio)

Speakers:

Karin Hoffmeister, MD, Versiti Blood Research Institute, Milwaukee, WI

Keith McCrae, MD, Cleveland Clinic, Cleveland, OH

Leveraging Real-World Data in Sickle Cell Disease to Identify and Study Specific Cohorts of Interest

Saturday 9:30 a.m. – 11:00 a.m. W308

Chair:

Charles Abrams, MD, University of Pennsylvania, Philadelphia, PA

Speakers:

Charles Abrams, MD, University of Pennsylvania, Philadelphia, PA

Welcome and Opening Remarks

Biree Andemariam, MD, University of Connecticut, Farmington, CT

Using Machine Learning to Analyze Sickle Cell Disease Hospital Utilization and Chronic Kidney Disease

Patty Steinert, PhD, MBA, Medical College of Wisconsin, Milwaukee, WI

Using CIBMTR to Track Patients on Gene Therapy for Long-Term Safety and Efficacy

Jeffrey Lebensburger, DO, University of Alabama at Birmingham, Birmingham, AL

Using RWD to Develop a Framework to Support SCD Treatment Research

Charles Abrams, MD, University of Pennsylvania, Philadelphia, PA

Panel Discussion and Audience Q&A

Julie Kanter, MD, University of Alabama at Birmingham, Birmingham, AL

Using Multiple RWD Sources to Identify People with SCD Eligible for Novel Therapies

Charles Abrams, MD, University of Pennsylvania, Philadelphia, PA

Panel Discussion and Audience Q&A

Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine

Saturday 9:30 a.m. – 11:00 a.m. W314

Co-Chairs:

Ann-Kathrin Eisfeld, MD, The Ohio State University, Columbus, OH

Sophie Zaaijer, PhD, University of California, Riverside,

Speakers:

Kellie Machlus, PhD, Harvard Medical School & Boston Children's Hospital, Boston, MA

Discovery Based on Population Structure: How to Faithfully Understand and Functionalize Novel Treatments

Adam de Smith, PhD, University of Southern California Keck School of Medicine, Los Angeles, CA

Decoding Bias in Disease Risk: The Role of Ancestry and Genomic Variant Clustering

Jesse Boehm, PhD, Break Through Cancer & MIT, Cambridge, MA

Moving Towards Precision Medicine: Influence of Germline and Ancestry on Preclinical Target Discovery

Grassroots Network Lunch

Saturday 11:15 a.m. – 12:15 p.m. Hyatt - Florida Ballroom

Chair:

Bart Lee Scott, MD, Fred Hutchinson Cancer Center, Seattle, WA

Speakers:

Tİtilope Fasipe, MD, PhD, Baylor College of Medicine & Texas Children's Hospital, Houston, TX

Dianna S. Howard, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

Jerome Seid, MD, Great Lakes Cancer Management Specialists (retired), Franklin, MI

Roy L. Silverstein, MD, Medical College of Wisconsin, Milwaukee, WI

Blood Presents: How to Get Published in a Peer Review Journal

Saturday 11:15 a.m. – 12:15 p.m. W314

Speakers:

Helen Heslop, MD, Baylor College of Medicine, Houston, TX

Andrew Roberts, MBBS, PhD, Walter Eliza Hall Institute, Melbourne, Victoria, Australia

Meet the Journal Editors: Blood Advances

Saturday 1:30 p.m. – 1:55 p.m. West Halls B3-B4 (Blood Journals Studio)

Speakers:

Olatoyosi Odenike, MD, University of Chicago Medicine, Chicago, IL

Andrew Weyrich, PhD, Oklahoma Medical Research Foundation, Oklahoma City, OK

Hemato-Logic: How to Share Your Cases with the ASH Image Bank and *Blood* Work

Saturday 2:00 p.m. – 2:45 p.m. West Halls B3-B4 (Blood Journals Studio)

Speakers:

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

ASH Clinical Practice Guidelines on Hydroxyurea for Sickle Cell Disease

Saturday 2:00 p.m. – 3:30 p.m. W311ABCD

Chair:

Venee N. Tubman, MD, MMSc, Texas Children's Hospital, Houston, TX

Speakers:

Aimee Hildenbrand, PhD, Nemours Children's Health, Wilmington, DE

Adherence Recommendations for Hydroxyurea for SCD

Marvin Reid, MBBS, PhD, Caribbean Institute for Health Research, Kingston, Jamaica

Monitoring Recommendations for Hydroxyurea for SCD

Jane Hankins, MD, MS, St. Jude Children's Research Hospital, Memphis, TN

Dosing Recommendations for Hydroxyurea for SCD

How to Create a Strong Visual Abstract

Saturday 3:00 p.m. – 4:00 p.m.

West Halls B3-B4 (Blood Journals Studio)

Speaker:

Mario Cazzola, MD, University of Pavia, Pavia, Italy

ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia

Saturday 4:00 p.m. – 5:30 p.m. Hyatt - Regency Ballroom OPQ

Chair:

Jacquelyn Powers, MD, Texas Children's Hematology Center, Houston, TX

Speakers:

Imo Akpan, MD, Columbia University Irving Medical Center, New York, NY

Ferritin, TSAT, and how low is too low: Diagnosis of iron deficiency in adults

Layla Van Doren, MD, MBA, Yale School of Medicine, New Haven, CT

Menstruating individuals: Evidence-based ferritin thresholds

Michelle Sholzberg, MD, MSc, FRCPC, University of Toronto, Toronto, Ontario, Canada

Screening and defining iron deficiency in pregnant individuals

Joint Session: Advancing Hematology Through Artificial Intelligence

Saturday 4:00 p.m. – 5:30 p.m. Hyatt - Regency Ballroom S

Education Program Advisory Panel and the Subcommittee on Artificial Intelligence

Co-Chairs:

Shannon McWeeney, PhD, Oregon Health & Science University, Portland, OR

Vijay Sankaran, MD, PhD, Howard Hughes Medical Institute, Boston Children's Hospital, Boston, MA

Speakers:

Shannon McWeeney, PhD, Oregon Health & Science University, Portland, OR

General Al:The Al Revolution in Healthcare: From Hype to Real-World Impact

Bo Wang, PhD, University of Toronto, Toronto, Ontario, Canada

Basic & Translational AI: Mapping the Human Cell Atlas: AI-Powered Insights into Health and Disease

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Diagnostics & Implementation: Smart Diagnostics: Implementing AI in Hematopathology

Karandeep Singh, MD, MMSc, University of California, San Diego, CA

Clinical Applications of Al: Al at the Bedside: Real-World Clinical Applications

ASH Clinical Practice Guidelines on Myelofibrosis

Saturday 4:00 p.m. – 5:30 p.m. W414CD

Chair:

Brady Stein, MD, Northwestern University Feinberg School of Medicine, Chicago, IL

Speakers:

Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA

Myelofibrosis Recommendation Highlights: Next-Generation Sequencing (NGS), Aspirin Therapy, and Iron Chelators

Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Jak Inhibitors in Myelofibrosis: Recommendations for Different Risk Profiles, Symptoms, and Treatment History

Natasha Szuber, MD, MSc, University of Montreal, Montreal, Quebec, Canada

Timing Transplantation and Pre-Transplant Therapy in Myelofibrosis: Recommendations for Optimal Management

Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology I

Saturday 6:30 p.m. – 8:00 p.m. Hyatt - Florida Ballroom A

Moderators:

Yolanda Fortenberry, PhD, Case Western Reserve University, Cleveland, IL

Nada Hamad, MSc Forensic, MBBS, FRACP, FRCPA, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia

Speakers:

Alejandro De Janon, MSc, Georgia Institute of Technology, Atlanta, GA

High Throughput and Long-Term Human Bone Marrow Organoids to Study Tumor Microenvironment and Drug Sensitivity in Acute Myeloid Leukemia **Ariel Leyte-Vidal**, University of California, San Francisco,

Identification and characterization of novel asciminib-resistant kinase domain mutations in BCR::ABL1

Breanna Maniaci, BS, Oregon Health & Science University, Portland, OR

Acquisition of dual CSF3R mutations enhance oncogenic signaling and MYC stability

Chijioke Nze, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX

Long-Term Lymphoma Follow-Up Survey (LTL-FUS)

Cilomar Martins de Oliveira Filho, Beth Israel Deaconess Medical Center, Boston, MA

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms

Claudia Cabrera, PhD, Washington University School of Medicine, St. Louis, MO

Targeting Nonsense-Mediated RNA Decay in Splicing Factor Mutant Myeloid Malignancies

Dejah Blake, MS, Emory University, Atlanta, GA

The impact of heme modulation on CAR T cell therapy

Jessica Stempel, MD, MHS, Yale School of Medicine, Yale Cancer Center, New Haven, CT

Impact of metformin on outcomes in older adults with classical myeloproliferative neoplasms

Veronica Canarte, BS, Emory University, Atlanta, GA

Characterization of novel factors that contribute to myeloma cell survival

Hematology Inclusion Pathway (HIP) Oral Presentations – Malignant Hematology II

Saturday 6:30 p.m. – 8:00 p.m. Hyatt - Florida Ballroom B

Moderators:

Anita D'Souza, MD, Medical College of Wisconsin, Milwaukee, WI

Randolph Lyde, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

Speakers:

Juan Balandrán, PhD, Instituto Mexicano Del Seguro, Mazatlán, Mexico

Inflammation at the core: MYD88 mutations and clonal hematopoiesis

Kevin Reyes, MD, University of California, San Francisco, San Francisco, CA

The Role of Immunogenomics on the Sequencing of T-cell Redirection Therapies in Relapsed/Refractory Multiple Myeloma

Luis Garcia, MD, University of California, San Francisco, San Francisco, CA

Single Institution Experience with a Consultative Model of Geriatric Assessment in Patients with Hematologic Malignancies undergoing Bone Marrow Transplant or Cellular Therapy

Michael Pineda, MD, Dana-Farber Cancer Institute, Boston, MA

Inducible Anti-CCR8 Producing CAR-T Cells For Specific Cancer Treg Ablation

Nicole Arellano, MS, University of Utah, Salt Lake City,

Dissecting the metabolic state of myeloproliferative neoplasms

Olivia Parker, BA, Rutgers University, New Brunswick, NJ

Immune-Mediated Thrombosis: Understanding the extracellular trap's role in clotting and resistance to lysis.

Omonike Oyelola, University of Connecticut Health Center, Farmington, CT

Myeloproliferative Neoplasms and the Bone Marrow Microenvironment (Currently Developing Complete Title)

Rigoberto De Jesus, MD, Washington University School of Medicine, St. Louis, MO

A Prospective Study of Whole Genome Sequencing (Chromo-Seq) as an Adjunct to Conventional Genomic Profiling in MDS

Vivian Altiery De Jesus, MD, MBE, Johns Hopkins University, Baltimore, MD

Impact of bone marrow immune microenvironment on the response to blinatumomab and checkpoint inhibitors in relapse ALL treated on ETCTN10003

Hematology Inclusion Pathway (HIP) Oral Presentations - Classical Hematology

Saturday 6:30 p.m. - 8:00 p.m. **Hyatt - Florida Ballroom C**

Moderators:

Imo Akpan, MD, Columbia University Irving Medical Center, New York, NY

Satiro De Oliveira, MD, University of California, Los Angeles, CA

Speakers:

Adekunle Alagbe, MD, PhD, University of Pittsburgh, Pittsburgh, PA

Interleukin-27 in vaso-occlusion in Sickle Cell Disease

Alex Pollock, MD, Arkansas Colleges of Health Education, Fort Smith, AR

Role of TRPV-1 and Histone Deacetylase 6 Pro-inflammatory Signaling in HbAA Mice

Halimat Olaniyan, MD, Indiana University, Indianapolis, IN

TETRIS: Timing of Exchange Transfusion in Sickle Cell Disease

Jesse Sanchez, MD, University of Colorado Anschutz, Aurora, CO

Clinical and Biomolecular Features of Non-JAK2 Erythrocytosis: A Single Center Experience

Luisanna Sanchez Ventura, MD, Indiana University, Indianapolis, IN

Clinical and Hematopoietic Profiles Associated with Sustained Hydroxyurea Response for Patients with Sickle Cell

NaShea Kendrick, PhD, Case Western Reserve University, Cleveland, OH

Neutrophil cathepsin G potentiates biased signaling through protease activated receptor 4 (PAR4)

Oluwafunke Kolawole, BS, Geisel School of Medicine at Dartmouth, Hanover, NH

Iron restriction via iron chelation on hematological outcomes in Sickle Cell-Hemoglobin C (HbSC) Disease

Tony Owusu, MD, Icahn School of Medicine at Mt. Sinai, New York, NY

Bleeding and Thrombosis in Patients with Cancer and Acute Venous Thromboembolism Requiring Urgent Proced

Victoria Heigh, MD, Mayo Clinic Alix School of Medicine, Phoenix, AZ

Characterizing the clinicopathologic features of bone marrow failure syndromes

Virginia Camacho, PhD, Boston Children's Hospital, Boston, MA

Tet2 Age Associated Somatic Mutations alter Megakaryocytes and Platelet Function

Hematology Inclusion Pathway (HIP) Oral Presentations - Health Services Outcomes

Saturday 6:30 p.m. - 8:00 p.m. Hyatt - Plaza Int'l F

Moderators:

Joanna Robles, MD, Wake Forest University School of Medicine, Winston-Salem, NC

Margo Rollins, MD, Emory School of Medicine, Atlanta, GA

Speakers:

Elizabeth Doss, BS, Brown University, Providence, RI

Evaluating the Efficacy of Brief Neurocognitive Assessments in Adults and Adolescents with Sickle Cell Disease

Jennifer Salako, MD, Meharry Medical College, Nashville, TN

Evaluating Risk Factors for Malnutrition in Children with & without Sickle Cell Disease in Northern Nigeria

Britney Bell, MD, Boston University Medical Center, Boston, MA

Piloting Health Literacy Universal Precautions to Impact Patient-Reported Outcomes in Patients with Hematologic Malignancies

Dominique Mosley, MD, Emory School of Medicine, Atlanta, GA

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with daraVCD

Sarah Addison, MD, Washington University School of Medicine, St. Louis, MO

Financial Toxicity in Young Patients with Multiple Myeloma

Valentina Ardila Avila, MD, Cleveland Clinic, Cleveland, OH

Obesity Associations with Chronic Graft-Versus-Host Disease

Helen Ajufo, MD, MS, Washington University School of Medicine, St. Louis, MO

Analysis of the North American Transplant Outcomes (NAM-TO) Study

Ayobami Olafimihan, MD, John H Stroger Jr Hospital of Cook County, Chicago, IL

Risks and Trends of Cancer in Sickle Cell Disease: A Multi-Year United States Population-Based Study

Nidhi Patel, DO, Wellstar Health, Acworth, GA

Assessing Disparities in Screening and Treatment of Iron Deficiency during Pregnancy

Olanipekun Lanny Ntukidem, MD, Trinity Health Ann Arbor, Ann Arbor, MI

Comparing 1-Year and 5-Year Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia and Non-Hodgkins Lymphoma (NHL): A Multi-Center Analysis of Sickle Cell Disease (SCD) Impact

Hematology Inclusion Pathway Reception

Saturday 8:00 p.m. – 9:00 p.m. Hyatt - Plaza Int'l DE

SUNDAY STUDIOS				
ASH Studio, West Hall C (non-CME)				
8:30 a.m 9:00 a.m.	MedEd Talks: Classical Hematology Advancement Mentorship Program (CHAMP)			
9:00 a.m. – 9:30 a.m.	Treating Fairly Talks: From Precision Medicine to Personalized Care: Meeting Patients			
	Where They Are			
11:00 a.m. – 11:30 a.m.	Treating Fairly Talks: Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations			
11:30 a.m 12:00 p.m.	MedEd Talks: Online Hematology Curriculum/Podcast			
1:30 p.m. – 2:00 p.m.	Treating Fairly Talks: A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary			
4:00 p.m. – 4:30 p.m.	Treating Fairly Talks: Promoting Language Equity in Care and Research			
ASH Wellness Studio, West Hall C (non-CME)				
9:05 a.m. – 9:15 a.m.	Sneaky Ways to Move More			
9:15 a.m. – 9:25 a.m.	The Chair Check			
11:05 a.m. – 11:15 a.m.	Reignite Your Resilience			
11:20 a.m. – 11:30 a.m.	Brain-Boosting Break			
11:35 a.m. – 11:45 a.m.	Emotional Freedom Technique			
4:05 p.m. – 4:15 p.m.	Snacks for Better Fuel			
4:15 p.m. – 4:25 p.m.	Center Yourself			
Blood Journals Studio, West Halls B3-B4 (non-CME)				
8:00 a.m. – 9:00 a.m.	Poster Walk: Chemotherapy-Free Treatments for Indolent and Aggressive B-Cell Non-			
	Hodgkin Lymphoma Hosted by Blood Neoplasia			
9:15 a.m. – 9:45 a.m.	Meet the Journal Editors: Blood Neoplasia			
11:15 a.m. – 12:15 p.m.	Poster Walk: Exploring and Targeting Emerging Mechanisms of Disease to Advance			
	Human Health Hosted by Blood Red Cells and Iron			
4:00 p.m. – 4:30 p.m.	Meet the Journal Editors: Blood			

SUNDAY

Medical Educators' Symposium

Sunday 7:00 a.m. – 9:00 a.m. Hyatt - Plaza Int'l DEFG

Chair:

Alexander Boucher, MD, University of Minnesota, Minneapolis, MN

Speakers:

Robert Stern, MD, Dana-Farber Cancer Institute, Boston, MA

Laura DeCastro, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

General Session 1: The Evolving Landscape of Cultural Terminology in Hematology

Jean M. Connors, MD, Harvard Medical School, Boston, MA

Jori May, MD, University of Alabama at Birmingham, Birmingham, AL

General Session 2: Tips and Tricks to Efficiently Handle Knowledge Gathering

Ronak Mistry, **DO**, University of Pennsylvania, Philadelphia, PA

Jonaphine Mata, MD, Johns Hopkins University, Baltimore, MD

General Session 3: Content Creation as Medical Educators

Ronak Mistry, **DO**, University of Pennsylvania, Philadelphia, PA

Jonaphine Mata, MD, Johns Hopkins University, Baltimore, MD

Breakout 1: Multimedia Integration into Educational Curricula

Marina Heskel, MD, University of California, San Francisco, CA

Reed E. Drews, MD, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA

Breakout 2: Mixed Methods Educational Strategies for All Learners

Robert Stern, MD, Dana-Farber Cancer Institute, Boston, MA

Rohini Jain, MD, University of California, San Francisco,

Breakout 3: Cultural Humility in Hematology Care

Sana Saif Ur Rehman, MD, Washington University in St. Louis, St. Louis, MO

Thomas Deloughery, MD, Oregon Health & Science University, Portland, OR

Breakout 4: Innovation in Education for the Current Generation

MedEd Talks: Classical Hematology Advancement Mentorship Program (CHAMP)

Sunday 8:30 a.m. – 9:00 a.m. West Hall C (ASH Studio)

Speaker:

Soo Park, MD, University of California, San Diego, CA

Meet the Journal Editors: Blood Neoplasia

Sunday 9:15 a.m. – 9:45 a.m.

West Halls B3-B4 (Blood Journals Studio)

Speakers:

Maria E. Figueroa, MD, University of Miami Miller School of Medicine, Miami, FL

Jonathan Licht, MD, University of Florida, Gainesville, FL

How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?

Sunday 9:30 a.m. – 11:00 a.m. Hyatt - Plaza Int'l HIJK

Chair:

Leonard Valentino, MD, Rush University Medical Center, New York, NY

Speakers:

Leonard Valentino, MD, Rush University Medical Center, New York, NY

Challenges to Clinical Trial Participation

Lanre Tunji-Ajayi, MS, Sickle Cell Awareness Group of Ontario, Pickering, Ontario, Canada

Patient Perspective

John M. Burke, MD, Rocky Mountain Cancer Centers, Aurora, CO

Engagement of Community Physicians in Clinical Trials

Fabio Dennstaedt, University Hospital and University of Bern, Bern, Switzerland

Moving Patients to Participants in Hematology Clinical Trials

Stephanie Valer Seremetis, MD, Novo Nordisk A/S, Plainsboro, NJ

Industry Perspective

Alysha Croker, PhD, Health Canada, Ottawa, Ontario, Canada

Government Perspective

Jeffrey Keefer, MD, PhD, IQVIA, Keswick, VA

Contract Research Organization Perspective

Michelle Feige, MSW, Accreditation of Human Research Protection Programs (AAHRPP), Washington, DC

Institutional Review Board Perspective

To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy

Sunday 9:30 a.m. – 11:00 a.m. W311ABCD

Chair:

Titilope Fasipe, MD, PhD, Baylor College of Medicine & Texas Children's Hospital, Houston, TX

Speakers:

Alexis Leonard, MD, St. Jude Children's Research Hospital, Memphis, TN

To Gene Therapy

Alexander Ngwube, MD, Baylor College of Medicine & Texas Children's Hospital, Houston, TX

Through Gene Therapy

Andrew Campbell, MD, Children's National Hospital, Washington, DC

Thereafter Gene Therapy

Rae Blaylark, University of Minnesota & Sickle Cell Foundation of Minnesota, Minneapolis, MN

Lived Experience Expert

Olujimi Olaghere, Sugarloaf Capital, Atlanta, GA

Lived Experience Expert

Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults

Sunday 9:30 a.m. – 11:00 a.m. W414CD

Chair:

Mikkael Sekeres, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Speakers:

Kah Poh (Melissa) Loh, MD, MS, University of Rochester Medical Center, Rochester, NY

Treatment Options for Older Adults with AML: Recommendations on Low-Dose Cytarabine, Azacitidine, and Decitabine Regimens as Monotherapy or Combinations

Luca Malcovati, MD, University of Pavia & IRCCS S. Matteo Hospital Foundation, Pavia, Italy

Treatment Options for Older Adults with AML and IDH1/IDH2 Mutations: Recommendations on HMA Monotherapy, Combinations with Venetoclax, and Targeted Therapies Maria Baer, MD, University of Maryland, Baltimore, MD

Recommendations for Treatment for Older Adults with AML and FLT3 Mutations

Leveraging Real-World Data in Multiple Myeloma for Regulatory Purposes

Sunday 9:30 a.m. – 11:00 a.m. West Hall E1

Chair:

Saad Usmani, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY

Speakers

Saad Usmani, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY

Welcome and Opening Remarks

Shaji Kumar, MD, Mayo Clinic, Rochester, MN

Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: Lessons from the ASH RC Multiple Myeloma Data Hub

Othman Akhtar, MD, MBBS, Medical College of Wisconsin, Milwaukee, WI

Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: Lessons from CIBMTR

Nicole Gormley, MD, United States Food and Drug Administration, Silver Spring, MD

Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: RWE Guidance from the FDA Perspective

Edward Laane, MD, PhD, European Medicines Agency, Tartu, Estonia

Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: RWE Guidance from the EMA Perspective

Sushmita Sen, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Using Real-World Data to Accelerate Research on Multiple Myeloma Patient Cohorts: RWE Considerations from the Industry Perspective

Saad Usmani, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY

Panel Discussion and Audience Q&A

LGBTQIA+ Community Networking Brunch

Sunday 11:00 a.m. – 12:30 p.m. Hyatt - Plaza Int'l DEFG

Moderators:

Jonas Jutzi, MD, PhD, Merck Co, Cambridge, MA

Ajay Major, MD, MBA, University of Colorado Cancer Center, Denver, CO

ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns

Sunday 11:15 a.m. – 12:30 p.m. Hyatt - Florida Ballroom

Chair:

Mary-Elizabeth Percival, MD, Seattle Cancer Care Alliance, Seattle, WA

Speakers:

Thomas Roades, MPP, Duke-Margolis Institute for Health Policy, Durham, NC

The interactions of the pharmaceutical system and how the competing demands of different stakeholders can influence cost and shortages

Emily Mackler, PharmD, YesRX, Ann Arbor, MI

Combatting drug shortages with drug repository programs

Brooke Boring, MPh, CPnT, Hematology/Oncology Pharmacy Association, Milwaukee, WI

Advocacy at the federal and state level and how practitioners can get engaged

Blood Advances Presents: How to Peer Review a Scientific Paper

Sunday 11:15 a.m. – 12:15 p.m.

W314

Speakers:

Andrew Weyrich, PhD, Oklahoma Medical Research Foundation, Oklahoma City, OK

MedEd Talks: Online Hematology Curriculum/ Podcast

Sunday 11:30 a.m. – 12:00 p.m. West Hall C (ASH Studio)

Speaker:

Ronak Mistry, DO, Hospital of University of Pennsylvania, Philadelphia, PA

Treating Fairly Rounds Lunch

Sunday 11:30 a.m. – 12:30 p.m. Hyatt - Manatee Spring

Co-Chairs:

Srinivas Devarakonda, MD, The Ohio State University, Columbus, OH

Yvonne Efebera, MD, MPH, Ohio Health, Columbus, OH

Speakers:

Rahma Warsame, MD, Mayo Clinic, Rochester, MN

Cesar Rodriguez Valdes, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Healthcare Access to Non-English Speaking Populations

Meet the Journal Editors: Blood

Sunday 4:00 p.m. – 4:30 p.m.

West Halls B3-B4 (Blood Journals

Studio)

Speakers:

Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany

Paula James, MD, Queen's University, Kingston, Ontario, Canada

ASH Clinical Practice Guidelines on Aplastic

Sunday 4:30 p.m. – 6:00 p.m. Hyatt - Plaza Int'l HIJK

Chair:

Phillip Scheinberg, MD, Hospital A Beneficencia Portuguesa, Sao Paulo, Brazil

Speakers:

Austin Kulasekararaj, MD, MBBS, FRCPath, **MRCP,** King's College Hospital & King's College Hospital NHS Foundation Trust, London, United Kingdom

Recommendations for Diagnosis of Aplastic Anemia

Kristin Shimano, MD, UCSF Benioff Children's Hospital, San Francisco, CA

Recommendations for transplant in patients with Aplastic Anemia

Emma Groarke, MD, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

Recommendations for IST and medical management of Aplastic Anemia

Early Faculty Career Development Session

Sunday 4:30 p.m. – 6:00 p.m. Hyatt - Regency Ballroom S

Chair:

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

Speakers:

Courtney Jones, PhD, Cincinnati Children's Hospital, Cincinnati, OH

Alexey Danilov, MD, PhD, City of Hope National Medical Center, Duarte, CA

Developing a Productive Research Program (How to Set up a New Laboratory)

Peter Kouides, MD, University of Rochester, Rochester, NY

Usha Perepu, MD, UT Health San Antonio, San Antonio, TX

Developing a Focused Area of Clinical Expertise

Courtney Jones, PhD, Cincinnati Children's Hospital, Cincinnati, OH

Alexey Danilov, MD, PhD, City of Hope National Medical Center, Duarte, CA

Peter Kouides, MD, University of Rochester, Rochester, NY

Usha Perepu, MD, UT Health San Antonio, San Antonio, TX

Setting Yourself Up for Sustained Success - Panel Discussion

Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults

Sunday 4:30 p.m. – 6:00 p.m. W304EFGH

Chair:

Douglas Cines, MD, University of Pennsylvania, Philadelphia, PA

Speakers:

Sylvain Audia, MD, PhD, University of Bourgogne, Dijon, France

Should adults with primary ITP requiring initial treatment receive steroids alone or steroids in combination with an additional agent? Recommendations from the ASH Guidelines

Camila Masias, MD, MPH, Miami Cancer Institute, Miami, Florida

What treatment should be given to adults with primary ITP who require therapy beyond steroids? Recommendations from the ASH Guidelines

Donald Arnold, MD, McMaster University, Hamilton, Ontario, Canada

Considerations on the Role of Splenectomy and Switching TPOs After Treatment Failure

MONDAY STUDIOS			
ASH Studio, West Hall C (non-CME)			
8:30 a.m. – 9:00 a.m.	Treating Fairly Talks: A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary		
10:00 a.m. – 10:30 a.m.	Treating Fairly Talks: Impact of Geography on Care		
12:00 p.m. – 12:30 p.m.	Treating Fairly Talks: Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations		
12:30 p.m. – 1:00 p.m.	MedEd Talks: Innovative Teaching Approaches for Adult Learning		
1:00 p.m. – 1:30 p.m.	Treating Fairly Talks: Breaking Financial Barriers to Care Through Affordable Innovation		
ASH Wellness Studio, West Hall C (non-CME)			
10:05 a.m. – 10:15 a.m.	Reset Your Posture		
10:15 a.m. – 10:25 a.m.	Happy Hands and Wrists		
12:05 p.m. – 12:15 p.m.	Emotional Freedom Technique		
12:20 p.m. – 12:30 p.m.	Reignite Your Resilience		
12:35 p.m. – 12:45 p.m.	Shake It Off		
2:35 p.m. – 2:45 p.m.	Plug Into Nature		
Blood Journals Studio, West Halls B3-B4 (non-CME)			
8:00 a.m. – 9:00 a.m.	Poster Walk: Rewiring T Cells: Emerging Strategies to Boost Cancer Immunotherapy		
	Hosted by Blood Immunology & Cellular Therapy		
10:00 a.m. – 10:30 a.m.	Meet the Journal Editors: Blood Red Cells & Iron		
12:00 p.m. – 12:20 p.m.	Meet the Journal Editors: Blood Global Hematology		
12:30 p.m. – 1:30 p.m.	Poster Walk: Leukemia in Latin America: Bridging Gaps in Genetics, Access, and		
	Innovation Hosted by Blood Global Hematology		

MONDAY

Back to Business Breakfast

Monday 8:00 a.m. - 9:00 a.m.

Hyatt - Florida Ballroom A

Chair:

Ross Levine, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Meet the Journal Editors: Blood Red Cells & Iron

Monday 10:00 a.m. - 10:30 a.m.

West Halls B3-B4 (Blood Journals

Studio)

Speaker:

Patrick Gallagher, MD, Nationwide Children's Hospital, Ohio State University, Columbus, OH

Laura Silvestri, PhD, San Raffaele Scientific Institute & Vita-Salute University, Milan, Italy

ASH-FDA Joint Symposium on Newly Approved Therapies I

Monday 10:30 a.m. - 12:00 p.m.

Hyatt - Regency Ballroom S

Meet the Journal Editors: Blood Global Hematology

Monday 12:00 p.m. – 12:20 p.m.

West Halls B3-B4 (Blood Journals

Studio)

Speaker:

Jorge Cortes, MD, Georgia Cancer Center at Augusta University, Augusta, GA

Celebrating Diverse Voices: Enriching Hematology Lunch

Monday 12:00 p.m. - 1:30 p.m. **Hyatt - Florida Ballroom A**

Moderators:

Sarwish Rafiq, PhD, Emory University School of Medicine, Atlanta, GA

Noha Soror, MD, MSc, University of Oklahoma, Oklahoma City, OK

Speaker:

Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York, NY

MedEd Talks: Innovative Teaching Approaches for Adult Learning

12:30 p.m. - 1:00 p.m. Monday West Hall C (ASH Studio)

Speaker:

Leslie Ellis, MD, Wake Forest University School of Medicine, Winston Salem, NC

ASH-FDA Joint Symposium on Newly Approved Therapies II

Monday 4:30 p.m. - 6:00 p.m.

Hyatt - Regency Ballroom S

ASH's SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care

Monday 4:30 p.m. - 6:00 p.m.

W230

Chair:

Alexis Thompson, MD MPH, Children's Hospital of Philadelphia, Philadelphia, PA

Alexis Thompson, MD MPH, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

10 Years of Progress: ASH's Sickle Cell Disease initiatives

Omar Niss, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Leveraging the ASH Research Collaborative SCD Research Network to Understand Underused Disease Modifying Therapies and Updates from Voxelotor Withdrawal

Michael DeBaun, MD, MPH, Vanderbilt University School of Medicine, Nashville, TN

Findings from "Sickle Cell Trait Does Not Cause 'Sickle Cell Crisis' Leading to Exertion Related Death: A Systematic Review"

Catherine Chunda-Liyoka, MD, MSc, University Teaching Hospitals - Childrens Hospitals, Ministry of Health, Lusaka, Zambia

Consortium on Newborn Screening in Africa – Diagnostic to Community Based Efforts

Robert Liem, MD, Lurie Children's Hospital, Chicago, IL

ASH SCD Clinical Guidelines and Implementation Tools in Action

ASH Hemostasis and Thrombosis Community Networking Reception

Monday 6:00 p.m. – 7:30 p.m.

Valencia Foyer

Center for Sickle Cell Disease Initiatives Reception

Monday 6:00 p.m. - 8:00 p.m.

W240

Women in Hematology Networking Event

Monday 7:30 p.m. – 9:30 p.m.

Hyatt - Plaza International Ballroom D-G

Speakers:

Tammuella Chrisentery-Singleton, MD, ATHN/Ochsner Clinic Foundation, New Orleans, LA

Leslie Ellis, MD, Wake Forest University School of Medicine, Winston Salem, NC

Ann Mullally, MD, Stanford University School of Medicine, Boston, MA

TRAINEE ACTIVITIES

ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience.

The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows.

These activities are open only to individuals with a blue trainee badge or by invitation.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

ASH-a-Palooza (non-CME)

The ASH-a-Palooza main entrance is through the Ports of Call special event space entrance, not through the main entrance to Sea World. To reach the correct entrance, enter Sea World at the cross section of Central Florida Parkway and Sea Harbor Drive. Upon entrance, drive on the outside of the parking lot until you see the Ports of Call signage.

Friday 12:00 p.m. – 5:00 p.m.

SeaWorld Sea Harbor Pavilions

Chair:

Agrima Mian, MD, Cleveland Clinic Foundation, Cleveland. OH

Designed for undergraduates, medical and graduate students, residents, and fellows, ASH-a-Palooza provides a variety of opportunities for trainees attending the ASH annual meeting. This event is only open to annual meeting attendees with a blue trainee badge.

ASH Talks: These sessions are 20-minute presentations, similar to a TED Talk, with dynamic speakers presenting timely topics.

Blood Drops: These sessions are 10-minute presentations designed to provide short bursts of learning. Each micro-learning session will be held twice in a row and will allow the audience to move easily between each presentation.

Blood Buddies: In-person trainees will have the opportunity to meet with leaders in the field! Trainees can sign up for a one-on-one Blood Buddy 10-minute mentoring session with a faculty member.

Blood Booths: Trainees will have the opportunity to explore interactive booths at ASH-a-Palooza. Chat with peers, take part in live training sessions, learn from experts, and more!

Trainee Welcome Reception: This informal social event immediately follows ASH-a-Palooza for in-person attendees. The reception provides the opportunity for undergraduates, medical and graduate students, residents, and fellows (DO, MD, and PhD) to network and celebrate with their peers.

ASH-a-Palooza Begins: Networking, Blood Booth Exploration, and Food! (non-CME)

Friday 12:00 p.m. – 12:40 p.m.

SeaWorld - Main Stage Pavilion

Global Hematology Trainee Networking Lunch

(non-CME)

Friday 12:00 p.m. – 12:40 p.m.

SeaWorld Networking Pavilion

Plenary Session: Performance by Dr. Rizzo Rouce GOD-CME

Friday 12:45 p.m. – 12:50 p.m.

SeaWorld - Main Stage Pavilion

Speaker:

Rayne Rouce, MD, Texas Children's Hospital, Houston, TX

Plenary Session: Welcome Message from the Trainee Council CORP.

Friday 12:51 p.m. – 1:00 p.m.

SeaWorld - Main Stage Pavilion

Speaker:

Agrima Mian, MD, Cleveland Clinic Foundation, Cleveland, OH

Plenary Session: ASH Talk #1 - Taking the Next Step (Career Transitions) (non-CME)

Friday 1:00 p.m. – 1:20 p.m.

SeaWorld - Main Stage Pavilion

Co-Chairs:

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH Agrima Mian, MD, Cleveland Clinic Foundation, Cleveland, OH

Speaker:

Ted Wun, MD, UC Davis School of Medicine, Sacramento, CA *Taking the Next Step (Career Transitions)*

Blood Buddies (non-CME)

Friday 1:30 p.m. – 3:50 p.m.

SeaWorld Blood Buddies Pavilion

Adult Clinical Classical Hematology

Jean M. Connors, MD, Mass General Brigham, Boston, MA Jessica Altman, MD, Northwestern University, Chicago, IL

Annemarie Fogerty, MD, Massachusetts General Hospital, Boston, MA

Alice Ma, MD, University of North Carolina, Chapel Hill, NC

Rakesh Mehta, MD, Indiana University School of Medicine, Indianapolis, IN

Ted Wun, MD, University of California, Davis, CA

Adult Clinical Malignant Hematology

Gabriela Hobbs, MD, Mass General Brigham, Boston, MA

Anita D'Souza, MD, Froedtert & Medical College of Wisconsin Cancer Center, Milwaukee, WI

Pedro Vianna, MD, Dana-Farber Cancer Institute, Boston, MA

Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH Ajay Major, MD, MBA, University of Colorado, Aurora, CO Allison Walker, MD, MBA, MPH, Moffitt Cancer Center, Powell, OH

BMT/Cellular Therapy - Pediatric and Adult

Basem William, MD, MRCP(UK), FACP, OhioHealth Marion General Hospital, Columbus, OH

Betty Hamilton, MD, Cleveland Clinic, Cleveland, OH Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH

Career Pathways

Nicole Gormley, MD, Food and Drug Administration, Silver Spring, MD

Margret Merino, MD, Food and Drug Administration, Washington, DC

Steven Gore, MD, National Cancer Institute, National Institutes of Health, Rockville, MD

Heather Stefanski, MD, PhD, National Marrow Donor Program, Thousand Oaks, CA

Relja Popovic, PhD, AbbVie, North Chicago, IL

Faraz Zaman, MD, Amgen, Thousand Oaks, CA

Future of Hematology (Artificial Intelligence)

Hemostasis and Thrombosis

Jori May, MD, University of Alabama at Birmingham, Birmingham, AL

Michael Holinstat, PhD, University of Michigan, Ann Arbor, MI

Kylee Martens, MD, Oregon Health & Science University, Portland, OR

Nicoletta Machin, DO, University of Pittsburgh, Pittsburgh, PA

Inclusion Pathways

Deirdra Terrell, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Melissa Alsina, MD, Moffitt Cancer Center, Tampa, FL

Chancellor Donald, MD, Tulane University School of Medicine, New Orleans, LA

Kerice Pinkney, MD, Joe DiMaggio Children's Hospital, Hollywood, FL

International Medical Graduates

Srikanth Nagalla, MD, Baptist Health South Florida, Miami, FL

Abhay Singh, MD, MPH, Cleveland Clinic, Cleveland, OH

Medical Education

Scott Moerdler, MD, Rutgers Cancer Institute, New Brunswick, NJ

Aditi Kamdar, MD, Texas Children's Cancer and Hematology Center, Houston, TX

Kathryn Lurain, MD, National Cancer Institute, Bethesda, MD

Rob Stern, MD, Brigham and Women's Hospital, Boston, MA

Pediatric Clinical Classical Hematology

Kaoru Takasaki, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Melissa Rose, DO, Nationwide Children's Hospital, Columbus, OH

E. Leila Jerome Clay, MD, MCTS, The Johns Hopkins University School of Medicine, Baltimore, MD

Seth Corey, MD, MPH, Cleveland Clinic, Cleveland, OH

Susan Creary, MD, MSc, Nationwide Children's Hospital Research Institute, Columbus, OH

Pediatric Clinical Malignant Hematology

Leidy Isenalumhe, MD, MS, Moffitt Cancer Center, Lutz, FL

PhD/Lab

Sherine Elsawa, PhD, University of New Hampshire, Durham, NH

Natarajan Muthusamy, DVM, PhD, The Ohio State University, Columbus, OH

Lawrence Boise, PhD, Emory University, Atlanta, GA Jos Melenhorst, PhD, Cleveland Clinic, Cleveland, OH

Quality Improvement and Health Services/Outcomes

Amy Billett, MD, Nemours Children's Health, Wilmington, DE Gregory Abel, MD, MPH, Dana-Farber Cancer Institute, Boston, MA

Blood Drops (non-CME)

Friday 1:30 p.m. – 2:00 p.m.

Seaworld Plaza Stations 1-12

ASH Advocacy

Stephanie Guarino, MD, Nemours Children's Health, Wilmington, DE

Career Development and Tips on Job Searching and Negotiation (for PhD, Clinicians, etc.)

Surbhi Sidana, MD, Stanford School of Medicine, Palo Alto CA

Career Development Programs for Fellows, Post docs, & Post-Fellowship

Yang Ding, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Career Pathways (Federal)

Daphne Friedman, MD, Duke University School of Medicine, Durham, NC

Early and Mid-Career Investigator Awards

Kylee Martens, MD, Oregon Health and Science University, Portland, OR

Inclusion Pathways

Bethany Samuelson Bannow, MD, Oregon Health and Science University, Portland, OR

International Medical Graduates

Srinivas Devarakonda, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Malignant Hematology (Journey)

Raul Cordoba, MD, PhD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain

PhD (Transitioning to Independence)

Florian Perner, Hannover Medical School, Hannover, Germany

Sickle Cell Disease

Payal Desai, MD, Levine Cancer Institute, Advocate Health, Wake Forest School of Medicine Charlotte, Charlotte, NC

Trainee Award Opportunities

Bria Carrithers, MD, University of Alabama, Birmingham, GA

Wellness

Amar Kelkar, MD, MPH, Dana-Farber Cancer Institute, Boston, MA

Plenary Session: ASH Talk #2 - Making the Most of Mentorship GON-CME)

Friday 2:10 p.m. – 2:30 p.m.

SeaWorld - Main Stage Pavilion

Co-Chairs:

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH Agrima Mian, MD, Cleveland Clinic Foundation, Cleveland, OH Speakers:

Soo Park, MD, University of California, San Diego, CA **Alfred Lee, MD, PhD,** Yale School of Medicine, New Haven, CT

Making the Most of Mentorship

Blood Drops (non-CME)

Friday 2:40 p.m. – 3:10 p.m. Seaworld Plaza Stations 1-12

ASH Advocacy

Amar Kelkar, MD, MPH, Dana-Farber Cancer Institute, Boston, MA

Career Development and Tips on Job Searching and Negotiation (for PhD, Clinicians, etc.)

Shannon Elf, PhD, Spencer Fox Eccles School of Medicine, Salt Lake City, UT

Career Development Programs for Fellows, Post docs, & Post-Fellowship

Cece Calhoun, MD, MPHS, MBA, Yale School of Medicine, New Haven, CT

Career Pathways

David Steensma, MD, Ajax Therapeutics, Cambridge, MA

Early and Mid-Career Investigator Awards

Patrizia Mondello, MD, Mayo Clinic, Rochester, MN

Inclusion Pathways

Esther Obeng, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

International Medical Graduates

Sumithira Vasu, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Malignant Hematology (Journey)

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

PhD (Transitioning to Independence)

Anna Marneth, PhD, Radboud University Medical Center, Nijmegen, Netherlands

Sickle Cell Disease

Matthew Porteus, MD, PhD, Stanford University, Stanford, CA

Trainee Award Opportunities

Wellness

Laura DeCastro, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

Blood Drops (non-CME)

Friday 3:20 p.m. – 3:50 p.m.

Seaworld Plaza Stations 1-12

ASH Advocacy

Jerome Seid, MD, FACP, Great Lakes Cancer Management Specialists, Macomb, MI

Career Development and Tips on Job Searching and Negotiation (for PhD, Clinicians, etc.)

Basem William, MD, MRCP(UK), FACP, OhioHealth Marion General Hospital, Marion, OH

Career Development Programs for Fellows, Post docs, & Post-Fellowship

Sara Taveras Alam, MD, The University of Texas Health Science Center at Houston, Houston, TX

Career Pathways

Christopher Heery, MD, Arcellx, Redwood City, CA

Early and Mid-Career Investigator Awards

Andres Chang, MD, PhD, Emory University, Atlanta, GA Inclusion Pathways

International Medical Graduates

Srikanth Nagalla, MD, Baptist Health South Florida, Miami, FL

Malignant Hematology (Journey)

Li-Wen Huang, MD, University of California at San Francisco, Burlingame, CA

PhD (Transitioning to Independence)

Anjali Mishra, PhD, Thomas Jefferson University, Philadelphia, PA

Trainee Award Opportunities

Nick Lee, MD, National Heart, Lung, and Blood Institute, Bethesda, MD

Sickle Cell Disease

Stefano Rivella, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

Wellness

Hearts of Hematology (non-CME)

Friday 3:00 p.m. – 3:50 p.m.

SeaWorld Networking Pavilion

Speaker:

Rob Stern, MD, Brigham and Women's Hospital, Boston, MA

Plenary Session: Message from the Committee on Training Chair GOOL-CME

Friday 4:00 p.m. – 4:10 p.m.

SeaWorld - Main Stage Pavilion

Speaker:

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

Plenary Session: Red Cell Rumble Game Show

Friday 4:10 p.m. – 4:45 p.m.

SeaWorld - Main Stage Pavilion

Plenary Session: Wrap-up and Closing Remarks

(non-CME)

Friday 4:45 p.m. – 5:00 p.m.

SeaWorld - Main Stage Pavilion

Trainee Welcome Reception CON-CME

Friday 5:00 p.m. – 7:00 p.m.

SeaWorld Sea Harbor Pavilions

SATURDAY

Career Development Lunch COO-CME

Saturday 11:15 a.m. – 12:15 p.m.

Hyatt - Windemere Ballroom

Chair:

Leidy Isenalumhe, MD, MS, Moffitt Cancer Center, Lutz, FL

This session provides trainees with an opportunity to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research; PhD careers; careers in industry settings; and careers in private and clinical practice.

There will be multiple tables dedicated to each career area and one faculty member at each table leading the discussion. A boxed lunch will be provided. This is a first-come, first-served event that is usually very well attended.

Administrative Careers in Hematology

Yvonne Efebera, MD, MPH, Ohio Health, Columbus, OH John Byrd, MD, University of Cincinnati, Cincinnati, OH Usha Perepu, MD, UT Health San Antonio, San Antonio, TX

Adult BMT/Cellular Therapy

Rawan Faramand, MD, Moffitt Cancer Center, Tampa, FL

Lori Muffly, MD, Stanford University, Stanford, CA

Gunjan Shah, MD, MS, Memorial Sloan Kettering, New York, NY

Azra Borogovac, MD, MS, City of Hope, Irvine, CA

Adult Clinical Classical Hematology

Ronak Mistry, DO, University of Pennsylvania, Philadelphia, PA

Alice Ma, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

Peter Kouides, MD, University of Rochester, Rochester, NY

Adult Clinical Malignant Hematology

Ajay Major, MD, MBA, University of Colorado Cancer Center, Denver, CO

Hira Shaikh, MD, University of Iowa Carver College of Medicine, Iowa City, IA

Jennifer Crombie, MD, Dana Farber Cancer Institute, Boston, MA

Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA

Community Practice

Camila Masias, MD, MPH, Miami Cancer Institute, Miami, FL Matthew Ulrickson, MD, MD Anderson Medical Center/ Banner Health, Gilbert, AZ

Geriatric Hematology

Maya Abdallah, MD, Boston University, Boston, MA Hira Mian, MD, McMaster University, Hamilton, Ontario, Canada

Tanya Wildes, MD, MSc, University of Nebraska, Omaha, NE

Government Careers

Donna DiMichele, MD, National Institutes of Health, Washington, DC

Hematology-Focused Fellowship Training Program

Ana Antun, MD, Emory University, Decatur, GA

Reed E. Drews, MD, Beth Israel Deaconess Medical Center, Boston, MA

Amy Zhou, MD, Washington University School of Medicine, Saint Louis, MO

Industry Careers

Relja Popovic, PhD, AbbVie, North Chicago, IL

Weili Sun, MD, PhD, Janssen Pharmaceutical, Los Angeles, California

Nina Shah, MD, AstraZeneca, South San Francisco, CA

International Graduate Hematology

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD **Saad Usmani, MD,** Memorial Sloan Kettering Cancer Center, New York, NY

Jessica Stempel, MD, MHS, Yale School of Medicine, New Haven, CT

International Opportunities in Hematology

Andres Gomez-De Leon, MD, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Eugenia Asare, MD, MBChB, Ghana Institute of Clinical Genetics, Accra, Ghana

Laboratory and Translational Hematology

Olga Guryanova, MD, PhD, University of Florida, Gainesville, FL

Bob Lowenberg, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands

Sherine Elsawa, PhD, University of New Hampshire, Durham, NH

Lifespan Hematology

Leidy Isenalumhe, MD, MS, Moffitt Cancer Center, Lutz, FL Dan Hart, PhD, Roche, Welwyn Garden City, United Kingdom Julie Kanter, MD, University of Alabama at Birmingham, Birmingham, Alabama

Medical Education in Hematology

Lori Rosenstein, MD, Gunderson Health, La Crosse, WI Catherine E. McGuinn, MD, Cornell University, New York, NY Leslie Ellis, MD, Wake Forest University School of Medicine, Winston Salem, NC

Medical Informatics & AI

Swami Iyer, MD, MD Anderson Cancer Center, Houston, TX Neil Zakai, MD, MSc, University of Vermont, Burlington, VT William Wood, MD, MPH, University of North Carolina At Chapel Hill Hospital, Chapel Hill, NC

Meet the ASH Trainee Council

Nick Lee, MD, National Heart, Lung, and Blood Institute, National Institutes of Health

Pediatric BMT/CAR-T

Neel Bhatt, MBBS, MPH, Fred Hutchinson Cancer Center, Seattle, WA

Kris Mahadeo, MD, Duke University, Houston, Texas **Dorothea Douglas, MD**, Nemours, Orlando, FL

Pediatric Classical Hematology

Neha Bhasin, MD, Beinoff Children's, Oakland, CA

Thomas Coates, MD, Children's Hospital of Los Angeles, Los Angeles, CA

Melissa Rose, DO, Nationwide Children's Hospital, Columbus, OH

Pediatric Hematology/Oncology

Deepa Bhojwani, MD, Children's Hospital of Los Angeles, Los Angeles, CA

Rayne Rouce, MD, Texas Children's Hospital, Houston, TX

Venee N. Tubman, MD MMSc, Texas Children's Cancer and Hematology Centers, Houston, TX

PhD Careers

Anna Beaudin, PhD, University of Utah, Salt Lake City, UT

Wolfgang Bergmeier, PhD, UNC School of Medicine, Chapel Hill, NC

Ze Zheng, Versiti Blood Research Institute, Milwaukee, WI

Women's Health

Bethany Samuelson Bannow, MD, PhD, Oregon Health & Science University, Portland, OR

Alecia Nero, MD, UT Southwestern Medical Center, Dallas, TX

Becky Zon, MD, Brigham and Women's Hospital, West Roxbury, MA

SUNDAY

Trainee Didactic Session: Basic Statistics for Hematologists (non-CME)

Sunday 11:15 a.m. – 12:15 p.m.

W308

Co-Chairs:

Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Reshma Ramlal, MD, Moffitt Cancer Center, Tampa, FL

Speakers:

Megan Othus, PhD, Fred Hutchinson Cancer Center, Seattle, WA

Sara Vesely, PhD, MPH, University of Oklahoma Health Sciences, Oklahoma City, OK

Trainee Didactic Session: Drug Development

(non-CME)

Sunday 11:15 a.m. – 12:15 p.m.

W307

Co-Chairs:

Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Reshma Ramlal, MD, Moffitt Cancer Center, Tampa, FL

Speakers:

Patricia LoRusso, DO, Yale University, New Haven, CT

Peter Marks, MD, PhD, Independent Consultant to the Pharmaceutical Industry, Washington, DC

Ifeyinwa Osunkwo, MD, Novo Nordisk, Waltham, MA

MONDAY

Trainee Didactic Session: Application of Microarray and Bioinformatics in Hematology

(non-CME)

Monday 12:15 p.m. – 1:15 p.m.

W307

Co-Chairs:

Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Reshma Ramlal, MD, Moffitt Cancer Center, Tampa, FL

Speakers:

Kathleen Freson, PhD, University of Leuven, Leuven, Belgium

Juliana Perez Botero, MD, Blood Center of Wisconsin, Rochester, MN

Trainee Didactic Session: Outcomes Research in Hematology (non-CME)

Monday 12:15 p.m. – 1:15 p.m.

W308

Co-Chairs:

Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Reshma Ramlal, MD, Moffitt Cancer Center, Tampa, FL

Speakers:

Scott Huntington, MD, MPH, Yale School of Medicine, New Haven, CT

Mengyang Di, MD, PhD, Fred Hutchinson Cancer Center & University of Washington, Seattle, WA

2025 SCIENTIFIC CATEGORIES

For the 2025 67th ASH Annual Meeting, abstracts were submitted in 76 different scientific categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by

category number. Oral Abstract Sessions titles begin with the category number and name. They are listed in the Program-at-a-Glance by date, time, and then by category number. The In-Person and Virtual Poster

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

100s - Red Cell Physiology and Disorders

- 101 Red Cells and Erythropoiesis, Excluding Iron
- 102 Iron Homeostasis and Biology in Physiological and Pathological Conditions
- 112 Thalassemia and Globin Gene Regulation
- 113 Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational
- 114 Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

200s - Leukocytes, Inflammation, and Immunology

- 201 Granulocytes, Monocytes, and Macrophages
- 203 Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

300s - Hemostasis, Thrombosis, and Vascular Wall Biology

- 301 Platelets and Megakaryocytes: Basic and Translational
- 311 Disorders of Platelet Number or Function: Clinical and Epidemiological
- 321 Coagulation and Fibrinolysis: Basic and Translational
- 322 Hemophilia A and B: Clinical and Epidemiological
- 323 Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological
- 330 Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational
- 331 Thrombotic Microangiopathies/ Thrombocytopenias: Clinical and Epidemiological
- 332 Thrombosis and Anticoagulation: Clinical and Epidemiological

400s - Transfusion Medicine

401 Blood Transfusion

500s - Hematopoiesis

- 501 Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
- 503 Clonal Hematopoiesis, Aging, and Inflammation
- 506 Bone Marrow Microenvironment
- 508 Bone Marrow Failure: Acquired
- 509 Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

600s - Hematologic Malignancies

- 602 Myeloid Oncogenesis: Basic
- 603 Lymphoid Oncogenesis: Basic
- 604 Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
- 605 Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
- 612 Acute Lymphoblastic Leukemias: Clinical and Epidemiological
- 613 Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation
- 614 Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis
- 615 Acute Myeloid Leukemias: Clinical and Epidemiological
- 616 Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies
- 617 Acute Myeloid Leukemias: Commercially Available Therapies
- 618 Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis
- 619 Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment

Scientific Categories 109

2025 SCIENTIFIC CATEGORIES

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

- 621 Lymphomas: Translational Molecular and Genetic
- 622 Lymphomas: Translational Non-Genetic
- 623 Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
- 624 Hodgkin Lymphomas: Clinical and Epidemiological
- 625 T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological
- 626 Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials
- 627 Aggressive Lymphomas: Targeted and Pharmacologic Therapies
- 628 Aggressive Lymphomas: Cellular Therapies
- 629 Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies
- 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
- 632 Chronic Myeloid Leukemia: Clinical and Epidemiological
- 634 Myeloproliferative Syndromes: Clinical and Epidemiological
- 636 Myelodysplastic Syndromes: Basic and Translational
- 637 Myelodysplastic Syndromes: Clinical and Epidemiological
- 641 Chronic Lymphocytic Leukemia: Basic and Translational
- 642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological
- 651 Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
- 652 MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological
- 653 Multiple Myeloma: Clinical and Epidemiological
- 654 Multiple Myeloma: Pharmacologic Therapies
- 655 Multiple Myeloma: Cellular Therapies

700s - Transplantation and Adoptive Cell Therapies

- 701 Experimental Transplantation: Basic and Translational
- 702 CAR-T Cell Therapies: Basic and Translational
- 703 Cellular Immunotherapies other than CAR-T Cells: Basic and Translational
- 704 Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities

- 711 Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products
- 721 Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities
- 722 Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution
- 723 Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence
- 732 Allogeneic Transplantation: Disease Response and Comparative Treatment Studies

800s - Gene Therapies, Chemical Biology, and Emerging Diagnostics

- 801 Gene Therapies
- 802 Chemical Biology and Experimental Therapeutics
- 803 Emerging Tools, Techniques, and Artificial Intelligence in Hematology

900s - Health Services, Quality Improvement, and Outcomes Research

- 900 Health Services and Quality Improvement: Hemoglobinopathies
- 901 Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies
- 902 Health Services and Quality Improvement: Lymphoid Malignancies
- 903 Health Services and Quality Improvement: Myeloid Malignancies
- 904 Outcomes Research: Hemoglobinopathies
- 905 Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies
- 906 Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders
- 907 Outcomes Research: Plasma Cell Disorders
- 908 Outcomes Research: Myeloid Malignancies
- 909 Education, Communication, and Workforce

110 Scientific Categories

ORAL ABSTRACT SESSIONS

The Oral Abstract Sessions will be held Saturday, December 6, through Monday, December 8. Each abstract presentation will be followed immediately by a question-and-answer period with the presenter. The Plenary Scientific

Session will be held Sunday, December 7, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY

9:30 a.m. - 11:00 a.m. Oral Abstract Sessions Gon-CME)

- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Mechanistic Insights into Sickle Cell Pathobiology and Disease Progression (7–12) W311ABCD
- 321. Coagulation and Fibrinolysis: Basic and Translational:
 Deciphering new and old conundrums of coagulation (13–18)
 W304EFGH
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Risk Assessment and Management of Thromboembolism in Cancer: Genomics, Biomarkers, and Real-World Evidence (19–24) W304ABCD
- 508. Bone Marrow Failure Acquired: Immune dysregulation and molecular insights (25–30) **Hyatt - Plaza Int'l HIJK**
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Prognostic Genetic and Therapeutic Response Factors in Adult and Pediatric B-ALL (31–36) W224CDGH
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Biological and Clinical Nuances in Patient Outcomes (37–42) Valencia Room W415BC
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Frontline treatment with intensive or lower-intensity regimens (43–48) Valencia Room W415A
- 621. Lymphomas: Translational Molecular and Genetic Subtyping strategies to unlock new therapeutic vulnerabilities (49–54)

 Tangerine Ballroom F1
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Front-line BTKi-based Combination Therapy in DLBCL and PCNSL (55–60) Tangerine Ballroom F3-4
- 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Overcoming Barriers in Frontline Therapy: Bispecific Antibodies for Older Adults with DLBCL (61–66) Tangerine Ballroom F2
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN (67–72) **W414AB**

- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Decoding the Molecular Drivers of response and resistance (73–78) Valencia Room W415D
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome (79–84) W414CD
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation (85–90) W224ABEF
- 653. Multiple Myeloma: Clinical and Epidemiological:
 Optimizing Immune-Based Therapies in Myeloma:
 From T-Cell Fitness to Clinical Outcomes (91–96)
 West Hall D2
- 654. Multiple Myeloma: Pharmacologic Therapies: Advancing the Standard: Improving Myeloma Treatment through Diagnosis, Maintenance and Relapse (97–102) West Hall E1
- 702. CAR-T Cell Therapies: Basic and Translational: In vivo CAR-T cell platforms and resistance mechanisms (103–108)

 Sunburst Room (W340)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications (109–114) Chapin Theater (W320)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Transformative Al and Omics Approaches in Hematologic Malignancies (115–120) **Hyatt - Regency Ballroom R**
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Transforming Care Delivery and the Patient Experience (121–126) W311EFGH
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Clinical decision making and supportive care (127–132) W230
- 907. Outcomes Research: Plasma Cell Disorders: Real world Outcomes of Targeted Immunotherapies in Patients with Multiple Myeloma (133–138)

 West Hall E2



12:00 p.m. - 1:30 p.m. Oral Abstract Sessions Gon-CME)

- 603. Lymphoid Oncogenesis: Basic Mechanistic studies of lymphoid leukemias and lymphomas (139–144) W224ABEF
- 622. Lymphomas: Translational Non-Genetic: Insights into immune niches of CNS and Hodgkin Lymphoma via multi-omic and spatial profiling (145–150) Tangerine Ballroom F1
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling, and Predictive Tools (151–156) Tangerine Ballroom F2
- Experimental Transplantation: Basic and Translational: GVHD, thymopoiesis and the host regenerative response (157–162)
 Chapin Theater (W320)

- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients (163–168) W331
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Donor selection and maintenance strategies (169–174) Sunburst Room (W340)
- 904. Outcomes Research: Hemoglobinopathies: Clinical Phenotypes and Outcomes in Hemoglobinopathies (175–180)

 W308

2:00 p.m. - 3:30 p.m. Oral Abstract Sessions Con-CME

- 101. Red Cells and Erythropoiesis, Excluding Iron: Nursing erythropoiesis in sickness and in health (181–186) W314
- Granulocytes, Monocytes, and Macrophages:
 Histiocytic and granulocytic Disorders (187–192)
 W312
- Platelets and Megakaryocytes: Basic and Translational: Novel mechanisms of platelet signaling (193–198)
 W304ABCD
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Thrombosis and thrombotic microangiopathy: New mechanisms and new therapies (199–204) W307
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Chromatin and transcriptional regulation in hematopoietic lineage commitment (205–210) W311EFGH
- 602. Myeloid Oncogenesis: Basic: Identification of new vulnerabilities in therapy-resistant AML (211–216) W414CD
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Redefining AML: Genetic, Phenotypic and Response-Based Insights (217–222) W414AB
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: FL and WM (223–228) Tangerine Ballroom F2
- 636. Myelodysplastic Syndromes: Basic and Translational: Innovative Approaches to Target Novel Vulnerabilities in MDS Pathobiology (229–234) Valencia Room W415D
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes (235–240) Valencia Room W415BC

- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Clonal evolution, tumor microenvironment and immunotherapy (241–246)
 - W224CDGH
- 654. Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/ Refractory Multiple Myeloma (247–252) West Hall D1
- 655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma (253–258)

 West Hall E1
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and Strategies (259–264) Chapin Theater (W320)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next Generation CAR-T Clinical Trials in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Multiple Myeloma (265–270) West Hall D2
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Acute and Chronic GVHD and Immune Reconstitution (271–276)
 W331
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: MRD Assays and Novel Drug Discovery Pipelines (277–282)
 - Hyatt Regency Ballroom R
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Barriers and bridges: Improving access to hematologic cancer care across diverse populations (283–288) W224ABEF
- 908. Outcomes Research: Myeloid Malignancies: Real-World Outcomes in AML (289–294) Valencia Room W415A

Oral Abstract Sessions Gon-CME 4:00 p.m. - 5:30 p.m.

- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Prognosis, the heart, and the kidney in SCD (295-300) W311ABCD
- 322. Hemophilia A and B: Clinical and Epidemiological: Prophylaxis Across the Age Spectrum (301–306) W304ABCD
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Insights into Diagnostics and Therapeutics of Bleeding in Inherited, Acquired Coagulopathies and BDUC (307-312) W304EFGH
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Bleeding: Real-World Insights Across Diverse Patient Populations (313-318) W307
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel strategies to overcome therapy resistance in AML (319-324) Valencia Room W415D
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Beyond Genomic Resistance: epigenetics, metabolism and more (325-330) W230
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Critical biomarkers and classifiers in B-ALL and T-ALL ontogeny and outcomes (331–336) W224CDGH
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel AML Biomarkers: Mechanisms, Mutations, and Targets (337-342) Valencia Room W415BC
- 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: From Detection to Decision: MRD as the Compass in AML (343-348) Valencia Room W415A

- 621. Lymphomas: Translational Molecular and Genetic: Towards Precision Medicine in Lymphoma: Multi-Omics Discovery of Prognostic and Predictive Biomarkers (349-354) **Tangerine Ballroom F1**
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Drivers, vulnerabilities and resistance in CML and MPN (355-360) W414AB
- 653. Multiple Myeloma: Clinical and Epidemiological: Genomic and Cytogenetic Drivers of Prognosis in Multiple Myeloma (361–366) West Hall D1
- 654. Multiple Myeloma: Pharmacologic Therapies: Are we achieving cures for multiple myeloma patients using early intervention strategies? (367–372) West Hall E1
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients (373-378) Sunburst Room (W340)
- 801. Gene Therapies: Advances in Gene Therapy for Blood Disorders (379-384) Chapin Theater (W320)
- 802. Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies? (385-390) W331
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Prediction Models and Novel Molecular Markers (391-396) Hyatt - Regency Ballroom R
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T and Bispecifics in Lymphoma - Real World Outcomes and Endpoints (397-402) W224ABEF
- 907. Outcomes Research: Plasma Cell Disorders: Innovations in Myeloma: Therapy, Prevention & Patient-Centered Care (403-408) West Hall E2

SUNDAY

Oral Abstract Sessions Con-CME 9:30 a.m. - 11:00 a.m.

- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Orphans of an orphan disease: HbSC and HbSBeta+ sickle cell Disease (409-414) W308
- 301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders (415–420) W304EFGH
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets, leukocytes, and endothelium in thrombotic and vascular disease (421-426) W307
- 506. Bone Marrow Microenvironment: The microenvironment in homeostasis and aging (427-432)

Hyatt - Regency Ballroom R

602. Myeloid Oncogenesis: Basic: Targeting the NPM1/KMT2A/Menin axis (865-870) W314

- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Therapy resistance across B-cell maturation - from B-ALL to myeloma (433–438) W224CDGH
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Emerging Treatment Paradigms in ALL (439–444) W224ABEF
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Lessons from across the age spectrum (445–450) Valencia Room W415BC
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: AML Biomarkers in Action: Prognosis, Risk, and Real-World Insights (451–456) Valencia Room W415A
- 621. Lymphomas: Translational Molecular and Genetic Decoding Lymphomagenesis through Multiomics (457–462)

 Tangerine Ballroom F1
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological -Immunotherapies for Follicular Lymphoma (463–468) West Hall D2
- 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Clinical and Biological Predictors of Outcome (469–474) Tangerine Ballroom F2
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Targeted Agents and Chemotherapy Intensification in Aggressive B-cell Lymphomas (475–480) Tangerine Ballroom F3-4

- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Between a Rock and a Ropeg -Innovative Therapies for MPNs (481–486) W414AB
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML (487–492) Valencia Room W415D
- 653. Multiple Myeloma: Clinical and Epidemiological: From Biomarkers to Biology: Evolving Risk Stratification and Disease Modeling in Multiple Myeloma (493–498) West Hall D1
- 702. CAR-T Cell Therapies: Basic and Translational: Product biology and single-cell states shaping CAR-T cell outcomes (499–504) Sunburst Room (W340)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Factors Influencing Transplant Outcomes (505–510) W331
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Biologic Predictors and Novel Platforms Integrating CAR T with Transplant (511–516) Chapin Theater (W320)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Redefining supportive care: Development of novel safety, patient engagement, and delivery models in hematologic oncology (517–522)

 W230

12:00 p.m. - 1:30 p.m. Oral Abstract Sessions Gon-CME

- 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Erythropoiesis, Inflammation and Hematologic Recovery: The Iron and Heme Drama Unfolds (523–528) W311EFGH
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: On the Horizon: Biomarkers Guiding Outcomes in Hemoglobinopathies (529–534) W311ABCD
- 322. Hemophilia A and B: Clinical and Epidemiological: Innovations Shaping the Future of Hemophilia Care (535–540) W304EFGH
- 401. Blood Transfusion: Transfusion Frontlines: Research Driving Safer, Smarter Care (541–546) Sunburst Room (W340)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological:
 Optimizing risk stratification, treatment, and diagnostics
 of ALL in the immunotherapy era (547–552)
 W224ABEF
- 622. Lymphomas: Translational Non-Genetic: T cell interactions in the lymphoma microenvironment the good and the bad (553–558)

 Tangerine Ballroom F1
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Fresh insight for Cutaneous and Virus-associated TCLs (559–564)

 Tangerine Ballroom F2

- 628. Aggressive Lymphomas: Cellular Therapies: Clinical Insights and Determinants of Resistance to Cellular Therapies in Aggressive Lymphomas (565–570)

 Tangerine Ballroom F3-4
- 651. Multiple Myeloma and Plasma Cell Dyscrasias:
 Basic and Translational: Emerging Myeloma Disease
 Mechanisms and Therapeutic Strategies (571–576)
 West Hall E1
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Redefining diagnosis, monitoring and treatment approaches (577–582) **West Hall E2**
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Biomarkers and Targets (583–588) Chapin Theater (W320)
- 723. Allogeneic Transplantation: Long-term Followup, Complications, and Disease Recurrence: Predicting and elucidating relapse (589–594) W331
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing (595–600) W304ABCD
- 908. Outcomes Research: Myeloid Malignancies: Treatment and Outcomes in the Real-World (601–606)
 W414CD

2:00 p.m. - 4:00 p.m.

Plenary Scientific Session (non-CME)

West Hall D2

4:30 p.m. - 6:00 p.m. Oral Abstract Sessions Con-CME

- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications - Lessons from Pre-clinical Models (619–624) Room 31
- 602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology (625-630) Seaport Ballroom ABCD
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL (631-636) **Marriott Grand Ballroom 5-6**
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis (637–642) Seaport Ballroom EFGH
- 622. Lymphomas: Translational Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses (643-648) Pacific Ballroom Salons 15-17
- 626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma (649-654) **Marriott Grand Ballroom 8-9**
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis (655-660) **Grand Hall D**

- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS (661-666) **Harbor Ballroom DEFG**
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma (667-672) Pacific Ballroom Salons 24-26
- 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond (673-678) Pacific Ballroom Salons 21-22
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity (679–684) **Marriott Grand Ballroom 2-4**
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities (685-690) Room 6B
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA (691-696)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis (697–702) Room 6CF
- 907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes (703-708) San Diego Ballroom AB

MONDAY

10:30 a.m. - 12:00 p.m. Oral Abstract Sessions Con-CME

- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Evidence in ITP (709-714) Room 29
- 322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term (715–720) Room 30
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance to Standard and Novel Therapies (721-726) Seaport Ballroom ABCD
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia (727-732) Marriott Grand Ballroom 11-13

- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML (733-738) **Grand Hall B**
- 621. Lymphomas: Translational Molecular and Genetic: Singlecell and Spatial Analyses in Indolent Lymphomas (739–744) **Marriott Grand Ballroom 5-6**
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas (745-750) **Marriott Grand Ballroom 8-9**
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stem Cell Biology in Myeloproliferative Syndromes (751–756) **Grand Hall C**

- 641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms (757–762)
 - Pacific Ballroom Salons 15-17
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma (763–768)

 Pacific Ballroom Salons 24-26
- 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma (769–774)

 Pacific Ballroom Salons 21-22
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant (775–780) Room 6A

- 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow Improving Access to Blood Cancer Treatments and Trials (781–786)

 San Diego Ballroom AB
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes (787–792)

 Seaport Ballroom EFGH
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases (793–798) Room 6B

2:45 p.m. – 4:15 p.m. Oral Abstract Sessions Gon-CME

- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: The Effects of Sickle Cell Disease on Organ Function (799–804)
 Room 33
- Granulocytes, Monocytes, and Macrophages: From Inflammation to Hemophagocytic Lymphohistiocytosis (805–810)
 Room 6DE
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis: Models, Risk Factors, and Outcomes (811–816) Room 28 A-D
- 506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease (817–822)

 Room 11
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs (823–828) Seaport Ballroom ABCD
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma (829–834) Ballroom 20CD
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell diseases (835–840) Marriott Grand Ballroom 2-4
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML (841–846) **Grand Hall C**
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment (847–852) **Grand Hall B**
- 621. Lymphomas: Translational Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas (853–858) Pacific Ballroom Salons 18-19

- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia (859–864) Marriott Grand Ballroom 11-13
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications (865–870)

 Pacific Ballroom Salons 15-17
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes (871–876) Seaport Ballroom EFGH
- 636. Myelodysplastic Syndromes: Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS (877–882) **Grand Hall D**
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life (883–888) Marriott Grand Ballroom 5-6
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis (889–894) Pacific Ballroom Salons 21-22
- 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse (895–900) Pacific Ballroom Salons 24-26
- 701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity (901–906)
 Room 6B
- 702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy (907–912) Room 6CF
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics (913–918) Marriott Grand Ballroom 8-9

- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies (919–924) Hall B
- 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival (925–930) Room 6A

907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies (931–936) San Diego Ballroom AB

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions Con-CME

- 101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease (937–942)
 Room 28 A-D
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences (943–948) **Grand Hall C**
- 602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia (949–954) Seaport Ballroom ABCD
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma (955–960) Ballroom 20CD
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies (961–966) Marriott Grand Ballroom 5-6
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World (967–972) Grand Hall B
- 622. Lymphomas: Translational Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies (973–978) Marriott Grand Ballroom 11-13
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas? (979–984) Pacific Ballroom Salons 15-17
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas (985–990) Pacific Ballroom Salons 18-19
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome (991–996) Seaport Ballroom EFGH
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis (997–1002) Harbor Ballroom DEFG
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia (1003–1008) Grand Hall D
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations (1009–1014)

 Marriott Grand Ballroom 8-9

- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM (1015–1020) Pacific Ballroom Salons 21-22
- 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma (1021–1026) Hall B
- 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma (1027–1032) Pacific Ballroom Salons 24-26
- 702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells (1033–1038) Room 6CF
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Avoiding GVHD and Improving Outcomes (1039–1044) Room 6B
- 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse (1045–1050) Room 6A
- 801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies (1051–1056) Room 33
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs (1057–1062) Marriott Grand Ballroom 2-4
- 904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease (1063–1068) Room 6DE



Now in a New Interview Format

Stay up to date on the latest in hematology research.

Blood podcast features authors of select articles recently published in Blood.



Subscribe and listen to Blood podcast wherever you get your podcasts.

- Apple Podcasts
- Spotify
- Amazon Music
- Overacst
- iHeartRadio
- Pandora



podcasts.bloodjournal.org



POSTER PRESENTATIONS

The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the Orange County Convention Center, West Halls B3-B4. Presenters will stand beside their posters during the evening Presentation times. Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 8:00 a.m. (Eastern time) each day, as

well as access posters from previous days on the virtual platform.

The Poster Hall hours are as follows:

Saturday, December 6 8:00 a.m. – 7:30 p.m.

Sunday, December 7 8:00 a.m. – 8:00 p.m.

Monday, December 8 8:00 a.m. – 8:00 p.m.

Poster Sessions are not offered for CME credit.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY, DECEMBER 6, 2025

8:00 a.m. - 7:30 p.m.

Poster Session I - Viewing Gon-CME

5:30 p.m. - 7:30 p.m. Poster Session I - Presentations (non-CME)

West Halls B3-B4

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1099–1123)
- 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster I (1124–1134)
- 112. Thalassemia and Globin Gene Regulation: Poster I (1135-1145)
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1146–1160)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1161–1199)
- 201. Granulocytes, Monocytes, and Macrophages: Poster I (1200–1223)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1224–1236)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster I (1237–1250)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1251–1274)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1275–1284)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster I (1285–1299)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I (1300–1315)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I (1316–1324)

- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I (1325–1339)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1340–1363)
- 401. Blood Transfusion: Poster I (1364-1371)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1372–1384)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I (1385–1401)
- 506. Bone Marrow Microenvironment: Poster I (1402–1412)
- 508. Bone Marrow Failure: Acquired: Poster I (1413–1434)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1435–1445)
- 602. Myeloid Oncogenesis: Basic: Poster I (1446-1473)
- 603. Lymphoid Oncogenesis: Basic: Poster I (1474-1486)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1487–1518)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1519–1539)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1540–1560)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I (1561–1582)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I (1583–1598)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1599–1638)

- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I (1639–1657)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I (1658–1690)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I (1691–1736)
- 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster I (1737–1744)
- 621. Lymphomas: Translational Molecular and Genetic: Poster I (1745–1772)
- 622. Lymphomas: Translational Non-Genetic: Poster I (1773-1793)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1794–1840)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I (1841–1855)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I (1856–1881)
- 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster I (1882–1903)
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster I (1904–1927)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster I (1928–1954)
- 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster I (1955–1972)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1973–1991)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1992–2012)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (2013–2053)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster I (2054–2066)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I (2067–2097)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I (2098–2106)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (2107–2137)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (2138–2180)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (2181–2197)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster I (2198–2252)

- 654. Multiple Myeloma: Pharmacologic Therapies: Poster I (2253–2289)
- 655. Multiple Myeloma: Cellular Therapies: Poster I (2290-2302)
- 701. Experimental Transplantation: Basic and Translational: Poster I (2303–2318)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster I (2319–2351)
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I (2352–2363)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I (2364–2400)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I (2401–2411)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I (2412–2445)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I (2446–2479)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I (2480–2510)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2511–2530)
- 801. Gene Therapies: Poster I (2531-2544)
- 802. Chemical Biology and Experimental Therapeutics: Poster I (2545–2554)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I (2555–2587)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I (2588–2603)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2604–2621)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I (2622–2647)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I (2648–2660)
- 904. Outcomes Research: Hemoglobinopathies: Poster I (2661-2676)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2677–2703)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I (2704–2783)
- 907. Outcomes Research: Plasma Cell Disorders: Poster I (2784–2823)
- 908. Outcomes Research: Myeloid Malignancies: Poster I (2824-2860)
- 909. Education, Communication, and Workforce: Poster I (2861–2875)

SUNDAY, DECEMBER 7, 2025

8:00 a.m. - 8:00 p.m. Poster Session II - Viewing Good CME

Poster Session II - Presentations (non-CME)

West Halls B3-B4

6:00 p.m. - 8:00 p.m.

 Red Cells and Erythropoiesis, Excluding Iron: Poster II (2876–2900) 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II (2901–2911)

112. Thalassemia and Globin Gene Regulation: Poster II (2912–2921)

- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II (2922–2937)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II (2938–2976)
- 201. Granulocytes, Monocytes, and Macrophages: Poster II (2977–2999)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (3000–3011)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster II (3012–3026)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (3027–3049)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (3050–3060)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster II (3061–3076)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II (3077–3092)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II (3093–3101)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II (3102–3116)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (3117–3140)
- 401. Blood Transfusion: Poster II (3141-3147)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (3148–3159)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II (3160–3177)
- 506. Bone Marrow Microenvironment: Poster II (3178-3187)
- 508. Bone Marrow Failure: Acquired: Poster II (3188-3210)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (3211–3222)
- 602. Myeloid Oncogenesis: Basic: Poster II (3223-3250)
- 603. Lymphoid Oncogenesis: Basic: Poster II (3251-3263)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (3264–3295)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (3296–3316)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (3317–3336)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II (3337–3359)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II (3360–3374)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (3375–3414)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II (3415–3433)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II (3434–3466)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II (3467–3511)

- 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster II (3512–3519)
- 621. Lymphomas: Translational Molecular and Genetic: Poster II (3520–3548)
- 622. Lymphomas: Translational Non-Genetic: Poster II (3549–3568)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3569–3616)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II (3617–3630)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II (3631–3657)
- 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster II (3658–3680)
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II (3681–3704)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster II (3705–3731)
- 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II (3732–3748)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3749–3768)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3769–3789)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3790–3829)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster II (3830–3841)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II (3842–3874)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II (3875–3882)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3883–3913)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3914–3957)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3958–3974)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster II (3975–4028)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster II (4029–4065)
- 655. Multiple Myeloma: Cellular Therapies: Poster II (4066-4079)
- 701. Experimental Transplantation: Basic and Translational: Poster II (4080–4095)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster II (4096–4128)
- 703. Cellular Immunotherapies other than CAR-T Cells: Poster II (4129–4140)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II (4141–4177)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II (4178–4188)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II (4189–4221)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II (4222–4256)

- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II (4257-4287)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (4288-4307)
- 801. Gene Therapies: Poster II (4308-4321)
- 802. Chemical Biology and Experimental Therapeutics: Poster II (4322-4330)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II (4331-4363)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II (4364-4379)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4380-4397)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II (4398-4424)

- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II (4425-4436)
- 904. Outcomes Research: Hemoglobinopathies: Poster II (4437-4453)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4454-4479)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II (4480-4561)
- 907. Outcomes Research: Plasma Cell Disorders: Poster II (4562-4601)
- 908. Outcomes Research: Myeloid Malignancies: Poster II (4602-4638)
- 909. Education, Communication, and Workforce: Poster II (4639-4653)

MONDAY, **DECEMBER 8, 2025**

8:00 a.m. - 8:00 p.m.

Poster Session III - Viewing Gon-CME



6:00 p.m. - 8:00 p.m.

Poster Session III - Presentations (non-CME)


West Halls B3-B4

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (4654-4677)
- 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster III (4678-4688)
- 112. Thalassemia and Globin Gene Regulation: Poster III (4689-4699)
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (4700-4715)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (4716-4754)
- 201. Granulocytes, Monocytes, and Macrophages: Poster III (4755-4776)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (4777-4789)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster III (4790-4803)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (4804-4827)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (4828-4837)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster III (4838-4853)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III (4854-4868)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III (4869–4877)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III (4878–4893)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4894-4918)

- 401. Blood Transfusion: Poster III (4919-4925)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4926-4937)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III (4938-4955)
- 506. Bone Marrow Microenvironment: Poster III (4956-4966)
- 508. Bone Marrow Failure: Acquired: Poster III (4967-4988)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4989-4999)
- 602. Myeloid Oncogenesis: Basic: Poster III (5000-5029)
- 603. Lymphoid Oncogenesis: Basic: Poster III (5030-5042)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (5043-5072)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (5073-5094)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (5095-5114)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III (5115-5136)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III (5137–5151)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (5152-5192)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III (5193-5211)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III (5212-5244)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III (5245-5290)
- 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster III (5291-5298)

- 621. Lymphomas: Translational Molecular and Genetic: Poster III (5299–5326)
- 622. Lymphomas: Translational Non-Genetic: Poster III (5327-5347)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (5348–5394)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III (5395–5408)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III (5409–5434)
- 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster III (5435–5457)
- 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III (5458–5481)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster III (5482–5507)
- 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III (5508–5525)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (5526–5544)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (5545–5567)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (5568–5608)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster III (5609–5620)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III (5621–5652)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III (5653–5661)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (5662–5692)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (5693–5735)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (5736–5751)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster III (5752–5807)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster III (5808–5845)
- 655. Multiple Myeloma: Cellular Therapies: Poster III (5846-5857)
- 701. Experimental Transplantation: Basic and Translational: Poster III (5858–5873)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster III (5874–5906)
- 703. Cellular Immunotherapies other than CAR-T Cells: Poster III (5907–5918)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III (5919–5955)

- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III (5956–5967)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III (5968–6001)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III (6002–6035)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III (6036–6064)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (6065–6086)
- 801. Gene Therapies: Poster III (6087-6099)
- 802. Chemical Biology and Experimental Therapeutics: Poster III (6100–6109)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III (6110–6143)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III (6144–6159)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6160–6176)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III (6177–6203)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III (6204–6215)
- 904. Outcomes Research: Hemoglobinopathies: Poster III (6216–6231)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6232–6258)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III (6259–6340)
- 907. Outcomes Research: Plasma Cell Disorders: Poster III (6341–6379)
- 908. Outcomes Research: Myeloid Malignancies: Poster III (6380–6416)
- 909. Education, Communication, and Workforce: Poster III (6417–6430)



The New ASH®-SAP 9 Available in the ASH Store

Don't miss the new American Society of Hematology Self-Assessment Program (ASH-SAP), Ninth Edition.

Includes new complimentary self-guided **ASH Q&A Bank App** with practice questions and tests.



Shop online at: hematology.org/Store

05 Dec 2025 Friday

SATELLITE SYMPOSIA

These symposia will take place on Friday, December 5, 2025, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in this program. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.

Satellite Symposia are not CME-accredited through ASH and are planned solely by the sponsoring organizations. Each symposium lists a contact person for accreditation information. An ASH meeting badge is not needed to attend these symposia.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

FRIDAY MORNING SYMPOSIA: 7:00 A.M. – 10:00 A.M.

Aligning Discovery with Clinical Practice: Applying Expert Consensus Guidelines to Improve Patient Outcomes in CLL/SLL

Friday 7:00 a.m. – 10:00 a.m. Virtual Symposium Only

This program is sponsored by and supported by AstraZeneca and Lilly. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

Chair:

Sameer Parikh, MD, Mayo Clinic, Rochester, MN

Speakers:

Matthew Cortese, MD, MPH, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Brian Hill, MD, PhD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Contact: Melanie Moletzsky moletzsky@nccn.org

Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma

Friday 7:00 a.m. – 10:00 a.m. Hyatt - Regency Ballroom R

This program is sponsored by and supported by AstraZeneca, Genentech, a member of the Roche Group, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.

Chair:

Laurie Sehn, MD, BC Cancer, Vancouver, British Columbia, Canada

Speakers:

Peter Martin, FRCPC, MD, MS, Weill Cornell Medicine, New York, NY

Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Mitchell Smith, MD, PhD, The Follicular Lymphoma Foundation, London, United Kingdom

Contact: Julie Dodds julie@theflf.org

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Acute Myeloid Leukemia

7:00 a.m. – 10:00 a.m. Hyatt - Regency TUV

This program is sponsored by and supported by educational grants from AbbVie Inc., Astellas, Daiichi Sankyo Inc., Kura Oncology, and Rigel Pharmaceuticals Inc.

Chair:

Neil Love, MD, Research to Practice, Miami, Florida

Speakers:

Harry Erba, MD, PhD, Duke University School of Medicine, Durham, NC

Amir Fathi, MD, Massachusetts General Hospital, Boston, MA

Tara Lin, MD, University of Kansas Medical Center, Kansas City, KS

Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Sylvia Eriksen meetings@researchtopractice.com

125

Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and non-BCMA Immunotherapies

Friday 7:00 a.m. – 10:00 a.m. Hyatt - Plaza Int'l HIJK

This program is sponsored by and supported by independent medical education grants from GSK, Johnson & Johnson and Regeneron Pharmaceuticals, Inc. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Multiple Myeloma.

Chair:

Sagar Lonial, MD, FACP, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

Speakers:

Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN

Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Amanda Loeber amanda.loeber@peerview.com

MASTER MDS for Enhanced Patient Care: Modern Advances with STandard and Emerging, Risk-adapted Treatment

Friday 7:00 a.m. – 10:00 a.m. Hyatt - Plaza Int'l DEFG

This program is sponsored by and supported by educational grants from Bristol Myers Squibb and Geron. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Myelodysplastic Syndromes.

Chair:

Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

Maria Diez-Campelo, MD, PhD, Hospital Clínico Universitario de Salamanca, Salamanca, Spain

Sangeetha Venugopal, MD, MS, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Contact: Amanda Loeber amanda.loeber@peerview.com

Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes

7:00 a.m. – 10:00 a.m. Valencia Room W415D

This program is sponsored by and supported by independent educational grants from Johnson & Johnson, Kura Oncology Inc., and Syndax. This CME/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Acute Myeloid Leukemia.

Chair:

David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FI

Speakers:

Emma Searle, MD, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom

Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Amanda Loeber amanda.loeber@peerview.com

Momentum in MDS: Making Progress and Shaping a Better Future

Friday 7:00 a.m. – 10:00 a.m. Tangerine Ballroom F2

This program is sponsored by and supported by independent educational grants from Agios Pharmaceuticals, Bristol Myers Squibb, Geron Corporation, Rigel Pharmaceuticals, and Taiho Oncology, Inc. This program is provided by The Myeolodysplastic Syndromes Foundation, Inc. in partnership with AKH Inc., Advancing Knowledge in Healthcare.

Chairs:

Moshe Mittelman, MD, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Valeria Santini, MD, AOU Careggi-University of Florence, Florence, Italy

Speakers:

Rafael Bejar, MD, PhD, University of California, San Diego, CA

Rena Buckstein, MD, FRCPC, Sunnybrook Health Sciences Centre, North York, Ontario, Canada

Carmelo Gurnari, MD, PhD, University of Tor Vergata, Rome, Italy

Robert Hasserjian, MD, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Moshe Mittelman, MD, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Valeria Santini, MD, AOU Careggi-University of Florence, Florence, Italy

David Steensma, MD, Ajax Therapeutics, Cambridge, MA

Arjan Van de Loosdrecht, MD, PhD, VU University Medical Center, Amsterdam, Netherlands

Contact: Lea Harrison

Iharrison@mds-foundation.org

Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies

Friday 7:00 a.m. – 10:00 a.m. Valencia Room W415BC

This program is sponsored by and supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Acute Lymphoblastic Leukemia.

Chair:

Nicola Gökbuget, MD, University Hospital, Frankfurt, Germany

Speakers:

Ibrahim Aldoss, MD, City of Hope National Medical Center, Duarte, CA

Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Amanda Loeber amanda.loeber@peerview.com

Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond

Friday 7:00 a.m. – 10:00 a.m. Valencia Room W415A

This program is sponsored by and supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals Inc. This CME/MOC/EBAH/AAPA activity is provided by PVI, Peer-View Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Non-Hodgkin Lymphoma.

Chair:

Max S. Topp, MD, Universitätsklinikum Würzburg, Würzburg, Germany

Speakers:

Sameh Gaballa, MD, H. Lee Moffitt Cancer Center, Tampa, FL

Deepa Jagadeesh, MD, MPH, Cleveland Clinic, Cleveland, OH

Contact: Amanda Loeber amanda.loeber@peerview.com

Paroxysmal Nocturnal Hemoglobinuria: What we have learned from the introduction of new therapies

Friday 7:00 a.m. – 10:00 a.m. Tangerine Ballroom F1

This program is sponsored by and supported by independent educational grants from AstraZeneca, Novartis, Roche, Sobi and Apellis.

Co-Chairs:

David Araten, MD, NYU Langone, New York, NY

Morag Griffin, FRCPath, MBChB, MRCP, Leeds Teaching Hospital NHS, Leeds, United Kingdom

Phillip Scheinberg, MD, Hospital Sao Jose, Beneficencia Portuguesa de São Paolo, São Paulo, Brazil

Speakers:

Louise Arnold, ACP, MSc, Leeds Teaching Hospital NHS, Leeds, United Kingdom

Camilla Frieri, MD, PhD, AORN San Giuseppe Moscati Avellino, Avellino, Italy

Xiaojun Huang, MD, PhD, Peking University People's Hospital, Beijing, China

Bhavisha Patel, MD, National Institutes of Health, Bethesda, MD

Daniel Payne, Leeds Teaching Hospital NHS, Leeds, United Kingdom

Regis Peffault De Latour, MD, Saint-Louis Hospital, Paris, France

Antonio Risitano, MD, PhD, AORN San Giuseppe Moscati Avellino, Avellino, Italy

Jeff Szer, BMedSc, MB, BS, AORN San Giuseppe Moscati Avellino, Avellino, Italy

Contact: Dawn McKnight dmcknight@kmgnet.com

Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care

Friday 7:00 a.m. – 10:00 a.m. Hyatt - Orlando Ballroom

This program is sponsored by and supported by independent educational grants from AstraZeneca, BeOne Medicines and Lilly. This CME/MOC/EBAH/ AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, CLL Society.

Chair:

John Gribben, MD, DSc, FRCP, FMedSci, FRCPath, Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, United Kingdom

Speakers:

Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center New York-Presbyterian & Columbia University Medical Center, New York, NY

Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Amanda Loeber amanda.loeber@peerview.com

Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data

7:00 a.m. – 10:00 a.m. W224CDGH

This program is sponsored by and supported by Indy Hematology Education Inc.

Chair:

Ruemu Birhiray, MD, Marian University: Wood College of Osteopathic Medicine & Indy Hematology Education Inc., Carmel, IN

Contact: Sam Ranger sranger@indyhematology.org

Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options & Modern Clinical Decision-making in Newly Diagnosed Disease

Friday 7:00 a.m. – 10:00 a.m. Hyatt - Regency Ballroom S

This program is sponsored by and supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the Health-Tree Foundation for Mantle Cell Lymphoma.

Chair:

Martin Dreyling, MD, PhD, Ludwig-Maximilian-University Munich, Munich, Germany

Speakers:

Kami Maddocks, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Christine Ryan, MD, Harvard Medical School & Dana-Farber Cancer Institute, Boston, MA

Contact: Amanda Loeber amanda.loeber@peerview.com

Rising to the Graft-vs-Host Disease Challenge: Progress in Treatment and Post-HCT Outcomes Across Hematologic Cancers

7:00 a.m. – 10:00 a.m. W331

This program is sponsored by and supported by independent educational grants from Incyte Corporation, Mesoblast Inc, Orca Bio, and Sanofi US. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the Blood & Marrow Transplant Information Network.

Chair

Zachariah Defilipp, MD, Massachusetts General Hospital, Boston, MA

Speakers:

Betty K. Hamilton, MD, Cleveland Clinic, Cleveland, OH **Amandeep Salhotra, MD,** City of Hope National Medical Center, Duarte, CA

Contact: Amanda Loeber amanda.loeber@peerview.com

Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment

Friday

7:00 a.m. – 10:00 a.m. Hyatt - Regency Ballroom OPQ

AbbVie and GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

Chair:

Thomas Martin, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Speakers:

Carol Huff, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Adriana Rossi, MD, Tisch Cancer Institute, New York, NY

Contact: Melanie Moletzsky moletzsky@nccn.org@nccn.org

Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders: Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond

Friday

7:00 a.m. – 10:00 a.m. W224ABEF

This program is sponsored by and supported by Pharmacosmos Therapeutics Inc.

Chair

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA

Speakers:

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA

Magdalena Lewandowska, MD, Innovative Hematology, Indianapolis, IN

Allyson Pishko, MD, University of Pennsylvania, Philadelphia, PA

Jenny Zhou, MD, University of California, San Diego, San Diego, CA

Contact: Hellen Tecle hellen.tecle@curehht.org 'Four' Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care with Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapies

Friday

11:00 a.m. – 2:00 p.m. Valencia Room W415D

This program is sponsored by and supported by an educational grant from Sanofi. Provided by Answers in CME.

Speakers:

Caitlin Costello, MD, University of California, San Diego, CA

Paul Richardson, MD, Harvard Medical School & Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Contact: Kaitlyn Hoster

hkaitlyn.hoster@answersincme.com

A Master Class in CP-CML: New Agents, Treatment Goals, and Clinical Challenges

Friday

11:00 a.m. – 2:00 p.m. Hyatt - Regency Ballroom R

This program is sponsored by and supported by Novartis Pharmaceuticals Corporation. Provided by Clinical Care Options, LLC.

Chair:

Jerald Radich, MD, Fred Hutchinson Cancer Center, Seattle, WA

Speakers:

Neil Shah, MD, PhD, University of California, San Francisco, CA

B. Douglas Smith, MD, Johns Hopkins University School of Medicine, Baltimore, MD

Contact: Ishana Fleurant Ifleurant@clinicaloptions.com

Accelerating Evidence Into Practice: Leveraging QI-Driven Insights and Practical Tools to Integrate Bispecific Antibodies Into Care for Patients With R/R DLBCL and FL

Friday 11:00 a.m. – 2:00 p.m.

This program is sponsored by and supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Genmab US, Inc.

Chair:

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speaker:

Caron Jacobson, MD, MMSc, Dana Farber Cancer Institute, New York, NY

Contact: Eryn Litvinas e.litvinas@primeinc.org

Advancing Hemophilia Care—Uniting Expert Insights and Community Voices to Shape the Future of Non-Factor Replacement Therapy

Friday 11:00 a.m. – 2:00 p.m. Hyatt - Orlando Ballroom

This program is sponsored by and supported by Novo Nordisk. Provided by Clinical Care Options, LLC.

Chair:

Steven Pipe, MD, University of Michigan, Ann Arbor, MI

Speakers

Stacy Croteau, MD, Harvard Medical School, Boston, MA Kristin Maher, MD, PhD, University of Washington, Seattle. WA

Contact: Ishana Fleurant Ifleurant@clinicaloptions.com

Advancing Outcomes in Lymphoma Care: A MasterClass on Integrating the CAR T-Cell Therapies into Clinical Practice

Friday 11:00 a.m. – 2:00 p.m. Hyatt - Regency Ballroom OPQ

This program is sponsored by and supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC.

Chair:

Stephen Ansell, MD, PhD, Mayo Clinic Comprehensive Cancer Center, Rochester, MN

Speakers:

Jeremy Abramson, MD, Harvard Medical School, Cambridge, MA

David Maloney, MD, PhD, University of Washington, Seattle, WA

Contact: Ishana Fleurant Ifleurant@clinicaloptions.com

Cases & Conversations™: Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Friday 11:00 a.m. – 2:00 p.m. W224ABEF

This program is sponsored by and supported by Geron Corporation (pending additional supporters).

Chair:

Naveen Pemmaraju, MD, Executive Director, MDACC Network & The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

Gabriela Hobbs, MD, Harvard Medical School, Cambridge, MA

Uwe Platzbecker, MD, Director of the Medical Clinic, University Hospital in Leipzig, Leipzig, Germany

Contact: Ronald Viggiani Irviggianimd@gmail.com

Cases from the Community: Investigators
Discuss Available Research Guiding the
Selection of Therapy for Patients with Chronic
Lymphocytic Leukemia

Friday 11:00 a.m. – 2:00 p.m. Hyatt - Regency TUV

This program is sponsored by and supported by educational grants from Abbvie Inc., AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Lilly.

Chair:

Neil Love, MD, Research to Practice, Miami, FL

Speakers:

Matthew S. Davids, MD, Dana-Farber Cancer Institute, Boston, MA

Bita Fakhri, MD, MPH, Stanford University, Stanford, CA

Constantine Tam, MD, MBBS, Monash University, Melbourne, South Australia, Australia

Jennifer Woyach, MD, The Ohio State University, Columbus, OH

Contact: Sylvia Eriksen meetings@researchtopractice.com

From Indolent to Aggressive: Case-Based Strategies Across the Spectrum of Systemic Mastocytosis

Friday 11:00 a.m. – 2:00 p.m. W224CDGH

This program is sponsored by and supported by an independent educational grant from Blueprint Medicines Corporation and provided by Integritas Communications.

Speaker:

Matthew Giannetti, MD, Associate Director, Brigham and Women's Hospital Mastocytosis Center, Boston, MA

Contact: Shannon Stevenson sstevenson@integritasgrp.com

Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Friday 11:00 a.m. – 2:00 p.m. Tangerine Ballroom F1

This program is sponsored by and supported by Servier, Jazz, and Amgen.

Chair:

Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

Aaron Logan, MD, PhD, University of California, San Francisco, CA

Hagop Kantarjian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Rob Pieters, MD, PhD, MSc, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

Claire Roddie, MD, PhD, University College London (UCL) Hospitals, London, United Kingdom

Contact: Ronald Viggiani Irviggianimd@gmail.com

Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

Friday 11:00 a.m. – 2:00 p.m. Tangerine Ballroom F2

This program is sponsored by and supported by educational grants from Kura Oncology, Inc. and Rigel Pharmaceuticals, Inc.

Chair:

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

Daniel Pollyea, MD, Clinical Director of Leukemia Services, University of Colorado, Denver, CO

Gail Roboz, MD, Professor of Medicine, Director of the Clinical and Translational Leukemia Program, Weill Medical College of Cornell University, New York, NY

Amer Zeidan, MD, Yale Cancer Center, New Haven, CT

Contact: Ronald Viggiani Irviggianimd@gmail.com, MD

Rare Clinical Spotlight: Exploring Castleman Disease, Cold Agglutinin Disease, and Acute Intermittent Porphyria

Friday

11:00 a.m. – 2:00 p.m. Hyatt - Plaza Intəl HIJK

This program is sponsored by and supported by Recordati Rare Diseases.

Speakers:

Catherine Broome, MD, Georgetown University, Washington, DC

Angelika Erwin, MD, PhD, Cleveland Clinic, Cleveland, OH

Sudipto Mukherjee, MD, PhD, MPH, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Ariela Noy, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Bruce Wang, MD, University of California, San Francisco,

Ilene Weitz, MD, Keck School of Medicine of USC, Los Angeles, CA

Contact: Carolyn Ciaramella cciaramella@medscapelive.com

Tailoring Bispecific Antibodies to Individualize R/R Follicular Lymphoma Care: A Case Based Discussion

Friday

11:00 a.m. – 2:00 p.m. W311EFGH

This program is sponsored by and supported by Genmab US, Inc. and AbbVie.

Chair:

Matthew Lunning, DO, University of Nebraska Medical Center, Omaha, NE

Speakers:

Natacha Bolanos, Lymphoma Coalition, Madrid, Spain

Chan Cheah, MD, Breakthrough Haematology, Nedlands, Western Australia, Australia

Contact: Carolyn Ciaramella cciaramella@medscapelive.com

Targeted Therapies in R/R PCNSL: New Frontiers in Treatment and Management

Friday

11:00 a.m. – 2:00 p.m. Hyatt - Plaza Intəl DEFG

This program is sponsored by and supported by Deciphera, a member of ONO Pharma.

Chair:

Christopher DeAngelo, MD, University of Nebraska Medical Center, Omaha, NE

Speakers:

Amitkumar Mehta, MD, University of Alabama at Birmingham, Birmingham, AL

Ashley Sumrall, MD, Atrium Health, Charlotte, NC

Contact: Carolyn Ciaramella cciaramella@medscapelive.com

The Growing Role of CAR T-Cell Therapy in Multiple Myeloma: New Data on Earlier Lines of Therapy, Expanding Access to Treatment

Friday

11:00 a.m. – 2:00 p.m. W230

This program is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Bristol Myers Squibb; Kite Pharma, Inc.; Arcellx, Inc.; and Legend Biotech.

Chair:

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL

Speakers:

Michael Bishop, MD, The David and Etta Jonas Center for Cellular Therapy University of Chicago Medicine, Chicago, II

Binod Dhakal, MD, MS, Medical College of Wisconsin, Milwaukee, Wisconsin

Contact: Kim DiGuiseppe kimberly.diguiseppe@haymarketmedical.com

Achieving Comprehensive Care for Chronic Immune Thrombocytopenia: Exploring Emerging Therapies to Address Patient-centric Hematological and Non-Hematological Outcomes

Friday 3:00 p.m. – 6:00 p.m. Hyatt - Regency Ballroom R

This program is sponsored by and supported by an educational grant from Sanofi. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Chair:

David Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA

Speakers:

Nicola Cooper, MD, FRCP, FRCPath, MA, Imperial College Healthcare & NHS Trust, London, United Kingdom

Cindy Neunert, MD, Columbia University Irving Medical Center, New York, NY

Contact: Margaret Walker margaret.walker@catalystmeded.com

Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management

Friday 3:00 p.m. – 6:00 p.m. Hyatt - Plaza Intəl HIJK

This program is sponsored by and supported by Alnylam U.S., Inc.

Chair:

Brendan Mcguire, MD, University of Alabama at Birmingham, Birmingham, AL

Speakers:

Akshata Moghe, MD, PhD, University of Texas Health Science Center, Houston, TX

Rebecca Karp, MD, Massachusetts General Hospital, Boston, MA

Contact: Carolyn Ciaramella cciaramella@medscapelive.com

Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access

Friday 3:00 p.m. – 6:00 p.m. W230

This program is sponsored by and supported by Roswell Park Alliance Foundation and Bristol Myers Squibb.

Co-Chairs:

Renier Brentjens, Deputy Director, Chair, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer, Buffalo, NY

Speakers:

Julio Chavez, MD, MS, Sr. Associate Consultant, Lymphoma Program Lead, Mayo Clinic, Jacksonville, FL

Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer, Buffalo, NY

Francisco Hernandez-Ilizaliturri, MD, Director of Lymphoma Research and Lymphoma Translational Research Lab, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Shernan Holtan, MD, Chief, Blood and Marrow Transplantation Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Frederick Locke, MD, Chair, Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

Bringing Emerging Treatments to All Patients: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices

Friday 3:00 p.m. – 6:00 p.m. Valencia Room W415BC

This program is sponsored by and supported by Indy Hematology Education Inc.

Chair:

Ruemu Birhiray, MD, Marian University: Wood College of Osteopathic Medicine & Indy Hematology Education Inc., Carmel, IN

Speakers:

Ralph Vincent Boccia, MD, The Center for Cancer and Blood Disorders, Bethesda, MD

Tara Graff, DO, MS, Mission Cancer and Blood, Des Moines, IA

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA

Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Sam Ranger sranger@indyhematology.org

Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations

Friday 3:00 p.m. – 6:00 p.m. Tangerine Ballroom F1

This program is sponsored by and supported by Servier Pharmaceuticals LLC.

Chair:

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA

Speakers

Jane Apperley, FRCP, FRCPath, MB, Department of Haematology Hammersmith Hospital Imperial College, London, United Kingdom

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Ronald Viggiani Irviggianimd@gmail.com

Cracking the Code: Menin Inhibitors and the Next Frontier in AML Treatment

Friday 3:00 p.m. – 6:00 p.m. W331

This program is sponsored by and supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Kura and Syndax.

Chair:

Joshua Zeidner, MD, University of North Carolina School of Medicine, Chapel Hill, NC

Speaker:

Justin Watts, MD, University of Miami/Sylvester Comprehensive Cancer Center (SCCC), Miami, FL

Contact: Eryn Litvinas e.litvinas@primeinc.org

Expert Second Opinion: Investigators Discuss the Optimal Management of Patients with Myelofibrosis and Systemic Mastocytosis

Friday 3:00 p.m. – 6:00 p.m. Hyatt - Regency TUV

This program is sponsored by and supported by educational grants from Blueprint Medicines, Bristol Myers Squibb, GSK, and Incyte Corporation.

Chair

Neil Love, MD, Research to Practice, Miami, FL

Speakers:

Claire Harrison, DM, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FI

Stephen Oh, MD, PhD, Washington University School of Medicine, St Louis, MO

Jeanne Palmer, Vice Chair and Section Chief for Hematology, Program Director for the Blood and Marrow Transplant Program, Mayo Clinic, Phoenix, AZ

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Sylvia Eriksen meetings@researchtopractice.com

Filling in the Gaps in Hemophilia Guideline Recommendations: Evidence-Based Strategies to Optimize Patient-Relevant Outcomes

Friday 3:00 p.m. – 6:00 p.m. Valencia Room W415A

This program is sponsored by and supported by an independent medical education grant from Sanofi.

Co-Chairs:

Lynn Malec, MD, MSc, Versiti Blood Research Institute, Milwaukee, WI

Allison Wheeler, MD, University of Washington School of Medicine, Seattle, WA

Speakers:

Lynn Malec, MD, MSc, Versiti Blood Research Institute, Milwaukee, WI

Shannon Meeks, MD, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, CA

Michael Recht, MD, PhD, National Bleeding Disorders Foundation, New York, **NY,** & Yale University, New Haven,

Annette von Drygalski, Director, Center for Bleeding and Clotting Disorders, University of California, San Diego, CA

Contact: Madelyne Fabrizio mfabrizio@i3health.com

Medical Crossfire®: Navigating GVHD Prophylaxis, Acute and Chronic Care - Targeted Strategies to Elevate Patient Outcomes

Friday 3:00 p.m. – 6:00 p.m. Tangerine Ballroom F2

This program is sponsored by and supported by Orca Bio.

Chair:

Mehdi Hamadani, MD, Medical College of Wisconsin, Milwaukee, WI

Speakers:

Amin Alousi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Corey Cutler, MD, FRCPC, MPH, Dana-Farber Cancer Institute, Boston, MA

Anna Sureda Balarí, MD, PhD, Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain

Contact: Ronald Viggiani Irviggianimd@gmail.com

Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs

Friday 3:00 p.m. – 6:00 p.m. Hyatt - Regency Ballroom OPQ

This program is sponsored by and supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC.

Chair:

Niels W.C.J. Van De Donk, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands

Speakers:

Jesús Berdeja, MD, Greco-Hainsworth Centers for Research, Nashville, TN

Amrita Krishnan, MD, City of Hope Cancer Center, Irvine, CA

Contact: Ishana Fleurant
Ifleurant@clinicaloptions.com

PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma

Friday 3:00 p.m. – 6:00 p.m. Tangerine Ballroom F3-4

This program is sponsored by and supported by Sanofi.

Chair:

Ajai Chari, MD, University of California, San Francisco, CA

Speakers:

María-Victoria Mateos, MD, PhD, Myeloma Unit, Director, University of Salamanca, Spain

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital Sorbonne University, Paris, France

Contact: Ronald Viggiani Irviggianimd@gmail.com

Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy: A Case-Based Discussion

Friday 3:00 p.m. – 6:00 p.m. W311EFGH

This program is sponsored by and supported by Genmab US, Inc. and AbbVie.

Chair:

Joshua Brody, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Speakers:

Elizabeth Brem, MD, UCI Health, Orange, CA

Lorna Warwick, BA, Lymphoma Coalition, Mississauga, Ontario, Canada

Contact: Carolyn Ciaramella cciaramella@medscapelive.com

Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management —A CME COMPETE™: SCD Edition

Friday

3:00 p.m. – 6:00 p.m. W224CDGH

This program is sponsored by and supported by Novo Nordisk Inc. Provided by Integritas Communications.

Speakers:

Lakiea Bailey, Director, Sickle Cell Consortium; Patient Advocate, Educator, Research Scientist, Cumming, GA

Modupe Idowu, MD, Director, Hematology/Oncology, UTHealth, Houston, TX

Nirmish Shah, MD, Associate Professor, Hematology, Duke University, Durham, NC

Contact: Shannon Stevenson sstevenson@integritasgrp.com

Visualizing Novel Pathways to Optimizing Care for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Friday

3:00 p.m. – 6:00 p.m. W224ABEF

This program is sponsored by and supported by Novartis Pharmaceuticals.

Contact: Kelly McGregor kmcgregor@mjhevents.com

EXPERT SECOND OPINION: Investigators
Discuss the Role of Novel Treatment
Approaches in the Care of Patients with
Follicular Lymphoma and Diffuse Large B-Cell
Lymphoma

Friday

7:00 p.m. - 10:00 p.m. Hyatt - Regency TUV

This program is sponsored by and supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, and Pfizer Inc.

Chair:

Neil Love, MD, Research to Practice, Miami, Florida

Speakers:

Nancy Bartlett, MD, Washington University School of Medicine, St. Louis, MO

Matthew Matasar, MD, MS, Rutgers University, New Brunswick, NJ

Loretta Nastoupil, MD, CommonSpirit Mercy Hospital, Durango, CO

Grzegorz Nowakowski, MD, Mayo Clinic, Rochester, MN

Pier Luigi Zinzani, MD, PhD, University of Bologna School of Medicine, Bologna, Italy

Contact: Sylvia Eriksen

meetings@researchtopractice.com

Hot Topics in Myelofibrosis Management: Navigating the Latest Therapeutic Advances in Clinical Practice

Friday

7:00 p.m. – 10:00 p.m. W331

This program is sponsored by and supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Geron and Karyopharm.

Chair:

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Speaker:

Lindsay Rein, MD, Duke University School of Medicine, Durham, NC

Contact: Eryn Litvinas e.litvinas@primeinc.org

PRODUCT THEATERS

Product Theaters as of October 19, 2025.

Check the mobile app for an updated list of Product Theaters.

Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. The Product Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY

A Treatment Option for Adults with Certain R/R DLBCL After ≥2 Prior Lines of Systemic Therapy

Saturday 11:30 a.m. - 12:30 p.m. **W209AB**

Sponsored by Pfizer Oncology

For in-person participants only

Speaker:

Michelle Fanale, MD, Pfizer Oncology

Frontline Therapy in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

11:30 a.m. - 12:30 p.m. Saturday **W203AB**

Sponsored by Johnson & Johnson

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Vipin Khare, MD, Johnson & Johnson

Hear Jen's Journey, Then Explore the Data

Saturday 11:30 a.m. – 12:30 p.m. **W204BC**

Sponsored by Novartis Pharmaceuticals Corpora-

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

This session will include a patient perspective

Speakers:

Sheeba Paul, PharmD, MBA, Novartis Pharmaceuticals Corporation

Vanita Patel, BS, MBA, Novartis Pharmaceuticals Corporation

Rapid NGS: Transforming Molecular Profiling of Myeloid and Lymphoid Malignancies

11:30 a.m. - 12:30 p.m. Saturday W209C

Sponsored by Thermo Fisher Scientific

For in-person participants only

Speakers:

Chris Allen, BSc, Thermo Fisher Scientific Sophie Rozenzhak, PhD, Thermo Fisher Scientific

Shifting Currents in Hemophilia Care: Exploring the Impact of Antithrombin Lowering

Saturday 11:30 a.m. – 12:30 p.m. W206A

Sponsored by Sanofi

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Amy Chen, PhD, Sanofi

Unlocking the Benefits of Time-Off Treatment with a BCL-2 Inhibitor as the Proven Backbone of Targeted, Fixed-Duration Therapy in CLL

Saturday 11:30 a.m. – 12:30 p.m. W208AB

Sponsored by AbbVie

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Wendy Sinai, PharmD, Abbvie

Unlocking the Potential of CAR T: When and Why it Matters

Saturday 11:30 a.m. – 12:30 p.m. W207BC

Sponsored by Bristol Myers Squibb

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Amy Marsala, MPH, MS, ANP-BC, Bristol Myers Squibb

SUNDAY

A Consideration for Patients with Relapsed or Refractory Multiple Myeloma

Sunday 8:00 a.m. – 9:00 a.m. W208AB

Sponsored by Johnson & Johnson

This presentation is intended for U.S. based registered meeting attendees

For in-person participants onlyy

Speaker:

Tonya Le Blanc, PhD, Johnson & Johnson

A New BsAb Treatment for R/R Multiple Myeloma After 4 Prior Lines

Sunday 8:00 a.m. – 9:00 a.m. W204BC

Sponsored by Regeneron

For in-person participants only

Speaker:

Tito Roccia, MD, Regeneron

Advancing Care in RRMM: Clinical Evidence for a BCMA-Directed Bispecific Antibody Treatment Option (Program will begin with a patient's own story)

Sunday 8:00 a.m. – 9:00 a.m. W209AB

Sponsored by Pfizer, Inc.

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

This session will include a patient perspective

Speaker:

David Hughes, PharmD, BCOP, MPH, Pfizer, Inc.

Cablivi (caplacizumab-yhdp) Real-World Evidence in 1,000+ Patients: Early Initiation Matters

Sunday 8:00 a.m. – 9:00 a.m. W207BC

Sponsored by Sanofi

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

This session will include a patient perspective

Speakers:

Dina Issa, PharmD, Sanofi Alessandro Ciarcia. Sanofi

Transforming Thalassemia Care: Introducing a New Treatment Option from Agios Pharmaceuticals

Sunday 8:00 a.m. – 9:00 a.m. W206A

Sponsored by Agios Pharmaceuticals

For in-person participants only

Speaker:

Jeremie Estepp, MD, Agios Pharmaceuticals

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

Sunday 11:30 a.m. – 12:30 p.m. W207BC

Sponsored by Geron Corporation

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Shyamala Navada, MD, MSCR, Geron Corporation

A New Treatment Option in Multiple Myeloma

Sunday 11:30 a.m. – 12:30 p.m. W208AB

Sponsored by GSK

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Elisabet Manasanch, MD, MHSc, GSK

Discover a New Way Forward With WAYRILZ

Sunday 11:30 a.m. – 12:30 p.m. W209C

Sponsored by Sanofi

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

This session will include a patient perspective

Speakers:

Brad Ward, PharmD, Sanofi Lika Dvali, MBA, Sanofi

Exploring a Subcutaneous Treatment Option in Hemophilia Care with HYMPAVZI (marstacimabhncg)

Sunday 11:30 a.m. – 12:30 p.m. W206A

Sponsored by Pfizer

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speakers:

Anu Gupta, PharmD, Pfizer Jennifer Schumacher, PhD, Pfizer Sangeeta Raje, PhD, Pfizer

First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Sunday 11:30 a.m. – 12:30 p.m. W203AB

Sponsored by Johnson & Johnson

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Ibrahim Saber, MD, Johnson & Johnson

Latest POLARIX Primary and 5-Year Outcomes

Data

Sunday 11:30 a.m. – 12:30 p.m. W209AB

Sponsored by Genentech

For in-person participants only

Speaker:

Connie Lee Batlevi, MD, PhD, Genentech

Reignite the Spark: Clinical Conversations about Jaypirca (pirtobrutinib)

Sunday 11:30 a.m. – 12:30 p.m. W204BC

Sponsored by Eli Lilly and Company

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speakers:

John Pagel, MD, PhD, Eli Lilly and Company Sarang Abhyankar, MD, Eli Lilly and Company

MONDAY

Introducing a Therapeutic Option in Relapsed/ Refractory Acute Leukemia

Monday 8:00 a.m. – 9:00 a.m. W208AB

Sponsored by Syndax Pharmaceuticals

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speakers:

Kim Tran, PharmD, Syndax Pharmaceuticals

Craig Freyer, PharmD, BCOP, Syndax Pharmaceuticals

Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL

Monday 8:00 a.m. – 9:00 a.m. W209C

Sponsored by Genmab and AbbVie

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Felipe Goncalves, MD, MBA, Genmab

First-Line Treatment Option for Anemia in Lower-Risk MDS COMMANDS Trial Overview

Monday 12:15 p.m. – 1:15 p.m. W209C

Sponsored by Bristol Myers Squibb

This presentation is intended for U.S. based registered meeting attendees For in-person participants only

Speaker:

Tracy Krimmel, DNP, Bristol Myers Squibb

From Innovation to Impact: Real Stories of Transformation in PNH Management

Monday 12:15 p.m. – 1:15 p.m. W207BC

Sponsored by Novartis Pharmaceuticals Corporation

This session will include a patient perspective

Speaker:

Jincy Paulose, MD, Novartis Pharmaceuticals Corporation

Making the Case for Early Use of CAR-T Therapy in Multiple Myeloma

Monday 12:15 p.m. – 1:15 p.m. W209AB

Sponsored by Johnson & Johnson

For in-person participants only

Speaker:

Deepu Madduri, MD, Johnson & Johnson

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

Monday 12:15 p.m. – 1:15 p.m. W208AB

Sponsored by Incyte Corporation

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

John Galvin, MD, MS, MPH, Incyte Corporation

INDUSTRY THEATERS

INDUSTRY THEATERS

Industry Theaters as of October 19, 2025.

Check the mobile app for an updated list of Industry Theaters.

Industry Theater presentations are company developed presentations that highlight medical devices, medical technology, non-FDA approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. The Industry Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SUNDAY

Studying Measurable Residual Disease by Phenotype and Genotype Using Flow Cytometry

Sunday 8:00 a.m. – 9:00 a.m. W209C

Sponsored by Beckman Coulter Life Sciences

For in-person participants only

Speakers:

Timothy Looney, PhD, Quest Diagnostics **Wolfgang Kern**, Munich Leukemia Lab **Eda Holl**, Beckman Coulter Life Sciences

MONDAY

Pyruvate Kinase Activation in Hemolytic Anemias and Insights into its Mechanism

Monday 12:15 p.m. – 1:15 p.m. W206A

Sponsored by Agios Pharmaceuticals

For in-person participants only

This session will include a patient perspective

Speakers:

Sarah Gheuens, MD, PhD, Agios Pharmaceuticals
Cassandra Trimnell, Sickle Cell 101 and Patient Advocacy

Cassandra Trimnell, Sickle Cell 101 and Patient Advocac Consultant

INDUSTRY FORUMS

Industry Forums as of October 19, 2025.

Check the mobile app for an updated list of Industry Forums.

Industry Forums are non-CME sessions developed by sponsoring companies with interactive discussions on topics focused on educational resources for the diagnosis and treatment of hematologic diseases, improvements or quality in health care, patient support services and/or treatment resources. Discussions feature various perspectives and roles including health care providers, company representatives, patients, caretakers, and patient advocates. The Industry Forum sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credit will not be offered.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY

Clinical Management and Unmet Needs in Immune Thrombocytopenia (ITP)

Saturday 8:00 a.m. – 9:00 a.m. W209AB

Sponsored by Novartis Pharmaceuticals Corporation

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Enhancing Sickle Cell Disease Care Through Patient Partnership

Saturday 8:00 a.m. – 9:00 a.m. W207BC

Sponsored by Pfizer

For in-person participants only

Moderators:

Reto Wirz, Pfizer

Emily Meier, Pfizer

Speakers:

Melanie Fields, MD, Washington University in St. Louis St. Louis Children's Hospital

Wally Smith, MD, VCU Health

Kevin Wake, MS, CHW

Mariah Jacqueline Scott, MS, MPH

Evolving Patient Support Programs: Access, Education and Affordability in Oncology Care

Saturday 8:00 a.m. – 9:00 a.m. W203AB

Sponsored by GSK

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Laurie Hart, BSN, RN, MD, GSK

Rethinking Control in Polycythemia Vera -Uncovering the Clinical Unmet Needs and Potential to Address Them with Emerging Therapies

Saturday 8:00 a.m. – 9:00 a.m. W204BC

Sponsored by Takeda Pharmaceuticals

For in-person participants only

Speakers:

Joseph Scandura, MD, PhD, Weill Cornell Medicine Pankit Vachhani, MD, PhD, University of Alabama at Birmingham

COMPANY SHOWCASES

Company Showcases as of October 19, 2025.

Check the mobile app for an updated list of Company Showcases.

Company Showcase presentations are 15-minute promotional presentations that provide an overview of the companies' services, pipeline products, clinical trials, or mission-based initiatives for a company, non-profit organization, or contract/clinical research organization. The Company Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY

Fast, Fresh, Fit: Unlocking the Potential of Cell Therapy through a Transformative, Scalable, and Accessible Approach to Impact More Patients Globally

Saturday 1:30 p.m. – 1:45 p.m. W208AB

Sponsored by Galapagos
For in-person participants only

Speaker:

Omotayo Fasan, MD, Galapagos

Charting Proteomic Landscapes of Relapse and Resistance in Hematological Malignancies

Saturday 3:30 p.m. – 3:45 p.m. W208AB

Sponsored by Pixelgen Technologies
For in-person participants only

Speaker:

Simon Fredriksson, PhD, Pixelgen Technologies

MONDAY

Innovative Transplant Strategies: Omidubicel Interim Phase II Results in Severe Aplastic Anemia

Monday 10:00 a.m. – 10:15 a.m. W209C

Sponsored by Gamida Cell For in-person participants only

Speaker:

Ronit Simantov, MD, Gamida Cell

CLINICAL TRIAL SHOWCASES

Clinical Trial Showcases as of October 19, 2025.

Check the mobile app for an updated list of Clinical Trial Showcases.

Clinical Trial Showcase presentations are 15-minute promotional presentations that provide an overview of the clinical trials offered by the company, non-profit organization, or contract/clinical research organization. The Clinical Trial Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credit will not be offered.

All events take place in the Orange County Convention Center unless indicated otherwise. All times are in Eastern time. Duplication/recording is prohibited.

SATURDAY

Evaluating Osivelotor in Sickle Cell Disease: Pivotal Trial UpdatesC

Saturday 1:30 p.m. – 1:45 p.m. W209AB

Sponsored by Pfizer

For in-person participants only

Speaker:

Geoffrey Allen, MD, Pfizer

The ALPHA3 Trial: Improving Outcomes Through the Combination of Next-gen CAR T and Advanced MRD Testing in LBCL

Saturday 3:30 p.m. – 3:45 p.m. W209C

Sponsored by Foresight Diagnostics

For in-person participants only

Speaker:

David Kurtz, MD, PhD, Foresight Diagnostics

SUNDAY

LIBRA – SCD: A Group Sequential Phase 2/3 Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)

Sunday 4:00 p.m. – 4:15 p.m. W208AB

Sponsored by Sanofi

For in-person participants only

Speaker:

Ahmed Daak, MD, PhD, MBA, Sanofi

LUMINA 3 – wAIHA: A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)

Sunday 4:15 p.m. – 4:30 p.m. W208AB

Sponsored by Sanofi

For in-person participants only

Speaker:

Ahmed Daak, MD, PhD, MBA, Sanofi

EXHIBITORS

Participating Exhibitors as of October 21, 2025

Exhibitors

Company Name	Booth Number
Abbott Molecular	1481
AbbVie	917
Accellix	110
Acrotech Biopharma	2143
Actinium Pharmaceuticals	734
Adaptive Biotechnologies Corporation	1701
ADC Therapeutics	736
Agilent Technologies	104
Agios Pharmaceuticals	1661
Allucent	1384
Alnylam Pharmaceuticals	685
American Association for Cancer Research	2103
American Porphyria Foundation	1905
American Society for Transplantation and Cellular Therapy (ASTCT)	784
American Society of Hematology	1101, Virtual
American Society of Pediatric Hematology Oncology (ASPHO)	2000
Amgen	451
Amyloidosis Foundation	1803
Amyloidosis Support Groups	1922
Apellis Pharmaceuticals	1229, 1328
Aplastic Anemia and MDS International Foundation, Inc.	477
AplusA	665
Aptitude Health	114
Arcellx	1363
argenx	101
Arima Genomics	1285
ARUP Laboratories	1180
Arvinas	171
Ascentage Pharma	911
Association for Value-Based Cancer Care	1903
Association of Cancer Care Centers	1925

EXHIBITORS

Association of PAs in Oncology	2024
Astellas Pharma US, Inc.	2031
AstraZeneca	1343
Autolus	1615
Azurity Pharmaceuticals, Inc	583
Bayer	2135
Beam Therapeutics	1963
Beckman Coulter Life Sciences	100
BeOne Medicines USA, Inc.	409
Binaytara	2004
Binding Site, Inc.	2171
Biocytogen	111
Blue Spark Technologies, Inc.	120
Blueprint Medicines	881
BostonGene	1581
Brazilian Association of Hematology, Hemotherapy and Cell Therapy	1914
Bristol Myers Squibb	721
Caidya	1468
Cancertools.org	783
Cardinal Health	577
Caribou Biosciences, Inc.	1173
Caris Life Sciences	281
Catalyst Oncology	167
Cencora	864
Cerba Research	164
Children's Hospital of Philadelphia	483
CIBMTR (Center for International Blood & Marrow Transplant Research)	782
Cincinnati Childrens Hospital Medical Center	2006
Citius Oncology	265
City of Hope	1573
Cleveland Clinic Cancer Institute	770
Clinical Education Alliance	142
CLL Society	1805
Cogent Biosciences	1981
College of American Pathologists	1902
Conexiant	154
Cooley's Anemia Foundation	1900
Cryo-Cell International	1972
CSL Behring	1221
СТІ	264
Cure HHT	2022
Curis, Inc.	1965

Current Health	158
Cycle Pharmaceuticals Ltd.	574
Daiichi Sankyo	1235
DAVA Oncology	2155, 2157
Deciphera Pharmaceuticals	2063
Diamond Blackfan Anemia Canada	1821
Diamond Blackfan Anemia Foundation Inc.	1823
Doximity	2001
Eli Lilly and Company	143
Emmes	136
Enable Injections	1081
Enliven Therapeutics	1282
Eurasian Hematology Oncology Group	2002
Eurofins Viracor	161
European Hematology Association	1482
European School of Haematology (ESH)	1920
Flatiron Health, Inc.	1111
Foresight Diagnostics	2165
Formedics	276
Fortrea	372
Foundation for Sickle Cell Disease Research	132
Foundation for the Accreditation of Cellular Therapy	1901
Foundation for Women and Girls with Blood Disorders	2008
Foundation Medicine	1816
Fred Hutchinson Cancer Center	1879
FuGENE Transfection	765
Galapagos	1681
Gamida Cell	317
Genentech	123
Genetix Biotherapeutics	1261
Genetron Health	728
Genmab	701
Genomic Testing Cooperative	2081
Geron Inc.	1211
Gilead and Kite Oncology	1301
Global Action Network for Sickle Cell & Other Inherited Blood Disorders	2010
GSK	1623
Halia Therapeutics	259
Harvest Integrated Research Organization Corp.	150
Haymarket Oncology	764
HCU Network America	1923
HealthTree Foundation	2016

EXHIBITORS

Histiocyte Society/Histiocytosis Association	1913
Hospital Israelita Albert Einstein	177
Ichnos Glenmark Innovation	103
ICON plc	2161
Imaging Endpoints II, LLC	981
Incyte Corporation	425
Infinity Bio Inc	116
Inizio	277
Intermountain Health	1906
International Myeloma Foundation	580
International Myeloma Society	1817
Invivoscribe, Inc.	217
INVIVYD	148
Ipsen Biopharmaceuticals	467
IQVIA Biotech	681
IQVIA Laboratories	683
JAMA Network	1927
Jazz Pharmaceuticals	1651
John Theurer Cancer Center	2149
Johnson & Johnson	1315
Kapadi, Inc.	172
Karius	1974
Karyopharm Therapeutics Inc.	1743
Kedrion Biopharma	664
Korean Society of Hematology (KSH)	1904
Kura Oncology	601
Kyowa Kirin, Inc.	611
Legend Biotech	401
Lunaphore	1982
Machaon Diagnostics, Inc.	475
Matrix Medical Communications	180
MD Anderson Cancer Center	1711
Med Learning Group	971, 1781
MedGenome	165
Medpace Inc.	2121
Medscape Oncology & Hematology	443
Melinta Therapeutics	1381
Menarini Silicon Biosystems	1775
Merck & Co., Inc.	201
Mesoblast Inc	873
Miltenyi Biomedicine GmbH	1271
MIMO Biosciences S.L.	122

Mission Bio	2129
MJH Life Sciences	361
Moffitt Cancer Center	2015
myTomorrows	273
Natera	371
National Blood Clot Alliance	1921
National Comprehensive Cancer Network (NCCN)	1801
NCODA	1910
Nemours Children's Health	476
NeoGenomics	1971
nference	178
NMDP	780
Northside Hospital	113
Northwell Health	2026
Novartis	642
Novo Nordisk Haemophilia Foundation	1280
Novo Nordisk Healthcare AG	1161
NURIX	865
Ochsner Health	146
Ohio State's Comprehensive Cancer Center-James Cancer I	Hospital & Solove Research
Institute	181, Virtual
OHSU Knight Cancer Institute	1809
Omeros Corporation	769
Oncology Learning Network	1978
Ontada	106
Open Health	1185
Optum	118
Orca Bio	1011
Ossium Health, Inc.	112
Oxford Gene Technology (OGT)	464
Ozette Technologies, Inc	2133
Parexel	260
Parse Biosciences	1480
Perceptive	1883
Pfizer, Inc.	1843
PharmaEssentia Corporation	1501
PharmaLegacy Laboratories	152
Pierre Fabre Pharmaceuticals	381
Pixelgen Technologies	182
Platelet Disorder Support Association	2012
Precipio, Inc.	275
Precision for Medicine	671

EXHIBITORS

Predicine	156
Primum Health	1184
PROTEINA Co., LTD.	1369
PSI CRO	1871
Pyruvate Kinase Deficiency International Alliance (PKDIA)	1917
Quest Diagnostics	1083
Ranfac Corp	367
Rapid Novor Inc.	2106
Rarity Bioscience	990
Recordati Rare Diseases	670, 672
Regeneron Pharmaceuticals, Inc.	901
Resilience	170
Rigel Pharmaceuticals	1601
Roswell Park Comprehensive Cancer Center	2179
RTI Catalyze	1907
Rutgers Cancer Institute/RWJBarnabas Health	2113
Sanguina, Inc.	481
Sanofi	943
Sarah Cannon Research Institute	1580
Saudi Society of Blood & Marrow Transplantation (SSBMT)	1912
Scopio Labs	584
Sebia	2009
Secura Bio Inc.	1373
Servier Pharmaceuticals	461
Silence Therapeutics	1383
Siteman Cancer Center	2020
SOBI, Inc	1643
Society for Immunotherapy of Cancer (SITC)	2014
Society of Hematologic Oncology	1813
Sonic Healthcare USA	1483
Spherix Global Insights	2159
SpringWorks Therapeutics	377
St. Jude Children's Research Hospital	1915
Star Therapeutics	102
STEMCELL Technologies	2125
Stemline Therapeutics, Inc.	1562
Sumitomo Pharma America	1675
Sutter Health	2169
Syndax Pharmaceuticals, Inc.	957
Syneos Health	619
Taiho Medical Affairs	2021
Taiho Oncology Commercial	1609

Takeda	1242
Team Telomere	1811
Telios Pharma, Inc.	793
Telo Genomics	785
Tempus	2108
Terns Pharmaceuticals	365
The Japanese Society of Hematology	1916
The Leukemia & Lymphoma Society is now Blood Cancer United	1717
The MDS Foundation, Inc.	1815
Theradex Oncology	117
Therakos LLC	1863
ThermoFisher	2071
Turkish Society of Hematology	2101
UCI Health	1807
United Porphyrias Association	1911
University of Cincinnati	2178
Vaniam Group	775
Vazyme	666
Vertex Pharmaceuticals Inc.	1831
Veterans Health Administration	1909
Visual Science	1970
Waldenstrom's Macroglobulinemia Foundation	1908
Wolters Kluwer	2007
Worldwide Clinical Trials	160
Wuhan Kindstar Medical Laboratory Limited Company	1181
X4 Pharmaceuticals	730
Xspray Pharma AB	128



American Society of Hematology

2025 ASH® Annual Meeting Webcasts

Get access to more than 400 hours of recorded content from the 2025 ASH Annual Meeting, including oral abstracts sessions and poster presentations.

WEBCAST PACKAGES AVAILABLE FOR PURCHASE

	WEBCAST PACKAGES				
Included Sessions	Invited Program Plus Oral Abstracts	Invited Program	Education Program Only	Scientific Program Only	Poster Presentations
Education Program	✓	✓	✓		
Scientific Program	✓	✓		✓	
General Sessions	✓	✓	✓	√	
Special Interest Sessions	✓	✓	✓	√	
Trainee Didactic Sessions	✓	✓	✓	✓	
Oral Abstracts Session* Please note that the webcast packages do not include the poster sessions.	√				
Poster Presentations					✓

^{*}Please note that the oral abstract sessions are only included as part of the Invited Program Plus Oral Abstracts webcast package.

WEBCAST PURCHASE PRICING Special discounted pricing available during the ASH Annual Meeting

Registration Category	BEST VALUE Invited Program Plus Oral Abstracts	Invited Program	Education Program Only	Scientific Program Only	Poster Presentations
Member	\$475.00	\$375.00	\$275.00	\$275.00	\$125.00
Non-member	\$675.00	\$575.00	\$375.00	\$375.00	\$150.00
Associate Member	\$250.00	\$200.00	\$145.00	\$145.00	\$50.00
International Associate Member	\$250.00	\$200.00	\$145.00	\$145.00	\$50.00
Graduate/Medical Student Member	\$250.00	\$200.00	\$145.00	\$145.00	\$50.00
Resident Member	\$250.00	\$200.00	\$145.00	\$145.00	\$50.00
Non-member in Training	\$250.00	\$200.00	\$145.00	\$145.00	\$50.00
Allied Health Professional	\$675.00	\$575.00	\$375.00	\$375.00	\$50.00
Honorary/Emeritus Member	\$250.00	\$200.00	\$145.00	\$145.00	\$50.00

Purchase the Webcast package at the ASH Store, located in West Hall C academy.hematology.org

ROWSE BY DISEAS

BROWSE BY DISEASE

AS OF 10/21/2025

The ASH annual meeting features sessions on every area of hematology. For attendees focused on a particular disease, we have assembled an index of oral sessions that will cover the chosen disease, listed by date and time.

This Index does not represent all available sessions; not every disease is represented here, and not all sessions are disease-specific. Check the virtual meeting platform and the meeting mobile app to search for sessions by the full list of keywords.

DISEASE	PAGE
Bleeding and Clotting	155
Bone Marrow Failure Syndrome	159
Genetic Disorders	161
Hemoglobinopathies	163
Immune Disorders	165
Lymphoid Malignancies	167
Metabolic Disorders	175
Myeloid Malignancies	177

Hematology 2025

Test your knowledge and earn CME credit at academy.hematology.org

EARN UP TO 88 CME/MOC CREDITS

Hematology 2025

AMERICAN SOCIETY of HEMATOLOGY Education Program[™] 67th ASH[®] Annual Meeting and Exposition December 6-9, 2025



FREE SHIPPING WHEN PURCHASED DURING THE ANNUAL MEETING

New Edition!

Free digital access available to 67th ASH Annual Meeting and Exposition attendees.



Print copy available to order at the ASH Store.

ashpublications.org/Hematology







The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASH designates this enduring educational activity for a maximum of 88.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

BLEEDING AND CLOTTING

BLEEDING AND CLOTTING

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Advances in Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders:Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond	Interact with Industry	W224ABEF	CME
Friday	7:00–10:00 a.m.	Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data	Interact with Industry	W224CDGH	CME
Friday	11:00 a.m2:00 p.m.	Advancing Hemophilia Care—Uniting Expert Insights and Community Voices to Shape the Future of Non-Factor Replacement Therapy	Interact with Industry	Hyatt - Orlando Ballroom	CME
Friday	3:00-6:00 p.m.	Achieving Comprehensive Care for Chronic Immune Thrombocytopenia: Exploring Emerging Therapies to Address Patient-centric Hematological and Non- Hematological Outcomes	Interact with Industry	Hyatt - Regency Ballroom R	CME
Friday	3:00-6:00 p.m.	BRINGING EMERGING TREATMENTS TO ALL PATIENTS: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices	Interact with Industry	Valencia Room W415BC	CME
Friday	3:00-6:00 p.m.	Filling in the Gaps in Hemophilia Guideline Recommendations: Evidence-Based Strategies to Optimize Patient-Relevant Outcomes	Interact with Industry	Valencia Room W415A	CME
Friday	3:00-6:00 p.m.	Visualizing Novel Pathways to Optimizing Care for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)	Interact with Industry	W224ABEF	CME
Friday	7:00–10:00 p.m.	Hot Topics in Myelofibrosis Management: Navigating the Latest Therapeutic Advances in Clinical Practice	Interact with Industry	W331	CME
Saturday	8:00–9:00 a.m.	Clinical Management and Unmet Needs in Immune Thrombocytopenia (ITP)	Interact with Industry	W209AB	
Saturday	8:00–9:00 a.m.	How I Navigate Arterial Thrombosis: A Hematologist's Perspective	Education Program	Hyatt - Bayhill 23	CME
Saturday	8:00–9:00 a.m.	How I Treat the Balancing Act of Anticoagulant Management in Hemoglobinopathies	Education Program	Hyatt - Bayhill 25-26	CME
Saturday	9:30–10:45 a.m.	Bleeding Disorder of Unknown Cause—What Do We Know?	Education Program	W307	CME
Saturday	9:30–10:45 a.m.	Immune Cytopenias: Addressing Challenges and Advancing Treatments	Education Program	Hyatt - Regency Ballroom S	CME
Saturday	9:30–11:00 a.m.	321. Coagulation and Fibrinolysis: Basic and Translational: Deciphering new and old conundrums of coagulation	Oral Abstract Session	W304EFGH	
Saturday	9:30–11:00 a.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Risk Assessment and Management of Thromboembolism in Cancer: Genomics, Biomarkers, and Real-World Evidence	Oral Abstract Session	W304ABCD	
Saturday	9:30–11:00 a.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome	Oral Abstract Session	W414CD	
Saturday	9:30–11:00 a.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Transformative Al and Omics Approaches in Hematologic Malignancies	Oral Abstract Session	Hyatt - Regency Ballroom R	
Saturday	11:15 a.m.–12:15 p.m.	Inherited Bleeding Disorders Poster Walk	Scientific Program	West Halls B3-B4	
Saturday	11:30 a.m12:30 p.m.	Shifting Currents in Hemophilia Care: Exploring the Impact of Antithrombin Lowering	Interact with Industry	W206A	
Saturday	2:00-3:15 p.m.	Complementopathies: Modern Diagnosis and Management	Education Program	Hyatt - Regency Ballroom S	CME
Saturday	2:00-3:15 p.m.	The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP	Education Program	W304EFGH	CME
Saturday	2:00-3:30 p.m.	301. Platelets and Megakaryocytes: Basic and Translational: Novel mechanisms of platelet signaling	Oral Abstract Session	W304ABCD	

BLEEDING AND CLOTTING

Day	Time	Session Title	Program	Location	CME
Saturday	2:00–3:30 p.m.	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Thrombosis and thrombotic microangiopathy: New mechanisms and new therapies	Oral Abstract Session	W307	
Saturday	4:00-5:15 p.m.	Between Clots and Complications: A New Era of Anticoagulation in Cancer	Education Program	West Hall D2	CME
Saturday	4:00-5:15 p.m.	Hemoglobinopathies and Increased Risk of Venous Thromboembolism	Education Program	W308	CME
Saturday	4:00-5:15 p.m.	Thromboinflammation	Scientific Program	W314	
Saturday	4:00-5:30 p.m.	322. Hemophilia A and B: Clinical and Epidemiological: Prophylaxis Across the Age Spectrum	Oral Abstract Session	W304ABCD	
Saturday	4:00–5:30 p.m.	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Insights into Diagnostics and Therapeutics of Bleeding in Inherited, Acquired Coagulopathies and BDUC	Oral Abstract Session	W304EFGH	
Saturday	4:00-5:30 p.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Bleeding: Real-World Insights Across Diverse Patient Populations	Oral Abstract Session	W307	
Saturday	4:00-5:30 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Prediction Models and Novel Molecular Markers	Oral Abstract Session	Hyatt - Regency Ballroom R	
Sunday	8:00–9:00 a.m.	Cablivi (caplacizumab-yhdp) Real-World Evidence in 1,000+ Patients: Early Initiation Matters	Interact with Industry	W207BC	
Sunday	8:00–9:00 a.m.	How I Optimize Hemophilia Management: The Role of Novel Treatments	Education Program	Hyatt - Bayhill 25-26	CME
Sunday	8:00-9:00 a.m.	How I Treat Clinical Management of Refractory ITP	Education Program	Hyatt - Bayhill 27	CME
Sunday	9:30–10:45 a.m.	Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders	Education Program	W304ABCD	CME
Sunday	9:30–10:45 a.m.	Harnessing The Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins	Scientific Program	W311EFGH	
Sunday	9:30–10:45 a.m.	Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery	Education Program	Hyatt - Regency Ballroom S	CME
Sunday	9:30–11:00 a.m.	301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders	Oral Abstract Session	W304EFGH	
Sunday	9:30–11:00 a.m.	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets, leukocytes, and endothelium in thrombotic and vascular disease	Oral Abstract Session	W307	
Sunday	9:30–11:00 a.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML	Oral Abstract Session	Valencia Room W415D	
Sunday	11:30 a.m12:30 p.m.	Discover a New Way Forward With WAYRILZ	Interact with Industry	W209C	
Sunday	11:30 a.m.–12:30 p.m.	Exploring a Subcutaneous Treatment Option in Hemophilia Care with HYMPAVZI (marstacimab-hncq)	Interact with Industry	W206A	
Sunday	12:00–1:30 p.m.	322. Hemophilia A and B: Clinical and Epidemiological: Innovations Shaping the Future of Hemophilia Care	Oral Abstract Session	W304EFGH	
Sunday	12:00–1:30 p.m.	401. Blood Transfusion: Transfusion Frontlines: Research Driving Safer, Smarter Care	Oral Abstract Session	Sunburst Room (W340)	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non- Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing	Oral Abstract Session	W304ABCD	
Sunday	4:00-4:15 p.m.	LIBRA – SCD : A Group Sequential Phase 2/3 Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)	Interact with Industry	W208AB	
Sunday	4:15-4:30 p.m.	LUMINA 3 – wAIHA: A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)	Interact with Industry	W208AB	

BLEEDING AND CLOTTING

BLEEDING AND CLOTTING

Day	Time	Session Title	Program	Location	CME
Sunday	4:30-5:45 p.m.	Arterial Disease and the Hematologist	Education Program	W307	CME
Sunday	4:30-5:45 p.m.	Decoding the Enigma: Challenges in Classical Hematology Consultations	Education Program	W304ABCD	CME
Sunday	4:30-5:45 p.m.	Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?	Education Program	Hyatt - Regency Ballroom R	CME
Sunday	4:30-6:00 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: The immune system's first move: early lymphocyte development to disease states	Oral Abstract Session	Hyatt - Regency Ballroom OPQ	
Sunday	4:30-6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Cancer, Clots and Coagulation	Oral Abstract Session	W308	
Sunday	4:30-6:00 p.m.	Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults	Special-Interest Sessions	W304EFGH	CME
Monday	10:30–11:45 a.m.	Creative and Novel Statistical Techniques to Design and Analyze Data for Trials Focused on Rare Hematologic Diseases	Scientific Program	Hyatt - Regency Ballroom R	
Monday	10:30-11:45 a.m.	Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients	Education Program	W307	CME
Monday	10:30 a.m12:00 p.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: The Evolving ITP Toolkit: Maximizing Efficacy, Minimizing Side Effects	Oral Abstract Session	W304EFGH	
Monday	10:30 a.m12:00 p.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Innovations in Thrombosis and Bleeding: Diagnostics, Therapeutics, and Predictive Modeling	Oral Abstract Session	W304ABCD	
Monday	2:45-4:00 p.m.	The Critical Role of Metabolism in Megakaryocyte and Platelet Biology	Scientific Program	W314	
Monday	2:45-4:15 p.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Game Changers in Platelet disorders: A Look at Novel Therapies	Oral Abstract Session	W304EFGH	
Monday	2:45-4:15 p.m.	331. Thrombotic Microangiopathies/ Thrombocytopenias: Clinical and Epidemiological: Old Dogs, New Tricks; Advances in Thrombotic Microangiopathy Diagnosis and Treatment	Oral Abstract Session	W307	
Monday	2:45-4:15 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care	Oral Abstract Session	W304ABCD	
Monday	4:30-6:00 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Drivers and Mast Cells and Blasts, Oh My! - Insights and Treatments for MPNs and Mastocytosis.	Oral Abstract Session	West Hall D2	
Monday	4:30-6:00 p.m.	801. Gene Therapies: Technological Developments in Gene Therapy	Oral Abstract Session	Sunburst Room (W340)	
Monday	4:30-6:00 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Risk Assessment, and Care Optimization, and Al, Ohmy! The Spectrum of Quality in Classical Hematology	Oral Abstract Session	W308	
Monday	4:30-6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps	Oral Abstract Session	W307	
Monday	4:30-6:00 p.m.	Special Symposium on the Basic Science in Hemostasis and Thrombosis	Scientific Program	Valencia Room W415D	
Monday	6:00-7:30 p.m.	ASH Hemostasis and Thrombosis Community Networking Reception	Special-Interest Sessions	Valencia Foyer	





ASH® is fighting for hematology in the face of executive orders and other federal actions that threaten research and, ultimately, the care of patients.



3. AMPLIFY

Use your voice on social media to spread awareness and support for the #Fight4Hematology!



4. DONATE

Contribute to the ASH Foundation to support additional ASH Awards to help ensure that hematologists can continue their vital research without interruption.



Together, we can drive meaningful change!

hematology.org/Fight4Hematology

BONE MARROW FAILURE SYNDROME

BONE MARROW FAILURE SYNDROME

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Momentum in MDS: Making Progress and Shaping a Better Future	Interact with Industry	Tangerine Ballroom F2	CME
Friday	7:00–10:00 a.m.	Paroxysmal Nocturnal Hemoglobinuria: What we have learned from the introduction of new therapies	Interact with Industry	Tangerine Ballroom F1	CME
Friday	7:00–10:00 p.m.	Hot Topics in Myelofibrosis Management: Navigating the Latest Therapeutic Advances in Clinical Practice	Interact with Industry	W331	CME
Saturday	9:30–11:00 a.m.	508. Bone Marrow Failure Acquired: Immune dysregulation and molecular insights	Oral Abstract Session	Hyatt - Plaza Int'l HIJK	
Saturday	2:00–3:15 p.m.	Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes	Scientific Program	Hyatt - Plaza Int'l HIJK	
Saturday	2:00-3:30 p.m.	501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Chromatin and transcriptional regulation in hematopoietic lineage commitment	Oral Abstract Session	W311EFGH	
Saturday	4:00–5:30 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel strategies to overcome therapy resistance in AML	Oral Abstract Session	Valencia Room W415D	
Saturday	4:00-5:30 p.m.	ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia	Special-Interest Sessions	Hyatt - Regency Ballroom OPQ	CME
Saturday	4:00-5:35 p.m.	JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia	Scientific Program	Hyatt - Plaza Int'l HIJK	
Sunday	9:30–10:45 a.m.	What's New and Current in the World of Bone Marrow Failure	Education Program	Hyatt - Regency Ballroom OPQ	CME
Sunday	12:00-1:30 p.m.	908. Outcomes Research: Myeloid Malignancies: Treatment and Outcomes in the Real-World	Oral Abstract Session	W414CD	
Sunday	4:30–5:45 p.m.	Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?	Education Program	Hyatt - Regency Ballroom R	CME
Sunday	4:30-6:00 p.m.	201. Granulocytes, Monocytes, and Macrophages: New findings in neutropenia and myelopoiesis	Oral Abstract Session	W314	
Sunday	4:30-6:00 p.m.	636. Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression	Oral Abstract Session	Valencia Room W415A	
Sunday	4:30-6:00 p.m.	908. Outcomes Research: Myeloid Malignancies: Real- World Experiences	Oral Abstract Session	W414CD	
Sunday	4:30-6:00 p.m.	ASH Clinical Practice Guidelines on Aplastic Anemia	Special-Interest Sessions	Hyatt - Plaza Int'l HIJK	CME
Monday	10:00–10:15 a.m.	Innovative Transplant Strategies: Omidubicel Interim Phase II Results in Severe Aplastic Anemia	Interact with Industry	W209C	
Monday	10:30 a.m.–12:00 p.m.	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Inheritance to Innovation	Oral Abstract Session	Hyatt - Plaza Int'l HIJK	
Monday	12:15–1:15 p.m.	From Innovation to Impact: Real Stories of Transformation in PNH Management	Interact with Industry	W207BC	
Monday	2:45-4:15 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care	Oral Abstract Session	W304ABCD	
Monday	4:30-6:00 p.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: New insights into inflammatory drivers of normal and clonal hematopoiesis	Oral Abstract Session	W312	
Monday	4:30-6:00 p.m.	508. Bone Marrow Failure Acquired: Therapeutic advancements in AA, PNH, and VEXAS	Oral Abstract Session	Hyatt - Plaza Int'l HIJK	
Monday	4:30-6:00 p.m.	801. Gene Therapies: Technological Developments in Gene Therapy	Oral Abstract Session	Sunburst Room (W340)	
Monday	4:30-6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps	Oral Abstract Session	W307	

NEWLY LAUNCHED

ASH® Treating Fairly Research Award

Awardees receive \$200,000 to continue vital research that addresses disparities in health outcomes in vulnerable populations.

This new award was launched as a part of ASH's increased awards funding intended to address threats to hematology research amid sudden and massive cuts to federal research grants, training opportunities, and federal programs. ASH's total awards commitment is more than \$20 million in 2025-2026 to address gaps in federal research funding.



hematology.org/TreatingFairly

APPLY NOW

Deadline: December 17, 2025



#Fight4Hematology

GENETIC DISORDERS

GENETIC DISORDERS

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Advances in Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders:Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond	Interact with Industry	W224ABEF	CME
Friday	11:00 a.m.–2:00 p.m.	From Indolent to Aggressive: Case-Based Strategies Across the Spectrum of Systemic Mastocytosis	Interact with Industry	W224CDGH	CME
Friday	3:00-6:00 p.m.	Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management	Interact with Industry	Hyatt - Plaza Int'l HIJK	CME
Friday	3:00-6:00 p.m.	Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management —A CME COMPETE™: SCD Edition	Interact with Industry	W224CDGH	CME
Saturday	9:30–11:00 a.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Mechanistic Insights into Sickle Cell Pathobiology and Disease Progression	Oral Abstract Session	W311ABCD	
Saturday	9:30-11:00 a.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: Transforming Care Delivery and the Patient Experience	Oral Abstract Session	W311EFGH	
Saturday	2:00-3:30 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: MRD Assays and Novel Drug Discovery Pipelines	Oral Abstract Session	Hyatt - Regency Ballroom R	
Saturday	4:00-5:30 p.m.	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Insights into Diagnostics and Therapeutics of Bleeding in Inherited, Acquired Coagulopathies and BDUC	Oral Abstract Session	W304EFGH	
Saturday	4:00–5:30 p.m.	801. Gene Therapies: Advances in Gene Therapy for Blood Disorders	Oral Abstract Session	Chapin Theater (W320)	
Sunday	8:00–9:00 a.m.	Transforming Thalassemia Care: Introducing a New Treatment Option from Agios Pharmaceuticals	Interact with Industry	W206A	
Sunday	9:30–11:00 a.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Between a Rock and a Ropeg - Innovative Therapies for MPNs	Oral Abstract Session	W414AB	
Sunday	12:00–1:30 p.m.	102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Erythropoiesis, Inflammation and Hematologic Recovery: The Iron and Heme Drama Unfolds	Oral Abstract Session	W311EFGH	
Sunday	12:00–1:30 p.m.	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Optimizing risk stratification, treatment, and diagnostics of ALL in the immunotherapy era	Oral Abstract Session	W224ABEF	
Sunday	4:00-4:15 p.m.	LIBRA – SCD : A Group Sequential Phase 2/3 Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)	Interact with Industry	W208AB	
Sunday	4:15-4:30 p.m.	LUMINA 3 – wAIHA : A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)	Interact with Industry	W208AB	
Sunday	4:30-6:00 p.m.	201. Granulocytes, Monocytes, and Macrophages: New findings in neutropenia and myelopoiesis	Oral Abstract Session	W314	
Sunday	4:30-6:00 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: The immune system's first move: early lymphocyte development to disease states	Oral Abstract Session	Hyatt - Regency Ballroom OPQ	
Sunday	4:30-6:00 p.m.	636. Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression	Oral Abstract Session	Valencia Room W415A	
Monday	10:30 a.m12:00 p.m.	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Inheritance to Innovation	Oral Abstract Session	Hyatt - Plaza Int'l HIJK	
Monday	12:15–1:15 p.m.	From Innovation to Impact: Real Stories of Transformation in PNH Management	Interact with Industry	W207BC	

GENETIC DISORDERS

Day	Time	Session Title	Program	Location	CME
Monday	12:15–1:15 p.m.	Pyruvate Kinase Activation in Hemolytic Anemias and Insights into its Mechanism	Interact with Industry	W206A	
Monday	4:30-6:00 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Erythroid differentiation	Oral Abstract Session	W311EFGH	
Monday	4:30-6:00 p.m.	508. Bone Marrow Failure Acquired: Therapeutic advancements in AA, PNH, and VEXAS	Oral Abstract Session	Hyatt - Plaza Int'l HIJK	
Monday	4:30-6:00 p.m.	602. Myeloid Oncogenesis: Basic: New insights in clonal evolution and models of disease	Oral Abstract Session	W414CD	
Monday	4:30-6:00 p.m.	801. Gene Therapies: Technological Developments in Gene Therapy	Oral Abstract Session	Sunburst Room (W340)	
Monday	4:30-6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps	Oral Abstract Session	W307	

HEMOGLOBINOPATHIES

HEMOGLOBINOPATHIES

Day	Time	Session Title	Program	Location	CME
Friday	3:00-6:00 p.m.	Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management —A CME COMPETE™: SCD Edition	Interact with Industry	W224CDGH	CME
Saturday	8:00–9:00 a.m.	Enhancing Sickle Cell Disease Care Through Patient Partnership	Interact with Industry	W207BC	
Saturday	8:00-9:00 a.m.	How I Treat the Balancing Act of Anticoagulant Management in Hemoglobinopathies	Education Program	Hyatt - Bayhill 25-26	CME
Saturday	9:30–10:45 a.m.	Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy	Scientific Program	Hyatt - Regency Ballroom OPQ	
Saturday	9:30–11:00 a.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Mechanistic Insights into Sickle Cell Pathobiology and Disease Progression	Oral Abstract Session	W311ABCD	
Saturday	9:30–11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Biological and Clinical Nuances in Patient Outcomes	Oral Abstract Session	Valencia Room W415BC	
Saturday	9:30–11:00 a.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: Transforming Care Delivery and the Patient Experience	Oral Abstract Session	W311EFGH	
Saturday	9:30–11:00 a.m.	Leveraging Real-World Data in Sickle Cell Disease to Identify and Study Specific Cohorts of Interest	Special-Interest Sessions	W308	
Saturday	11:15 a.m.–12:15 p.m.	Career Development Lunch	Trainee Activities and Services	Hyatt - Windemere Ballroom	
Saturday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Session	W331	
Saturday	12:00-1:30 p.m.	904. Outcomes Research: Hemoglobinopathies: Clinical Phenotypes and Outcomes in Hemoglobinopathies	Oral Abstract Session	W308	
Saturday	2:00-3:15 p.m.	Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy	Scientific Program	Sunburst Room (W340)	
Saturday	2:00-3:15 p.m.	Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease	Scientific Program	W308	
Saturday	2:00-3:30 p.m.	ASH Clinical Practice Guidelines on Hydroxyurea for Sickle Cell Disease	Special-Interest Sessions	W311ABCD	CME
Saturday	4:00–5:15 p.m.	Hemoglobinopathies and Increased Risk of Venous Thromboembolism	Education Program	W308	CME
Saturday	4:00-5:30 p.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Prognosis, the heart, and the kidney in SCD	Oral Abstract Session	W311ABCD	
Saturday	4:00-5:30 p.m.	801. Gene Therapies: Advances in Gene Therapy for Blood Disorders	Oral Abstract Session	Chapin Theater (W320)	
Sunday	8:00-9:00 a.m.	Transforming Thalassemia Care: Introducing a New Treatment Option from Agios Pharmaceuticals	Interact with Industry	W206A	
Sunday	9:30–10:45 a.m.	Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery	Education Program	Hyatt - Regency Ballroom S	CME
Sunday	9:30–11:00 a.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Orphans of an orphan disease: HbSC and HbSBeta+ sickle cell Disease	Oral Abstract Session	W308	
Sunday	9:30–11:00 a.m.	To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy	Special-Interest Sessions	W311ABCD	CME
Sunday	12:00-1:30 p.m.	102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Erythropoiesis, Inflammation and Hematologic Recovery: The Iron and Heme Drama Unfolds	Oral Abstract Session	W311EFGH	

HEMOGLOBINOPATHIES

Day	Time	Session Title	Program	Location	CME
Sunday	12:00–1:30 p.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: On the Horizon: Biomarkers Guiding Outcomes in Hemoglobinopathies	Oral Abstract Session	W311ABCD	
Sunday	4:00-4:15 p.m.	LIBRA – SCD : A Group Sequential Phase 2/3 Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)	Interact with Industry	W208AB	
Sunday	4:15–4:30 p.m.	LUMINA 3 – wAIHA : A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)	Interact with Industry	W208AB	
Sunday	4:30-5:45 p.m.	Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?	Education Program	Hyatt - Regency Ballroom R	CME
Sunday	4:30-5:45 p.m.	Sickle Cell Therapies: The Who, What, When, and Where	Education Program	West Hall D2	CME
Sunday	4:30-6:00 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis: clinical relevance	Oral Abstract Session	W311EFGH	
Sunday	4:30-6:00 p.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Therapies in Sickle Cell Disease: Finding Progress in Existing Drugs	Oral Abstract Session	W311ABCD	
Monday	10:30–11:45 a.m.	Transfusion Medicine for Practicing Hematologists: How to Prevent and Treat Potentially Fatal Reactions in Sickle Cell Disease	Education Program	W308	CME
Monday	10:30 a.m.–12:00 p.m.	112. Thalassemia and Globin Gene Regulation: Murine models and a clinical approach to reduce toxicity, modulate hemoglobin F and improve outcomes in thalassemia	Oral Abstract Session	W311ABCD	
Monday	10:30 a.m12:00 p.m.	909. Education, Communication, and Workforce: Innovating to Bridge Gaps and Improve Access: Education, Communication, and Workforce in Hematology	Oral Abstract Session	Hyatt - Regency Ballroom OPQ	
Monday	12:15–1:15 p.m.	First-Line Treatment Option for Anemia in Lower-Risk MDS COMMANDS Trial Overview	Interact with Industry	W209C	
Monday	12:15–1:15 p.m.	From Innovation to Impact: Real Stories of Transformation in PNH Management	Interact with Industry	W207BC	
Monday	12:15–1:15 p.m.	Pyruvate Kinase Activation in Hemolytic Anemias and Insights into its Mechanism	Interact with Industry	W206A	
Monday	2:45-4:00 p.m.	Biology-Based Management of Iron Toxicity and Overload in Hematology Practice	Education Program	Hyatt - Regency Ballroom OPQ	CME
Monday	2:45-4:00 p.m.	Joint Session with ASPHO: Transition to Adult Care in Malignant and Classical Hematology	Education Program	Hyatt - Regency Ballroom S	CME
Monday	2:45–4:15 p.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Translational Therapeutics - Emerging Targets in Sickle Cell Disease	Oral Abstract Session	W308	
Monday	2:45-4:15 p.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: From Screening to Access: Pathways to Improving Care	Oral Abstract Session	W311ABCD	
Monday	4:30-6:00 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Erythroid differentiation	Oral Abstract Session	W311EFGH	
Monday	4:30-6:00 p.m.	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization	Oral Abstract Session	Hyatt - Regency Ballroom R	
Monday	4:30-6:00 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects	Oral Abstract Session	W331	
Monday	4:30-6:00 p.m.	904. Outcomes Research: Hemoglobinopathies: Global burden of Hemoglobinopathies: From Crisis to Care	Oral Abstract Session	W311ABCD	
Monday	4:30-6:00 p.m.	ASH's SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care	Special-Interest Sessions	W230	

IMMUNE DISORDERS

IMMUNE DISORDERS

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Rising to the Graft-vs-Host Disease Challenge: Progress in Treatment and Post-HCT Outcomes Across Hematologic Cancers	Interact with Industry	W331	CME
Friday	3:00-6:00 p.m.	Medical Crossfire®: Navigating GVHD Prophylaxis, Acute and Chronic Care - Targeted Strategies to Elevate Patient Outcomes	Interact with Industry	Tangerine Ballroom F2	CME
Saturday	9:30–10:45 a.m.	Immune Cytopenias: Addressing Challenges and Advancing Treatments	Education Program	Hyatt - Regency Ballroom S	CME
Saturday	9:30–10:45 a.m.	Strategies To Improve Outcomes After Hematopoietic Cell Transplantation and Adoptive Cell Therapy	Scientific Program	W331	
Saturday	9:30–11:00 a.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome	Oral Abstract Session	W414CD	
Saturday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational: In vivo CAR-T cell platforms and resistance mechanisms	Oral Abstract Session	Sunburst Room (W340)	
Saturday	12:00–1:30 p.m.	701. Experimental Transplantation: Basic and Translational: GVHD, thymopoiesis and the host regenerative response	Oral Abstract Session	Chapin Theater (W320)	
Saturday	2:00-3:15 p.m.	Complementopathies: Modern Diagnosis and Management	Education Program	Hyatt - Regency Ballroom S	CME
Saturday	2:00–3:15 p.m.	Down the Rabbit Hole: An Update on Histiocytic Disorders	Education Program	Hyatt - Regency Ballroom OPQ	CME
Saturday	2:00–3:30 p.m.	201. Granulocytes, Monocytes, and Macrophages: Histiocytic and granulocytic Disorders	Oral Abstract Session	W312	
Saturday	2:00–3:30 p.m.	301. Platelets and Megakaryocytes: Basic and Translational: Novel mechanisms of platelet signaling	Oral Abstract Session	W304ABCD	
Saturday	2:00–3:30 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Acute and Chronic GVHD and Immune Reconstitution	Oral Abstract Session	W331	
Saturday	4:00-5:30 p.m.	801. Gene Therapies: Advances in Gene Therapy for Blood Disorders	Oral Abstract Session	Chapin Theater (W320)	
Saturday	4:00-5:30 p.m.	802. Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies?	Oral Abstract Session	W331	
Sunday	8:00-9:00 a.m.	How I Treat Clinical Management of Refractory ITP	Education Program	Hyatt - Bayhill 27	CME
Sunday	9:30–11:00 a.m.	301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders	Oral Abstract Session	W304EFGH	
Sunday	9:30–11:00 a.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML	Oral Abstract Session	Valencia Room W415D	
Sunday	11:30 a.m.–12:30 p.m.	Discover a New Way Forward With WAYRILZ	Interact with Industry	W209C	
Sunday	12:00–1:30 p.m.	401. Blood Transfusion: Transfusion Frontlines: Research Driving Safer, Smarter Care	Oral Abstract Session	Sunburst Room (W340)	
Sunday	12:00–1:30 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Biomarkers and Targets	Oral Abstract Session	Chapin Theater (W320)	
Sunday	4:00–4:15 p.m.	LIBRA – SCD : A Group Sequential Phase 2/3 Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)	Interact with Industry	W208AB	
Sunday	4:15-4:30 p.m.	LUMINA 3 – wAIHA : A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)	Interact with Industry	W208AB	
Sunday	4:30-6:00 p.m.	201. Granulocytes, Monocytes, and Macrophages: New findings in neutropenia and myelopoiesis	Oral Abstract Session	W314	
Sunday	4:30-6:00 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: The immune system's first move: early lymphocyte development to disease states	Oral Abstract Session	Hyatt - Regency Ballroom OPQ	

IMMUNE DISORDERS

Day	Time	Session Title	Program	Location	CME
Sunday	4:30-6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Cancer, Clots and Coagulation	Oral Abstract Session	W308	
Monday	10:30 a.m.–12:00 p.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: The Evolving ITP Toolkit: Maximizing Efficacy, Minimizing Side Effects	Oral Abstract Session	W304EFGH	
Monday	10:30 a.m.–12:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging CAR-T Cell Therapies for Acute Leukemias and Autoimmune Diseases	Oral Abstract Session	Valencia Room W415D	
Monday	10:30 a.m.–12:00 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Clinical and Translational Insights	Oral Abstract Session	Sunburst Room (W340)	
Monday	2:45-4:15 p.m.	331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Old Dogs, New Tricks; Advances in Thrombotic Microangiopathy Diagnosis and Treatment	Oral Abstract Session	W307	
Monday	2:45-4:15 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Enhancing Immune Therapy in MM	Oral Abstract Session	West Hall D1	
Monday	4:30–5:45 p.m.	How to Prevent and Manage Infections in Immunocompromised Patients in the Era of Immunotherapy and Growing Antibiotic Resistance	Education Program	Hyatt - Regency Ballroom OPQ	CME
Monday	4:30-6:00 p.m.	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization	Oral Abstract Session	Hyatt - Regency Ballroom R	

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Aligning Discovery With Clinical Practice: Applying Expert Consensus Guidelines To Improve Patient Outcomes in CLL/SLL	Interact with Industry	Virtual Symposium Only	
Friday	7:00–10:00 a.m.	Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma	Interact with Industry	Hyatt - Regency Ballroom R	
Friday	7:00–10:00 a.m.	Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies	Interact with Industry	Valencia Room W415BC	
Friday	7:00–10:00 a.m.	Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond	Interact with Industry	Valencia Room W415A	
Friday	7:00–10:00 a.m.	Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care	Interact with Industry	Hyatt - Orlando Ballroom	
Friday	7:00–10:00 a.m.	Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data	Interact with Industry	W224CDGH	
Friday	7:00–10:00 a.m.	Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options & Modern Clinical Decision-making in Newly Diagnosed Disease	Interact with Industry	Hyatt - Regency Ballroom S	
Friday	7:00–10:00 a.m.	Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment	Interact with Industry	Hyatt - Regency Ballroom OPQ	
Friday	11:00 a.m2:00 p.m.	'Four' Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care with Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapies	Interact with Industry	Valencia Room W415D	
Friday	11:00 a.m2:00 p.m.	Accelerating Evidence Into Practice: Leveraging QI-Driven Insights and Practical Tools to Integrate Bispecific Antibodies Into Care for Patients With R/R DLBCL and FL	Interact with Industry	W331	
Friday	11:00 a.m2:00 p.m.	Advancing Outcomes in Lymphoma Care: A MasterClass on Integrating the CAR T-Cell Therapies into Clinical Practice	Interact with Industry	Hyatt - Regency Ballroom OPQ	
Friday	11:00 a.m2:00 p.m.	Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia	Interact with Industry	Hyatt - Regency TUV	
Friday	11:00 a.m2:00 p.m.	Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care	Interact with Industry	Tangerine Ballroom F1	
Friday	11:00 a.m2:00 p.m.	The Growing Role of CAR T-Cell Therapy in Multiple Myeloma: New Data on Earlier Lines of Therapy, Expanding Access to Treatment	Interact with Industry	W230	
Friday	3:00-6:00 p.m.	Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access	Interact with Industry	W230	
Friday	3:00-6:00 p.m.	Bringing Emerging Treatments to All Patients: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices	Interact with Industry	Valencia Room W415BC	
Friday	3:00-6:00 p.m.	Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs	Interact with Industry	Hyatt - Regency Ballroom OPQ	
Friday	3:00-6:00 p.m.	PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma	Interact with Industry	Tangerine Ballroom F3-4	
Friday	7:00–10:00 p.m.	EXPERT SECOND OPINION: Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma	Interact with Industry	Hyatt - Regency TUV	
Saturday	8:00-9:00 a.m.	How I Treat Multiple Myeloma Progression after Upfront Quadruplet Therapy	Education Program	Hyatt - Bayhill 31-32	CME
Saturday	9:30–10:45 a.m.	Dissecting Enhancer Function in Hematopoietic Development and Disease	Scientific Program	W312	
Saturday	9:30–10:45 a.m.	Dissecting Enhancer Function in Hematopoietic	Scientific Program	W312	

Day	Time	Session Title	Program	Location	CME
Saturday	9:30–10:45 a.m.	Exploring the Origins of Multiple Myeloma: Germline Predisposition and Early Deregulations	Scientific Program	West Hall D1	
Saturday	9:30–11:00 a.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Risk Assessment and Management of Thromboembolism in Cancer: Genomics, Biomarkers, and Real-World Evidence	Oral Abstract Session	W304ABCD	
Saturday	9:30–11:00 a.m.	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Prognostic Genetic and Therapeutic Response Factors in Adult and Pediatric B-ALL	Oral Abstract Session	W224CDGH	
Saturday	9:30–11:00 a.m.	621. Lymphomas: Translational – Molecular and Genetic - Subtyping strategies to unlock new therapeutic vulnerabilities	Oral Abstract Session	Tangerine Ballroom F1	
Saturday	9:30–11:00 a.m.	627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Front-line BTKi-based Combination Therapy in DLBCL and PCNSL	Oral Abstract Session	Tangerine Ballroom F3-4	
Saturday	9:30-11:00 a.m.	629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Overcoming Barriers in Frontline Therapy: Bispecific Antibodies for Older Adults with DLBCL	Oral Abstract Session	Tangerine Ballroom F2	
Saturday	9:30–11:00 a.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation	Oral Abstract Session	W224ABEF	
Saturday	9:30–11:00 a.m.	653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Immune-Based Therapies in Myeloma: From T-Cell Fitness to Clinical Outcomes	Oral Abstract Session	West Hall D2	
Saturday	9:30–11:00 a.m.	654. Multiple Myeloma: Pharmacologic Therapies: Advancing the Standard: Improving Myeloma Treatment through Diagnosis, Maintenance and Relapse	Oral Abstract Session	West Hall E1	
Saturday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational: In vivo CAR-T cell platforms and resistance mechanisms	Oral Abstract Session	Sunburst Room (W340)	
Saturday	9:30–11:00 a.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications	Oral Abstract Session	Chapin Theater (W320)	
Saturday	9:30–11:00 a.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Transformative Al and Omics Approaches in Hematologic Malignancies	Oral Abstract Session	Hyatt - Regency Ballroom R	
Saturday	9:30–11:00 a.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Clinical decision making and supportive care	Oral Abstract Session	W230	
Saturday	9:30–11:00 a.m.	907. Outcomes Research: Plasma Cell Disorders: Real-world Outcomes of Targeted Immunotherapies in Patients with Multiple Myeloma	Oral Abstract Session	West Hall E2	
Saturday	11:15 a.m.–12:15 p.m.	Career Development Lunch	Trainee Activities and Services	Hyatt - Windemere Ballroom	
Saturday	11:30 a.m12:30 p.m.	A Treatment Option for Adults with Certain R/R DLBCL After ≥2 Prior Lines of Systemic Therapy	Interact with Industry	W209AB	
Saturday	11:30 a.m12:30 p.m.	Frontline Therapy in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma	Interact with Industry	W203AB	
Saturday	11:30 a.m.–12:30 p.m.	Rapid NGS: Transforming Molecular Profiling of Myeloid and Lymphoid Malignancies	Interact with Industry	W209C	
Saturday	11:30 a.m.–12:30 p.m.	Unlocking the Benefits of Time-Off Treatment with a BCL-2 Inhibitor as the Proven Backbone of Targeted, Fixed-Duration Therapy in CLL	Interact with Industry	W208AB	
Saturday	11:30 a.m12:30 p.m.	Unlocking the Potential of CAR T: When and Why it Matters	Interact with Industry	W207BC	
Saturday	12:00-1:30 p.m.	603. Lymphoid Oncogenesis: Basic - Mechanistic studies of lymphoid leukemias and lymphomas	Oral Abstract Session	W224ABEF	

Day	Time	Session Title	Program	Location	CME
Saturday	12:00–1:30 p.m.	622. Lymphomas: Translational - Non-Genetic: Insights into immune niches of CNS and Hodgkin Lymphoma via multi-omic and spatial profiling	Oral Abstract Session	Tangerine Ballroom F1	
Saturday	12:00–1:30 p.m.	624. Hodgkin Lymphomas: Clinical and Epidemiological: Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling, and Predictive Tools	Oral Abstract Session	Tangerine Ballroom F2	
Saturday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Session	W331	
Saturday	12:00–1:30 p.m.	723. Allogeneic Transplantation: Long-term Follow- up, Complications, and Disease Recurrence: Donor selection and maintenance strategies	Oral Abstract Session	Sunburst Room (W340)	
Saturday	1:30-1:45 p.m.	Fast, Fresh, Fit: Unlocking the Potential of Cell Therapy through a Transformative, Scalable, and Accessible Approach to Impact More Patients Globally	Interact with Industry	W208AB	
Saturday	2:00–3:15 p.m.	Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges	Education Program	W230	CME
Saturday	2:00-3:15 p.m.	Innovative Models of Lymphoma	Scientific Program	West Hall E2	
Saturday	2:00–3:15 p.m.	Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma	Education Program	Tangerine Ballroom F1	CME
Saturday	2:00–3:30 p.m.	501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Chromatin and transcriptional regulation in hematopoietic lineage commitment	Oral Abstract Session	W311EFGH	
Saturday	2:00-3:30 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: FL and WM	Oral Abstract Session	Tangerine Ballroom F2	
Saturday	2:00-3:30 p.m.	641. Chronic Lymphocytic Leukemia: Basic and Translational: Clonal evolution, tumor microenvironment and immunotherapy	Oral Abstract Session	W224CDGH	
Saturday	2:00-3:30 p.m.	654. Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/ Refractory Multiple Myeloma	Oral Abstract Session	West Hall D1	
Saturday	2:00–3:30 p.m.	655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma	Oral Abstract Session	West Hall E1	
Saturday	2:00-3:30 p.m.	703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and Strategies	Oral Abstract Session	Chapin Theater (W320)	
Saturday	2:00–3:30 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next Generation CAR-T Clinical Trials in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Multiple Myeloma	Oral Abstract Session	West Hall D2	
Saturday	2:00-3:30 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Acute and Chronic GVHD and Immune Reconstitution	Oral Abstract Session	W331	
Saturday	2:00-3:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Barriers and bridges: Improving access to hematologic cancer care across diverse populations	Oral Abstract Session	W224ABEF	
Saturday	3:30-3:45 p.m.	Charting Proteomic Landscapes of Relapse and Resistance in Hematological Malignancies	Interact with Industry	W208AB	
Saturday	3:30-3:45 p.m.	The ALPHA3 Trial: Improving Outcomes Through the Combination of Next-gen CAR T and Advanced MRD Testing in LBCL	Interact with Industry	W209C	
Saturday	4:00–5:15 p.m.	Between Clots and Complications: A New Era of Anticoagulation in Cancer	Education Program	West Hall D2	CME
Saturday	4:00-5:15 p.m.	Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why?	Education Program	Tangerine Ballroom F3-4	CME
Saturday	4:00-5:15 p.m.	Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician	Education Program	Tangerine Ballroom F2	CME

Day	Time	Session Title	Program	Location	CME
Saturday	4:00-5:30 p.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Bleeding: Real-World Insights Across Diverse Patient Populations	Oral Abstract Session	W307	
Saturday	4:00-5:30 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel strategies to overcome therapy resistance in AML	Oral Abstract Session	Valencia Room W415D	
Saturday	4:00-5:30 p.m.	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Beyond Genomic Resistance: epigenetics, metabolism and more	Oral Abstract Session	W230	
Saturday	4:00-5:30 p.m.	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Critical biomarkers and classifiers in B-ALL and T-ALL ontogeny and outcomes	Oral Abstract Session	W224CDGH	
Saturday	4:00–5:30 p.m.	621. Lymphomas: Translational – Molecular and Genetic: Towards Precision Medicine in Lymphoma: Multi-Omics Discovery of Prognostic and Predictive Biomarkers	Oral Abstract Session	Tangerine Ballroom F1	
Saturday	4:00-5:30 p.m.	653. Multiple Myeloma: Clinical and Epidemiological: Genomic and Cytogenetic Drivers of Prognosis in Multiple Myeloma	Oral Abstract Session	West Hall D1	
Saturday	4:00-5:30 p.m.	654. Multiple Myeloma: Pharmacologic Therapies: Are we achieving cures for multiple myeloma patients using early intervention strategies?	Oral Abstract Session	West Hall E1	
Saturday	4:00-5:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients	Oral Abstract Session	Sunburst Room (W340)	
Saturday	4:00-5:30 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Prediction Models and Novel Molecular Markers	Oral Abstract Session	Hyatt - Regency Ballroom R	
Saturday	4:00-5:30 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T and Bispecifics in Lymphoma - Real World Outcomes and Endpoints	Oral Abstract Session	W224ABEF	
Saturday	4:00-5:30 p.m.	907. Outcomes Research: Plasma Cell Disorders: Innovations in Myeloma: Therapy, Prevention & Patient-Centered Care	Oral Abstract Session	West Hall E2	
Saturday	4:00-5:35 p.m.	JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia	Scientific Program	Hyatt - Plaza Int'l HIJK	
Sunday	8:00–9:00 a.m.	A New BsAb Treatment for R/R Multiple Myeloma After 4 Prior Lines	Interact with Industry	W204BC	
Sunday	8:00-9:00 a.m.	Chemotherapy-free treatments for indolent and aggressive B-cell non-Hodgkin lymphoma	Scientific Program	West Halls B3-B4	
Sunday	9:30-10:45 a.m.	Treatment Refinement in Multiple Myeloma	Education Program	West Hall E2	CME
Sunday	9:30-11:00 a.m.	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Therapy resistance across B-cell maturation - from B-ALL to myeloma	Oral Abstract Session	W224CDGH	
Sunday	9:30–11:00 a.m.	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Emerging Treatment Paradigms in ALL	Oral Abstract Session	W224ABEF	
Sunday	9:30–11:00 a.m.	621. Lymphomas: Translational – Molecular and Genetic - Decoding Lymphomagenesis through Multiomics	Oral Abstract Session	Tangerine Ballroom F1	
Sunday	9:30–11:00 a.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Immunotherapies for Follicular Lymphoma	Oral Abstract Session	West Hall D2	
Sunday	9:30–11:00 a.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Clinical and Biological Predictors of Outcome	Oral Abstract Session	Tangerine Ballroom F2	
Sunday	9:30–11:00 a.m.	627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Targeted Agents and Chemotherapy Intensification in Aggressive B-cell Lymphomas	Oral Abstract Session	Tangerine Ballroom F3-4	

Day	Time	Session Title	Program	Location	CME
Sunday	9:30–11:00 a.m.	653. Multiple Myeloma: Clinical and Epidemiological: From Biomarkers to Biology: Evolving Risk Stratification and Disease Modeling in Multiple Myeloma	Oral Abstract Session	West Hall D1	
Sunday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational: Product biology and single-cell states shaping CAR-T cell outcomes	Oral Abstract Session	Sunburst Room (W340)	
Sunday	9:30–11:00 a.m.	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Biologic Predictors and Novel Platforms Integrating CAR T with Transplant	Oral Abstract Session	Chapin Theater (W320)	
Sunday	9:30–11:00 a.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Redefining supportive care: Development of novel safety, patient engagement, and delivery models in hematologic oncology	Oral Abstract Session	W230	
Sunday	9:30–11:00 a.m.	Leveraging Real-World Data in Multiple Myeloma for Regulatory Purposes	Special-Interest Sessions	West Hall E1	
Sunday	11:30 a.m.–12:30 p.m.	A New Treatment Option in Multiple Myeloma	Interact with Industry	W208AB	
Sunday	11:30 a.m12:30 p.m.	First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma	Interact with Industry	W203AB	
Sunday	11:30 a.m.–12:30 p.m.	Latest POLARIX Primary and 5-Year Outcomes Data	Interact with Industry	W209AB	
Sunday	11:30 a.m12:30 p.m.	Reignite the Spark: Clinical Conversations about Jaypirca (pirtobrutinib)	Interact with Industry	W204BC	
Sunday	11:30 a.m.–12:30 p.m.	Treating Fairly Rounds Lunch	Special-Interest Sessions	Hyatt - Manatee Spring	CME
Sunday	12:00–1:30 p.m.	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Optimizing risk stratification, treatment, and diagnostics of ALL in the immunotherapy era	Oral Abstract Session	W224ABEF	
Sunday	12:00–1:30 p.m.	622. Lymphomas: Translational - Non-Genetic: T cell interactions in the lymphoma microenvironment - the good and the bad	Oral Abstract Session	Tangerine Ballroom F1	
Sunday	12:00–1:30 p.m.	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Fresh insight for Cutaneous and Virus-associated TCLs	Oral Abstract Session	Tangerine Ballroom F2	
Sunday	12:00–1:30 p.m.	628. Aggressive Lymphomas: Cellular Therapies: Clinical Insights and Determinants of Resistance to Cellular Therapies in Aggressive Lymphomas	Oral Abstract Session	Tangerine Ballroom F3-4	
Sunday	12:00–1:30 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Emerging Myeloma Disease Mechanisms and Therapeutic Strategies	Oral Abstract Session	West Hall E1	
Sunday	12:00-1:30 p.m.	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Redefining diagnosis, monitoring and treatment approaches	Oral Abstract Session	West Hall E2	
Sunday	2:00-4:00 p.m.	Plenary Scientific Session	Oral Abstract Session	West Hall D2	
Sunday	4:30–5:45 p.m.	The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It	Scientific Program	Sunburst Room (W340)	
Sunday	4:30-6:00 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: The immune system's first move: early lymphocyte development to disease states	Oral Abstract Session	Hyatt - Regency Ballroom OPQ	
Sunday	4:30-6:00 p.m.	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Adapted Treatment and Immune Targeting for Frontline and Relapsed ALL in Pediatric and Adults	Oral Abstract Session	W224CDGH	
Sunday	4:30-6:00 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Novel Treatments for and Insights into Mantle Cell Lymphoma	Oral Abstract Session	Tangerine Ballroom F2	
Sunday	4:30-6:00 p.m.	628. Aggressive Lymphomas: Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas	Oral Abstract Session	Tangerine Ballroom F3-4	
Sunday	4:30-6:00 p.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL	Oral Abstract Session	W224ABEF	

Day	Time	Session Title	Program	Location	CME
Sunday	4:30-6:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic, Gene Regulatory, Immune Evolution in MM	Oral Abstract Session	West Hall E2	
Sunday	4:30-6:00 p.m.	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: New therapies and treatment goals for AL amyloidosis	Oral Abstract Session	Tangerine Ballroom F1	
Sunday	4:30-6:00 p.m.	654. Multiple Myeloma: Pharmacologic Therapies: Bi, Tri and Beyond: Innovations in Bispecific and Trispecific Antibodies for Multiple Myeloma	Oral Abstract Session	West Hall E1	
Sunday	4:30-6:00 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Quality of Life and Supportive Care in Lymphoid Malignancies	Oral Abstract Session	W230	
Sunday	4:30-6:00 p.m.	907. Outcomes Research: Plasma Cell Disorders: Therapeutic Toxicity in Multiple Myeloma: Real-World Evidence and Clinical Approaches	Oral Abstract Session	West Hall D1	
Sunday	4:30-6:00 p.m.	908. Outcomes Research: Myeloid Malignancies: Real- World Experiences	Oral Abstract Session	W414CD	
Monday	8:00–9:00 a.m.	Unlocking the Potential for a Bispecific Antibody in 3L+DLBCL and 3L+FL	Interact with Industry	W209C	
Monday	10:30–11:45 a.m.	Asparaginase in ALL/LBL: Balancing the Risk/Benefit of New Efficacious Preparations	Education Program	W230	CME
Monday	10:30–11:45 a.m.	Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally	Scientific Program	Tangerine Ballroom F2	
Monday	10:30–11:45 a.m.	Invasion of the Immunotherapies: Where We Are and Where We Are Going in Leukemia, Lymphoma, and Myeloma	Education Program	West Hall D2	CME
Monday	10:30-11:45 a.m.	Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit	Education Program	West Hall D1	CME
Monday	10:30 a.m12:00 p.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Innovations in Thrombosis and Bleeding: Diagnostics, Therapeutics, and Predictive Modeling	Oral Abstract Session	W304ABCD	
Monday	10:30 a.m12:00 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel targets and drugs	Oral Abstract Session	Valencia Room W415BC	
Monday	10:30 a.m12:00 p.m.	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Predicting and improving outcomes in common and rare subgroups of pediatric ALL	Oral Abstract Session	W224CDGH	
Monday	10:30 a.m.–12:00 p.m.	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell Lymphoma	Oral Abstract Session	Tangerine Ballroom F1	
Monday	10:30 a.m.–12:00 p.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-world data to assess CAR outcomes and frailty	Oral Abstract Session	Tangerine Ballroom F3-4	
Monday	10:30 a.m.–12:00 p.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: MRD Guided Therapy and Emergence of Resistance	Oral Abstract Session	W224ABEF	
Monday	10:30 a.m12:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: T Cell-Redirecting Therapies in Myeloma: Novel therapeutic strategies and biology	Oral Abstract Session	West Hall E1	
Monday	10:30 a.m12:00 p.m.	702. CAR-T Cell Therapies: Basic and Translational: Mechanisms of CAR-T cell toxicity and persistence	Oral Abstract Session	W331	
Monday	10:30 a.m.–12:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging CAR-T Cell Therapies for Acute Leukemias and Autoimmune Diseases	Oral Abstract Session	Valencia Room W415D	
Monday	10:30 a.m.–12:00 p.m.	907. Outcomes Research: Plasma Cell Disorders: Special Populations in Plasma Cell Disorders: Efficacy and Safety of Therapies in Real-World Settings	Oral Abstract Session	West Hall E2	
Monday	12:15–1:15 p.m.	Making the Case for Early Use of CAR-T Therapy in Multiple Myeloma	Interact with Industry	W209AB	
Monday	12:15–1:15 p.m.	MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients	Interact with Industry	W208AB	

Day	Time	Session Title	Program	Location	CME
Monday	12:15–1:15 p.m.	Trainee Didactic Session: Outcomes Research in Hematology	Trainee Activities and Services	W308	
Monday	12:30-1:30 p.m.	Leukemia in Latin America: Bridging Gaps in Genetics, Access, and Innovation	Scientific Program	West Halls B3-B4	
Monday	2:45-4:00 p.m.	B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders?	Education Program	West Hall D2	CME
Monday	2:45-4:00 p.m.	Epigenomic Frontiers in the Diagnosis of Hematological Malignancies	Scientific Program	W230	
Monday	2:45-4:00 p.m.	Genomics in Pediatric Acute Leukemia Risk Stratification	Education Program	W224CDGH	CME
Monday	2:45-4:00 p.m.	Joint Session with ASPHO: Transition to Adult Care in Malignant and Classical Hematology	Education Program	Hyatt - Regency Ballroom S	CME
Monday	2:45-4:00 p.m.	Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR-Ts, allo-HSCT - How, When, and Why?	Education Program	West Hall E2	CME
Monday	2:45-4:15 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL	Oral Abstract Session	Tangerine Ballroom F1	
Monday	2:45-4:15 p.m.	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: From bench to bedside and retrospective studies to inform treatment consideration in TCL	Oral Abstract Session	Tangerine Ballroom F2	
Monday	2:45-4:15 p.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-World data on clinical predictors of outcome	Oral Abstract Session	Tangerine Ballroom F3-4	
Monday	2:45-4:15 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Enhancing Immune Therapy in MM	Oral Abstract Session	West Hall D1	
Monday	2:45-4:15 p.m.	653. Multiple Myeloma: Clinical and Epidemiological: Novel Baseline and Dynamic Risk Factors in Multiple Myeloma	Oral Abstract Session	West Hall E1	
Monday	2:45-4:15 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Optimizing CAR T-Cell Therapy: Focus on Adjuvant Strategies and Toxicity	Oral Abstract Session	Sunburst Room (W340)	
Monday	2:45-4:15 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond	Oral Abstract Session	W331	
Monday	2:45-4:15 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Enhancing Clinical Decision- Making with Next-Generation Molecular and Cellular Technologies	Oral Abstract Session	Hyatt - Regency Ballroom R	
Monday	2:45-4:15 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Novel topics in CAR-T and T-cell engager therapies	Oral Abstract Session	W224ABEF	
Monday	2:45-4:15 p.m.	908. Outcomes Research: Myeloid Malignancies: Health Disparities and Patient-Centred Care	Oral Abstract Session	W414CD	
Monday	4:30-5:45 p.m.	Monoclonal Gammopathies of Clinical Significance	Education Program	West Hall E2	CME
Monday	4:30-5:45 p.m.	Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias	Scientific Program	W224CDGH	
Monday	4:30-6:00 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Follicular Lymphoma	Oral Abstract Session	Tangerine Ballroom F2	
Monday	4:30-6:00 p.m.	628. Aggressive Lymphomas: Cellular Therapies: Emerging Approaches to Enhance Cellular Therapies and Real World Outcomes in Aggressive Lymphomas	Oral Abstract Session	Tangerine Ballroom F3-4	
Monday	4:30-6:00 p.m.	629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Improving Outcomes in Rare Large Cell Lymphomas	Oral Abstract Session	Tangerine Ballroom F1	
Monday	4:30-6:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Determinants of Immunotherapy Response in Multiple Myeloma	Oral Abstract Session	West Hall E1	

Day	Time	Session Title	Program	Location	CME
Monday	4:30-6:00 p.m.	653. Multiple Myeloma: Clinical and Epidemiological: Direct from podium to clinic	Oral Abstract Session	West Hall D1	
Monday	4:30-6:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Advancing Cell Therapies in T Cell Malignancies and AML	Oral Abstract Session	Valencia Room W415BC	
Monday	4:30-6:00 p.m.	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization	Oral Abstract Session	Hyatt - Regency Ballroom R	
Monday	4:30-6:00 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects	Oral Abstract Session	W331	
Monday	4:30-6:00 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Innovations to address real- world barriers and optimize delivery of CAR-T and bispecific antibody therapies	Oral Abstract Session	W224ABEF	
Monday	4:30-6:00 p.m.	903. Health Services and Quality Improvement: Myeloid Malignancies: Where smarter care begins: technological innovations and quality improvement in myeloid malignancies	Oral Abstract Session	W314	

METABOLIC DISORDERS

METABOLIC DISORDERS

Day	Time	Session Title	Program	Location	CME
Friday	3:00-6:00 p.m.	Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management	Interact with Industry	Hyatt - Plaza Int'l HIJK	CME
Saturday	9:30–10:45 a.m.	Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy	Scientific Program	Hyatt - Regency Ballroom OPQ	
Saturday	9:30–11:00 a.m.	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN	Oral Abstract Session	W414AB	
Saturday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Session	W331	
Saturday	4:00-5:30 p.m.	801. Gene Therapies: Advances in Gene Therapy for Blood Disorders	Oral Abstract Session	Chapin Theater (W320)	
Saturday	4:00-5:30 p.m.	ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia	Special-Interest Sessions	Hyatt - Regency Ballroom OPQ	CME
Sunday	9:30–11:00 a.m.	301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders	Oral Abstract Session	W304EFGH	
Sunday	9:30–11:00 a.m.	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets, leukocytes, and endothelium in thrombotic and vascular disease	Oral Abstract Session	W307	
Sunday	12:00–1:30 p.m.	102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Erythropoiesis, Inflammation and Hematologic Recovery: The Iron and Heme Drama Unfolds	Oral Abstract Session	W311EFGH	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non- Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing	Oral Abstract Session	W304ABCD	
Monday	10:30 a.m.–12:00 p.m.	112. Thalassemia and Globin Gene Regulation: Murine models and a clinical approach to reduce toxicity, modulate hemoglobin F and improve outcomes in thalassemia	Oral Abstract Session	W311ABCD	
Monday	2:45-4:00 p.m.	Biology-Based Management of Iron Toxicity and Overload in Hematology Practice	Education Program	Hyatt - Regency Ballroom OPQ	CME
Monday	4:30-6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps	Oral Abstract Session	W307	

Notes:


Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Acute Myeloid Leukemia	Interact with Industry	Hyatt - Regency TUV	CME
Friday	7:00–10:00 a.m.	MASTER MDS for Enhanced Patient Care: \underline{M} odern \underline{A} dvances with \underline{ST} andard and \underline{E} merging, \underline{R} isk-adapted Treatment	Interact with Industry	Hyatt - Plaza Int'l DEFG	CME
Friday	7:00–10:00 a.m.	Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes	Interact with Industry	Valencia Room W415D	CME
Friday	7:00–10:00 a.m.	Momentum in MDS: Making Progress and Shaping a Better Future	Interact with Industry	Tangerine Ballroom F2	CME
Friday	7:00–10:00 a.m.	Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data	Interact with Industry	W224CDGH	CME
Friday	11:00 a.m.–2:00 p.m.	A Master Class in CP-CML: New Agents, Treatment Goals, and Clinical Challenges	Interact with Industry	Hyatt - Regency Ballroom R	CME
Friday	11:00 a.m.–2:00 p.m.	Cases & Conversations™ Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice	Interact with Industry	W224ABEF	CME
Friday	11:00 a.m2:00 p.m.	Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies	Interact with Industry	Tangerine Ballroom F2	CME
Friday	3:00-6:00 p.m.	BRINGING EMERGING TREATMENTS TO ALL PATIENTS: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices	Interact with Industry	Valencia Room W415BC	CME
Friday	3:00-6:00 p.m.	Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations	Interact with Industry	Tangerine Ballroom F1	CME
Friday	3:00-6:00 p.m.	Cracking the Code: Menin Inhibitors and the Next Frontier in AML Treatment	Interact with Industry	W331	CME
Saturday	8:00–9:00 a.m.	Rethinking Control in Polycythemia Vera - Uncovering the Clinical Unmet Needs and Potential to Address Them with Emerging Therapies	Interact with Industry	W204BC	
Saturday	9:30-11:00 a.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Mechanistic Insights into Sickle Cell Pathobiology and Disease Progression	Oral Abstract Session	W311ABCD	
Saturday	9:30–11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Biological and Clinical Nuances in Patient Outcomes	Oral Abstract Session	Valencia Room W415BC	
Saturday	9:30–11:00 a.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies: Frontline treatment with intensive or lower- intensity regimens	Oral Abstract Session	Valencia Room W415A	
Saturday	9:30–11:00 a.m.	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN	Oral Abstract Session	W414AB	
Saturday	9:30–11:00 a.m.	632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Decoding the Molecular Drivers of response and resistance	Oral Abstract Session	Valencia Room W415D	
Saturday	9:30–11:00 a.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome	Oral Abstract Session	W414CD	
Saturday	9:30–11:00 a.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications	Oral Abstract Session	Chapin Theater (W320)	

Day	Time	Session Title	Program	Location	СМЕ
Saturday	9:30–11:00 a.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Transformative Al and Omics Approaches in Hematologic Malignancies	Oral Abstract Session	Hyatt - Regency Ballroom R	
Saturday	9:30–11:00 a.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Clinical decision making and supportive care	Oral Abstract Session	W230	
Saturday	11:15 a.m.–12:15 p.m.	Career Development Lunch	Trainee Activities and Services	Hyatt - Windemere Ballroom	
Saturday	11:30 a.m.–12:30 p.m.	Hear Jen's Journey, Then Explore the Data	Interact with Industry	W204BC	
Saturday	11:30 a.m12:30 p.m.	Rapid NGS: Transforming Molecular Profiling of Myeloid and Lymphoid Malignancies	Interact with Industry	W209C	
Saturday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Session	W331	
Saturday	12:00–1:30 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Donor selection and maintenance strategies	Oral Abstract Session	Sunburst Room (W340)	
Saturday	2:00-3:15 p.m.	Down the Rabbit Hole: An Update on Histiocytic Disorders	Education Program	Hyatt - Regency Ballroom OPQ	CME
Saturday	2:00-3:30 p.m.	201. Granulocytes, Monocytes, and Macrophages: Histiocytic and granulocytic Disorders	Oral Abstract Session	W312	
Saturday	2:00-3:30 p.m.	501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Chromatin and transcriptional regulation in hematopoietic lineage commitment	Oral Abstract Session	W311EFGH	
Saturday	2:00-3:30 p.m.	602. Myeloid Oncogenesis: Basic: Identification of new vulnerabilities in therapy-resistant AML	Oral Abstract Session	W414CD	
Saturday	2:00-3:30 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Redefining AML: Genetic, Phenotypic and Response-Based Insights	Oral Abstract Session	W414AB	
Saturday	2:00-3:30 p.m.	636. Myelodysplastic Syndromes: Basic and Translational: Innovative Approaches to Target Novel Vulnerabilities in MDS Pathobiology	Oral Abstract Session	Valencia Room W415D	
Saturday	2:00-3:30 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes	Oral Abstract Session	Valencia Room W415BC	
Saturday	2:00-3:30 p.m.	703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and Strategies	Oral Abstract Session	Chapin Theater (W320)	
Saturday	2:00-3:30 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Acute and Chronic GVHD and Immune Reconstitution	Oral Abstract Session	W331	
Saturday	2:00-3:30 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: MRD Assays and Novel Drug Discovery Pipelines	Oral Abstract Session	Hyatt - Regency Ballroom R	
Saturday	2:00-3:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Barriers and bridges: Improving access to hematologic cancer care across diverse populations	Oral Abstract Session	W224ABEF	
Saturday	2:00-3:30 p.m.	908. Outcomes Research: Myeloid Malignancies: Real- World Outcomes in AML	Oral Abstract Session	Valencia Room W415A	
Saturday	3:30-3:45 p.m.	Charting Proteomic Landscapes of Relapse and Resistance in Hematological Malignancies	Interact with Industry	W208AB	
Saturday	4:00-5:15 p.m.	Between Clots and Complications: A New Era of Anticoagulation in Cancer	Education Program	West Hall D2	CME
Saturday	4:00-5:30 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel strategies to overcome therapy resistance in AML	Oral Abstract Session	Valencia Room W415D	
Saturday	4:00-5:30 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel AML Biomarkers: Mechanisms, Mutations, and Targets	Oral Abstract Session	Valencia Room W415BC	

Day	Time	Session Title	Program	Location	CME
Saturday	4:00-5:30 p.m.	619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: From Detection to Decision: MRD as the Compass in AML	Oral Abstract Session	Valencia Room W415A	
Saturday	4:00-5:30 p.m.	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Drivers, vulnerabilities and resistance in CML and MPN	Oral Abstract Session	W414AB	
Saturday	4:00-5:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients	Oral Abstract Session	Sunburst Room (W340)	
Saturday	4:00-5:30 p.m.	801. Gene Therapies: Advances in Gene Therapy for Blood Disorders	Oral Abstract Session	Chapin Theater (W320)	
Saturday	4:00-5:30 p.m.	802. Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies?	Oral Abstract Session	W331	
Saturday	4:00-5:30 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Prediction Models and Novel Molecular Markers	Oral Abstract Session	Hyatt - Regency Ballroom R	
Saturday	4:00-5:30 p.m.	ASH Clinical Practice Guidelines on Myelofibrosis	Special-Interest Sessions	W414CD	CME
Saturday	4:00-5:35 p.m.	JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia	Scientific Program	Hyatt - Plaza Int'l HIJK	
Sunday	9:30-10:45 a.m.	What's New and Current in the World of Bone Marrow Failure	Education Program	Hyatt - Regency Ballroom OPQ	CME
Sunday	9:30–11:00 a.m.	301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders	Oral Abstract Session	W304EFGH	
Sunday	9:30-11:00 a.m.	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets, leukocytes, and endothelium in thrombotic and vascular disease	Oral Abstract Session	W307	
Sunday	9:30-11:00 a.m.	602. Myeloid Oncogenesis: Basic: Targeting the NPM1/KMT2A/Menin axis	Oral Abstract Session	W314	
Sunday	9:30–11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Lessons from across the age spectrum	Oral Abstract Session	Valencia Room W415BC	
Sunday	9:30–11:00 a.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: AML Biomarkers in Action: Prognosis, Risk, and Real-World Insights	Oral Abstract Session	Valencia Room W415A	
Sunday	9:30-11:00 a.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Between a Rock and a Ropeg - Innovative Therapies for MPNs	Oral Abstract Session	W414AB	
Sunday	9:30-11:00 a.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML	Oral Abstract Session	Valencia Room W415D	
Sunday	9:30-11:00 a.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Factors Influencing Transplant Outcomes	Oral Abstract Session	W331	
Sunday	9:30–11:00 a.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Redefining supportive care: Development of novel safety, patient engagement, and delivery models in hematologic oncology	Oral Abstract Session	W230	
Sunday	9:30-11:00 a.m.	Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults	Special-Interest Sessions	W414CD	CME
Sunday	9:30-11:05 a.m.	JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging	Scientific Program	W312	
Sunday	12:00–1:30 p.m.	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Redefining diagnosis, monitoring and treatment approaches	Oral Abstract Session	West Hall E2	
Sunday	12:00–1:30 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and elucidating relapse	Oral Abstract Session	W331	
Sunday	12:00-1:30 p.m.	908. Outcomes Research: Myeloid Malignancies: Treatment and Outcomes in the Real-World	Oral Abstract Session	W414CD	
Sunday	12:30-1:30 p.m.	ASH-EHA Joint Symposium	Marquee Sessions	West Hall D2	CME

Day	Time	Session Title	Program	Location	СМЕ
Sunday	2:00-4:00 p.m.	Plenary Scientific Session	Oral Abstract Session	West Hall D2	
Sunday	4:30-5:45 p.m.	The Changing Face of Chronic Myelogenous Leukemia	Education Program	W414AB	CME
Sunday	4:30-6:00 p.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: Novel approaches in suppressing clonal hematopoiesis	Oral Abstract Session	W312	
Sunday	4:30-6:00 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance mechanisms and targeting approaches	Oral Abstract Session	Valencia Room W415D	
Sunday	4:30-6:00 p.m.	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and chemotherapy combinations in AML	Oral Abstract Session	Chapin Theater (W320)	
Sunday	4:30-6:00 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis	Oral Abstract Session	Valencia Room W415BC	
Sunday	4:30-6:00 p.m.	636. Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression	Oral Abstract Session	Valencia Room W415A	
Sunday	4:30-6:00 p.m.	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: New therapies and treatment goals for AL amyloidosis	Oral Abstract Session	Tangerine Ballroom F1	
Sunday	4:30-6:00 p.m.	908. Outcomes Research: Myeloid Malignancies: Real- World Experiences	Oral Abstract Session	W414CD	
Monday	8:00-9:00 a.m.	Introducing a Therapeutic Option in Relapsed/Refractory Acute Leukemia	Interact with Industry	W208AB	
Monday	10:30–11:45 a.m.	Targeted Therapy for AML (Triplets and More)	Education Program	W414CD	CME
Monday	10:30 a.m.–12:00 p.m.	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Inheritance to Innovation	Oral Abstract Session	Hyatt - Plaza Int'l HIJK	
Monday	10:30 a.m.–12:00 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel targets and drugs	Oral Abstract Session	Valencia Room W415BC	
Monday	10:30 a.m12:00 p.m.	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin inhibitors and FLT3 inhibitors in AML	Oral Abstract Session	Chapin Theater (W320)	
Monday	10:30 a.m.–12:00 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Decoding the Immunopathobiology of Acute Myeloid Leukemia	Oral Abstract Session	W414AB	
Monday	10:30 a.m12:00 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Lower risk Myelodysplastic Syndromes and Myelodysplastic/ Myeloproliferative Neoplasms	Oral Abstract Session	Valencia Room W415A	
Monday	10:30 a.m.–12:00 p.m.	702. CAR-T Cell Therapies: Basic and Translational: Mechanisms of CAR-T cell toxicity and persistence	Oral Abstract Session	W331	
Monday	10:30 a.m.–12:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging CAR-T Cell Therapies for Acute Leukemias and Autoimmune Diseases	Oral Abstract Session	Valencia Room W415D	
Monday	10:30 a.m.–12:00 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Clinical and Translational Insights	Oral Abstract Session	Sunburst Room (W340)	
Monday	12:15–1:15 p.m.	First-Line Treatment Option for Anemia in Lower-Risk MDS COMMANDS Trial Overview	Interact with Industry	W209C	
Monday	12:30–1:30 p.m.	Leukemia in Latin America: Bridging Gaps in Genetics, Access, and Innovation	Scientific Program	West Halls B3-B4	
Monday	1:30-2:30 p.m.	Ernest Beutler Lecture and Prize	Marquee Sessions	West Hall D2	CME
Monday	2:45-4:00 p.m.	Biology-Based Management of Iron Toxicity and Overload in Hematology Practice	Education Program	Hyatt - Regency Ballroom OPQ	CME
Monday	2:45-4:00 p.m.	Mechanisms that Direct and Derail Lineage-Specific Gene Expression Programs in Myelopoiesis	Scientific Program	Valencia Room W415D	
Monday	2:45-4:15 p.m.	501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism and signaling in hematopoietic stem cell fate	Oral Abstract Session	W311EFGH	
Monday	2:45-4:15 p.m.	506. Bone Marrow Microenvironment: The microenvironment in regenerative and pre/malignant hematopoiesis	Oral Abstract Session	Hyatt - Plaza Int'l HIJK	

Day	Time	Session Title	Program	Location	CME
Monday	2:45-4:15 p.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Optimizing Standards of Care	Oral Abstract Session	Valencia Room W415A	
Monday	2:45-4:15 p.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies: Pediatric, adolescent and young adult AML	Oral Abstract Session	Valencia Room W415BC	
Monday	2:45-4:15 p.m.	632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Therapeutic agents to enhance patient outcomes	Oral Abstract Session	Chapin Theater (W320)	
Monday	2:45-4:15 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Beyond JAK Inhibition - Therapeutic Innovation and Transplant Strategies in Myelofibrosis	Oral Abstract Session	W414AB	
Monday	2:45-4:15 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond	Oral Abstract Session	W331	
Monday	2:45-4:15 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Enhancing Clinical Decision-Making with Next-Generation Molecular and Cellular Technologies	Oral Abstract Session	Hyatt - Regency Ballroom R	
Monday	2:45-4:15 p.m.	908. Outcomes Research: Myeloid Malignancies: Health Disparities and Patient-Centred Care	Oral Abstract Session	W414CD	
Monday	4:30-6:00 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Erythroid differentiation	Oral Abstract Session	W311EFGH	
Monday	4:30-6:00 p.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: New insights into inflammatory drivers of normal and clonal hematopoiesis	Oral Abstract Session	W312	
Monday	4:30-6:00 p.m.	602. Myeloid Oncogenesis: Basic: New insights in clonal evolution and models of disease	Oral Abstract Session	W414CD	
Monday	4:30-6:00 p.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: AML Medley: Mutations, complications, classifications	Oral Abstract Session	W414AB	
Monday	4:30-6:00 p.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies: Combination regimens and targeted therapies	Oral Abstract Session	Chapin Theater (W320)	
Monday	4:30-6:00 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Drivers and Mast Cells and Blasts, Oh My! - Insights and Treatments for MPNs and Mastocytosis.	Oral Abstract Session	West Hall D2	
Monday	4:30-6:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Determinants of Immunotherapy Response in Multiple Myeloma	Oral Abstract Session	West Hall E1	
Monday	4:30-6:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Advancing Cell Therapies in T Cell Malignancies and AML	Oral Abstract Session	Valencia Room W415BC	
Monday	4:30-6:00 p.m.	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization	Oral Abstract Session	Hyatt - Regency Ballroom R	
Monday	4:30-6:00 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects	Oral Abstract Session	W331	
Monday	4:30-6:00 p.m.	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Precision AML Care; Reducing Relapse and Enhancing Survival	Oral Abstract Session	Valencia Room W415A	
Monday	4:30-6:00 p.m.	903. Health Services and Quality Improvement: Myeloid Malignancies: Where smarter care begins: technological innovations and quality improvement in myeloid malignancies	Oral Abstract Session	W314	
Tuesday	9:45–11:15 a.m.	Presidential Symposium	Marquee Sessions	West Hall D2	CME



LYNOZYFICTM (linvoseltamab-gcpt) injection, for intravenous use Brief Summary of Prescribing Information

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, INCLUDING IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

- Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur
 in patients receiving LYNOZYFIC. Initiate treatment with LYNOZYFIC step-up dosing to
 reduce the risk of CRS. Manage CRS, withhold LYNOZYFIC until CRS resolves, and modify the
 next dose or permanently discontinue based on severity [see Dosage and Administration
 (2.2, 2.4, 2.5) and Warnings and Precautions (5.1)].
- Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS during treatment. Manage neurologic toxicity, including ICANS, withhold LYNOZYFIC until neurologic toxicity, including ICANS resolves, and modify the next dose or permanently discontinue based on severity [see Dosage and Administration (2.2, 2.4, 2.5) and Warnings and Precautions (5.2)].
- Because of the risk of CRS and neurologic toxicity, including ICANS, LYNOZYFIC is available
 only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)
 called the LYNOZYFIC REMS [see Warnings and Precautions (5.3)].

1 INDICATIONS AND USAGE

LYNOZYFIC is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Cytokine Release Syndrome (CRS)

LYNOZYFIC can cause cytokine release syndrome (CRS), which can be serious or life-threatening. In LINKER-MM1, CRS occurred in 46% (54/117) of patients who received LYNOZYFIC at the recommended dose, with Grade 1 CRS occurring in 35% (41/117) of patients, Grade 2 in 10% (12/117), and Grade 3 in 0.9% (1/117) [see Adverse Reactions (6.1)]. Thirty-eight percent (45/117) of patients had CRS following step-up dose 1, including 1 patient who experienced Grade 3 CRS; 8% (9/117) had an initial CRS event following a subsequent dose. Seventeen percent (19/113) of patients developed CRS after step-up dose 2, 10% (11/111) developed CRS after the first full 200 mg dose of LYNOZYFIC, and 3.6% (4/110) developed CRS after the second full dose. Recurrent CRS occurred in 20% (23/117) of patients. The median time to onset of CRS from the end of infusion was 11 (range: -1 to 184) hours after the most recent dose with a median duration of 15 (range: 1 to 76) hours.

Clinical signs and symptoms of CRS included, but were not limited to pyrexia, chills, hypoxia, tachycardia, and hypotension.

Administer pretreatment medications and initiate therapy according to LYNOZYFIC step-up dosing to reduce the incidence and severity of CRS [see Dosage and Administration (2.2) and Dosage and Administration (2.3)].

Monitor patients for signs and symptoms of CRS after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur.

At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care; withhold LYNOZYFIC until CRS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity [see Dosage and Administration (2.5)].

Infusion Related Reactions

Infusion-related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. In the patients who were treated with the recommended step-up dosing regimen and pretreatment medications [see Dosage and Administration (2.2) and Dosage and Administration (2.3)], the rate of IRR was 9% [11/117 including Grade 2 IRR (4.3%) and Grade 3 IRR (1.7%)]. For IRR, interrupt or slow the rate of infusion or permanently discontinue LYNOZYFIC based on severity of reaction [see Dosage and Administration (2.5)].

LYNOZYFIC is available only through a restricted program under a REMS [see Warnings and Precautions (5.3)].

5.2 Neurologic Toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome

LYNOZYFIC can cause serious or life-threatening neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS) [see Adverse Reactions (6.1)].

In LINKER-MM1, neurologic toxicity occurred in 54% of patients, with Grade 3 or 4 neurologic toxicity occurring in 8% at the recommended dose [see Adverse Reactions (6.1)]. Neurologic toxicities included ICANS, depressed level of consciousness, encephalopathy, and toxic encephalopathy.

ICANS occurred in 8% of patients who received LYNOZYFIC with the recommended dosing regimen, including Grade 3 events in 2.6%. Most patients experienced ICANS following step-up dose 1 (5%). Two patients (1.8%) experienced initial ICANS following step-up dose 2 and one patient developed the first occurrence of ICANS following a subsequent full dose of LYNOZYFIC. Recurrent ICANS occurrent in one patient. The median time to onset of ICANS was 1 (range: 1 to 4) day after the most recent dose with a median duration of 2 (range: 1 to 11) days. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.

The most common clinical signs and symptoms of ICANS are confusion, depressed level of consciousness, and lethargy. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate the patient; provide supportive therapy and consider further management per current practice guidelines. Withhold LYNOZYFIC until ICANS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity [see Dosage and Administration (2.5)]. Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity occur at any time.

Due to the potential for neurologic toxicity, including ICANS, patients receiving LYNOZYFIC are at risk of confusion and depressed consciousness. Advise patients to refrain from driving, or operating heavy or potentially dangerous machinery, for 48 hours after completion of each of the step-up doses [see Dosage and Administration (2.2)] and in the event of new onset of any neurological symptoms, until symptoms resolve.

LYNOZYFIC is available only through a restricted program under a REMS [see Warnings and Precautions (5.3)].

5.3 LYNOZYFIC REMS

LYNOZYFIC is available only through a restricted program under a REMS called the LYNOZYFIC REMS because of the risks of CRS and neurologic toxicity, including ICANS [see Warnings and Precautions (5.1, 5.2)].

Notable requirements of the LYNOZYFIC REMS include the following:

- · Prescribers must be certified with the program by enrolling and completing training.
- Prescribers must counsel patients receiving LYNOZYFIC about the risk of CRS and neurologic toxicity, including ICANS, and provide patients with LYNOZYFIC Patient Wallet Card.
- Pharmacies and healthcare settings that dispense LYNOZYFIC must be certified with the LYNOZYFIC REMS program and must verify prescribers are certified through the LYNOZYFIC REMS program.
- Wholesalers and distributors must only distribute LYNOZYFIC to certified pharmacies or healthcare settings.

Further information about the LYNOZYFIC REMS program is available at LynozyficREMS.com or by telephone at 1-855-212-6391.

5.4 Infections

LYNOZYFIC can cause serious, life-threatening, or fatal infections. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, serious infections, including opportunistic infections, occurred in 42% of patients, with Grade 3 or 4 infections in 38% and fatal infections in 4% [see Adverse Reactions (6.1)]. The most common serious infection reported (>10%) were pneumonia and sepsis. Two cases of progressive multifocal leukoencephalopathy (PML) occurred in patients receiving LYNOZYFIC.

Monitor patients for signs and symptoms of infection and immunoglobulin levels prior to and during treatment with LYNOZYFIC and treat appropriately. Administer prophylactic antimicrobials, antibiotics, antifungals, antivirals, vaccines, and subcutaneous or intravenous immunoglobulin (IVIG) according to guidelines, including prophylaxis for PJP and herpesviruses *[see Dosage and Administration (2.3)]*.

Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity of the infection [see Dosage and Administration (2.5)].

5.5 Neutropenia

LYNOZYFIC can cause neutropenia and febrile neutropenia.

In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, decreased neutrophil count occurred in 62% of patients with Grade 3 or 4 decreased neutrophil count in 47%. Febrile neutropenia occurred in 8% of patients [see Adverse Reactions (6.1)].

Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local guidelines. Monitor patients with neutropenia for signs of infection. Withhold LYNOZYFIC based on severity [see Dosage and Administration (2.5)].

5.6 Hepatotoxicity

LYNOZYFIC can cause hepatotoxicity.

In LINKER-MM1, elevated ALT occurred in 46% of patients, with Grade 3 or 4 ALT elevation occurring in 6%; elevated AST occurred in 61% of patients, with Grade 3 or 4 AST elevation occurring in 10% of patients who received the recommended dose. Grade 3 or 4 total bilirubin elevations occurred in 1.7% of patients [see Adverse Reactions (6.1)]. Liver enzyme elevation can occur with or without concurrent CRS.

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity [see Dosage and Administration (2.5)].

5.7 Embryo-Fetal Toxicity

Based on its mechanism of action, LYNOZYFIC may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LYNOZYFIC and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Cytokine Release Syndrome [see Warnings and Precautions (5.1)]
- Neurologic Toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome [see Warnings and Precautions (5.2)]
- Infections [see Warnings and Precautions (5.4]
- Neutropenia [see Warnings and Precautions (5.5)]
- Hepatotoxicity [see Warnings and Precautions (5.6)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Relapsed or Refractory Multiple Myeloma

The safety of LYNOZYFIC was evaluated in LINKER-MM1 [see Clinical Studies (14]]. Patients (n=117) received a single step-up dose of 5 mg on Day 1 and 25 mg on Day 8, and the first treatment dose of 200 mg on Day 15. Patients then received 200 mg intravenously once weekly from Week 4 to Week 13, followed by 200 mg every 2 weeks from Week 14. In the Phase 2 portion of the study, patients who achieved and maintained VGPR or better at or after Week 24 and received at least 17 doses of 200 mg were able to receive every 4-week dosing. The median duration of treatment was 47 weeks (range 1, 151); 55% of patients were exposed for 9 months or longer and 36% were exposed for 1 year or longer.

The median age of patients who received LYNOZYFIC was 70 years (range: 37 to 91 years); 55% were male; 71% were White, 17% were Black or African American, and 9% were Asian.

Serious adverse reactions occurred in 74% of patients who received LYNOZYFIC. Serious adverse reactions that occurred in >5% of patients included cytokine release syndrome (27%), pneumonia (13%), COVID-19 (7%), and acute kidney injury (5%). Fatal adverse reactions occurred in 7% of patients, and included sepsis (3.4%), chronic kidney disease (0.9%), pneumonia (0.9%), tumor lysis syndrome (0.9%), and encephalopathy (0.9%).

Permanent discontinuation of LYNOZYFIC due to adverse reactions occurred in 16% of patients. Adverse reactions leading to discontinuation that occurred in at least 2 patients included sepsis, pneumonia, and encephalopathy.

Dosage interruptions or delays of LYNOZYFIC due to adverse reactions occurred in 74% of patients. Adverse reactions which required a dosage interruption or delay in >10% of patients included neutropenia (29%), upper respiratory tract infection (18%), pneumonia (15%), and COVID-19 infection (11%).

The most common adverse reactions (≥20%) were musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea. The most common Grade 3 to 4 laboratory abnormalities (≥30%) were decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count.

Table 7 summarizes the adverse reactions in LINKER-MM1.

Table 7: Adverse Reactions (≥10%) in Patients With Relapsed or Refractory Multiple Myeloma Who Received LYNOZYFIC in LINKER-MM1

Advance December	LYNOZYFIC (N=117)	
Adverse Reaction	All Grades (%)	Grade 3 or 4 (%)
Musculoskeletal and connective tissue disorders		
Musculoskeletal pain*	53	3.4#
Immune system disorders		
Cytokine release syndrome	46	0.9#
Hypogammaglobulinemia	13	0.9#
Respiratory, thoracic and mediastinal disorders		
Cough*	39	0
Dyspnea*	21	0.9#
Nasal congestion	16	0
Infections and infestations		
Upper respiratory tract infection*	35	6#
Pneumonia ^{a±}	28	21
COVID-19	17	5
Urinary tract infections*	16	8#
Sepsis	10	6
Gastrointestinal disorders		
Diarrhea	35	1.7#
Nausea	23	0
Vomiting	19	0
Constipation	17	0
General disorders and administration site conditions		
Fatigue*	34	0
Edema*	19	0.9#
Pyrexia	17	0
Nervous system disorders		
Headache*	22	0.9#
Encephalopathy ^{±,b}	18	3.4
Sensory Neuropathy*	13	0.9
Metabolism and nutrition disorders		
Decreased appetite	15	0.9#
Skin and subcutaneous tissue disorders		
Rash ^c	15	1.7#
Psychiatric disorders		
Insomnia	13	0
Vascular disorders		
Hypertension	10	4.3#

^{*}Includes other related terms.

Clinically significant adverse reactions that occurred in <10% of patients treated with LYNOZYFIC included IRR, motor dysfunction, febrile neutropenia, ICANS, CMV infection, and PML.

Table 8: Select Laboratory Abnormalities (≥5% for Grade 3 or 4) That Worsened From Baseline in Patients With Multiple Myeloma Treated With LYNOZYFIC in LINKER-MM1

Laboratory Abnormality ^a	LYNOZYFIC (N=117) ^b	
	All Grades (%)	Grade 3 or 4 (%)
Hematology	<u>'</u>	
Lymphocyte count decreased	97	92
Hemoglobin decreased	72	42
Platelet count decreased	64	19
White blood cell count decreased	63	31
Neutrophil count decreased	62	47
Chemistry	·	
Aspartate aminotransferase increased	61	10

Table 8: Select Laboratory Abnormalities (≥5% for Grade 3 or 4) That Worsened From Baseline in Patients With Multiple Myeloma Treated With LYNOZYFIC in LINKER-MM1 (continued)

Laboratory Abnormality ^a	LYNOZYFIC (N=117) ^b	
	All Grades (%)	Grade 3 or 4 (%)
Phosphorus decreased	55	24
Creatinine increased	47	7
Alanine aminotransferase increased	46	6

^aLaboratory tests were graded according to NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Version 5.0.

DRUG INTERACTIONS

7.1 Effects of LYNOZYFIC on Other Drugs

Certain CYP substrates

Monitor for toxicity unless otherwise recommended in the Prescribing Information of certain CYP substrates where minimal changes in the concentration may lead to serious adverse reactions when used concomitantly with LYNOZYFIC.

Linvoseltamab-gcpt causes the release of cytokines [see Clinical Pharmacology (12.2)] that may suppress cytochrome P450 (CYP) enzyme activity. Concomitant use with LYNOZYFIC increases CYP substrate exposure which may increase the risk of adverse reactions related to these substrates. Increased CYP substrate exposure is more likely to occur from initiation of the LYNOZYFIC step-up dosing schedule up to 14 days after the first 200 mg dose, and during and after CRS [see Warnings and Precautions (5.1)].

USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on the mechanism of action, LYNOZYFIC may cause fetal harm when administered to a pregnant woman *Isee Clinical Pharmacology (12.1)1.* There are no available data on the use of LYNOZYFIC in pregnant women to evaluate for a drug associated risk. No animal reproductive or developmental toxicity studies have been conducted with LYNOZYFIC

Linvoseltamab-gcpt causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on the finding of B-cell depletion in non-pregnant animals, linvoseltamab-qcpt can cause B-cell lymphocytopenia in infants exposed to linvoseltamab-gcpt in-utero. Human immunoglobulin (lgG) is known to cross the placenta after the first trimester of pregnancy; therefore, linvoseltamab-gcpt has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.

LYNOZYFIC is associated with hypogammaglobulinemia, therefore, assessment of immunoglobulin levels in newborns of mothers treated with LYNOZYFIC should be considered. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2 Lactation

Risk Summary

There are no data on the presence of linvoseltamab-qcpt in human milk, the effects on the breastfed child, or the effects on milk production. Maternal IgG is known to be present in human milk.

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with LYNOZYFIC and for 3 months after the last dose.

8.3 Females and Males of Reproductive Potential

LYNOZYFIC may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating treatment with LYNOZYFIC.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of LYNOZYFIC.

8.4 Pediatric Use

The safety and effectiveness of LYNOZYFIC have not been established in pediatric patients.

8.5 Geriatric Use

Of the 117 patients with relapsed or refractory multiple myeloma who received LYNOZYFIC, 42 (36%) of patients were 65 to 74 years of age and 31 (26%) were 75 years of age and older [see Clinical Studies (14)]. No overall differences in safety or effectiveness were observed in patients 65 years of age and older, including patients 75 years of age and older, when compared with younger patients.

12 CLINICAL PHARMACOLOGY

12.6 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the study described below with the incidence of anti-drug antibodies in other studies, including those of linvoseltamab-gcpt.

During treatment in LINKER-MM1 (evaluated through 30 months) [see Clinical Studies (14)], 1% (2/192) of LYNOZYFIC-treated patients developed anti-linvoseltamab-gcpt antibodies. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of linvoseltamab products is unknown.

REGENERON*

Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591) ©2025 Regeneron Pharmaceuticals, Inc. All rights reserved. US.LYN.25.05.0004 07/25

^{*}Only Grade 3 adverse reactions occurred. *Includes fatal outcome.

^aPneumonia includes atypical pneumonia, COVID-19 pneumonia, PJP, pneumonia, pneumonia cytomegaloviral, pneumonia fungal, pneumonia influenzal, and pneumonia viral.

Encephalopathy includes agitation, amnesia, cognitive disorder, confusional state, delirium,

depressed level of consciousness, encephalopathy (including hyperammonemic and toxic encephalopathy), irritability, lethargy, memory impairment, mental status changes, somnolence, and excludes ICANS.

Rash includes dermatitis acneiform, dermatitis contact, drug eruption, erythema, rash, rash erythematous, rash maculo-papular, rash pruritic, and stasis dermatitis

The denominator used to calculate the rate varied from 106 to 117 based on the number of patients with a baseline value and at least one post-treatment value

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

Cytokine Release Syndrome (CRS): LYNOZYFIC can cause CRS, which can be serious or life-threatening. In LINKER-MM1, CRS occurred in 46% (54/117) of patients who received LYNOZYFIC at the recommended dose, with Grade 1 CRS occurring in 35% (41/117) of patients, Grade 2 in 10% (12/117), and Grade 3 in 0.9% (1/117). Thirty-eight percent (45/117) of patients had CRS following step-up dose 1, including 1 patient who experienced Grade 3 CRS; 8% (9/117) had an initial CRS event following a subsequent dose. Seventeen percent (19/113) of patients developed CRS after step-up dose 2, 10% (11/111) developed CRS after the first full 200-mg dose of LYNOZYFIC, and 3.6% (4/110) developed CRS after the second full dose. Recurrent CRS occurred in 20% (23/117) of patients. The median time to onset of CRS from the end of infusion was 11 (range: -1 to 184) hours after the most recent dose, with a median duration of 15 (range: 1 to 76) hours.

Clinical signs and symptoms of CRS included, but were not limited to pyrexia, chills, hypoxia, tachycardia, and hypotension. Administer pretreatment medications and initiate therapy according to LYNOZYFIC step-up dosing to reduce the incidence and severity of CRS. Monitor patients for signs and symptoms of CRS after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur.

At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care; withhold LYNOZYFIC until CRS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity.

Infusion Related Reactions

Infusion-related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. In the patients who were treated with the recommended step-up dosing regimen and pretreatment medications, the rate of IRR was 9% [11/117 including Grade 2 IRR (4.3%) and Grade 3 IRR (1.7%)]. For IRR, interrupt or slow the rate of infusion or permanently discontinue LYNOZYFIC based on severity of reaction.

Neurologic Toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome: LYNOZYFIC can cause serious or lifethreatening neurologic toxicity, including ICANS. In LINKER-MM1, neurologic toxicity occurred in 54% of patients, with Grade 3 or 4 neurologic toxicity occurring in 8%, at the recommended dose. Neurologic toxicities included ICANS, depressed level of consciousness, encephalopathy, and toxic encephalopathy. ICANS occurred in 8% of patients who received LYNOZYFIC with the recommended dosing regimen, including Grade 3 events in 2.6%. Most patients experienced ICANS following step-up dose 1 (5%). Two patients (1.8%) experienced initial ICANS following step-up dose 2 and one patient developed the first occurrence of ICANS following a subsequent full dose of LYNOZYFIC. Recurrent ICANS occurred in one patient. The median time to onset of ICANS was 1 (range: 1 to 4) day after the most recent dose with a median duration of 2 (range: 1 to 11) days. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of

The most common clinical signs and symptoms of ICANS are confusion, depressed level of consciousness, and lethargy. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate the patient; provide supportive therapy and consider further management per current practice guidelines. Withhold LYNOZYFIC until ICANS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity. Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity, including ICANS occur at any time.

Due to the potential for neurologic toxicity, including ICANS, patients receiving LYNOZYFIC are at risk of confusion and depressed consciousness. Advise patients to refrain from driving, or operating heavy or potentially dangerous machinery, for 48 hours after completion of

each of the step-up doses and in the event of new onset of any neurological symptoms, until symptoms resolve.

LYNOZYFIC REMS: LYNOZYFIC is available only through a restricted program under a REMS called the LYNOZYFIC REMS because of the risks of CRS and neurologic toxicity, including ICANS.

Infections: LYNOZYFIC can cause serious, life-threatening, or fatal infections. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, serious infections, including opportunistic infections, occurred in 42% of patients, with Grade 3 or 4 infections in 38% and fatal infections in 4%. The most common serious infection reported (≥10%) were pneumonia and sepsis. Two cases of progressive multifocal leukoencephalopathy (PML) occurred in patients receiving LYNOZYFIC.

Monitor patients for signs and symptoms of infection and immunoglobulin levels prior to and during treatment with LYNOZYFIC and treat appropriately. Administer prophylactic antimicrobials, antibiotics, antifungals, antivirals, vaccines, and subcutaneous or intravenous immunoglobulin (IVIG) according to guidelines, including prophylaxis for PJP and herpesviruses. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity of the infection.

Neutropenia: LYNOZYFIC can cause neutropenia and febrile neutropenia. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, decreased neutrophil count occurred in 62% of patients with Grade 3 or 4 decreased neutrophil count in 47%. Febrile neutropenia occurred in 8% of patients.

Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local guidelines. Monitor patients with neutropenia for signs of infection. Withhold LYNOZYFIC based on severity.

Hepatotoxicity: LYNOZYFIC can cause hepatotoxicity. In LINKER-MM1, elevated ALT occurred in 46% of patients, with Grade 3 or 4 ALT elevation occurring in 6%; elevated AST occurred in 61% of patients, with Grade 3 or 4 AST elevation occurring in 10% of patients who received the recommended dose. Grade 3 or 4 total bilirubin elevations occurred in 1.7% of patients. Liver enzyme elevation can occur with or without concurrent CRS.

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity.

Embryo-Fetal Toxicity: Based on its mechanism of action, LYNOZYFIC may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LYNOZYFIC and for 3 months after the last dose.

Adverse Reactions

The most common adverse reactions (≥20%) are musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea. The most common Grade 3 or 4 laboratory abnormalities (≥30%) are decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count.


Use in Specific Populations

Lactation: Advise not to breastfeed.

Please see accompanying Brief Summary of Prescribing Information, including Boxed WARNING, for LYNOZYFIC on the preceding pages.

Reference: 1. LYNOZYFIC (linvoseltamab-gcpt) full U.S. prescribing information. Regeneron Pharmaceuticals, Inc.; 2025.

REGENERON*



LYOOZYFIC* (linvoseltamab-gcpt) Injection 5mg I 200mg

For eligible patients with 5L+ R/R multiple myeloma¹

To explore a new option in 5L+ R/R multiple myeloma, visit Booth 901 at the 2025 ASH® Annual Meeting.

INDICATION AND USAGE

LYNOZYFIC is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

- Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Initiate treatment with LYNOZYFIC step-up dosing to reduce the risk of CRS. Manage CRS, withhold LYNOZYFIC until CRS resolves, and modify the next dose or permanently discontinue based on severity.
- Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS during treatment. Manage neurologic toxicity, including ICANS, withhold LYNOZYFIC until neurologic toxicity, including ICANS resolves, and modify the next dose or permanently discontinue based on severity.
- Because of the risk of CRS and neurologic toxicity, including ICANS, LYNOZYFIC is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the LYNOZYFIC REMS.

5L+, fifth line or later; R/R, relapsed/refractory.

Please see additional IMPORTANT SAFETY INFORMATION and accompanying Brief Summary of full Prescribing Information, including Boxed WARNING, for LYNOZYFIC on the preceding pages.